The 7th International Conference on Head & Neck Cancer was supported by Grant Number R13DE019081 from the National Institute Of Dental & Craniofacial Research and the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Dental & Craniofacial Research and the National Cancer Institute of the National Institutes of Health.
MEETING EDUCATIONAL OBJECTIVES

The conference is designed to facilitate discussion among practitioners, trainees, and researchers with an emphasis on how collaborative, multi-disciplinary treatment and rehabilitation can lead to the best oncologic, functional and quality of life outcomes for head and neck cancer patients. The participation of four disciplines of Medical Oncology, Radiation Oncology, Diagnostic Imaging and Head and Neck Surgery will ensure educational interaction within and between specialties that can strengthen multidisciplinary collaborative relationships.

At the conclusion of this event, participants will be able to:

A. Understand the current environment in Head and Neck Cancer care and research within and between the multiple disciplines represented. Including:

1) The impact of induction chemotherapy and concurrent chemoradiotherapy on oncologic and functional outcomes of patient with advanced head and neck cancer.
2) The benefits and shortcomings of treating head and neck cancer patients with new radiation delivery methods such as Intensity Modulated Radiotherapy or particles such as proton therapy.
3) The existing and potential roles of novel molecularly-targeted agents in the treatment of head and neck cancer.
4) The role of functional imaging modalities in pre-treatment staging and assessment of treatment response.
5) The changing role of the surgeon in patients treated with primarily non-surgical means.
6) The impact of new breakthroughs in surgical technology including: 1) robotic surgery, 2) endoscopic approaches to the neck and thyroid gland, 3) image guided treatment of skull base neoplasms, 4) sentinel node mapping, 5) new reconstructive approaches, 5) new powered instrumentation and hemostatic devices.

B. Recognize the important role of nurses, speech pathologists, audiologists, nutritionists, social workers, pain specialists, mental health practitioners, physical therapists, dental oncologists in achieving maximal functional outcomes and proper functional assessment and reporting of functional results of new treatments programs.

C. Be familiar with emerging research breakthroughs that are helping us to better understand the pathogenesis and treatment of head and neck cancer including:

1) Novel high throughput laboratory approaches to analyze tumors and biofluids including cDNA microrarrays, array CGH, SNP arrays and integrative genomics.
2) Animal models of head and neck cancer.
3) The significance of human papilloma virus elements and or antibodies in tumors and biofluids.
4) Pre-clinical evaluation of novel therapeutics.
5) Early detection of oral pre-malignancy and cancer and chemopreventive approaches.
6) The use of biomarkers in treatment selection.
Pacific and Sierra Conference Suites and Club Room (Fourth, Fifth & Atrium Levels)

Marriott Floor Plans (continued)

Pacific

Sierra

Pacific/Fifth/Sierra conference suites and Club Room
(Fourth, Fifth & Atrium Levels)

Yerba Buena Gardens

Pacific and Sierra Conference Suites and Club Room (Fourth, Fifth & Atrium Levels)

FUTURE AHNS MEETINGS

AHNS 2009 Annual Meeting
during the Combined Otolaryngology Society Meetings (COSM)
May 27 - 31, 2009 (AHNS meeting dates May 30-May 31)
JW Marriott Desert Ridge Resort
Phoenix, AZ

AHNS 2010 Annual Meeting
during the Combined Otolaryngology Society Meetings (COSM)
May 12 - 16, 2010 (AHNS meeting dates May 12-13, 2010)
Grand Hyatt Las Vegas at the Cosmopolitan Resort Casino
Las Vegas, NV

AHNS 2010 Research Workshop on Biology,
Prevention & Treatment of Head & Neck Cancer
October 28 - October 30, 2010
Hyatt Regency Crystal City
Arlington, VA

AHNS 2011 Annual Meeting
during the Combined Otolaryngology Society Meetings (COSM)
April 28 - May 1, 2011
(COSM dates, AHNS meeting dates to be determined)
Sheraton Chicago Hotel & Towers
Chicago, IL

8th International Conference on Head & Neck Cancer
July 21 - 25, 2012
Metro Toronto Convention Center
Toronto, ON, Canada
MISSION STATEMENT

The purpose of this society is to promote and advance the knowledge of prevention, diagnosis, treatment and rehabilitation of neoplasms and other diseases of the head and neck, to promote and advance research in diseases of the head and neck, and to promote and advance the highest professional and ethical standards.

HISTORY OF THE SOCIETY


The contributions made by the two societies forming the AHNS are significant in the history of surgery in the United States. Dr. Hayes Martin conceived the Society of Head and Neck Surgeons in 1954, a surgeon considered by many to be the “father of modern head and neck tumor surgery.” The purpose of the society was to exchange and advance the scientific knowledge relevant to the surgery of head and neck tumors (exclusive of brain surgery) with an emphasis on cancer of the head and neck. Two years later, The American Society for Head and Neck Surgery was organized with the goal to “facilitate and advance knowledge relevant to surgical treatment of diseases of the head and neck, including reconstruction and rehabilitation; promote advancement of the highest professional and ethical standards as they pertain to the practice of major head and neck surgery; and to honor those who have made major contributions in the field of head and neck surgery, or have aided in its advancement”.

The new Society remains dedicated to the common goals of its parental organizations.

WHY JOIN THE AHNS?

The American Head and Neck Society is an organization of physicians, scientists and allied health professionals dedicated to improving the understanding of Head and Neck Cancer and the care of patients afflicted with that disease. Membership is open to a wide variety of interested individuals in several categories that differ both in terms of responsibility and level of involvement in the society.

THE BENEFITS OF AHNS MEMBERSHIP:

• Interaction with colleagues dedicated to promoting and advancing the knowledge of prevention, diagnosis, treatment, and rehabilitation of neoplasms and other diseases of the head and neck
• Member rates on all meeting registration fees
• The honor of being a part of our worldwide network of surgeons, physicians and health care professionals dedicated to the prevention and treatment of head and neck cancer
• Opportunities to partake in educational offerings, including those planned by the society and those co-sponsored by the society
• Opportunity to post regional meetings and courses on the AHNS “Related Meetings” web page
• Access to the AHNS member contact information in the “Members Only” section of our web site
• Monthly e-newsletter and annual paper newsletter with updates about the society and head & neck surgery
• Ability to apply for research grant awards offered yearly
• Opportunity to participate on committees and to vote at the annual business meeting

For more information about AHNS membership and to apply on-line, please visit www.ahns.info/membercentral, call +1-310-437-0559, ext. 110 or stop by the membership booth located by registration.
The new American Head and Neck Society was founded as a merger of, the Society of Head and Surgeons (SHNS) and the American Society for Head and Neck Surgery (ASHNS), in 1998. The SHNS was founded under the leadership of General Surgeons Hayes Martin, William MacComb and Grant Ward in 1952. A parallel society the ASHNS was established by Otolaryngologists John Conley, George Sisson, and others in 1958.

Both societies became well established, and ran parallel to each other. The SHNS membership consisted primarily of general surgeons, plastic surgeons and surgical oncologists, while membership in the ASHNS was largely comprised of otolaryngologists. Early on, significant hostility and disrespect was evident in members of both organizations who viewed one another as competitive. However, dispassionate individuals from each group recognized that the two societies possessed similar goals and objectives. Several combined activities were undertaken, beginning with the Advanced Training Council and occasional combined annual meetings and head and neck workshops. In 1984, under the leadership of Paul B. Chretien, MD (SHNS), the first combined International Conference on Head and Neck Cancer was planned by a committee representing leadership of both societies. This meeting followed a successful NCI Head and Neck Oncology Research Workshop initiated in 1980 to address the clinical and research advances in multidisciplinary care. The success of these collaborative activities and the quadrennial International Conferences brought the societies closer together.

The notion of amalgamation was discussed as early as 1960. The first formal meeting on the topic was held in Atlanta on October 15, 1989. The discussions continued over a period of time, with several ups and downs. These issues were brought for discussion in each individual society, as well as the joint training council. After the 1996 International Conference on Head and Neck Cancer in Toronto, the leaders of SHNS seriously considered the merger of the two organizations, and active discussions began. After extensive deliberation, the merger agreement was prepared, and The American Head and Neck Society was born in 1998 under the leadership of co-presidents Ashok Shaha and K. Thomas Robbins.

It is now 50 years since the founding of the ASHNS and 10 years since the birth of the new society. Many young members may not be aware of this tumultuous history. Clearly, the new society represents the full breadth of head and neck surgeons in North America and includes a broader representation of the multiple disciplines with a special interest in furthering the care of head and neck cancer patients. Happy Anniversary, American Head and Neck Society.

Ashok Shaha, MD
K. Thomas Robbins, MD
Ernest A. Weymuller, Jr. MD
Gregory Wolf, MD
Gregory Wolf, M.D., F.A.C.S., is Chair of the Department of Otolaryngology – Head and Neck Surgery at the University of Michigan Medical Center in Ann Arbor, MI. He obtained his undergraduate education at the University of Notre Dame and his medical degree at the University of Michigan School of Medicine. He subsequently completed a two-year general surgical training at Georgetown University followed by a residency in otolaryngology at the State University of New York. After residency, he became a fellow in the Tumor Immunology Section in the Division of Cancer Treatment at the National Cancer Institute in Bethesda, MD.

In 1980, he joined the faculty at the University of Michigan Department of Otolaryngology–Head and Neck Surgery. He has acted in multiple capacities during his tenure at the University of Michigan, including being Director of the Head and Neck Surgery Division, Director of the Head and Neck Oncology Fellowship Training Program and Director of the Head and Neck Oncology Program for the University of Michigan Comprehensive Cancer Center. He became Professor in 1989 and eventually Chair of the University of Michigan Department of Otolaryngology–Head and Neck Surgery in 1993. He has served on numerous institutional committees including two terms as a Director of the Faculty Group Practice and has served as Councilor for the Advisory Council of the NIDCD, NIH. Dr. Wolf has been the principal investigator for numerous research efforts and clinical trials in the treatment of head and neck cancers, including the landmark national Veteran’s Affairs Cooperative Study for organ preservation in advanced laryngeal cancer which created a revolutionary change in the management of these cancers. He has authored over 200 original research articles and book chapters and has been an invited speaker at countless regional, national, and international symposiums. He was President of the American Head and Neck Society (2007-2008). He is the recipient of numerous awards including the Presidential Citation from the American Head and Neck Society in 2002, the Triological Society Vice-Presidential Citation in 2006 and the Honor Award from the American Academy of Otolaryngology-Head and Neck Surgery in 1988, as well as multiple citations in Best Doctors in America and Who’s Who in the World. Dr. Wolf has dedicated his life to the care of patients and has been one of the most influential physician scientists in the history of head and neck cancer surgery.

Ernest A. Weymuller, Jr. was born in New York City. He graduated from Dartmouth College, BA (1962) and Harvard Medical School, MD (1966). After completing his Surgical Internship and Junior Assistant Residency at Vanderbilt University Hospital (1966-68), he served as a Captain, USAF Medical Corps (1968-70), thereafter completing Otolaryngology training at Massachusetts Eye and Ear Infirmary (1970-73).

He began his postgraduate career in 1973 with Boston Ear Nose and Throat Associates and was appointed Associate Director of the Head and Neck Tumor Clinic at Massachusetts Eye and Ear Infirmary. He returned to academic medicine in 1978 as an Assistant Professor at the University of Washington. He became Professor and Vice-Chairman in 1985, and Chairman of the Department of Otolaryngology-Head and Neck Surgery in 1992. Current local responsibilities include Co-directorship of the UW Head and Neck Oncology Fellowship; Principal Investigator, Oto-HNS NIH Training Grant; and Surgeon-in-Chief, UW Medical Center.

He has over 100 publications in peer reviewed journals, has co-authored two surgical atlases, contributed 30 chapters to various textbooks, and serves on numerous editorial review boards. His major areas of academic focus are the development and testing of the UW Head and Neck Quality of Life Instrument and the establishment of an International Head and Neck Cancer Database.

National activities include President of the American Head and Neck Society (2000-01), Senior Examiner of the American Board of Otolaryngology and he serves on the National Advisory Council of NIDCD. He has chaired AAO-HNS committees on Ethics (1991-94), Research (1992-1997), Research Liaison and Development (1997-1999), and is now a member of the Board of Directors. Dr. Weymuller has presented invited lectures at the University of Toronto (Abbott Lecturer), the British National Head and Neck Society, National Cancer Center of Singapore (Ministry of Health), National Head and Neck Meeting in India (Hiranandani Oration), and the International Congress of Head and Neck Cancer in Rio de Janeiro, Brazil. He was recently awarded Honorary Fellowship in the Royal Australasian College of Surgeons (2005).

Dr. Weymuller’s day-to-day clinical activities focus on sinus surgery and head and neck cancer management. Ernie and Alice Crownover Weymuller have enjoyed 40 years of marriage and are extraordinarily proud of their children, EA III and Sims, and their respective families.
Dr. Jeffrey N. Myers received his undergraduate degrees in Biochemistry at the University of Pennsylvania. He then continued to study at the University of Pennsylvania where he acquired his medical (MD) and doctoral (PhD) degrees both in 1991. His residency training in otolaryngology was completed at the University of Pittsburgh in 1996 and then completed his fellowship training in advanced oncologic head surgery at M. D. Anderson Cancer Center in 1997. In September 1997 he began as Assistant Professor in the Department of Head and Neck Surgery at the University of Texas M. D. Anderson Cancer Center. He became Deputy Chair for Academic Programs in Head and Neck Surgery in 2004 and in 2006 became Professor of Surgery and Director of Research.

He is currently an American Board of Otolaryngology-certified head and neck surgeon with basic and translational research expertise in various aspects of tumor biology. He is a principal investigator on numerous trials and has several grants to his credit, including an R01 grant, and a T32 Training grant. He is also a Co-PI and Project Co-Leader on a P50 Head and Neck SPORE grant and Program Director and Core Leader on a P30 Cancer Center Support Grant.

Dr. Myers has over 100 publications in peer reviewed journals, has co-authored two books and has contributed to chapters in over 19 textbooks. He also serves on the editorial board of several peer-reviewed journals including Laryngoscope, Cancer, Head Neck, American Journal of Otolaryngology, Annals of Surgical Oncology, and Cancer Research.


Dr. Myers clinical, basic science and translational research interests are in the metastasis of oral tongue cancer.

Dr. Jeff Myers and his wife Lisa have enjoyed 18 years of marriage and are the proud parents of three young energetic boys, Keith 16, Brett 13 and Blake 7.

Waun Ki Hong, M.D., is a leading authority on head, neck and lung cancers and one of the founders of cancer chemoprevention. Dr. Hong is Head of the Division of Cancer Medicine and Professor of Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. He is an American Cancer Society Professor and holds the Samsung Distinguished University Chair in Cancer Medicine.

Beginning in the early 1980’s, Dr. Hong’s organ preservation research established new treatment standards that have enormously improved quality of life for advanced laryngeal cancer patients. His seminal chemoprevention research has clearly shown that high-dose retinoids can reverse oral carcinogenesis—a proof of principle that has led to a new paradigm for cancer chemoprevention. He continues an active research program in chemoprevention with multiple clinical trials, and his molecularly-targeted approaches have the potential to significantly improve the morbidity and mortality of head/neck cancer and lung cancers. Dr. Hong’s research offers the possibility that cancer can be indefinitely delayed and possibly prevented, thus offering patients throughout the world many more healthy years of life.

Dr. Hong is the recipient of numerous national and international awards including AACR’s Joseph A. Burchenal and Rosenthal Foundation Awards, ASCO’s David Karnofsky Award, and a prestigious American Cancer Society Clinical Research Professorship. He served as president of AACR in 2001. More recently, he received the AACR/Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research and is currently an elected member of the ASCO Board of Directors.

In addition to his research and clinical work, Dr. Hong has played a pivotal role in shaping public policy. He is on the Board of Scientific Advisors for NCI, and has served as an advisor for numerous other national organizations. He has trained and nurtured hundreds of young physicians and scientists from around the world, and has played an active role in increasing international collaborations in cancer research.
Hayes Martin Biography

Hayes Martin was born in Dayton, a small town in north central Iowa. He attended the University of Iowa at Iowa Falls before being accepted to the medical school in 1913 on the same campus, finishing 4 years later in a class of 20.

World War I began in April 1917 while Hayes was in his final year of medical school. Many of his classmates at the medical school were in the Army ROTC units; however, Dr. Martin opted for the Navy, which he joined on the day America entered the war. He traveled to Europe on the USS Arkansas and was assigned to his permanent duty station at the U.S. Navy Air Station, La Trinite Sur Mer, France – a small seaside village on the southern coast of Brittany. The purpose of this base was antisubmarine warfare using blimps and kite balloons. Dr. Martin was made commanding officer of the air station for a brief period of time when the line officer in charge had become ill; it was a unique position for a medical officer in the Navy to take command during wartime.

After the war, Dr. Martin returned to the U.S and sought out an internship at the old Poly Clinic Hospital in New York City, which was temporarily made into a Veteran’s Administration hospital. Part of his internship was spent at Bellevue in the fourth surgical division, where he felt he would have the best possible training in general surgery. The chief of the second division was John A. Hartwell, MD, the distinguished surgeon memorialized by the Fellow’s Room in the library of the New York Academy of Medicine. Dr. Hartwell suggested that Dr. Martin go to Memorial Hospital to learn about cancer.

Dr. Martin received an internship at Memorial in the summer of 1922 and stayed on as a resident until 1923. He then had two years at the second surgical service at Bellevue, where he operated to his heart’s content and got the surgical education he so strongly desired. Once he finished his residency, Dr. Martin returned to Memorial where he joined as clinical assistant surgeon on the staff.

Dr. Martin made the use of aspiration biopsy on all solid tumors popular throughout Memorial. Now, this procedure is done throughout the world. Dr. Martin co-authored the first report on the subject published in the Annals of Surgery. Numerous other articles followed, including Dr. Martin’s two most famous publications, “Cancer of the Head and Neck,” published in two issues of the Journal of the American Medical Association in 1948, and “Neck Dissection,” appearing in Cancer in 1951. These two papers were so extensively requested that the American Cancer Society made reprints by the thousands available to those who requested them as many as 20 years after publication. Dr. Martin’s bibliography encompasses more than 160 articles.

In 1934, Dr. Martin was appointed Chief of the Head and Neck Service at Memorial Hospital. It wasn’t until 1940 that surgery began to take over as the treatment of choice for the majority of cancers of the head and neck. In that year, the beginnings of improved anesthesia permitted advances in surgery. Later, during World War II, antibiotics became available and surgery began to dominate much of head and neck cancer management.

Dr. Martin wrote extensively on many subjects, most within the realm of head and neck surgery. His ideal was to be the complete head and neck surgeon and he treated a wide variety of head and neck abnormalities. His book, Surgery of the Head and Neck Tumors, was published in 1957.

Dr. Martin retired from active practice in 1957 at the age of 65. He performed his last operation at Memorial Hospital, assisted by Dr. Elliot Strong, in October 1959, but continued to see patients in his office until he passed away in 1977.

EVALUATION & CME CREDIT FORMS

Please complete the meeting evaluation form and return to the registration desk.

Visit the CME kiosk to print your CME credit form on-site.
Dr. Carolyn Dresler’s current appointments are at the Fay W. Boozman College of Public Health at the University of Arkansas. She left the position of Head of the Group for Tobacco and Cancer at the International Agency for Research on Cancer in Lyon, France at the end of December. Dr. Dresler’s background consists of training at Memorial Sloan Kettering in Surgical Oncology and the University of Toronto in Thoracic and Cardiac Surgery (U.S. Board Certified), and she is also U.S. Board Certified in General Surgery. Dr. Dresler then practiced at Washington University (St. Louis, MO) and at Fox Chase Cancer Center (Philadelphia, PA) as a thoracic surgical oncologist. She was involved in numerous clinical trials through CALGB, ECOG and RTOG while at Washington University and Fox Chase. While at Fox Chase Cancer Center, she also developed a translational research project exploring genetic susceptibility to lung cancer relative to sex and smoking.

Dr. Dresler left clinical medicine to be the Medical Director for Research and Development for Smoking Control at GlaxoSmithKline Consumer Healthcare. While at GSK, she was involved with global tobacco control issues, albeit it from the pharmaceutical commercial side. In addition to helping launch the nicotine transdermal patch into China, she was the medical director responsible for the development of a buccally absorbed nicotine lozenge, a new delivery device for nicotine replacement therapy. For this project, and others within the pharmaceutical industry, Dr. Dresler oversaw design and completion of phase I through phase IV trials. Presently, she is trying to combine this expertise to help develop a very cost-effective smoking cessation product that will be of significant value in the developing world.

In 2002-2003 Dr. Dresler completed a Master in Public Administration at the Kennedy School of Government at Harvard University. She pursued this additional education because of a desire to be involved with international tobacco control in a non-commercial sphere. Her academic interests involve the biologic initiation of tobacco related cancers, the diagnosis and treatment of lung cancer, nicotine addiction particularly as it affects smoking cessation, the susceptibility of women to lung cancer and the global issues of tobacco control. Dr. Dresler is unique in being an experienced thoracic surgical oncologist who also has expertise in nicotine addiction, cessation and multiple aspects of global tobacco control.

FUTURE AHNS MEETINGS

**AHNS 2009 Annual Meeting**
during the Combined Otolaryngology Society Meetings (COSM)
May 27 - 31, 2009 (AHNS meeting dates May 30-May 31)
JW Marriott Desert Ridge Resort
Phoenix, AZ

**AHNS 2010 Annual Meeting**
during the Combined Otolaryngology Society Meetings (COSM)
May 12 - 16, 2010 (AHNS meeting dates May 12-13, 2010)
Grand Hyatt Las Vegas at the Cosmopolitan Resort Casino
Las Vegas, NV

**AHNS 2010 Research Workshop on Biology, Prevention & Treatment of Head & Neck Cancer**
October 28 - October 30, 2010
Hyatt Regency Crystal City
Arlington, VA

**AHNS 2011 Annual Meeting**
during the Combined Otolaryngology Society Meetings (COSM)
April 28 - May 1, 2011
(COSM dates, AHNS meeting dates to be determined)
Sheraton Chicago Hotel & Towers
Chicago, IL

**8th International Conference on Head & Neck Cancer**
July 21 - 25, 2012
Metro Toronto Convention Center
Toronto, ON, Canada
Although he looked and sounded like an English nobleman, Dr John Conley was born in Carnegie, Pennsylvania, a small steel mill town just outside of Pittsburgh. He graduated from the University of Pittsburgh and later its school of medicine. He interned at Mercy Hospital in Pittsburgh. During that year, the nuns who ran the hospital suggested that Dr. Conley take a residency in cardiology and come back to Mercy as their cardiologist. He went to Kings County Hospital in Brooklyn, a very busy city hospital with a huge patient population. Shortly after he began his training, he had an arrhythmia diagnosed as paroxysmal atrial tachycardia. Little was known about this benign condition at that time. Dr. Conley was told that cardiology was too stressful and that he should go into an easier, less-stressful field with better working hours, like ENT. He did an otolaryngology residency at Kings County Hospital. This was followed by four years of military service during World War II, which included experience in otolaryngology and plastic and reconstructive and maxillofacial surgery in the U.S. Army Medical Corps, both in this country and in the South Pacific theater. Exposure to the reconstruction of war wounds would prove invaluable to him later on in applying these principles to reconstruction following ablative head and neck surgery.

Dr. Conley returned to New York City after the war. He became an assistant and then an associate of Dr George T. Pack, a technically superb general oncologic surgeon at Memorial Hospital who taught Dr. Conley major ablative surgery of the head and neck. They worked day and night catching up with the backlog of surgery that was neglected during the war years. The combination of his training in otolaryngology, the exposure to ablative surgery, and the World War II experience in reconstructive surgery set the stage for Dr Conley to evolve his unique approach to head and neck surgery.

Ironically, despite the admonition of the cardiologists about hard work, Dr. Conley did a prodigious amount of major head and neck reconstructive surgery. This proved to be more than ample to provide training to many fellows. His commitment to education is further attested to by the position he held for many years as Clinical Professor of Otolaryngology at the College of Physicians and Surgeons at Columbia University. He loved his appointment at Columbia and particularly his involvement in teaching the residents.

Dr. Conley’s vast surgical experience, together with active research interests, led to the authorship of almost 300 contributions to the scientific literature, and eight books. As a result of his productivity and rhetorical eloquence, he was very much in demand as a speaker in this country and abroad. He gave many prestigious eponymous lectures in our field and received many awards for his work, including the Philip H. Hench Award as the Distinguished Alumnus of the University of Pittsburgh School of Medicine, and the DeRoaldes and Newcomb Awards of the American Laryngological Association.

Dr. Conley’s contributions to the scientific literature, many technical innovations and surgical experience placed him in the position to receive many honors and important leadership positions, such as President of the American Academy of Otolaryngology and Ophthalmology, member of the Board of Governors of the American College of Surgeons, founding member of the Society of Head and Neck Surgeons, and founding member and first President of the American Society for Head and Neck Surgery. During those years, Dr Conley used, to the great benefit of us all, his wisdom and diplomacy in carrying out such high-level responsibilities.
Christopher O'Brien Biography

CHRISTOPHER O'BRIEN, MD, AM

Christopher O'Brien, A.M., graduated in medicine from the University of Sydney in 1976 and then completed his residency and surgical training at Royal Prince Alfred Hospital (RPAH). He then completed clinical fellowships in head and neck surgery and oncology in England and the United States and, in 1987, returned to Australia, where he joined the staff of RPAH as a consultant head and neck surgeon. There he contributed to the expansion of the clinical service, making it one of the largest in the country, and also established a comprehensive head and neck database. That database is the largest in Australasia and one of the largest in the world. He also established a basic research program and an international clinical fellowship program under the umbrella of the Sydney Head and Neck Cancer Institute, which he founded in 2002.

Professor O'Brien has two postgraduate degrees from the University of Sydney—a Masters of Surgery for his basic research in microvascular surgery and a Doctorate in Medicine for his work on the management of metastatic cancer in the neck.

He has authored more than 100 scientific papers and 17 book chapters and has been honored with invitations to many countries and institutions as a visiting professor and guest lecturer, including invitations to give numerous prestigious named lectures: the Hayes Martin Lecture in Washington in 2004, the Eugene Myers International Lecture in Los Angeles in 2005, the inaugural Jatin P. Shah Lecture in Prague in 2006, and the Semon Lecture in London in 2006. He was also made an Honorary Fellow of the Royal College of Surgeons of England in recognition of his contribution to the training of young British surgeons.

In 1998, Professor O'Brien founded the Australian and New Zealand Head and Neck Society, a multidisciplinary society comprising surgeons of all disciplines, radiation and medical oncologists, and allied health professionals. He was President of the Society in 2004. The Society is flourishing and will hold its 10th Annual Scientific Meeting in 2008. Professor O'Brien is also a member of the American Head and Neck Society and was invited to join the Council in 2005.

In 2003, Professor O'Brien became Director of the Sydney Cancer Centre, based at Royal Prince Alfred Hospital and the University of Sydney, while maintaining all of his clinical, teaching, and research responsibilities. He has developed a proposal to transform the Sydney Cancer Centre into a $150 million world-class comprehensive cancer center, and that project is moving forward with great momentum.

Professor O'Brien is widely known to the people of Australia for his many appearances over the last 12 years on the award-winning reality TV program RPA, and on Australia Day 2005 he was made a Member the Order of Australia (AM) for his services to medicine. He is a devoted husband and father with many interests, including running, skiing, reading and playing guitar.

Unfortunately, in November 2006, Professor O'Brien was diagnosed with a malignant brain tumor. His initial treatment has been successful, and he continues his therapy with a fully positive and confident outlook. He stepped down from all of his clinical and administrative positions at the time of his diagnosis in order to concentrate on his recovery.

Professor O'Brien is currently writing a book and continues to mentor and guide registrars and fellows in clinical research and their training.
Jatin P. Shah Biography

JATIN P. SHAH, MD, PHD, (HON) FACS, FRCS (HON), FDSRCS (HON), FRACS (HON)

Professor Jatin P. Shah graduated from the Medical College of MS University in Baroda, India, and received his training in Surgical Oncology and Head and Neck Surgery at Memorial Sloan Kettering Cancer Center. He is Professor of Surgery, at the Weil Medical College of Cornell University, and Chief of the Head and Neck Service, Leader of the Head and Neck Disease Management Team, and holds The Elliott W. Strong Chair in Head and Neck Oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Dr. Shah is a national and international leader in the field of head and neck surgery, having served as President of The New York Cancer Society, The New York Head and Neck Society, The Society of Head and Neck Surgeons, The North American Skull Base Society and the International Academy of Oral Oncology. He is Founder of The International Federation of Head and Neck Oncologic Societies, in 1986. He currently serves as Chairman of the AJCC task force on Head and Neck. He was Chairman of the Joint Council for advanced training in head and neck oncologic surgery in the USA. He was also Chairman of The 4th International Conference on Head and Neck Cancer in Toronto in 1996. He has served in varying capacities for The American Board of Surgery, and The American College of Surgeons.

Professor Shah has been the recipient of numerous awards from various parts of the world, and is the recipient of honorary fellowships from The Royal Society of Medicine Visiting Professorship in 1997. In recognition of his outstanding contributions, and World Leadership in Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, has established The “Jatin Shah Chair in Head and Neck Surgery and Oncology”, The International Federation of Head and Neck Oncologic Societies has established “The Jatin Shah Lecture”, at it’s world congresses, and the American Head and Neck Society has established the “Jatin Shah Symposium” at it’s annual meeting.

Milton J. Dance, Jr. Lecture

C. RENE LEEMAN, MD, PHD

René Leemans, MD, PhD received his residency training in General Surgery at Andreas Hospital and in Otolaryngology at VU University Medical Center (Vumc), both in Amsterdam. The same University awarded him his PhD in 1992. He received a Dutch Cancer Society grant from 1992 to 1994 to further specialise in head and neck oncological and microvascular reconstructive surgery. This training was completed at the departments of Otolaryngology Head and Neck Surgery of the VUmc (then headed by Dr. G.B. Snow), the Netherlands Cancer Institute in Amsterdam, and in the Plastic Surgery Unit at Canniesburn Hospital in Glasgow, UK (head: Mr. D.S. Soutar).

Hereafter he joined the department of Otolaryngology Head and Neck Surgery at the VUmc Amsterdam where he rose through the rank reaching, where he currently holds the chair of the Department and is Professor of Otolaryngology-Head and Neck Surgery. He is co-director of the VUmc Cancer Center Amsterdam.

His special interests include head and neck oncology, microvascular surgery, and basic research.

He is a member of the Steering Committee and chair of the surgery subcommittee of the Head and Neck Co-operative Group of the EORTC, and chair of the Dutch Cooperative Group on Head and Neck Oncology (NWHHT). He serves on the board of the International Federation of Head and Neck Oncologic Societies (IFHNOS) and is a founding member of the European Head and Neck Society (EHNS), presently serving as its first general secretary. He is the general secretary-elect of the International Academy of Oral Oncology (IAOO).

He co-authored more than 250 papers and book chapters on head and neck oncology and is regularly invited to speak at international conferences and tutor at courses. He serves on the editorial board of eight journals.

He is Director of the Otolaryngology Residency Program and the Advanced Fellowship Program in Head and Neck Surgery and Oncology at the VU University Medical Centre Amsterdam.
Jeanne Vance’s and Laddie Dance’s dream for cancer patients to see their future as an opportunity for hope and peace of mind is realized every day by the patients at the Milton J. Dance Jr. Head and Neck Rehabilitation Center. It achieved what they set out to do: alleviate fear of the word ‘cancer’ as well as the disease itself. People say you’ll live a lot longer if you think positive, have fun and laugh more. This was so true of Laddie Dance who lived a full and prosperous 76 years. Last November, Laddie died of a heart attack at his home in Manalapan, Florida, and is truly missed by his family, friends, and many Baltimoreans. However, his philanthropy and moral outreach to cancer victims and their families will live on forever.

A prominent race horse auctioneer and co-owner of 2000 champion older horse, Lemon Drop Kid, Laddie Dance saw life and the world as an opportunity—time that shouldn’t be wasted on feeling sorry for oneself. This was frequently evidenced by the spirit in his voice when he called an auction and the gleam in his eye when he saw a great horse, beautiful women or fantastic business opportunity,” remarks his wife Jeanne.

Laddie Dance frequently shared his vitality for life with cancer patients he met at annual head and neck rehabilitation conferences held by the Dance Center. He loved to share stories and anecdotes of his life experiences rather than dwell on things that were beyond his control.

Laddie’s life and philanthropy were of particular significance to Andy Szulinski, a former radio announcer for WFBR and the first patient treated at the Center. “We accidentally met on a plane coming back from the West Coast, says Mr. Szulinski. “You know how it is. When you have surgical scars, you tend to spot the same kind of scars on other people. The plane landed, Laddie came up to me and we started talking. He made me feel like I was the most important guy on earth…like somebody cared and that I wasn’t alone. You’ll never find a guy with a more positive attitude. He is not a quitter.”

When asked if he felt his ‘accidental’ meeting with Laddie was a coincidence or fate, Mr. Szulinski profoundly replied, “I don’t think that there are any coincidences in life. Everything happens for a reason. Coincidence is a term that people use when they fail to believe that there is a higher power.”

“Meeting Laddie was the icing on the cake,” Mr. Szulinski adds. “It completed the circle for me. I had met someone who helped me recover from surgery. I was gratified and humbled through his generosity, which directly affected my recuperation process. I was particularly grateful that all of the recuperative therapies were intertwined. Knowing that I was going to have the kind of support provided to me by the Center made a huge difference to me, because there isn’t a lonelier feeling on earth than finding out you have cancer. The whole caring atmosphere was like getting a package beautifully gift-wrapped. You felt like you weren’t alone. The feeling you get from the Center is extremely positive, a feeling like…we are going to beat this thing and you are going to live a normal life.”

Others who knew Laddie also remember his confident and assertive attitude.

“Laddie always had a remarkable presence and spirit about him. He was optimistic and firm about his beliefs. When he took a stand, he never backed down. A real man’s man, he was,” says Lee Thomas, Laddie’s long-time friend and lawyer. “It seemed like Laddie knew everybody, thousands of people. He was well-known and thought of throughout the Baltimore-Washington region and up and down the East Coast as a racing horse expert and top-notch auctioneer.”

Laddie knew horse breeds and lines better than some people know their own relatives. He was good at it because he did his homework. A 45-year employee of Fasig-Tipton, he loved and knew the art of auctioneering inside out. Auctioneering came to him naturally though, probably because his father, Milton J. Dance, Sr. was also a veteran of the profession.

Laddie had the good fortune of not having to worry about money, but he was in no way an elitist. “You’d be just as likely to see him chatting with those who cleaned the stable as the owner of the track,” says Mr. Thomas. “Nor was he political. He was very clear about what he liked, and how he felt, and he didn’t mince words. You always knew where you stood with him and that is probably what made him so special. What you saw, is what you got.”

What Baltimore’s healthcare community received was the benefit of the Dance endowment’s great philanthropy as well as decisive thoughts on the purpose and value offered through a head and neck rehabilitation center for cancer victims. For this, the Greater Baltimore Medical Center is very grateful and would like to sincerely thank Ms. Vance and Laddie Dance for their philanthropy and outreach to cancer patients. We look forward to serving more cancer patients and helping them to survive and cope through stronger and better medical/social services, advanced technology, research, education and cancer maintenance programs.
Keynote Address

JENNIFER R. GRANDIS, MD

Jennifer Rubin Grandis, M.D, F.A.C.S. was born and raised in Pittsburgh. She received her undergraduate education at Swarthmore College and her medical degree from the University of Pittsburgh. She completed her residency in the Department of Otolaryngology at the University of Pittsburgh in conjunction with a one-year laboratory research fellowship. Dr. Grandis joined the faculty in 1993 at the University of Pittsburgh where she is currently a Professor of Otolaryngology with a secondary appointment in the Department of Pharmacology. In addition to serving as the leader of the head and neck cancer program within the University of Pittsburgh Cancer Institute, Dr. Grandis is also the Vice-Chair for Research in the Department of Otolaryngology.

Dr. Grandis has focused her research efforts on the biology of head and neck squamous cell carcinoma. Her translational research program is dedicated to increasing our understanding of the genetic and epigenetic alterations that contribute to the development of head and neck cancer with the overall goal of identifying biomarkers, which can serve as therapeutic targets for new prevention and treatment strategies.

She has maintained peer-reviewed funding for her research studies since 1993 and is presently the principal investigator on several NIH grants including a Specialized Program of Research Excellence (SPORE) in head and neck cancer from NCI. Dr. Grandis was elected to the American Society for Clinical Investigation in 2002. She has extensive experience with the grant review process having been a member of the NIH/CSR Metabolic Pathology Study Section (2000-2003) and she served as Chair of the Tumor Cell Biology Study Section (2003-2006).

Dr. Grandis and her husband, Donald J. Grandis, M.D., have been married for 17 years. They have two children, Benjamin and Anna.

Keynote Address

PATRICIA A. HUDGINS, MD

Dr. Patricia A. Hudgins is Professor of Neuroradiology at Emory University, Atlanta GA, where she is Director of Head and Neck Radiology. Her clinical practice includes all of head and neck imaging, with an emphasis on caring for patients with head and neck cancer. Pre-treatment staging and post-treatment surveillance examinations comprise most of her radiology practice.

Dr. Hudgins is a recognized educator in the field, and lectures locally and nationally at both radiology and otolaryngology meetings, including at the Armed Forces Institute of Pathology. Dr. Hudgins has served as President of the American Society of Head and Neck Radiology and American Society of Neuroradiology.

Dr. Hudgins received her medical degree at the University of California, San Francisco, and completed her radiology residency and neuroradiology fellowship at the same institution. Over her 18-year academic career she has published 74 papers, 15 chapters, and has been a frequent presenter at major radiology meetings. Her area of research interest is in surveillance imaging, CT and MR appearance of the treated primary site, flap reconstructions, and nodal surveillance and staging head and neck cancer.
Keynote Lecture

JENS OVERGAARD, MD

Professor Jen Overgaard is the Head of the Department of Experimental Clinical Oncology, Aarhus University Hospital in Denmark and Director of the Danish Graduate School for Clinical Oncology. He has forged a stellar career marked by groundbreaking clinical research that has altered the standards of cancer care around the world. Dr. Overgaard was the first to show clinically that the experimental radiation sensitizer Misonidazole is beneficial in head and neck cancer, thus validating the importance of hypoxia as a radioresistance agent.

Keynote Lecture

RICHARD SHAW, MD, DRCS, FDS

Richard J. Shaw, MD, FRCS, FDS was born and raised in England and trained first in dentistry at Bristol University then in medicine in Glasgow University, before embarking on a surgical training rotation in the West of Scotland leading to the award of the FRCS. He then continued his surgical registrar training in oral and maxillofacial surgery in Liverpool and subsequently the new inter-specialty fellowship in head and neck surgery.

Richard has a keen interest in many area of head and neck oncology including prognostic factors, microvascular reconstruction and oral rehabilitation but has also made it his business to gain a foothold in molecular oncology. In 2004, he was awarded a Royal College of Surgeons of England Research Fellowship enabling him to undertake and present his thesis entitled “Epigenetic biomarkers in head and neck cancer.” This research has been rewarded by a number of prizes including those from the British Association of Oral & Maxillofacial Surgeons, as well as international awards from the International Congress on Oral Cancer and the European Association of Cranio-Maxillofacial Surgery.

In 2007, Richard was appointed as a Senior Lecturer in Head & Neck Surgery at the University of Liverpool and also joined the faculty of the Maxillofacial Unit at University Hospital Aintree as an Honorary Consultant.

Richard is married to Gillian, also a surgeon specializing in obstetrics & gynaecology, and they like to spend their free time skiing, scuba diving and exploring the Highlands of Scotland.
Charles W. Cummings was born in Boston, Massachusetts in November of 1935. He graduated from Deerfield Academy in 1953, Dartmouth College in 1957, and the University of Virginia Medical School in 1961. He was an Intern at Dartmouth, did a year a General Surgery Residency at University of Virginia. He entered the Air Force in 1963, was discharged July 1965, and entered residency training in Otolaryngology-Head and Neck Surgery at Massachusetts Eye and Ear Infirmary, finishing the program in 1968.

He was in private practice in Boston and the clinical staff at the Harvard Medical School and Massachusetts Eye and Ear Infirmary until the end of 1975 when he moved Upstate Medical Center in Syracuse, New York as an Associate Professor in the Department of Otolaryngology- Head and Neck Surgery. Two years later, January 1, 1978, he assumed Chairmanship of the Department of Otolaryngology-Head and Neck Surgery at the University of Washington where he remained until the end of 1990. He then became Director of the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins. In 2003, Dr Cummings stepped down as Chairman and is a Distinguished Service Professor at Johns Hopkins and is still caring for patients. He now is Senior Medical Director/Vice President for Johns Hopkins Medicine International and the Interim Chairman for the Department of Dermatology.

Dr Cummings has written over 125 scientific papers and is the senior editor of the 5-volume text Otolaryngology-Head and Neck Surgery, which is in its fourth edition. He, as well, has co-authored two surgical atlases, one on laryngeal surgery and another on surgical access and reconstruction.

He served as a Director of the American Board of Otolaryngology, has served as Chairman of the Residency Review Committee and Chairman of the Advisory Council for Otolaryngology to the American College of Surgeons. He was Chief of Staff of the Johns Hopkins Hospital from 1997 to 1999 and serves on the Board of Directors of Johns Hopkins Medicine. He is a past president of the American Association for Academic Departments of Otolaryngology, American Broncho-Esophagological Association, the American Academy of Otolaryngology-Head and Neck Surgery, and the American Society for Head and Neck Surgery.

He is married to Jane Drake Cummings and has three children and six grandchildren.

Distinguished Service Award

HELMUTH GOEPFERT, MD

Helmut Goepfert M.D. is a Professor of Surgery and Chairman of the Department of Head and Neck Surgery at the University of Texas, M.D. Anderson Cancer Center. He had a very early exposure to medicine and surgery growing up in Chile. His father was a surgeon in Santiago, Chile and exposed Dr. Helmuth to patient care rounds when he was a youngster. This piqued an interest in biology, chemistry, physics, and mathematics.

Dr. Helmuth graduated with the highest grades in his medical school class in 1961. After graduation, a six-month internship was performed in surgery, neurology, and pediatrics. In medical school, he worked on research projects including determining the effect of radioactive iodine-131 on mice thyroid. He was also involved in an epidemiological study of pinworm infestations in a suburban shanty town in Santiago, Chile in 1957.

In 1962, Dr. Helmuth began his surgery residency in Valdivia, and in 1964, he arrived in the United States at the University of California, Los Angeles and began a fellowship in medical oncology looking at primarily solid tumor chemotherapy under the direction of Dr. W. Longmire. This exposure to systemic therapy for solid malignancy at UCLA opened the door for Dr. Helmuth at the University of Texas M.D. Anderson Cancer Center. In 1966 he worked as a project research investigator in the department of radiation therapy looking at the role of regional chemotherapy at this institution mentored by Dr. John Stehlin. As the Department of Head and Neck Surgery was evolving at that time, he was transferred to the Head and Neck Surgery Section under Dr. Richard Jesse who became chairman of the section of head and neck surgery in 1968 following the retirement of William S. MacComb.

Dr. Helmuth became board-certified in otolaryngology head and neck surgery in 1974 and began his academic career immediately following his residency as the section head of otolaryngology head and neck surgery at the University of Texas at Houston. He was 38 years of age at that time and the only full-time faculty with all other faculty being part-time. Although a section chief at the University of Texas at Houston at Herman Hospital, he always maintained a “part-time” appointment at the University of Texas M.D. Anderson Cancer Center. For four years, this dual role was maintained, but his desire to be a full-time cancer care provider in an environment solely dedicated to this always emerged. Dr. Helmuth saw the gradual move of internal medicine to take over the “medical treatment” of cancer and the evolution of the field of medical oncology.

Helmuth was appointed professor and chairman of the Department of Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center in January of 1982. One of his first missions was the creation of the interdisciplinary tumor conference which he created based upon the model of the radiotherapy planning sessions.
Thomas Carey is a Distinguished Research Scientist and Professor of Cancer Biology and Immunology in the Department of Otolaryngology. He is also a Professor of Pharmacology, and the Director and Associate Chair for Research for the Department of Otolaryngology/Head and Neck Surgery. He co-directs the Head and Neck Oncology Program of University of Michigan Comprehensive Cancer Center.

Dr. Carey graduated from St. Lawrence University with a B.S. in Biology and received his PhD degree in Biochemical Pharmacology from the State University of New York at Buffalo after doing his dissertation work at the Roswell Park Memorial Cancer Institute. He was an NIH post-doctoral Fellow with Dr. Lloyd Old at the Memorial Sloan Kettering Institute prior to joining the faculty at the University of Michigan.

Dr. Carey directs the Laboratory of Cell Biology and Immunology in the Kresge Hearing Research Institute as well as the Laboratory of Head and Neck Cancer Biology in the Cancer Center. The main themes of NIH funded research in Dr. Carey’s two labs are: mechanisms progression response to therapy in head and neck cancer; and mechanisms of autoimmune hearing loss mediated by antibodies to inner ear antigens.

Dr. Carey chaired the Department of Oral Medicine, Pathology, and Oncology in the School of Dentistry from 2001 to 2006. He has published more than 150 journal articles, authored 19 chapters, and co-edited one book. Dr. Carey has mentored hundreds of undergraduate, graduate, medical and post-doctoral students. He has been honored by the University of Michigan with the University of Michigan Senior Research Scientist Lectureship, University of Michigan Distinguished Research Scientist Award, and the Undergraduate Research Opportunity Program Faculty Recognition Award for Outstanding Mentorship. He has also been honored for his work by the United States Jaycees as one of the Ten Outstanding Young Men in the Nation, as well as by his undergraduate Alma Mater with the St. Lawrence University Distinguished Alumni Citation, and the St. Lawrence University Sol Feinstone Humanitarian Award.

Avraham Eisbruch, MD, graduated from Tel Aviv University Medical School. He completed a residency in Radiation Oncology at Washington University in St. Louis and a fellowship in Medical Oncology at MD Anderson Hospital. In 1992 he joined the faculty of the Department of Radiation Oncology at the University of Michigan in Ann Arbor, and since 1994 he has been a member of the Head and Neck Oncology Program. His clinical research interest concentrates on assessing the therapeutic benefit of radiation sensitization of head and neck cancer by chemotherapy, using highly conformal radiotherapy to reduce late complications of therapy and improving patients’ quality of life, and developing metrics to assess the benefits of this technology. He pioneered clinical research in reducing xerostomia by sparing the major and minor salivary glands, and in identifying and sparing the important swallowing structures, striving to reduce dysphagia after chemo-irradiation of head and neck cancer.

Susan G. Fisher, Ph.D is currently Professor and Interim Chair in the Department of Community and Preventive Medicine at the University of Rochester in Rochester, New York. She is Chief of the Division of Epidemiology and also serves as a member of the faculty in both the Department of Biostatistics and the Cancer Center at the University. Dr. Fisher received a Bachelor of Science degree from Johns Hopkins, a Master’s in Biostatistics from Georgetown University and a doctorate in epidemiology from the University of Illinois School of Public Health. As Assistant Chief of the Veterans Administration Cooperative Studies Program at Hines, Illinois for 10 years, Dr. Fisher has extensive experience in the design, conduct, and analysis of national, multi-center clinical trials. Several of these studies represent significant contributions in the fields of otolaryngology, oncology and cardiology. Emanating from her collaboration on the VA Larynx Preservation Study Dr. Fisher has completed extensive work and publications addressing the study design, treatment, prognostic factors, quality of life and molecular markers specific to laryngeal cancer.

Dr. Fisher’s major area of independent research has been in the field of oncology with a particular interest in virally-induced malignancies. She has conducted large epidemiologic investigations of gastric, cervical and breast cancer and post-transplant lymphomas. Most recently, Dr. Fisher has focused her efforts on the role of Simian Virus 40 (SV40) in cancer. She is currently conducting an NCI-funded study to investigate the association between non-Hodgkin lymphoma and SV40. Susan also is very active in graduate teaching of epidemiology and statistical methodologies.
Dr. Forastiere has authored or co-authored more than 200 articles and 50 book chapters. These include the integration of platinum-based chemotherapy and radiotherapy for organ preservation, post-operative management of high-risk head and neck cancer, the development of taxanes in head and neck cancer and most recently investigating agents that target the epidermal growth factor receptor signaling pathway.

Dr. Forastiere is Professor of Oncology, and Otolaryngology, Head and Neck Surgery, and Radiation Oncology and Molecular Sciences at The Johns Hopkins University School of Medicine. She is a graduate of New York Medical College (1975) and completed a Research Fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center in 1980. She was Senior Investigator at the National Cancer Institute-Baltimore Cancer Research Program and on the faculty of the University of Maryland School of Medicine from 1980-1982. Dr. Forastiere was then appointed to the faculty of the University of Michigan Medical School and was Director of Hematology-Oncology at the Ann Arbor Veterans Administration Medical Center from 1982-1988. She has been on the faculty of The Johns Hopkins School of Medicine since 1988.

Dr. Forastiere is the Co-Principal Investigator of the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer at Johns Hopkins. She is the Principal Investigator of the Eastern Cooperative Oncology Group (ECOG) Institutional Grant (1993-Present) and Director of the ECOG Clinical Trials Research Office (1993-Present). She was the Chair of the Head and Neck Committee for ECOG (1993-2006) and co-chair of the Head and Neck Committee of the Radiation Therapy Oncology Group. Dr. Forastiere currently serves as the Medical Oncology co-Chair of the NCI Head and Neck Cancer Steering Committee and she is the Chairperson of the National Comprehensive Cancer Network (NCCN) Head and Neck Cancer Guidelines Panel. Dr. Forastiere served on the Board of Directors of the American Society of Clinical Oncology. She was Chair of the Education Committee, Chair of the Committee on Public Issues and Government Relations and was Chair of the Career Development Committee. She is an Associate Editor for the Journal of Clinical Oncology. Dr. Forastiere has authored or co-authored more than 200 articles and 50 book chapters.

Dr. Jonsen is Emeritus Professor of Ethics in Medicine at the School of Medicine, University of Washington, where he was Chairman of the Department of Medical History and Ethics from 1987 - 1999. He is now Co-director, Program in Medicine and Human Values, California Pacific Medical Center, San Francisco. From 1972 to 1987, he was Chief of the Division of Medical Ethics, School of Medicine, University of California, San Francisco. Prior to that, he was President of the University of San Francisco, where he taught in the Departments of Philosophy and Theology. He received his doctorate from the Department of Religious Studies, Yale University, in 1967. His earlier education was at Gonzaga University in Spokane and Santa Clara University in California.

The Institute of Medicine, National Academy of Sciences, elected Dr. Jonsen a member in 1980 and he has served twice on its Council. He was Chair of NABER, the National Advisory Board on Ethics in Reproduction (1991-1996) and a member of the National Research Council Committee on AIDS Research (1987-1992). He served as Commissioner on the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1974-1978) and on The President’s Commission for the Study of Ethical Problems in Medicine (1979-82). He is a member of the Medical Advisory Panel, Blue Cross-Blue Shield Association (1986-present). Professor Jonsen has served on the Educational Commission for Foreign Medical Graduates, the American Board of Medical Specialties and the National Board of Medical Examiners. He has been Visiting Professor at Harvard Medical School, Georgetown University, The Johns Hopkins Medical School, Maastricht Institute for HealthCare Ethics, Netherlands, and Visiting Scholar, National Library of Medicine, National Institutes of Health. In 1999-2000 he was Visiting Professor of Bioethics, Yale University and in 2002, Visiting Professor, University of Virginia School of Law.


Professor Jonsen has been honored with the McGovern Award of the American Osler Society, the Annual Award of the Society for Health and Human Values, the Davies Award of the American College of Physicians, The Lifetime Achievement Award of the American Association of Bioethics and Humanities and a John Simon Guggenheim Fellowship.
Officers of the AHNS

President: Gregory T. Wolf, MD
Ann Arbor, MI

President-Elect: Wayne M. Koch, MD
Baltimore, MD

Vice President: John A. Ridge, MD, PhD
Philadelphia, PA

Secretary: Dennis H. Kraus, MD
New York, NY

Treasurer: Mark K. Wax, MD
Portland, OR

Past-Presidents:
- Randal S. Weber, MD
  Houston, TX
- John J. Coleman, III, MD
  Indianapolis, IN
- Patrick J. Gullane, MD
  Toronto, ON, Canada

Fellows-At-Large:
- Gary L. Clayman, MD, DDS (2005-2008)
  Houston, TX
- Marion E. Couch, MD, PhD (2007-2010)
  Chapel Hill, NC
- Ramon Esclamado, MD (2007-2010)
  Durham, NC
- Gerry F. Funk, MD (2005-2008)
  Iowa City, IA
- Peter C. Neligan, MD (2007-2010)
  Seattle, WA
  Sydney, Australia
- Bert W. O’Malley, Jr., MD (2006-2009)
  Philadelphia, PA
  Jackson, MS
- Guy J. Petruzzelli, MD, PhD (2006-2009)
  Chicago, IL

Committees of the AHNS

Advanced Training Council (ATC):
- Ashok R. Shaha, MD (Chair) 2002-2012
- William M. Lydiatt, MD (Secretary) 2007-2012
- Karen T. Pitman, MD 2003-2008
- Gary L. Clayman, MD, DDS 2004-2009
- Jeremy L. Freeman, MD 2004-2009
- John A. Ridge, MD, PhD 2004-2009
- Joseph A. Califano, MD 2007-2012
- Ara A. Chalian, MD 2007-2012
- Douglas B. Chepeha, MD 2007-2012
- Barry L. Wenig, MD 2007-2012

CME Compliance Committee:
- Ellie Maghami, MD (Chair) 2007-2009
- Dennis H. Kraus, MD (Ex Officio) 2007-2010
- John A. Ridge, MD, PhD 2006-2008
- Marion E. Couch, MD, PhD 2006-2008
- Terry A. Day, MD, FACS 2006-2008
- Floyd “Chris” Holsinger, MD 2006-2008
- Frank R. Miller, MD 2006-2008

Constitution and By-Laws Committee:
- David W. Eisele, MD (Chair) 2004-2010
- Dennis H. Kraus, MD (Ex Officio) 2007-2010
- Elizabeth A. Blair, MD 2004-2010
- Ann M. Gillenwater, MD 2006-2009
- Brandon G. Bentz, MD 2007-2010
- Paul L. Friedlander, MD 2007-2010

Credentials Committee:
- Gregory T. Wolf, MD (Chair) 2007-2008
- Dennis H. Kraus, MD (Ex Officio) 2007-2010
- John J. Coleman, III, MD 2005-2008
- Randal S. Weber, MD 2006-2009
- John A. Ridge, MD, PhD 2007-2010
- Eben L. Rosenthal, MD 2007-2010

Data Base Committee:
- Marc D. Coltrera, MD (Chair) 2007-2009
- Paul M. Spring, MD 2006-2008
- Douglas B. Villaret, MD 2006-2008
- Daniel G. Deschler, MD 2007-2009
- Miriam Lango, MD 2007-2009
- Ellie Maghami, MD 2007-2009

Education Committee:
- Floyd “Chris” Holsinger, MD (Chair) 2007-2010
- Roger J. Levin, MD 2003-2009
- Anna Maria Pou, MD 2004-2010
- Richard O. Wein, MD 2005-2008
- James P. Malone, MD 2005-2008
- David Myssiorek, MD 2005-2008
- Ralph W. Gilbert, MD 2006-2009
- Gady Har-El, MD 2006-2009
- Andrew McWhorter, MD 2006-2009
- Douglas Trask, MD 2006-2009
- Marilene B. Wang, MD 2006-2009
- Rui Fernandes, MD, DMD 2007-2010
- David Goldenberg, MD 2007-2010
- David I. Rosenthal, MD 2007-2010

AD-HOC Endocrine Committee:
- Gary L. Clayman, MD, DDS (Chair) 2007-2010
- Ashok R. Shaha (Ex Officio) 2007-2010
- Guan-Yang Duh, MD 2007-2010
- Keith S. Heller, MD 2007-2010
- Gregory L. Randolph, MD 2007-2010
- Maisie Shindo, MD 2007-2010
- Robert A. Sofferman, MD 2007-2010
- David J. Terris, MD 2007-2010
- Ralph P. Tufano, MD 2007-2010

Fellowship and Scholarship Committee:
- Marilene B. Wang, MD (Chair) 2007-2010
- Gerry F. Funk, MD 2003-2009
- Mimi S. Kokoska, MD 2005-2008
- Joseph A. Califano, MD 2006-2009
- William R. Carroll, MD 2007-2010
- David L. Schwartz, MD 2007-2010
- Duane A. Sewell, MD 2007-2010

Finance Committee:
- Gady Har-El, MD (Chair) 2007-2010
- Mark K. Wax, MD (Ex Officio) 2004-2010
- Amy Chen, MD, MPH 2006-2009
- Douglas B. Chepeha, MD 2007-2010
### Committees of the AHNS

#### History Committee:
- Randal S. Weber, MD (Chair) 2006-2008
- Gregory T. Wolf, MD 2004-2008
- William B. Armstrong, MD 2006-2008
- Bhuvanesh Singh, MD, PhD 2006-2008
- Joseph A. Brennan, MD 2007-2009
- Bruce J. Davidson, MD 2007-2009

#### Nominating Committee:
- Randal S. Weber, MD (Chair) 2007-2008
- Patrick J. Gullane, MD, FACS 2005-2008
- John J. Coleman, III, MD 2006-2009
- Brian B. Burkey, MD 2007-2010
- Erich M. Sturgis, MD 2007-2010

#### Prevention Committee:
- Gady Har-El, MD (Chair) 2007-2010
- Christine G. Gourin, MD 2003-2010
- Anna Maria Pou, MD 2003-2010
- Wendell O. Yarbrough, MD 2004-2010
- Jonathan Irish, MD, FACS 2004-2010
- William B. Armstrong, MD 2005-2008
- John W. Werning, MD 2005-2008
- Elizabeth A. Blair, MD 2007-2010
- Ann M. Gillenwater, MD 2007-2010
- Daniel D. Lydiatt, MD, DDS 2007-2010

#### Publications Committee:
- Bevan Yueh, MD (Chair) 2006-2008
- Paul A. Levine, MD (Ex Officio) 2006-2008
- David J. Adelstein, MD 2006-2008
- Joy O. Boyle, MD 2006-2008
- Bruce H. Campbell, MD 2006-2008
- Andre L. Carvalho, MD, PhD 2006-2008
- Claudio R. Cernea, MD 2006-2008
- D. Gregory Farwell, MD, FACS 2006-2008
- Robert L. Ferris, MD, PhD 2006-2008
- Gerry F. Funk, MD 2006-2008
- Neal D. Futran, MD, DMD 2006-2008
- Eric Genden, MD 2006-2008
- Patrick Ha, MD 2006-2008
- Floyd “Chris” Holsinger, MD 2006-2008
- Greg A. Kremp, MD 2006-2008
- Stephen Y. Lai, MD 2006-2008
- Cherie-Ann O. Nathan, MD 2006-2008
- David G. Pfister, MD 2006-2008
- John A. Ridge, MD, PhD 2006-2008
- Eben L. Rosenthal, MD 2006-2008
- Bhuvanesh Singh, MD, PhD 2006-2008
- Erich M. Sturgis, MD 2006-2008
- Ralph P. Tufano, MD 2006-2008
- J. Trad Wadsworth, MD 2006-2008
- George H. Yao, MD 2006-2008
- Dennis H. Kraus, MD 2007-2009
- Alfred Simental, MD 2007-2009
- Gregory T. Wolf, MD 2007-2009
- Wayne M. Koch, MD 2006-2009
- Joseph A. Califano, MD 2005-2008
- Douglas B. Chepeha, MD 2005-2008
- Ehab Y. Hanna, MD 2005-2008
- Miriam Lango, MD 2005-2008
- John A. Ridge, MD, PhD 2005-2008
- Richard J. Wong, MD 2005-2008
- Michael Kupferman, MD 2006-2009
- Stephan Y. Lai, MD 2006-2009
- James W. Racco, MD, PhD, FACS 2006-2009
- Eben L. Rosenthal, MD 2006-2009
- Eric Genden, MD 2007-2010
- Hernan E. Gonzalez, MD 2007-2010
- Neil Gross, MD 2007-2010

#### AD-HOC Quality Committee:
- Randal S. Weber, MD (Co-Chair) 2006-2009
- Amy Chen, MD, MPH (Co-Chair) 2006-2009
- David J. Adelstein, MD 2006-2009
- Alfonsus J. Balm, MD 2006-2009
- Bruce H. Campbell, MD 2006-2009
- Bruce J. Davidson, MD 2006-2009
- Christine G. Gourin, MD 2006-2009
- Amy C. Hessel, MD 2006-2009
- Wayne M. Koch, MD 2006-2009
- Thom R. Loree, MD 2006-2009
- William M. Lydiatt, MD 2006-2009
- Snehal Patel, MD, MS, FRCS 2006-2009
- John A. Ridge, MD, PhD 2006-2009
- David I. Rosenthal, MD 2006-2009
- Robert L. Witt, MD, FACS 2006-2009
- Bevan Yueh, MD 2006-2009
- Jonathan J. Beitler, MD, MBA, FACR 2007-2010
- Arlene A. Forastiere, MD 2007-2010
- David Goldstein, MD, FRCS 2007-2010
- Kerstin M. Stenson, MD 2007-2010

#### Relative Value and CPT Advisory Committee:
- Wayne M. Koch, MD (Chair) 2006-2009
- Dennis H. Kraus, MD (Ex Officio) 2007-2010
- William B. Armstrong, MD 2006-2009
- Carol R. Bradford, MD 2006-2009
- Paul L. Friedlander, MD 2006-2009
- William M. Lydiatt, MD 2006-2009
- John A. Ridge, MD, PhD 2006-2009
- Richard V. Smith, MD 2006-2009
- Bert W. O’Malley, Jr., MD 2007-2010

#### Research Committee:
- Jay O. Boyle, MD (Chair) 2006-2009
- Francisco J. Civantos, MD (Co-Chair) 2005-2008
- Robert L. Ferris, MD, PhD (Co-Chair) 2006-2009
- Joseph A. Califano, MD 2005-2008
- Douglas B. Chepeha, MD 2005-2008
- Ehab Y. Hanna, MD 2005-2008
- Miriam Lango, MD 2005-2008
- John A. Ridge, MD, PhD 2005-2008
- Richard J. Wong, MD 2005-2008
- Michael Kupferman, MD 2006-2009
- Stephan Y. Lai, MD 2006-2009
- James W. Racco, MD, PhD, FACS 2006-2009
- Eben L. Rosenthal, MD 2006-2009
- Eric Genden, MD 2007-2010
- Hernan E. Gonzalez, MD 2007-2010
- Neil Gross, MD 2007-2010

#### Website Committee:
- Marion E. Couch, MD, PhD (Chair) 2003-2009
- William M. Lydiatt, MD (Co-Chair) 2003-2009
- Dennis H. Kraus, MD (Ex Officio) 2007-2010
- David W. Eisele, MD 2003-2009
- Andrew J. Nemechek, MD 2003-2009
- John R. Saunders, Jr., MD 2003-2009
- Terance T. Tsue, MD 2003-2009
- Brian B. Burkey, MD 2006-2009
- Richard J. Wong, MD 2006-2009

### Representatives

#### American College of Surgeons Board of Governors

#### American Board of Otolaryngology Liaison
- Floyd “Chris” Holsinger, MD (2007-2010)

#### American College of Surgeons Commission on Cancer
- Amy Chen, MD (2006-2008)

#### Archives of Otolaryngology Associate Editor
- Bevan Yueh, MD (2006-2008)

#### Archives of Otolaryngology News Editor
- Carol R. Bradford, MD (2004-2010)

[www.ahns.info](http://www.ahns.info)
2008 Program Committee:

Ernest A. Weymuller, MD  
[Conference Chair]  
Jeffrey N. Myers, MD, PhD  
[Program Chair]  
Marc D. Coltrera, MD  
[Informatics and Technology Chair]  
Jonathan Irish, MD, FACS  
[Proffered Papers Chair]  
Erich M. Sturgis, MD (Posters Chair)  
David J. Adelstein, MD  
Petra Ambrosch, MD  
K. Kian Ang, MD, PhD  
Jose Baselga, MD  
Jacques Bernier, MD, PhD  
Jay O. Boyle, MD  
Carol R. Bradford, MD  
Patrick J. Bradley, FRCS, MBA  
Patrick G. Bridger, MD  
David M. Brizel, MD  
Joseph A. Califano, MD  
Thomas E. Carey, PhD  
Claudio R. Cernea, MD  
Anthony T.C. Chan, MD  
Gary L. Clayman, MD, DDS  
Ezra E. W. Cohen, MD  
John J. Coleman, III, MD  
Marion E. Couch, MD, PhD  
Anil D'Cruz, MD  
Daniel G. Deschler, MD  
Fernando L. Dias, MD, PhD  
Sonja A. Duffy, PhD, RN  
David W. Eisele, MD  
Adel K. El-Naggar, MD, PhD  
Samy El-Sayed, MD, FFR, FRCR, FRCP  
Robert L. Ferris, MD, PhD  
Daniel M. Fliss, MD  
Arlene A. Forastiere, MD  
Jeremy L. Freeman, MD, FACS  
Satoshi Fukuda, MD, PhD  
Christine G. Gourin, MD  
Jennifer R. Grandis, MD  
Ellen R. Gritz, PhD  
Patrick J. Gullane, MD  
J. Silvio Gutkind, PhD  
Ehab Y. Hanna, MD  
Sheng-Po Hao, MD  
Paul M. Harari, MD  
Keith S. Heller, MD  
Wesley L. Hicks, Jr., MD  
Henry T. Hoffman, MD  
Waun Ki Hong, MD  
Jean-Claude Horiot, MD  
David J. Howard, MD  
Patricia A. Hudgins, MD  
Jennifer L. Hunt, MD, M.Ed  
Fadlo Khuri, MD  
Merrill S. Kies, MD  
Kwang Hyun Kim, MD, PhD  
Wayne M. Koch, MD  
Luiz K. Kowalski, MD, PhD  
Pierre Lavertu, MD  
Nancy Lee, MD  
Jean-Louis LeFebvre, MD  
Scott M. Lippman, MD  
Reuben Lotean, PhD  
Home A. Macapinlac, MD  
Anthony A. Mancuso, MD  
Jesus E. Medina, MD  
William M. Mendenhall, MD  
Randall P. Morton, MD  
Suresh Mukherji, MD  
Cherie-Ann O. Nathan, MD  
Piero Nicolai, MD  
Christopher J. O'Brien, MD, AM  
John C. O'Brien, Jr., MD  
Metin T. Onerci, MD  
Brian O'Sullivan, MD, PhD  
Guy J. Petruzzelli, MD  
David G. Pfister, MD  
Karen T. Pitman, MD  
Marshall R. Posner, MD  
Sultan A. Pradhan, MD  
David Raben, MD  
Peter H. Rhys-Evans, FRCS  
John A. Ridge, MD, PhD  
Jatin P. Shah, MD, FACS  
Ashok R. Shaha, MD  
Eric J. Sherman, MD  
Bhuvanesh Singh, MD, PhD  
Giuseppe Spriano, MD  
Wolfgang Steiner, MD  
Carlos Suarez, MD  
Myung-Whun Sung, MD  
Yoo P. Talini, MD  
Michiel van den Brekel, MD, PhD  
Carter Van Waes, MD, PhD  
Everett E. Vokes, MD  
Mark K. Wax, MD  
Randal S. Weber, MS  
William I. Wei, MS, FACS  
Jochen A. Werner, MD  
William Westra, MD  
Anthony Po Wing Yuen, MBBS  
Bevan Yueh, MD

Conference Leadership

AHNS President
Gregory T. Wolf, MD

Conference Chair
Ernest A. Weymuller, MD

Program Chair
Jeffrey N. Myers, MD, PhD

Proffered Papers Chair
Jonathan Irish, MD

Posters Chair
Erich M. Sturgis, MD

Informatics and Technology Chair
Marc Coltrera, MD

Program Co-Chairs

Radiation Oncology Representatives
Kie-Kian Ang, MD, PhD  
Paul M. Harari, MD

Medical Oncology Representatives
Arlene A. Forastiere, MD  
Merrill S. Kies, MD

Radiology Representative
Patricia A. Hudgins, MD

Basic/Translational Research Representative
Jennifer R. Grandis, MD

Rehabilitation/QOL Representatives
Bevan Yueh, MD  
Jan S. Lewin, PhD
# Past Presidents

## The American Head and Neck Society

<table>
<thead>
<tr>
<th>Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Thomas Robbins, MD</td>
<td>1999</td>
</tr>
<tr>
<td>Ashok R. Shaha, MD</td>
<td>1999</td>
</tr>
<tr>
<td>Jesus E. Medina, MD</td>
<td>2000</td>
</tr>
<tr>
<td>Ernest A. Weymuller, Jr., MD</td>
<td>2001</td>
</tr>
<tr>
<td>Keith S. Heller, MD</td>
<td>2002</td>
</tr>
<tr>
<td>Paul A. Levine, MD</td>
<td>2003</td>
</tr>
<tr>
<td>Jonas T. Johnson, MD</td>
<td>2004</td>
</tr>
<tr>
<td>Patrick J. Gullane, MD</td>
<td>2005</td>
</tr>
<tr>
<td>John J. Coleman, III, MD</td>
<td>2006</td>
</tr>
<tr>
<td>Randal S. Weber, MD</td>
<td>2007</td>
</tr>
</tbody>
</table>

## The American Society for Head and Neck Surgery

<table>
<thead>
<tr>
<th>Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>John J. Conley, MD*</td>
<td>1959-61</td>
</tr>
<tr>
<td>Paul H. Holinger, MD*</td>
<td>1961-63</td>
</tr>
<tr>
<td>Joseph H. Ogura, MD*</td>
<td>1963-65</td>
</tr>
<tr>
<td>John F. Daly, MD*</td>
<td>1965-67</td>
</tr>
<tr>
<td>W. Franklin Keim, MD*</td>
<td>1967-69</td>
</tr>
<tr>
<td>George A. Sisson, MD*</td>
<td>1969-70</td>
</tr>
<tr>
<td>John S. Lewis, MD</td>
<td>1970-71</td>
</tr>
<tr>
<td>Burton J. Soboroff, MD*</td>
<td>1971-72</td>
</tr>
<tr>
<td>Edwin W. Croke, Jr., MD</td>
<td>1972-73</td>
</tr>
<tr>
<td>Charles M. Norris, MD</td>
<td>1973-74</td>
</tr>
<tr>
<td>Daniel Miller, MD*</td>
<td>1974-75</td>
</tr>
<tr>
<td>Emanuel M. Skolnick, MD*</td>
<td>1975-76</td>
</tr>
<tr>
<td>George F. Reed, MD*</td>
<td>1976-77</td>
</tr>
<tr>
<td>John A. Kirchner, MD</td>
<td>1977-78</td>
</tr>
<tr>
<td>William M. Trible, MD*</td>
<td>1978-79</td>
</tr>
<tr>
<td>Loring W. Pratt, MD</td>
<td>1979-80</td>
</tr>
<tr>
<td>J. Ryan Chandler, MD</td>
<td>1980-81</td>
</tr>
<tr>
<td>Douglas B. Bryce, MD</td>
<td>1981-82</td>
</tr>
<tr>
<td>Jerome C. Goldstein, MD</td>
<td>1982-83</td>
</tr>
<tr>
<td>Paul H. Ward, MD</td>
<td>1983-84</td>
</tr>
<tr>
<td>Hugh F. Biller, MD</td>
<td>1984-85</td>
</tr>
<tr>
<td>Robert W. Cantrell, MD</td>
<td>1985-86</td>
</tr>
<tr>
<td>John M. Lore, Jr., MD*</td>
<td>1986-87</td>
</tr>
<tr>
<td>Charles J. Krause, MD</td>
<td>1987-88</td>
</tr>
<tr>
<td>Eugene N. Myers, MD</td>
<td>1988-89</td>
</tr>
<tr>
<td>Willard N. Fee, Jr., MD</td>
<td>1989-90</td>
</tr>
<tr>
<td>Helmut Goepfert, MD</td>
<td>1990-91</td>
</tr>
<tr>
<td>Michael E. Johns, MD</td>
<td>1991-92</td>
</tr>
<tr>
<td>Bryon J. Bailey, MD</td>
<td>1992-93</td>
</tr>
<tr>
<td>James Y. Suen, MD</td>
<td>1993-94</td>
</tr>
<tr>
<td>Gary L. Schechter, MD</td>
<td>1994-95</td>
</tr>
<tr>
<td>Charles W. Cummings, MD</td>
<td>1995-96</td>
</tr>
<tr>
<td>Nicholas J. Cassisi, MD</td>
<td>1996-97</td>
</tr>
<tr>
<td>Dale H. Rice, MD</td>
<td>1997-98</td>
</tr>
</tbody>
</table>

## The Society of Head and Neck Surgeons

<table>
<thead>
<tr>
<th>Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayes Martin, MD*</td>
<td>1954</td>
</tr>
<tr>
<td>Hayes Martin, MD*</td>
<td>1955</td>
</tr>
<tr>
<td>Hayes Martin, MD*</td>
<td>1956</td>
</tr>
<tr>
<td>Hayes Martin, MD*</td>
<td>1957</td>
</tr>
<tr>
<td>Grant Ward, MD*</td>
<td>1958</td>
</tr>
<tr>
<td>Danely P. Slaughter, MD*</td>
<td>1959</td>
</tr>
<tr>
<td>Arnold J. Kremen, MD</td>
<td>1960</td>
</tr>
<tr>
<td>Arnold J. Kremen, MD</td>
<td>1961</td>
</tr>
<tr>
<td>H. Mason Morfit, MD</td>
<td>1962</td>
</tr>
<tr>
<td>H. Mason Morfit, MD</td>
<td>1963</td>
</tr>
<tr>
<td>Calvin T. Kloop, MD*</td>
<td>1964</td>
</tr>
<tr>
<td>Harry W. Southwick, MD*</td>
<td>1965</td>
</tr>
<tr>
<td>Edgar L. Frazell, MD*</td>
<td>1966</td>
</tr>
<tr>
<td>Oliver H. Beahrs, MD*</td>
<td>1967</td>
</tr>
<tr>
<td>Arthur G. James, MD</td>
<td>1968</td>
</tr>
<tr>
<td>William S. MacComb, MD*</td>
<td>1969</td>
</tr>
<tr>
<td>Ralph R. Braun, MD*</td>
<td>1970</td>
</tr>
<tr>
<td>Harvey W. Baker, MD*</td>
<td>1971</td>
</tr>
<tr>
<td>Charles C. Harrold, MD</td>
<td>1972</td>
</tr>
<tr>
<td>Robin Anderson, MD</td>
<td>1973</td>
</tr>
<tr>
<td>Alfred Ketcham, MD</td>
<td>1974</td>
</tr>
<tr>
<td>Richard H. Jesse, MD*</td>
<td>1975</td>
</tr>
<tr>
<td>Condict Moore, MD</td>
<td>1976</td>
</tr>
<tr>
<td>Donald P. Shedd, MD</td>
<td>1977</td>
</tr>
<tr>
<td>William A. Maddox, MD</td>
<td>1978</td>
</tr>
<tr>
<td>John C. Gaisford, MD</td>
<td>1979</td>
</tr>
<tr>
<td>Robert G. Chambers, M.D.*</td>
<td>1980</td>
</tr>
<tr>
<td>Elliot W. Strong, MD</td>
<td>1981</td>
</tr>
<tr>
<td>John M. Moore, MD</td>
<td>1982</td>
</tr>
<tr>
<td>Alvin L. Watne, MD</td>
<td>1983</td>
</tr>
<tr>
<td>Darrell A. Jaques, MD</td>
<td>1984</td>
</tr>
<tr>
<td>Alando J. Ballantyne, MD*</td>
<td>1985</td>
</tr>
<tr>
<td>Frank C. Marchetta, MD*</td>
<td>1986</td>
</tr>
<tr>
<td>William R. Nelson, MD</td>
<td>1987</td>
</tr>
<tr>
<td>Robert D. Harwick, MD</td>
<td>1988</td>
</tr>
<tr>
<td>James T. Helsper, MD</td>
<td>1989</td>
</tr>
<tr>
<td>M.J. Jurkiewicz, MD</td>
<td>1990</td>
</tr>
<tr>
<td>Jatin P. Shah, MD</td>
<td>1991</td>
</tr>
<tr>
<td>Oscar Guillamondegui, MD</td>
<td>1992</td>
</tr>
<tr>
<td>Stephen Ariyan, MD</td>
<td>1993</td>
</tr>
<tr>
<td>J. Edward M. Young, MD</td>
<td>1994</td>
</tr>
<tr>
<td>Michael B. Flynn, MD</td>
<td>1995</td>
</tr>
<tr>
<td>Robert M. Byers, MD</td>
<td>1996</td>
</tr>
<tr>
<td>John R. Saunders, Jr., MD</td>
<td>1997</td>
</tr>
<tr>
<td>Ronald H. Spiro, MD</td>
<td>1998</td>
</tr>
</tbody>
</table>

*Deceased*
AHNS Past Lectures
& Awards

PAST HAYES MARTIN LECTURERS

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>William S. MacComb, MD</td>
<td>1972</td>
</tr>
<tr>
<td>Oliver H. Beahrs, MD</td>
<td>1973</td>
</tr>
<tr>
<td>Arthur G. James, MD</td>
<td>1974</td>
</tr>
<tr>
<td>Charles C. Harrold, MD</td>
<td>1975</td>
</tr>
<tr>
<td>Edgar L. Frazell, MD</td>
<td>1976</td>
</tr>
<tr>
<td>Harry W. Southwick, MD</td>
<td>1977</td>
</tr>
<tr>
<td>Harvey W. Baker, MD</td>
<td>1978</td>
</tr>
<tr>
<td>Edward F. Scanlon, MD</td>
<td>1979</td>
</tr>
<tr>
<td>Condict Moore, MD</td>
<td>1980</td>
</tr>
<tr>
<td>Richard H. Jesse, MD</td>
<td>1981</td>
</tr>
<tr>
<td>Milton Edgerton, MD</td>
<td>1982</td>
</tr>
<tr>
<td>John J. Conley, MD</td>
<td>1983</td>
</tr>
<tr>
<td>William A. Maddox, MD</td>
<td>1984</td>
</tr>
<tr>
<td>Alfred S. Ketcham, MD</td>
<td>1985</td>
</tr>
<tr>
<td>Donald P. Shedd, MD</td>
<td>1986</td>
</tr>
<tr>
<td>Elliot W. Strong, MD</td>
<td>1987</td>
</tr>
<tr>
<td>M.J. Jurkiewicz, MD</td>
<td>1988</td>
</tr>
<tr>
<td>George A. Sisson, MD</td>
<td>1989</td>
</tr>
<tr>
<td>Alando J. Ballantyne, MD</td>
<td>1990</td>
</tr>
<tr>
<td>Ian Thomas Jackson, MD</td>
<td>1991</td>
</tr>
<tr>
<td>John M. Lore, MD</td>
<td>1992</td>
</tr>
<tr>
<td>Ronald H. Spiro, MD</td>
<td>1993</td>
</tr>
<tr>
<td>John G. Batsakis, MD</td>
<td>1994</td>
</tr>
<tr>
<td>Helmuth Goepfert, MD</td>
<td>1995</td>
</tr>
<tr>
<td>Joseph N. Attie, MD</td>
<td>1996</td>
</tr>
<tr>
<td>Blake Cady, MD</td>
<td>1997</td>
</tr>
<tr>
<td>Jatin P. Shah, MD</td>
<td>1998</td>
</tr>
<tr>
<td>Jean-Louis H. LeFebvre, MD</td>
<td>1999</td>
</tr>
<tr>
<td>Robert M. Byers, MD</td>
<td>2000</td>
</tr>
<tr>
<td>William Wei, MD</td>
<td>2001</td>
</tr>
<tr>
<td>Eugene Myers, MD</td>
<td>2002</td>
</tr>
<tr>
<td>Michael Johns, MD</td>
<td>2003</td>
</tr>
<tr>
<td>Christopher J. O’Brien, MD</td>
<td>2004</td>
</tr>
<tr>
<td>Richard K. Reznick, MD, MEd</td>
<td>2005</td>
</tr>
<tr>
<td>Keith S. Heller, MD</td>
<td>2006</td>
</tr>
<tr>
<td>Jesus E. Medina, MD, FACS</td>
<td>2007</td>
</tr>
</tbody>
</table>

PAST JOHN J. CONLEY LECTURERS

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Hughes, MD</td>
<td>2001</td>
</tr>
<tr>
<td>Rabbi David Saperstein</td>
<td>2002</td>
</tr>
<tr>
<td>Jonathan D. Moreno, MD</td>
<td>2003</td>
</tr>
<tr>
<td>David C. Leach, MD</td>
<td>2004</td>
</tr>
<tr>
<td>James F. Battey Jr., MD</td>
<td>2005</td>
</tr>
<tr>
<td>John Stone, MD, MACP</td>
<td>2006</td>
</tr>
<tr>
<td>Kenneth I. Shine, MD</td>
<td>2007</td>
</tr>
</tbody>
</table>

DISTINGUISHED SERVICE AWARDS

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jatin P. Shah, MD</td>
<td>1989</td>
</tr>
<tr>
<td>Stephan Ariyan, MD</td>
<td>1990</td>
</tr>
<tr>
<td>Ashok R. Shaha, MD</td>
<td>1991</td>
</tr>
<tr>
<td>Elliot W. Strong, MD</td>
<td>1995</td>
</tr>
<tr>
<td>John J. Coleman, III MD</td>
<td>1999</td>
</tr>
<tr>
<td>David L. Larson, MD</td>
<td>1999</td>
</tr>
<tr>
<td>Harold J. Wanebo, MD</td>
<td>1999</td>
</tr>
<tr>
<td>Jonas T. Johnson, MD</td>
<td>2001</td>
</tr>
<tr>
<td>Helmuth Goepfert, MD</td>
<td>2003</td>
</tr>
<tr>
<td>Mark D. Coltrera, MD</td>
<td>2004</td>
</tr>
<tr>
<td>Wayne Koch, MD</td>
<td>2005</td>
</tr>
<tr>
<td>John A. Ridge, MD, PhD</td>
<td>2006</td>
</tr>
<tr>
<td>Ernest A. Weymuller, Jr., MD</td>
<td>2007</td>
</tr>
</tbody>
</table>

SPECIAL RECOGNITION AWARDS

<table>
<thead>
<tr>
<th>Lecturer</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul B. Chyetien, MD</td>
<td>1984</td>
</tr>
<tr>
<td>John M. Lore, Jr., MD</td>
<td>1985</td>
</tr>
<tr>
<td>William S. MacComb, MD</td>
<td>1986</td>
</tr>
<tr>
<td>Calvin T. Klopp, MD</td>
<td>1987</td>
</tr>
<tr>
<td>Edgar L. Fazell, MD</td>
<td>1988</td>
</tr>
<tr>
<td>Harvey W. Baker, MD</td>
<td>1989</td>
</tr>
<tr>
<td>Vahram Y. Bakamjian, MD</td>
<td>1991</td>
</tr>
<tr>
<td>Jean-Louis Lefevbre, MD</td>
<td>1995</td>
</tr>
</tbody>
</table>
The Robert Maxwell Byers Award, in the amount of $1000, is for the best clinical or basic science research paper submitted for presentation at the annual meeting of the American Head and Society.

Robert Maxwell Byers, M.D. was born in Union Hospital, Baltimore, Maryland on September 24, 1937. He grew up on the Eastern Shore of Maryland in the small town of Elkton. Very active in the varsity sports of baseball, basketball and track during his high school years, he continued his athletic participation at Duke University along with his pre-med studies. He entered the University of Maryland Medical School in Baltimore in 1959, where he excelled in his medical studies and received membership in AOA and the Rush Honor Medical Society. The highlight of his sophomore year was his 1961 marriage to Marcia Davis, a high school sweetheart. During his junior year, he was commissioned an Ensign in the United States Naval Reserve and later rose to the rank of Captain in 1986.

In 1963, Dr. Byers begin his general surgical residency with Dr. Robert Buxton at the University Hospital in Baltimore. Five years later, as a fully trained general surgeon, he went to the Republic of Vietnam with the 1st Marine Division where he received a unit commendation medal and a combat action ribbon. On return to the United States, he spent a year at Quonset Point, Rhode Island Naval Hospital as Chief of Surgery. In 1969, he was certified by the American Board of Surgery. After discharge from the Navy in 1970, Dr. Byers and his family moved to Houston, Texas where he began a fellowship in Surgical Oncology at the University of Texas M.D. Anderson Cancer Center under the guidance of Drs. R. Lee Clark, Richard Martin, Ed White, William MacComb, Richard Jesse and Alando J. Ballantyne. This move proved to be a decisive event, as he never left. His career in Head and Neck Surgical Oncology was born, nurtured, and matured during the 31 years of his academic/clinical practice at the University of Texas M.D. Anderson Cancer Center.

During his tenure at M.D. Anderson Cancer Center he rose through the ranks from Assistant Professor in 1972 to Associate Professor in 1976 and, finally, Professor and Surgeon in 1981. In 1998, he was honored with the Distinguished Alando J. Ballantyne Chair of Head and Neck Surgery. He is the author or co-author of over 200 published papers, book chapter and monographs. He has given invited lectures all over the world. Most recently (1999), he was selected to give the Hayes Martin Memorial Lecture at the 5th International Conference on Head and Neck Cancer. He has been President of the American Radium Society and President of the Society of Head and Neck Surgeons both in 1995 – 1996. His research interests and his expertise have been focused on cancer of the oral cavity, head and neck cancer in young people and treatment of the neck involved with metastatic cancer with a particular interest in various neck dissections. Dr. Byers is a member of many prestigious societies, of which the Southern Surgical Association, the Texas Surgical Society, the American College of Surgeons and the Society of Surgical Oncologists are but a few. He is a peer reviewer for many medical journals and on the Editorial Board of three. During his 31 years at the University of Texas M.D. Anderson Cancer Center, he has participated in the surgical education of over 300 residents and fellows, many of who have gone on to become prominent members of the specialty. The youth community of Houston has benefited from his coaching expertise in baseball and basketball while he has indulged in the hobbies of hunting, travel, and collecting toy soldiers.

2008 BEST PAPER AWARD WINNERS

**Robert Maxwell Byers Award:** Andrew Sikora, MD, University of Texas MD Anderson Cancer Center for S361: BIDIRECTIONAL ASSOCIATION BETWEEN ANOGENITAL AND ORAL-CAVITY/PHARYNGEAL CARCINOMAS IN MEN: STRONGER IN THE NEVER MARRIED

**Fanconi Anemia Award:** Maie St. John, MD, UCLA for S091: CYCLOOXYGENASE-2-DEPENDENT REGULATION OF E-CADHERIN: IL-1p INDUCES TRANSCRIPTIONAL REPRESSORS ZEB1 AND SNAIL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

**Best Resident Basic Science Research Paper:** Bernard M. Tijink, MD, VU University, Amsterdam, The Netherlands for S346: IMPROVED TUMOR TARGETING OF ANTI-EGFR NANOBODIES THROUGH ALBUMIN BINDING: TAKING ADVANTAGE OF MODULAR NANOBODY TECHNOLOGY

**Best Resident Clinical Paper:** Amy S. Ketcham, MD, Medical University of South Carolina for S015: A COMPARISON OF OUTCOMES IN MINIMALLY INVASIVE VIDEO-ASSISTED THYROIDECTOMY VS. OPEN THYROIDECTOMY

**Best Prevention and Early Detection Papers – 1st Place:** Hiang Khoon Tan, MD, Institut Gustave-Roussy, Villejuif, France for S052: QUANTITATIVE METHYLATION ANALYSES OF RESECTION MARGINS PREDICT LOCAL RECURRENCES AND DISEASE SPECIFIC DEATHS IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMAS

**2nd Place:** Seema Sethi, MD, Henry Ford Hospital, Detroit, MI for S053: NONINVASIVE DETECTION OF HPV AND ASSOCIATED GENETIC ALTERATIONS IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS
Alando J. Ballantyne, M.D., a giving teacher, dedicated surgeon, and a devoted husband and father, is memorialized by the Alando J. Ballantyne Resident Research Pilot Grant. This award, in the amount of $10,000, is for the best grant application by a resident.

Alando, known simply as Jay, grew up in a loving Mormon home that taught him the values of family, excellence, integrity and hard work. Jay graduated Phi Beta Kappa from the University of Arizona and was then awarded a scholarship to Columbia Medical School. During World War II, Jay served as an army captain and medical doctor and had the good fortune to meet his wife, Maria, in San Antonio. In 1947, Dr. Ballantyne became the first resident at the new M.D. Anderson Hospital in Houston. After his year-long residency, he went for further training at the Mayo Clinic in Rochester, Minnesota. He returned to the Anderson staff in 1952, where he quickly advanced from Assistant Surgeon in the Head and Neck Service to Associate Surgeon, and then from 1974 until his retirement in 1994, held the title of Surgeon and Professor of Surgery in the Department of Head and Neck Surgery as well as the title of Ashbel Smith Professor.

Dr. Ballantyne is credited as the first surgeon in the United States to pioneer modified radical neck dissection. His contributions to his subspecialty, the result of an undying curiosity and uncanny powers of observations, have been published in numerous scientific papers and book chapters. Jay lectured at local, national, and international forums and loved his travels. He held memberships in many distinguished medical and surgical societies and served as President and Hayes Martin Lecturer of the Society of Head and Neck Surgeons and President of the Texas Surgical Society.

To honor the contributions of this world-renowned surgeon, the Cynthia and George Mitchell Foundation established the Alando J. Ballantyne Distinguished Chair in Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center.

Dr. Ballantyne’s contributions to the subspecialty of Head and Neck cancer surgery have been the result of an undying curiosity and uncanny powers of observation. He was the father of conservative surgery, removing the cancer while preserving the function. He had a relentless desire to eradicate his patients’ disease, yet was able to balance this fervor with a desire to maintain quality of life for all his patients.

Always an advocate of reconstruction and preservation of cosmesis as well as function, those fortunate enough to have worked with him and been taught by him are forever indebted to his wisdom, surgical expertise, and devotion to his patients. He was beloved by his patients, admired by his peers and idolized by his family.

The Alando J. Ballantyne Resident Research Pilot Grant is funded by the generous contributions of members of the Ballantyne family, including Dr. Gilchrist L. Jackson, a respected member of the American Head and Neck Society.
The American Head & Neck Society has continued to provide grant funds for residents, fellows and young faculty pursuing research in head & neck cancer.

Research has been supported at such prestigious institutions as Harvard University, the University of Virginia, the University of Alabama, and the University of Kentucky.

Funds provided by the AHNS are used to support grants awarded jointly by the AHNS and the American College of Surgeons and the American Academy of Otolaryngology – Head and Neck Surgery.

Congratulations to the 2008 Research Grant Award Winners

AHNS ALANDO J. BALLANYNE
RESIDENT RESEARCH PILOT GRANT

Rolando Rosas, MD, MSc $10,000.00
University of Minnesota-Twin Cities, MN
“Differentiation of Squamous Cancers with PPAR gamma”

AHNS PILOT GRANT

Daniel Schneider, MD $10,000.00
University of Minnesota-Twin Cities, MD
“Human Papilloma Virus Association with HNSCC”

Christopher Towe, MD $10,000.00
Memorial Sloan-Kettering Cancer Center, New York, NY
“Characterizing the Inhibition of SCCRO by Ubiquitinated Proteins”

AHNS/AAO-HNSF YOUNG INVESTIGATOR COMBINED AWARD

Brandon Bentz, MD $39,095
University of Utah, Salt Lake City, UT
“Non-Retinoid Metabolite’s of beta-Carotene and p53 in Head and Neck Cancer”

Mark Jameson, MD, PhD $40,000
The Rector and Visitors of the University of Virginia, Charlottesville, VA
“CABYR: A Novel Cancer-Testis Antigen in Head and Neck Squamous Cell Carcinoma”

Please check ahns.info for more information regarding future AHNS research awards.
The American Head & Neck Society is accredited by the Accreditation Council for Continuing Medical Education (A.C.C.M.E.) to sponsor Continuing Medical Education for physicians. The American Head & Neck Society designates this Continuing Medical Education Activity for:

**31 credits**
in Category 1 of the Physicians Recognition Awards for the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

CME Worksheet for the 7th International Conference on Head and Neck Cancer: This is not your CME credit form. Please use the worksheet below to track the number of CME hours you attend for each activity. Your CME credit form can be found inside your registrant bag.

**To receive your CME credit:**

Turn in your CME form at registration to have your CME certificated mailed to you after the meeting. Please allow 4-6 weeks for processing.

Print your CME certificate on-site at special CME kiosks at the South Registration Desk.

---

**CME WORKSHEET**

Fill in the number of hours you attended each activity in the chart below to track your CME credits.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Credits Available</th>
<th>Hours Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SATURDAY, JULY 19, 2008</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Instructional Courses 09:00-11:00</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Instructional Courses 10:30-11:30</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Instructional Courses 13:00-14:00</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Instructional Courses 14:00-15:00</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Instructional Courses 15:30-16:30</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td><strong>Total Credits Available for Saturday, July 19, 2008:</strong> 5.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SUNDAY, JULY 20, 2008</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John J. Conley Lecture: A Global Picture of the Tobacco Epidemic</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Keynote Address: Molecular and Physiologic Issues: The Future is Now</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 10:45 - 12:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Lunch with the Professors 12:30 - 13:30</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 13:45 - 15:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 15:45 - 17:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total Credits Available for Sunday, July 20, 2008:</strong> 6.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MONDAY, JULY 21, 2008</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHNS Presidential Address: Tailored Treatment, Teamwork, Tradeoffs and</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Tradition: Head &amp; Neck Surgical Oncology in the Genomic Era</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHNS Research Awards</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Keynote Address: Targeting Signaling Pathways in Head and Neck Cancer</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Christopher O'Brien Lecture: Management of Malignant Melanoma</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 10:45 - 12:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Lunch with the Professors 12:30 - 13:30</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 13:45 - 15:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 15:45 - 17:15</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total Credits Available for Monday, July 21, 2008:</strong> 7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TUESDAY, JULY 22, 2008</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York Head and Neck Society Lecture: Nasopharyngeal Cancer</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Keynote Lecture: Radiation Therapy</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Hayes Martin Lecture: Molecular Targets for Treatment and Prevention</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 10:30 - 12:00</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Lunch with the Professors 12:15 - 13:15</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 13:30 - 15:00</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 15:30 - 17:00</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total Credits Available for Tuesday, July 22, 2008:</strong> 7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WEDNESDAY, JULY 23, 2008</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keynote Lecture: Epigenetics and Oral Cancer</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Milton J. Dance, Jr. Lecture: Evaluation and Management of the N0 Neck</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 09:30 - 11:00</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td>Panels/Proffered Papers 11:00 - 12:30</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total Credits Available for Wednesday, July 23, 2008:</strong> 4.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL CREDITS</strong></td>
<td><strong>31.0</strong></td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>EVENT</td>
<td>LOCATION</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td><strong>IC01: BASIC SCIENCE 101: APPLICATION OF ONCOGENOMICS/PROTEOMICS IN HEAD AND NECK CANCER RESEARCH</strong></td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td><strong>IC02: INSTRUCTIONAL COURSE: SENTINEL NODE MAPPING IN HEAD AND NECK SURGERY</strong></td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td><strong>IC03: INSTRUCTIONAL COURSE: SPECIAL TECHNIQUES IN RADIOTHERAPY XRT, PROTONS AND NEUTRONS</strong></td>
<td>SIERRA H</td>
</tr>
<tr>
<td></td>
<td><strong>IC04: TUMOR BOARD: EARLY LARYNX</strong></td>
<td>SIERRA I</td>
</tr>
<tr>
<td></td>
<td><strong>IC05: TUMOR BOARD: MELANOMA/NON-MELANOMA SKIN CANCER</strong></td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td><strong>IC06: TUMOR BOARD: OROPHARYNX</strong></td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td><strong>IC07: TUMOR BOARD: ENDOSCOPIC SURGERY OF THE SKULL BASE</strong></td>
<td>NOB HILL A</td>
</tr>
<tr>
<td></td>
<td><strong>IC08: TUMOR BOARD: THYROID NODULES AND PARATHYROID DISEASE</strong></td>
<td>SIERRA B</td>
</tr>
<tr>
<td>10:30 - 11:30</td>
<td><strong>IC09: INSTRUCTIONAL COURSE: COMBINED THERAPY FOR OROPHARYNX CANCER</strong></td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td><strong>IC10: INSTRUCTIONAL COURSE: MANAGEMENT OF INTERMEDIATE AND ADVANCED LARYNX CANCER</strong></td>
<td>SIERRA H</td>
</tr>
<tr>
<td></td>
<td><strong>IC11: INSTRUCTIONAL COURSE: MINIMALLY INVASIVE THYROID</strong></td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td><strong>IC12: INSTRUCTIONAL COURSE: NUTS AND BOLTS OF TISSUE BANKING</strong></td>
<td>SIERRA I</td>
</tr>
<tr>
<td></td>
<td><strong>IC13: INSTRUCTIONAL COURSE: QUALITY STANDARDS FOR HEAD AND NECK ONCOLOGY</strong></td>
<td>SIERRA B</td>
</tr>
<tr>
<td></td>
<td><strong>IC14: INSTRUCTIONAL COURSE: REIMBURSEMENT IN HEAD AND NECK SURGERY: INFLUENCES FROM THE LOCAL TO NATIONAL LEVEL</strong></td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td><strong>IC15: INSTRUCTIONAL COURSE: SURGICAL TECHNIQUE ON SALIVARY GLANDS</strong></td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td><strong>IC16: TUMOR BOARD: METASTATIC/ RECURRENT (AGGRESSIVE) THYROID CANCER</strong></td>
<td>NOB HILL A</td>
</tr>
<tr>
<td>13:00 - 14:00</td>
<td><strong>IC17: BASIC SCIENCE 101: INTRODUCTION TO IMMUNOBIOLOGY AND STEM CELLS</strong></td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td><strong>IC18: INSTRUCTIONAL COURSE: HEAD AND NECK RECONSTRUCTION</strong></td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td><strong>IC19: INSTRUCTIONAL COURSE: MINI-COURSE ON SURGICAL TECHNIQUE FOR LARYNX: THE ROLE OF PARTIAL LARYNGECTOM</strong></td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td><strong>IC20: INSTRUCTIONAL COURSE: SCREENING AND EARLY DIAGNOSIS OF ORAL CANCER</strong></td>
<td>SIERRA H</td>
</tr>
<tr>
<td></td>
<td><strong>IC21: INSTRUCTIONAL COURSE: THYROID CANCER</strong></td>
<td>NOB HILL A</td>
</tr>
<tr>
<td></td>
<td><strong>IC22: TUMOR BOARD: ORAL CAVITY</strong></td>
<td>SIERRA I</td>
</tr>
<tr>
<td></td>
<td><strong>IC23: TUMOR BOARD: SALIVARY AND LATERAL SKULL BASE</strong></td>
<td>SIERRA B</td>
</tr>
<tr>
<td>13:00 - 15:00</td>
<td><strong>IC24: INSTRUCTIONAL COURSE: HEAD AND NECK ULTRASOUND</strong></td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td><strong>IC25: INSTRUCTIONAL COURSE: ADJUVANT/POSTOPERATIVE THERAPY</strong></td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td><strong>IC26: INSTRUCTIONAL COURSE: ENDOSCOPIC OFFICE-BASED PROCEDURES</strong></td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td><strong>IC27: INSTRUCTIONAL COURSE: ELECTRONIC MEDICAL RECORD SYSTEMS IN HEAD AND NECK ONCOLOGIC PRACTICE</strong></td>
<td>SIERRA H</td>
</tr>
<tr>
<td></td>
<td><strong>IC28: INSTRUCTIONAL COURSE: IRB/GRANTS</strong></td>
<td>SIERRA I</td>
</tr>
<tr>
<td></td>
<td><strong>IC29: INSTRUCTIONAL COURSE: MINIMALLY INVASIVE PARATHYROID</strong></td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td><strong>IC30: INSTRUCTIONAL COURSE: MULTIDISCIPLINARY HEAD AND NECK CANCER CARE IN THE COMMUNITY</strong></td>
<td>NOB HILL A</td>
</tr>
<tr>
<td></td>
<td><strong>IC31: INSTRUCTIONAL COURSE: SYSTEMIC THERAPY</strong></td>
<td>SIERRA B</td>
</tr>
<tr>
<td>15:30 - 16:30</td>
<td><strong>IC32: BASIC SCIENCE 101: INTRODUCTION TO TARGETED THERAPY</strong></td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td><strong>IC33: INSTRUCTIONAL COURSE: ROLE OF MID-LEVEL PROVIDERS IN A HEAD AND NECK CANCER SURGERY PRACTICE</strong></td>
<td>SIERRA H</td>
</tr>
<tr>
<td></td>
<td><strong>IC34: INSTRUCTIONAL COURSE: QUALITY OF LIFE</strong></td>
<td>SIERRA I</td>
</tr>
<tr>
<td></td>
<td><strong>IC35: INSTRUCTIONAL COURSE: ROBOTICS IN HEAD AND NECK SURGERY</strong></td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td><strong>IC36: INSTRUCTIONAL COURSE: SKULL BASE TECHNIQUES</strong></td>
<td>SIERRA B</td>
</tr>
<tr>
<td></td>
<td><strong>IC37: INSTRUCTIONAL COURSE: SPEECH AND SWALLOWING REHABILITATION</strong></td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td><strong>IC38: TUMOR BOARD: HYPOPHARYNX</strong></td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td><strong>IC39: TUMOR BOARD: VASCULAR TUMORS</strong></td>
<td>NOB HILL A</td>
</tr>
<tr>
<td>16:30 - 17:30</td>
<td>INFORMATION SESSION ON HEAD AND NECK FELLOWSHIPS</td>
<td>YERBA SALON 10-11</td>
</tr>
</tbody>
</table>
Saturday is devoted to individual instructional courses, tumor boards and basic sciences courses. Space is limited and courses are subject to an additional charge. All courses are available for CME credit.

09:00 - 10:00  INSTRUCTIONAL COURSES

IC01  BASIC SCIENCE 101: APPLICATION OF ONCOGENOMICS/PROTEOMICS IN HEAD AND NECK CANCER RESEARCH
Eduardo Mendez, MD and Mark E. Whipple, MD

This course will focus on the use of high-throughput genome and protein data for head and neck cancer research. We will provide a comprehensive background on these technologies and address the most common applications for cancer research with emphasis on head and neck cancer. We will also address the various analytical tools commonly used for high-throughput data and focus on result interpretation.

At the conclusion of the course, the participants will have increased knowledge in all these areas and, in particular, will have a thorough understanding of the following:

- The concept of the Central Dogma: how genetic information is transcribed and translated into proteins with particular attention into the molecules most promising for cancer research (i.e. DNA, mRNA, iRNA, Proteins, Antibodies, etc.).
- The basic tools and platforms to collect high-throughput (genome-wide) data from genetic information.
- The various bioinformatic tools to summarize and analyze high-throughput data in the context of cancer research.
- The most common applications of these technologies for cancer research.
- The current efforts to use oncogenic/proteomics in head and neck cancer research – a literature review of the most significant findings.

IC02  INSTRUCTIONAL COURSE: SENTINEL NODE MAPPING IN HEAD AND NECK SURGERY
Francisco J. Civantos, MD (Course Chair) and Carol R. Bradford, MD

The purpose of this course is to familiarize practicing surgeons with the state-of-the-art for the intraoperative detection and sampling of radiolabelled lymphatic tissues. Special emphasis will be placed on patient selection and surgical technique. We will address the use of these techniques for both cutaneous and mucosal lesions.

At the conclusion of the course, the participants will have increased their knowledge in all of these areas, and in particular will have a thorough understanding of and be able to describe:

- The potential reductions in morbidity achievable through sentinel node biopsy in appropriately selected patients.
- The issues related to potential morbidity involved in surgical re-exploration and the potential for false negatives, and how to minimize these risks through patient selection and proper technique.
- Developing technologies and their potential role in the future development of radioguided surgery of the head and neck.

IC03  INSTRUCTIONAL COURSE: SPECIAL TECHNIQUES IN RADIOTHERAPY XRT, PROTONS AND NEUTRONS
George E. Laramore, MD and Allan F. Thorton, Jr., MD, DABR

At the conclusion of this course, the participants will be able to understand and discuss:

- The changes in treatment techniques for head and neck cancer starting with simple parallel opposed fields, to 3-dimensional conformal fields, to intensity modulated radiotherapy (IMRT), to image guided radiotherapy (IGRT).
- The critical role that improved imaging techniques for both tumor and critical normal structures have played in allowing improved radiation dose localization.
- The distinctions between biological and physical targeting of various types of particle radiotherapy as exemplified by fast neutrons and high energy protons and to explain the rationale for the use of each type of radiotherapy in clinical settings.
- The emerging role of heavy ion (carbon) radiotherapy in the treatment of head and neck cancer.
IC04 TUMOR BOARD: EARLY LARYNX
Chris Holsinger, MD (Course Chair), William Morrison, MD and Jorge Pinho, MD

At the conclusion of this course, participants will be able to understand and identify the following:

• Proper clinical, endoscopic, and radiographic evaluation of T1-T2 squamous carcinomas of the larynx, glottic and supraglottic, highlighting:
  – Limitations of the current TNM staging system
  – Appropriate use of CT, MRI and PET for this disease

• Functional assessment of both speech and swallowing before and after therapy.

• Indications for resection via transoral minimally invasive techniques (phonosurgery, laser microsurgery, with and without robotics).

• Role of open surgical techniques using vertical partial laryngectomy, open horizontal supraglottic laryngectomy, and the supracricoid partial laryngectomies.

• Role of altered fractionation for early laryngeal carcinoma.

• Role of IMRT for early laryngeal carcinoma.

IC05 TUMOR BOARD: MELANOMA/NON-MELANOMA SKIN CANCER
Dennis H. Kraus, MD (Course Chair) and Eric J. Lentsch, MD

At the conclusion of the course, participants will be able to:

• Identify high risk head and neck melanoma primary patients who would potentially benefit from lymphoscintigraphy and sentinel node biopsy.

• Understand the technical challenges and nuances of lymphoscintigraphy and sentinel node biopsy in the head and neck melanoma patient.

• Define the role of adjuvant therapy in both the high risk melanoma and non-melanoma head and neck skin cancer patient.

IC06 TUMOR BOARD: OROPHARYNX
William M. Mendenhall, MD (Course Chair), Maura L. Gillison, MD, PhD and K. Thomas Robbins, MD

This course will deal particularly with oropharynx cancer. It will address the following issues in relation to the diagnosis, evaluation and treatment of oropharynx cancer:

• Discuss treatment selection

• New radiotherapy techniques

• The role of surgery

• The optimal combination of irradiation fractionation schedule and adjuvant chemotherapy

At the conclusion of the course, the participants will have increased their knowledge in all these areas, and in particular, will have a thorough understanding of and be able to describe:

• How to identify and clinically evaluate a patient with oropharynx cancer.

• Will have knowledge of new radiotherapy techniques for treatment.

• How to effectively evaluate the role of surgery.

IC07 TUMOR BOARD: ENDOSCOPIC SURGERY OF THE SKULL BASE
Ehab Y. Hanna, MD (Course Chair) and Ricardo L. Carrau, MD

Endoscopic access to the skull base is gaining rapid popularity for surgical management of neoplastic and non-neoplastic conditions of the cranial base. This course offers a systematic paradigm to select the most appropriate approach based on the location and pathology of the lesion to be treated. The advantages, disadvantages, limitations, and specific indications of each approach will be described with illustrative clinical examples and operative videos. The morbidity associated with endoscopic approaches will be discussed and strategies for avoidance and management of complications will be emphasized. Clinical and histopathologic factors that correlate with outcome and prognosis will also be highlighted. The overall safety and efficacy of each surgical approach will be critically appraised.
At the conclusion of the course, the participants will be able to:

- Understand the complex surgical anatomy and recognize the various pathologic entities involving the base of the skull.
- Identify the most suited surgical approach for specific tumors, its advantages and limitations.

This course will use a didactic format to illustrate how to select the optimal surgical approach, open and endoscopic, for patients with skull base tumors. Illustrative examples will be used for each approach using digital slides and video. These examples will highlight the pros and cons of each approach and the specific indications for utilizing it depending on the nature and location of the tumor.

**IC08 TUMOR BOARD: THYROID NODULES AND PARATHYROID DISEASE**

Keith S. Heller, MD (Course Chair) and Miljenko Bura, MD, PhD

At the conclusion of the course, participants will be able to:

- Understand the role of ultrasonography in the evaluation of thyroid nodules.
- Understand the role of preoperative cytology and intraoperative frozen section in the extent of surgery for thyroid nodules.
- Identify pitfalls in minimally invasive (single gland) parathyroid exploration.

**INSTRUCTIONAL COURSES**

**IC09 INSTRUCTIONAL COURSE: COMBINED THERAPY FOR OROPHARYNX CANCER**

Bonnie Glisson, MD, Mitchell Machtay, MD and John A. Ridge, MD, PhD

This instructional course will discuss current approaches to the multidisciplinary management of cancer of the oropharynx, including presentations from the perspective of radiation oncologists, medical oncologists, and head and neck surgeons.

At the conclusion of the course, participants will be able to:

- Identify patients most likely to benefit from combined therapy for oropharynx cancer.
- Select appropriate radiation and chemotherapy regimens for combined modality therapy of oropharynx cancer.
- Appreciate the role of surgery as an adjunctive, supportive, and primary modality in the treatment of advanced oropharynx cancer.

**IC10 INSTRUCTIONAL COURSE: MANAGEMENT OF INTERMEDIATE AND ADVANCED LARYNX CANCER**

Arlene A. Forastiere, MD, Metin T. Önerci, MD and Andy Trotti, MD

At the conclusion of this course, participants will be able to:

- Describe the adverse events and QOL issues associated larynx preservation approaches.
- Describe the role of chemotherapy in larynx preservation of intermediate and advanced stage larynx cancer.

**IC11 INSTRUCTIONAL COURSE: MINIMALLY INVASIVE THYROID**

Alfred Simental, MD, Maisie Shindo, MD and Conrad I. Timon, MD

This course will deal with low volume thyroid disease and improved surgical techniques that will benefit the surgical team and patient.

At the conclusion of the course, the participants will have increased their knowledge in the following areas and should be able to describe:

- Important surgical landmarks including the neurovascular supply to the thyroid gland and larynx.
- Patients and tumors that would be suitable candidates for minimally invasive thyroid surgery.
- Advantages of illumination, magnification, and visualization with the use of endoscopes.
- The use of EMG monitoring of laryngeal function during thyroid surgery.
- Challenges with hemostasis during thyroid surgery.
- The outcomes from single and multi-institutional cases.
- The potential disadvantages in time, cost, and patient care.
IC12 INSTRUCTIONAL COURSE: NUTS AND BOLTS OF TISSUE BANKING  SIERRA I
Adel El-Naggar, MD and Michelle Williams, MD
At the conclusion of the course, participants will be able to:
• Identify structural and functional principles of tissue banking.
• Understand operational aspects and goals.
• Understand regulatory and privacy issues.
• Understand database and linkage.
• Identify quality control programs and governance.

IC13 INSTRUCTIONAL COURSE: QUALITY STANDARDS FOR HEAD AND NECK ONCOLOGY  SIERRA B
Amy Chen, MD, Brian O’Sullivan, MD and Randall S. Weber, MD
This course will deal particularly with the methodology for establishing and implementing quality standards for treating patients with cancer of the head and neck.
At the conclusion of this course, the participants will have increased their knowledge and be able to discuss:
• How deviation in quality of care impact the economics and disease outcome for head and neck cancer care.
• The methodology for assessing the level of evidence as it relates to establishing quality of care parameters.
• How quality standards relate to but differ from practice guidelines.
• The methodology for developing quality of care guidelines that are disease and site specific for head and neck cancer.
• Understand the role of quality standards in assessing the value of care delivered by different disciplines and the multidisciplinary team collectively.
• How deviations in quality of care impacts the economics and disease outcomes for head and neck cancer care.

IC14 INSTRUCTIONAL COURSE: REIMBURSEMENT IN HEAD AND NECK SURGERY: INFLUENCES FROM THE LOCAL TO NATIONAL LEVEL  YERBA SALON 15
David L. Callender, MD, Daniel D. Lydiatt, DDS, MD and William M. Lydiatt, MD
At the conclusion of the course, participants will be able to:
• Gain a better understanding of current regulations and market forces affecting medical centers with special emphasis on academic institutions.
• Understand the importance of downstream revenue to the health of the medical institution.
• Gain a better understanding of the worth of the head and neck surgeon to a medical institution.
• Understand the importance of payer mix and referral patterns.
• Gain an appreciation for what the hospital can do to support a head and neck practice.

IC15 INSTRUCTIONAL COURSE: SURGICAL TECHNIQUE ON SALIVARY GLANDS  YERBA SALON 12-13
David W. Eisele, MD and Randall P. Morton, MD
At the conclusion of the course, participants will be able to:
• Understand the indications for various types of parotidectomy.
• Understand methods for safe performance of parotidectomy.
• Understand avoidance and management of complications of parotidectomy.
• Understand management of malignant parotid neoplasms.

IC16 TUMOR BOARD: METASTATIC/RECURRENT (AGGRESSIVE) THYROID CANCER  NOB HILL A
Gary L. Clayman, MD (Course Chair) and Gady Har-El, MD
At the conclusion of the course, participants will be able to:
• Determine what the optimal role of surgery is for patients with lymph node metastatic disease.
• Determine what are the indications and complications for post operative radiation therapy in patients with invasive disease of the laryngopharyngeal organs.
• Determine what is the optimal monitoring strategy for patients with aggressive thyroid malignancies.
INSTRUCTIONAL COURSES

IC17 BASIC SCIENCE 101: INTRODUCTION TO IMMUNOBIOLOGY AND STEM CELLS  YERBA SALON 14
Robert L. Ferris, MD, PhD and Mark E. Prince, MD

This course will deal particularly with applications of basic immunological principles to head and neck cancers and the role of stem cells in progression or recurrence of disease. The potential for use of advances in understanding of immunobiology and stem cells as it relates to therapy of head and neck cancer will be discussed.

At the conclusion of this course, the participants will have increased knowledge of immunobiology and stem cells in head and neck cancer, and have a thorough understanding of recent advances in these areas, and be able to describe:

• How immune/inflammatory systems contribute to head and neck cancer and may contribute to head and neck cancer.
• The potential and current role of immunotherapy in head and neck cancer prevention, detection, and therapy.
• The significance of stem cells in head and neck cancer progression and recurrence.
• The potential utility of recent advances in stem cells for the treatment of head and neck cancer.

IC18 INSTRUCTIONAL COURSE: HEAD AND NECK RECONSTRUCTION  YERBA SALON 15
Bruce Haughey, MD and Peter Neligan, MD

At the conclusion of the course, participants will be able to:

• Gain an appreciation for identifying potential technical problems with head and neck reconstructions.
• Develop an algorithm for avoiding complications.
• Gain an appreciation for dealing with specific complications as they arise.

IC19 INSTRUCTIONAL COURSE: MINI-COURSE ON SURGICAL TECHNIQUE FOR LARYNX: THE ROLE OF PARTIAL LARYNGECTOMY  YERBA SALON 10-11
Javier Gavilán, MD (Course Chair), Lev Bedrin, MD, PhD, and Yoav Talmi, MD

This part of the course will discuss the role of partial laryngectomy for the patient with cancer of the larynx, emphasizing details in relation to preoperative evaluation and patient selection. The oncologic decalogue for laryngeal cancer treatment will be addressed:

• Cancer of the larynx is not a single disease, but a spectrum of lesions.
• Life is more important than voice.
• Good results can only be achieved by curing the “easy” cases.
• The first treatment is the most likely to succeed.
• There must be a physician responsible for the treatment from the beginning to the end.
• More is not always better. The use of combined therapy must be justified and protocols must be reserved for advanced disease.
• Do not let the primary hide the neck.
• Postoperative radiotherapy is not a substitute for free surgical margins.
• Survival statistics are inappropriate to measure success in early glottic cancer.
• There is no treatment of choice but choices of treatment. Classifications are made for end-stage reporting, not for treatment planning.
• Become familiar with the technique of stapler laryngectomy.
• Understand the benefits and clinical applications.
• Recognize the possibilities of its application in your practice.

At the end of the course, the participants will have increased their knowledge in the management of patients with cancer of the larynx and should have a better understanding of the indications and results of partial laryngectomy.

IC20 INSTRUCTIONAL COURSE: SCREENING AND EARLY DIAGNOSIS OF ORAL CANCER  SIERRA H
Ann M. Gillenwater, MD (Course Chair) and David T. Wong, DDM, DMS

This course will discuss detection and diagnosis of oral cancer and precancer. Oral cancer is a major health problem worldwide. Although patients with early disease have better chances for cure and good functional outcome, most patients still present with advanced tumors. To improve outcomes we must improve detection and diagnosis of early neoplastic changes. Current strategies for screening for oral neoplasia, and techniques for diagnosis and management of
Scientific Program

precancerous conditions will be reviewed. Emerging technologies such as fluorescence imaging and salivary genomics and proteomics will be described and their potential role in oral cancer screening and diagnosis will be discussed.

At the conclusion of the course, the participants will have an increased understanding of the following topics:

• How to identify and clinically evaluate a patient with a precancerous oral condition such as leukoplakia, erythroplakia, or lichen planus.
• A clinical framework for staging and prognostication of oral precancerous conditions.
• Current management options for patients with oral precancer.
• Potential role of technologies such as fluorescence imaging and spectroscopy to aid visualization and diagnosis of oral lesions.
• Exciting new advances in strategies to identify cancer biomarkers in saliva for oral cancer screening.

IC21 INSTRUCTIONAL COURSE: THYROID CANCER
Jeremy L. Freeman, MD (Course Chair), Bryan McIver, MBChB, PhD,
David G. Pfister, MD and Jatin P. Shah, MD

Objectives:

• To define the indications for surgery in patients with thyroid nodules with emphasis on risk stratification
• To define the extent of surgery in patients with proven cancer
• To discuss the role of re-operation for patients with rising thyroglobulin
• To discuss newer and innovative treatments for RAI refractory disease

At the conclusion of this course the participants should be able to have a sound knowledge of:

• Risk stratification for well differentiated thyroid cancer.
• Extent of surgery for well differentiated and medullary thyroid carcinoma.
• The significance and role of management of a rising thyroglobulin: New modalities for management of RAI refractory disease.

IC22 TUMOR BOARD: ORAL CAVITY
Mark L. Urken, MD (Course Chair), Fernando L. Dias, MD,
David Raben, MD and Alexander D. Rapidis, MD, DDS, PhD

This course will deal with squamous cell cancer and minor salivary gland cancer arising in the oral cavity. The discussion will address the following issues with respect to the pretreatment evaluation, therapeutic decision making, role of adjuvant therapy and rehabilitation.

At the conclusion of the course, participants will be able to:

• Understand the staging of oral cavity cancer, with special attention to prognostic factors not included in the current staging systems.
• Understand appropriate imaging of patients prior to deciding on therapeutic approach.
• Understand the management of the mandible and of the N0 and N+ neck.
• Understand issues regarding the reconstruction of soft tissues of the oral cavity, of the mandible and of palatopharyngeal reconstruction.
• Identify outcomes for oncologic intervention outcome for functional recovery.

IC23 TUMOR BOARD: SALIVARY AND LATERAL SKULL BASE
Eugene N. Myers, MD (Course Chair),
Franco DeMonte, MD and Sandro J. Stoeckli, MD

At the conclusion of this course, participants should be able to:

• Clinically evaluate a patient with advanced malignancy of the parotid gland.
• Outline the appropriate investigative imaging with emphasis on areas of potential tumor extension beyond the parotid gland.
• Understand how to treat advanced malignancy of the parotid gland including management of the facial nerve and surgical approaches for skullbase and parapharyngeal extension.
• Outline the options for postoperative adjuvant therapy.
IC24 INSTRUCTIONAL COURSE: HEAD AND NECK ULTRASOUND (SPECIAL 2 HR COURSE)
Anil T. Ahuja, MD, Marc D. Coltrera, MD, Yolanda YP Lee, MD and Robert A. Sofferman, MD

The role of ultrasound (gray scale and Doppler) in the head and neck is well-established. The superficial location of the thyroid, neck nodes, and salivary glands makes them ideally suited for ultrasound assessment.

In the thyroid and the salivary glands specific sonographic features help to accurately predict the nature of the masses and an ultrasound guided fine needle aspiration cytology (FNAC) provides confirmatory evidence. This helps in pre-operative planning, counseling patients and identifying those who will benefit from surgery.

Ultrasound combined with FNAC also helps in evaluating neck nodes particularly in patients with a known head and neck carcinoma. This helps in accurate staging and post-treatment follow up. Specific sonographic appearances also help to identify the numerous benign lesions in the neck which may mimic nodal metastases.

At the conclusion of the course, attendees will be familiar with:
• Characteristic sonographic features and the role of ultrasound in thyroid and parotid malignancies.
• Characteristic sonographic features to identify neck node metastases and the role of neck ultrasound in follow up of cancer patients.
• Characteristic sonographic features of common mimics of neck node metastases.
• The role of ultrasound guided FNAC in head & neck cancer.

AHNS ACKNOWLEDGES CONTRIBUTIONS IN-KIND FROM UNITED MEDICAL INSTRUMENTS

IC25 INSTRUCTIONAL COURSE: ADJUVANT/POSTOPERATIVE THERAPY
Jennifer E. Tseng, MD and Upendra Parvathaneni, MD

This course will discuss contemporary management of patients who have advanced resectable head and neck cancer.

At the conclusion of the course, participants will know how to:
• Assess the Relative Risk of Individual Tumors
• Select Tumors for Postoperative Therapy
• Individualize the Intensity of Postoperative Therapy
• Select Tumors for Treatment with:
  – “Standard Fractionation” Radiation Therapy
  – Intensified Radiation Therapy
  – CERT
  – Integrate Possible Future Developments in Molecularly Targeted Therapy into the Postoperative Setting.

IC26 INSTRUCTIONAL COURSE: ENDOSCOPIC OFFICE-BASED PROCEDURES
Henry T. Hoffman, MD and Christine G. Gourin, MD

This course will address office-based approaches to head and neck disorders with a focus on utilization of fiberoptic endoscopic techniques. Specific topics addressed include the in-office evaluation and treatment of disorders affecting the pharynx, larynx and esophagus. Instrumentation as well as anesthetic, biopsy and injection techniques are presented.

IC27 INSTRUCTIONAL COURSE: ELECTRONIC MEDICAL RECORD SYSTEMS IN A HEAD AND NECK ONCOLOGIC PRACTICE
Peter E. Andersen, MD

At the conclusion of this course, participants will be able to:
• Discuss the impact of an electronic medical record on a head and neck oncologic practice.
• Understand essential elements of systems to ensure a good choice when selecting an EMR system.
• Understand how to integrate an EMR system into a head and neck oncologic practice.
Scientific Program

IC28 INSTRUCTIONAL COURSE: IRB/GRANTS

Bhuvanesh Singh, MD, PhD (Course Chair) and Mark S. Chambers, DMD, MS

An Institutional Review Board (IRB) is a federally mandated organization of scientific and non-scientific persons, whose charge is to review research studies involving human subjects to ensure subject safety and welfare. While responsibility for the conduct of a research study ultimately lies with the Principal Investigator, an IRB is to ensure that any research study under its jurisdiction is in compliance with federal, state, and institutional regulations.

At the conclusion of the Course, participants will be able to:
- Describe the historical perspectives, ethical principles, and Federal regulations associated with the conduct of research with human participants.
- Have a clear understanding of what constitutes informed consent and how it must be applied in research involving humans.
- Describe basic information on the regulations and policies governing research with investigational drugs, biologics, and devices.
- Describe the ethical issues and Federal regulations in force during the conduct of Social/Behavioral research, records based research, and genetics research with human participants.
- Describe confidentiality in research, HIPAA requirements, vulnerable populations, and Federal Compliance.
- Describe cost principles, grant award restrictions, proper stewardship of funds, accounting basics, and strategies for success in research.

IC29 INSTRUCTIONAL COURSE: MINIMALLY INVASIVE PARATHYROID

Maisie Shindo, MD and Brendan C. Stack, Jr., MD

This course will review the salient features of hyperparathyroidism with an emphasis upon single gland primary hyperparathyroidism.

At the conclusion of this course, the participants will have a thorough understanding of and be able to describe:
- Minimally invasive parathyroid surgery techniques, including anterior approach, radioguided, lateral approach and local anesthesia.
- Indications for focused, small incision parathyroid surgery.
- Expected risks, benefits and outcome of minimal access parathyroid procedures.
- Appropriate application of these techniques on patients with hyperparathyroidism.

IC30 INSTRUCTIONAL COURSE: MULTIDISCIPLINARY HEAD & NECK CANCER CARE IN THE COMMUNITY

Barbara A. Conley, MD, Roger J. Levin, MD and Karen D. Schupak, MD

This course will deal with squamous cancers of the head and neck diagnosed and treated in a community setting.

At the conclusion of the course, participants will have increased knowledge in the following areas:
- Which treatment modality options to suggest for the newly diagnosed patient with locally advanced squamous cancer of the head and neck.
- How to manage toxicities during and after treatment for locally advanced squamous cancers of the head and neck.
- How to manage non-metastatic recurrent or second primary cancers, including indications for surgery and re-irradiation regimens.
- How to treat metastatic cancers of the head and neck.
- What supportive care is helpful for patients with head and neck cancers.
- How to obtain needed expertise in the community.

IC31 INSTRUCTIONAL COURSE: SYSTEMIC THERAPY

Ezra Cohen, MD and Renato G. Martins, MD

At the conclusion of the course, participants will be able to:
- Discuss the role of systemic therapy in patients with locally advanced disease.
- Discuss the role of systemic therapy in the neoadjuvant and concomitant chemoradiotherapy settings.
- Discuss the role of systemic therapy in the palliation of recurrent/metastatic head and neck cancer.
### SATURDAY

**INSTRUCTIONAL COURSES**

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Course Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC32</td>
<td>BASIC SCIENCE 101: INTRODUCTION TO TARGETED THERAPY</td>
<td>YERBA SALON 14</td>
<td>Seungwon (Steve) Kim, MD and Eben L. Rosenthal, MD</td>
</tr>
</tbody>
</table>

At the conclusion of this course, participants will be able to:

- Understand the overview of anti-epidermal growth factor receptor (EGFR) based therapies including small molecule tyrosine kinase inhibitors (Tarceva) and antibody based therapies (Eribitux).
- Identify mechanism of action of antibody and small molecule based therapies.
- Understand current indications for anti-EGFR based therapies in head and neck cancer in the United States.
- Identify mechanism of action of antibody mediated therapy in both receptor blocking function and antibody-dependent cell-mediated cytotoxicity.
- Understand the targeted therapies on the horizon through a review of agents in advanced stage clinical trials in Europe.
- Search for new molecular targets in head and neck cancer.

---

### SUNDAY

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Course Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC33</td>
<td>INSTRUCTIONAL COURSE: ROLE OF MID-LEVEL PROVIDERS IN A HEAD AND NECK CANCER SURGERY PRACTICE</td>
<td>SIERRA H</td>
<td>Jennifer Alpard, PA-c and Carol Stimson, RN</td>
</tr>
</tbody>
</table>

At the conclusion of the course, the participants will be able to:

- Define and contrast physician assistants and nurse practitioners
  - Brief history of each position
  - Difference in roles in practice
- Advantage of mid-level providers in head and neck surgery practice
  - Presurgery, inpatient and postsurgery care - maintain relationship with patient and family as contact person
  - Advantage of consistency with established provider will result in decreased hospital stay, decrease in patient/health care costs over time

---

### MONDAY

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Course Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC34</td>
<td>INSTRUCTIONAL COURSE: QUALITY OF LIFE</td>
<td>SIERRA I</td>
<td>Barbara A. Murphy, MD and Bevan Yueh, MD</td>
</tr>
</tbody>
</table>

This course will have two primary foci. First, we will discuss the concept of quality of life and its measurement. We will compare and contrast quality of life research with symptom research. We will then discuss the pros and cons of using self-reported measures versus objective measures to assess symptom burden. During the second part of the session, we will highlight the challenges in reporting and interpreting QOL findings. We will discuss so-called abstruse findings and introduce the concept of clinically meaningful changes. We will discuss methods for calculating a minimally clinically important difference and show how it can be used to improve the clarity of communicating QOL findings.

At the conclusion of the course, the participants will have increased their knowledge in all of these areas, and in particular, will have a more thorough understanding of:

- The distinction between quality of life and symptom outcomes
- The pros and cons of using patient reported outcomes and objective measures of symptom burden.
- The reasons that quality of life data are difficult to interpret; and
- Methods that can be used to make the communication of QOL findings clinically interpretable.

---

### TUESDAY

<table>
<thead>
<tr>
<th>Course Code</th>
<th>Course Title</th>
<th>Location</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC35</td>
<td>INSTRUCTIONAL COURSE: ROBOTICS IN HEAD AND NECK SURGERY</td>
<td>YERBA SALON 10-11</td>
<td>Ehab Y. Hanna, MD, David J. Terris, MD and Gregory S. Weinstein, MD</td>
</tr>
</tbody>
</table>

This course will describe the experimental and clinical progress that has been made in the evolution of robotic head and neck surgery. The specific issues that will be addressed include:

- Historical Background
- Technological Innovations
- Experimental/Proof of Principle
- Instrumentation
Scientific Program

- Human Experience
- Clinical Trials
- Robotic Sinonasal and Skull Base Resections
- Transoral Robotic Surgery (TORS) for Benign and Malignant Conditions.
- Challenges and Potential Future Applications

At the conclusion of this course, participants will have a thorough understanding of and be able to describe:
- The systematic evolution of robotic surgery in the head and neck.
- The fundamental elements inherent to incremental advantages of robotic surgery.
- The current and potential future clinical applications of robotic surgery in head and neck surgery.

**IC36 INSTRUCTIONAL COURSE: SKULL BASE TECHNIQUES**

Guy J. Petruzzelli, MD, PhD and Carl H. Snyderman, MD

At the conclusion of the course, the participants will be able to:
- Recognize the anatomical basis for endonasal approaches to the cranial base.
- Contrast the relative advantages and disadvantages of transcranial and transnasal approaches for craniofacial resection of sinonasal malignancies.
- Understand the principles of skull base surgery for sinonasal malignancies.

**IC37 INSTRUCTIONAL COURSE: SPEECH AND SWALLOWING REHABILITATION**

Jan S. Lewin, MD, Jeri A. Logeman, MD, PhD and Albert L. Merati, MD

At the conclusion of the course, participants will be able to:
- Understand important anatomic and physiologic features of normal speech and swallowing function.
- Become updated as to new research findings as they relate to the preservation of speech and swallowing function after treatment for head and neck cancer.
- Differentiate between valid findings and misconceptions associated with swallowing in treated head and neck cancer patients as well as the misconceptions associated with functional tracheoesophageal (TE) voice restoration after total laryngectomy.
- Learn important medical and surgical pre-treatment information to preserve speech and swallowing function in patients who will be treated for head and neck cancer.

**IC38 TUMOR BOARD: HYPOPHARYNX**

David L. Schwartz, MD and Stéphane Temam, MD

At the conclusion of this course, participants will be able to:
- Provide an overview of conservative surgery for early stage disease and reconstructive surgery for advanced stage disease.
- Review the literature and clinical results for non-surgical organ-sparing approaches.
- Present practical examples of IMRT treatment technique.
- Discuss management of post-radiotherapy complications, as well as indications and details of salvage surgery for post-radiotherapy recurrences.

**IC39 TUMOR BOARD: VASCULAR TUMORS**

Elizabeth A. Blair, MD and James L. Netterville, MD

At the conclusion of this course, participants will be able to:
- Identify and describe various vascular lesion malformations in the head and neck.
- Describe the workup and treatment of vascular tumors.
- Describe various surgical approaches to treatment of vascular tumors of the head and neck.

**INFORMATION SESSION ON HEAD AND NECK FELLOWSHIPS**

The American Head & Neck Society cordially invites you, your otolaryngology residents and other residents to come and learn about the typical fellowship, meet fellowship program directors and converse with former fellows over cocktails.
<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>OPENING CEREMONIES AND INVOCATION</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>09:00 - 09:45</td>
<td>JOHN J. CONLEY LECTURE: &quot;A GLOBAL PICTURE OF THE TOBACCO EPIDEMIC&quot;</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td>KEYNOTE ADDRESS: &quot;MOLECULAR AND PHYSIOLOGIC ISSUES: THE FUTURE IS NOW&quot;</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td>PANEL: CANCER PREVENTION – BEHAVIOR</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td></td>
<td>PANEL: IMAGING: STAGING</td>
<td>YERBA SALON 3-4</td>
</tr>
<tr>
<td></td>
<td>PANEL: LYMPHOGRAPHY AND SENTINEL NODE BIOPSY OF THE HEAD AND NECK</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td></td>
<td>PANEL: PRACTICE GUIDELINES AND QUALITY OF CARE INDICATORS</td>
<td>YERBA SALON 5-6</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: BASIC SCIENCE: GENE EXPRESSION</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: THYROID I</td>
<td>YERBA SALON 1-2</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: HUMAN PAPILLOMAVIRUS</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: OUTCOMES: QUALITY OF LIFE</td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: OUTCOMES: SURGERY</td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>LWP01: AHNS DATABASE</td>
<td>PACIFIC A</td>
</tr>
<tr>
<td></td>
<td>LWP02: CANCER PREVENTION AND PREMALIGNANCY</td>
<td>PACIFIC B</td>
</tr>
<tr>
<td></td>
<td>LWP03: CT/MRI FOR ASSESSING TREATMENT RESPONSE</td>
<td>PACIFIC C</td>
</tr>
<tr>
<td></td>
<td>LWP04: IMAGE GUIDED SURGERY</td>
<td>PACIFIC E</td>
</tr>
<tr>
<td></td>
<td>LWP05: IMAGING FOR SURVEILLANCE</td>
<td>PACIFIC F</td>
</tr>
<tr>
<td></td>
<td>LWP06: PET SCANNING</td>
<td>PACIFIC H</td>
</tr>
<tr>
<td></td>
<td>LWP07: THYROID/PARATHYROID</td>
<td>PACIFIC I</td>
</tr>
<tr>
<td></td>
<td>LWP08: ULTRASOUND IN HEAD AND NECK CANCER STAGING</td>
<td>PACIFIC J</td>
</tr>
<tr>
<td>13:45 - 15:15</td>
<td>PANEL: FUNCTIONAL IMAGING</td>
<td>YERBA SALON 3-4</td>
</tr>
<tr>
<td></td>
<td>PANEL: HEAD AND NECK AROUND THE WORLD</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td></td>
<td>PANEL: HEAD AND NECK CANCER VIROLOGY</td>
<td>YERBA SALON 5-6</td>
</tr>
<tr>
<td></td>
<td>PANEL: SKULL BASE, IMAGING, IMAGE GUIDED AND ENDOSCOPIC APPROACHES</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: BEST OF OUTCOMES</td>
<td>YERBA SALON 1-2</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: NECK I/SENTINEL NODE</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: SALIVARY GLAND</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: OUTCOMES: PALLIATIVE/SUPPORTIVE CARE/REHABILITATION</td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: TRANSLATIONAL: BIOLOGICAL</td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td>15:45 - 17:15</td>
<td>PANEL: FIXING SHORTFALLS IN DATA COLLECTION: A WORLDWIDE, EVIDENCE-BASED APPROACH</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td></td>
<td>PANEL: GENOMICS/PROTEOMICS IN HEAD AND NECK CANCERS</td>
<td>YERBA SALON 5-6</td>
</tr>
<tr>
<td></td>
<td>PANEL: LOCALLY ADVANCED LARYNX CANCER</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td></td>
<td>PANEL: POST-TREATMENT IMAGING AND COMPLICATIONS</td>
<td>YERBA SALON 3-4</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: BASIC SCIENCE: EPIDEMIC, IMMUNE OR EXOGENOUS FACTORS</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: BEST OF BASIC SCIENCE</td>
<td>YERBA SALON 1-2</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: PARATHYROID/THYROID II</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: SKULL BASE I</td>
<td>YERBA SALON 15</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: RISK FACTORS/PREVENTION/SCREENING</td>
<td>YERBA SALON 14</td>
</tr>
<tr>
<td>17:30 - 1900</td>
<td>SUNDAY POSTER SESSION WITH WINE &amp; CHEESE</td>
<td>GOLDEN GATE HALL</td>
</tr>
<tr>
<td>19:00 - 21:00</td>
<td>INTERNATIONAL WELCOME RECEPTION</td>
<td>YERBA SALON 9</td>
</tr>
</tbody>
</table>
OPENING CEREMONIES AND INVOCATION
YERBA SALON 7-8

08:00 - 09:00

JOHN J. CONLEY LECTURE:
“A GLOBAL PICTURE OF THE TOBACCO EPIDEMIC”
YERBA SALON 7-8

09:00 - 09:45
Carolyn Dresler, MD, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Introduction by Gregory T. Wolf, MD

09:45 - 10:15
KEYNOTE ADDRESS:
“MOLECULAR AND PHYSIOLOGIC ISSUES: THE FUTURE IS NOW”
YERBA SALON 7-8

09:45 - 10:15
Patricia A. Hudgins, MD, Emory University, Atlanta, Georgia, USA
Introduction by Suresh Mukherji, MD

EXHIBIT HALL OPEN

10:00 - 16:00

10:45 - 12:15
SCIENTIFIC SESSIONS – Panels
YERBA SALON 8
LYMPHOSCINTIGRAPHY AND SENTINEL NODE BIOPSY OF THE HEAD AND NECK

Panel Moderator: Francisco J. Civantos, MD

Introduction and Overview
Francisco J. Civantos, MD

Sentinel Node Biopsy for Melanoma and Other Cutaneous Malignancy
Dennis H. Kraus, MD

Sentinel Node Biopsy for Squamous Cell Carcinoma of the Oral Cavity
Gary L. Ross, MD

Patient Selection and Preoperative Imaging
Chung-Hwan Baek, MD, PhD

Sentinel Node Biopsy for Carcinoma of the Upper Aerodigestive Tract Beyond the Oral Cavity
Jochen A. Werner, MD

Conclusions and Case Presentations
Francisco J. Civantos, MD

This panel will cover current concepts and discuss controversies related to the intraoperative detection and sampling of radiolabelled tissues. Special emphasis will be placed on state of the art and emerging technologies. We will address the use of these techniques for both cutaneous and mucosal lesions.

At the conclusion of this panel, participants will be able to:

- Identify appropriate preoperative imaging and accepted indications in melanoma.
- Understand different approaches to the intraparotid sentinel node.
- Identify borderline or controversial uses of the technique in melanoma.
- Understand the role of sentinel node biopsy for endoscopically accessible lesions of the hypopharynx or supraglottis.
- Understand the role of sentinel node biopsy for oral cancer, including results of the ACOSOG trial and European trial.
- Understand controversies regarding surgical techniques and the emerging technologies available.
- Understand the role of formal lymphadenectomy under radioguidance.
- Identify the pros and cons of applying this technology for mucosal lesions.
**IMAGING: STAGING**

Panel Moderator: Suresh Mukherji, MD  
PET in the Staging of Head and Neck Cancer  
Steven J. Feigenberg, MD

Imaging Parameters Relevant to Estimating the Response and Outcome After Radio-Chemotherapy  
Rainald Knecht, MD, PhD

Imaging Update of the AJCC Staging System  
Suresh Mukherji, MD

Current Concepts and Controversies of Ultrasound Evaluation of Cervical Lymph Node Metastases  
Anil T. Ahuja, MD

At the conclusion of the panel, the participants will be able to:

- Understand the latest developments of imaging advances in head and neck cancer.

**CANCER PREVENTION – BEHAVIOR**

Panel Moderator: Ellen R. Gritz, PhD

Treating Nicotine Dependence in the Oncologic Context  
Robert A. Schnoll, PhD

Preventing and Managing Acute Psychosocial Distress Arising from Body Image Disturbance  
Michelle C. Fingeret, PhD

The Interrelationship of Health Behaviors and Outcomes Among Head and Neck Cancer Patients  
Sonia A. Duffy, PhD

Public Awareness Programs Related to Head and Neck Cancer  
Terry A. Day, MD

This panel will address topics relating to the prevention and control of head and neck cancer, with an emphasis on behavioral risk factors and psychosocial oncology/quality of life.

At the conclusion of the panel, the participants will be able to:

- Understand the critical reasons for treating nicotine dependence among cancer patients, identify the correlation of continued tobacco use, and effective tobacco cessation treatments for this population.

- Understand the multidimensional nature of body image and its influence on psychosocial functioning in head and neck cancer patients, including associations between smoking behavior and body image, and recognize the benefits of providing psychosocial services targeting body image concerns.

- Understand the interrelationship of health behaviors that are detrimental to the quality of life, recurrence, and survival among head and neck cancer patients, identify the effects of health behaviors on selected biomarkers (IL-6 and HPV), and identify evidence-based strategies to treat the health behavior problems of head and neck cancer patients.

- Review ongoing international awareness events related to head and neck cancers, discuss the role of screening for oral cancer, and understand how to lead an awareness program in your community.

**PRACTICE GUIDELINES AND QUALITY OF CARE INDICATORS**

Panel Moderator: Henry T. Hoffman, MD

Guidelines for Chemoradiation for O.P. and Larynx: Analysis of Level of Evidence  
Arlene A. Forastiere, MD

Linking Pay for Performance and Quality Improvements in a Publicly Funded Health Care System  
Jonathan Irish, MD, FRCSC

Post-treatment Follow-up Strategy in Oral Cavity and Oropharynx Cancer  
Myung-Whun Sung, MD

Why Is There Controversy About Optimal Management?  
Randal S. Weber, MD

At the conclusion of this panel, participants will be able to:

- Access useful defining practice guidelines.

- Identify the value and shortcomings of practice guidelines.

- Identify the emerging concepts defining quality of care in a manner that focuses on relevance to clinical practice.
PROFFERED PAPERS

BASIC SCIENCE: GENE EXPRESSION

Moderators: Igor Reshetov, MD and Carter van Waes, MD, PhD

S001: GENETIC EXPRESSION ANALYSIS IN RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) Y. A. Chalian1, 2, J. L. Freeman1, 1Mount Sinai Hospital, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada

S002: DIFFERENTIAL EXPRESSION OF MICRORNA’S IN HEAD AND NECK SQUAMOUS CELL CARCINOMA STEM-CELLS B. Joshua1, L. E. Ailles1, Y. Shimono1, M. F. Clark1, M. Wang2, I. L. Weissman1, M. J. Kaplan1, 1Stanford University School of Medicine, Stanford, CA; 2National University of Singapore, Singapore, Singapore

S003: PRETREATMENT BCL-2 EXPRESSION PREDICTS CHEMORADIATION FAILURE IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA A. C. Nichols1, W. A. Michaud2, W. C. Faquin2, J. W. Rocco4, 1Massachusetts Eye and Ear Infirmary, Boston, MA; 2MGH Cancer Center, Boston, MA; 3MGH Dept. of Pathology, Boston, MA; 4Massachusetts Eye and Ear Infirmary, Boston, MA

S004: IMMUNOHISTOCHEMICAL MARKERS TO PREDICT OUTCOME IN CHEMORADIATION TREATMENT OF HEAD AND NECK CANCERS G. B. van den Brekel1, M. W. van den Brekel1, A. J. Balm1, A. C. Bega1, N. Armstrong1, C. R. Rasch1, E. Schuring2, J. van der Waal2, M. F. van Velthuysen1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands; 2University Medical Center Groningen, Groningen, The Netherlands

S005: CORRELATION OF P16 STATUS, EGFR AND CYCLIN D1 EXPRESSION WITH PATHOLOGIC NODAL STATUS IN HEAD AND NECK CANCER A. Agrawal1, K. Jatanad1, J. McLoughlin1, A. Roos1, D. E. Schuller1, J. C. Lang1, 1The Ohio State University, Columbus, OH

S006: DECREASED GAMMA-3-CATEXIN EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN T1 AND T2 TUMOURS IN ORAL SQUAMOUS CELL CARCINOMA M. H. Narkia Matkol1, M. Pukkila2, E. Lipponen2, V. Kosma4, 1Kuopio University Hospital and Kuopio University, Kuopio, Finland; 2Kuopio University Hospital and Kuopio University, Kuopio, Finland; 3Tampere University, Tampere, Finland; 4Kuopio University Hospital, Kuopio, Finland

S007: PREVALENCE OF MGMT METHYLATION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA AND IMPACT ON CLINICAL OUTCOMES Z. Abou Chacra1, E. Bisson1, L. Guertin1, X. Weng2, P. Nguyen-Tan3, J. Tabel1, L. Robin2, S. Giraud2, B. Fortin3, D. Soulziere3, 1Department of Head and Neck Surgery, Centre Hospitalier Universite Montreal, Montreal, PQ, Canada; 2Department of Radiation Oncology, CHUM, Montreal, PQ, Canada; 3Department of Radiation Oncology, CHUM, Montreal, PQ, Canada

S008: AKT ACTIVATION IN HNSCC PREDICTS RELAPSE IN PATIENTS WITH HPV-POSITIVE HEAD AND NECK CANCER Y. Xu1, B. Brown2, A. S. Whigham1, B. B. Burkey1, J. L. Netterville3, R. J. Sinar1, W. G. Yarbrough2, 1Vanderbilt University, Nashville, TN; 2Vanderbilt University, Nashville, TN; 3Vanderbilt University, Nashville, TN

S009: PROTEIN KINASE CK2 SUBUNITS DIFFERENTIALLY REGULATE TRANSCRIPTION FACTORS AND TARGET GENES IMPlicated IN HEAD AND NECK CANCER M. S. Brown1, O. Diao2, A. Pattathayil2, C. Allen1, Z. Chen2, C. Van Waes2, 1NIH-NIDCD and CRTP/Pfizer, Bethesda, MD; 2NIH-NIDCD, Bethesda, MD

CLINICAL: THYROID I

Tim Baker, MD and Ara A. Chalian, MD

S010: IMPACT OF 2002 AJCC GUIDELINES IN LYMPH NODE EVALUATION FOR WDTCS M. K. Steeves1, 1Mount Sinai Hospital, Toronto, ON, Canada

S011: PATTERNS OF CERVICAL LN METASTASIS IN PATIENTS WITH RECURRENT/PERSISTENT PAPILLARY THYROID CANCER UNDERGOING LATERAL NECK DISSECTION T. J. Farron1, R. P. Tsufano1, S. Mitchell1, 1Johns Hopkins School of Medicine, Baltimore, MD

S012: SURGICAL MANAGEMENT OF TRACHEAL INVASION BY WELL DIFFERENTIATED THYROID CANCERS K. Tae1, Y. Lee1, J. Jeong1, S. Cho1, C. Park1, 1Hanyang University Hospital, Seoul Republic of Korea

S013: THE NO-TIE TECHNIQUE USING THE HARMONIC SCALPEL IN TOTAL THYROIDECTOMY WITH CND: A PROSPECTIVE RANDOMIZED STUDY Y. Koh1, S. Lee1, E. Choi2, 1Soonchunhyang University College of Medicine, Bucheon, Republic of Korea; 2Yonsei University College of Medicine, Seoul, Republic of Korea

S014: MULICENTER PANDOMIZED TRIAL ON HARMONIC SCALPEL VS. CONVENTIONAL HEMOSTASIS IN TOTAL THYROIDECTOMY: PRELIMINARY RESULTS L. Carvalho1, A. Sanabria2, L. P. Kawalski3, on behalf of the BHNCSCG4 1Hospital de Cancer de Barretos, Barretos, Brazil; 2Universidad de La Sabana, Bogota, Colombia; 3Hospital ACCa-argo, Sao Paulo, Brazil; 4Brazilian Head and Neck Cancer Study Group, Brazil

S015: A COMPARISON OF OUTCOMES IN MINIMALLY INVASIVE AND VARIOUS INVASIVE THYROIDECTOMIES VS. OPEN THYROIDECTOMY A. S. Ketcham1, J. D. Herzig1, E. J. Huntsch1, F. S. Lee1, M. B. Gillespie1, K. G. Haeng1, J. D. Osguthorpe1, J. Fernandes1, M. S. Richardson1, T. A. Day1, 1Medical University of South Carolina, Charleston, SC

S016: MANAGEMENT OF RECURRENT LARYNGEAL NERVE INVASION BY LOCALLY INVASIVE WELL DIFFERENTIATED THYROID CANCER K. Tae1, Y. Lee1, Y. Lee1, R. Ryo1, K. Kim1, 1Hanyang University Hospital, Seoul, Republic of Korea

S017: RECURRENT LARYNGEAL NERVE PALS AFTER THYROIDECTOMY. A SYSTEMATIC REVIEW J. Leeman1, G. Bruch1, H. Abdalsalam2, R. Oakley1, A. Oribi1, R. Simo1, 1Guy’s Hospital, London, United Kingdom; 2Al Hazar University, Cairo, Egypt

S018: IDENTIFICATION AND PROTECTION OF THE EXTERNAL BRANCH OF THE SUPERIOR LARYNGEAL NERVE DURING THYROIDECTOMY N. A. Pagedar1, J. L. Freeman1, 1Mount Sinai Hospital, Toronto, ON, Canada

HUMAN PAPILLOMAVIRUS

Moderators: Jan Klozar, MD and Mark K. Wax, MD

S019: PREVALENCE, MORPHOLOGY AND PROGNOSIS OF HUMAN PAPILLOMAVIRUS IN TONSILLAR CANCER A. Lugrinbohl1, M. Sanders2, J. Spiro2, 1Thomas Jefferson University, Philadelphia, PA; 2University of Connecticut, Farmington, CT
S020: A COMPARATIVE ANALYSIS OF HUMAN PAPILLOMAVIRUS INFECTION IN TONSILLAR, GLOTTIC AND TONGUE CANCERS
S.Lee1, N.Cho2, E.Choi2, S.Kim2, 1College of Medicine, Chung-Ang University, Seoul, Republic of Korea; 2Yonsei University College of Medicine, Seoul, Republic of Korea

S021: CHRONIC PERIODONTITIS, SMOKING AND HUMAN PAPILLOMAVIRUS 16 INTERACTION IN BASE OF TONGUE CANCERS
M.Tezal1, M.A.Sullivan2, D.Stoler3, T.Melendez1, A.Hyland2, P.J.Smalldino2, N.Rigail2, T.Loree4, 1State University of New York at Buffalo, Buffalo, NY; 2Roswell Park Cancer Institute, Buffalo, NY

S022: PREVALENCE OF HPV 16 AND 18 GENOME IN PALATINE TONSILS OF THE GENERAL POPULATION

S023: HUMAN PAPILLOMAVIRUS AND TOBACCO USE IN BASE OF TONGUE CANCERS
P.J.Smalldino1, D.I.Stoler1, M.A.Sullivan1, N.R.Rigail1, S.R.Popal1, W.L.Hicks, Jr.1, M.Zerziana1, D.F.Gaile1, G.R.Anderson1, T.R.Loree1, 1Roswell Park Cancer Institute, Buffalo, NY

S024: EFFECT OF HPV ON TREATMENT OUTCOME AND SURVIVAL IN OROPHARYNGEAL CARCINOMA ANALYSIS OF THE RANDOMIZED DAHANCA 5&7 TRIALS
Fussen1, J.G.Eriksen1, T.Tramm2, J.Alsetn1, S.H.Duto12, J.Overgaard1, 1Dept. of Experimental Clinical Oncology, Aarhus, Denmark; 2Dept. of Pathology, Aarhus, Denmark

S025: POSSIBLE VIRAL ETIOLOGY FOR ORAL TONGUE CANCERS IN PATIENTS WITH NON DRINKING/SMOKE ETIOLOGY AND NO HPV SEQUENCES
X.Li2, A.O.Reilly3, G.Ulpo2, E.Moore3, J.Kasperbauer4, D.Kademani4, D.Smith5, 1OMS, West China College of Stomatology, Sichuan University, Chengdu, China; 2Division of Experimental Pathology, Mayo Clinic, Rochester, MN; 3Otolaryngology, Mayo Clinic, Rochester, MN; 4Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, MN

S026: ORAL CAVITY CANCER IN YOUNG PATIENTS: EVIDENCE OF AN ASSOCIATION WITH HPV16
M.E.Zafaro1, G.L2, C.A.Viamonte1, A.K.El-Naggar2, M.D.Williams2, C.Zhao2, Q.Wei2, E.M.Sturgis2, 1Baylor College of Medicine, Houston, TX; 2MD Anderson Cancer Center, Houston, TX

S027: RADIATION THERAPY INDUCES AN IMMUNOLOGIC CLEARANCE OF HPV POSITIVE HNSCC IN MICE
W.C.Spanos1, D.W.Lee2, M.E.Anderson1, A.Hoover1, J.H.Lee2, 1University of Iowa, Iowa City, IA; 2University of Iowa, Iowa City

OUTCOMES: QUALITY OF LIFE

Moderators: Douglass B. Chepeha, MD Jan Olhoffson, MD

S028: PRE-TREATMENT CLINICAL FACTORS PREDICT RESPONSE TO TREATMENT IN REGARDS TO POST-TREATMENT QUALITY OF LIFE
M.W.Davies1, E.J.Weymuller2, N.D.Futran2, J.McDowell2, B.Yueh2, 1University of South Florida, Tampa, FL; 2University of Washington, Seattle, WA; 3Puget Sound VA Research Group, Seattle, WA; 4University of Minnesota, Minneapolis, MN

S029: LONG-TERM ACCEPTANCE OF MAJOR SURGERY AND QUALITY OF LIFE OF ADVANCED HEAD AND NECK CANCER SURVIVORS
J.G.V.Harling1, L.P.Kowalski1, A.C. Camargo Hospital, Sao Paulo, Brazil

S030: MEASUREMENT PROPERTIES OF THE DISABILITIES OF THE ARM, SHOULDER AND HAND QUESTIONNAIRE IN HEAD AND NECK CANCER PATIENTS
D.P.Goldstein1, J.C.Irish1, D.Chepeha2, J.Ringash1, R.W.Gilbert1, D.H.Brown1, P.Gullane1, A.Davis3, 1Princess Margaret Hospital, Toronto, ON, Canada; 2University of Michigan, Ann Arbor, MI; 3Mayo Clinic, Rochester, MN; 4University of Western Ontario, London, ON, Canada

S031: SWALLOWING QUALITY OF LIFE IN ADVANCED LARYNX AND HYPOPHARYNX CANCER TREATED WITH ORGAN PRESERVATION VS. SURGERY
L.Zhang1, N.Read2, E.Wiingast2, K.Chu2, V.Venkatase2, J.Yoo3, J.Franklin2, H.Hammern2, K.Fung1, 1University of Western Ontario, London, ON, Canada; 2University of Minnesota, Minneapolis, MN; 3University of California, Los Angeles, CA

S032: LONG-TERM HEALTH-RELATED QUALITY OF LIFE
D.Funk1, L.H.Karnell1, A.J.Christensen1, 1University of Iowa, Iowa City

S033: SCREENING FOR DYSFUNCTION TO PROMOTE MDT INTERVENTION USING THE UNIVERSITY OF WASHINGTON QUALITY OF LIFE QUESTIONNAIRE
S.N.Rogers1, D.Lowe2, 1Evidence-based Practice Research Centre, Liverpool, United Kingdom; 2Regional Maxillofacial Unit, Liverpool, United Kingdom

S034: CONTINUED ALCOHOL USE IN PATIENTS WITH HEAD AND NECK CANCER
A.E.Buckwalter1, L.H.Karnell1, A.J.Christensen1, M.W.Vander Weg1, G.F.Funk2, 1University of Iowa, Iowa City, IA; 2University of Iowa, Iowa City

S035: RISK OF TREATMENT AT HIGHEST VOLUME FACILITIES RESULTS IN BETTER ODDS FOR SURVIVAL IN LARYNGEAL CANCER
A.Y.Chen1, A.Pavlick2, W.Flanders1, M.Talpans1, E.M.Ward2, 1Emory University, Atlanta, GA; 2American Cancer Society, Atlanta, GA

S036: DEVELOPMENT OF A PATIENTS CONCERNS INVENTORY (PCI): A WAY OF IMPROVING OUT-PATIENT CONSULTATION & PATIENT EMPOWERMENT
S.N.Rogers1, J.El-Sheikha2, D.Lowe2, 1Evidence-based Practice Research Centre, Liverpool, United Kingdom; 2Medical Student, Manchester, United Kingdom; 3Regional Maxillofacial Unit, Liverpool, United Kingdom

OUTCOMES: SURGERY

Moderators: Robert L. Ferris, MD, PhD and Mark K. Wax, MD

S037: THE ROLE OF AGGRESSIVE SALVAGE SURGERY IN TREATING PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
C.St.Williot1, T.A.Day1, J.D.Horning1, M.B.Gillespie1, E.J.Lentsch1, 1Medical University of South Carolina, Charleston, SC

S038: NOMOGRAM FOR DISEASE-SPECIFIC SURVIVAL IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
R.R.Lorenz1, M.W.Kattan1, D.J.Adelstein1, J.Saxton1, R.M.Eisclamado1, W.T.Lee1, J.Scharpf1, M.Strome1, 1Cleveland Clinic, Cleveland, OH; 2University of Colorado Colorado Health Sciences Center, Denver, CO

S039: COST-UTILITY ANALYSIS OF C02 LASER EXCISION VS. STANDARD FRACTIONATED EXTERNAL BEAM RADIATION (50 GY/4 WEEKS)
F.M.Hippings1, D.Enepike1, Sunkesrer Health Science Centre/Odette Cancer Centre, Toronto, ON, Canada; 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada

S040: QUALITY OF LIFE IN INDIAN PATIENTS UNDERGOING TOTAL LARYNGECTOMY WITH PRIMARY TRACHEO-ESOPHAGEAL PUNCTURE (TEP)
M.S.Deshpande1, D.A.Chaukar1, V.Rao1, A.Kakade1, P.S.Pat1, P.Chaturved1, A.K.D.Cruz1, 1Tata Memorial Hospital, Mumbai, India

S041: VALIDATION OF THE HISTOLOGICAL RISK ASSESSMENT MODEL IN HNSCC: AN INTERIM ANALYSIS
D.Broghail1, A.Thielken2, R.Smith2, N.Skeel2, A.Negassa2, B.Wang3, M.Delacure4, M.Prytowski5, M.Brandwein-Gensler1, 1Montefiore Medical Center, Bronx, NY; 2Johannes Gutenberg, Mainz Germany; 3Albert Einstein College of Medicine, Bronx, NY; 4New York University, New York, NY

S042: OUTCOME OF PATIENTS TREATED SURGICALLY FOR LYMPH NODE METASTASES FROM CUTANEOUS SQUAMOUS CELL CARCINOMA
B.Givi1, P.F.Andersen1, B.S.Diggs1, M.K.Wax1, N.D.Gross1, 1Oregon Health & Sciences University, Portland, OR
S043: POORER OUTCOMES FOR YOUNGER PATIENTS WITH ORAL CANCER
D. Goldenberg¹, C. Hollenbeak², ¹Penn State College of Medicine, Hershey, PA; ²Penn State College of Medicine, Hershey, PA

S044: FIVE YEAR OUTCOME DATA IN ORAL AND OROPHARYNGEAL CANCER - A COHORT OF 500 PATIENTS PRESENTING OVER A TWO YEAR PERIOD
C. Liew¹, J. McMahon¹, G. Robertson², G. Robertson³, J. McManners⁴, F. McKenzie⁵, S. Hislop⁵, A. Carton⁶, A. White⁷, J. Devine¹,
¹South Glasgow University Hospitals, Glasgow, United Kingdom; ²Beatson Oncology Centre, Glasgow, United Kingdom; ³University of Glasgow Medical School, Glasgow, United Kingdom; ⁴Forth Valley Hospitals, Stirling, United Kingdom; ⁵Crosshouse Hospital, Kilmarnock, United Kingdom; ⁶Monklands Hospital, Airdrie, United Kingdom; ⁷Royal Alexandra Hospital, Paisley, United Kingdom

S045: ELECTIVE NECK DISSECTION FOR STAGE II TONGUE CANCER
T. Asakage¹, S. Kishimoto², M. Saikawa³, ¹University of Tokyo, Tokyo, Japan; ²Tokyo Medical Dental University, Tokyo, Japan; ³National Cancer Center Hospital East, Chiba, Japan

12:15 - 13:45
LUNCH ON YOUR OWN/POSTER VIEWING/EXHIBIT VIEWING

12:30 - 13:30
LUNCH WITH THE PROFESSORS

Optional educational lunches are available during the Sunday lunch hour. Space is limited and courses are subject to an additional charge. All courses are available for CME credit.

LWP01 AHNS DATABASE
Marc D. Coltrera, MD and Sefik A. Hosal, MD
PACIFIC A

LWP02 CANCER PREVENTION AND PREMALIGNANCY
Terry A. Day, MD and Joel B. Epstein, DMD, MSD, FRCD
PACIFIC B

LWP03 CT/MRI FOR ASSESSING TREATMENT RESPONSE
Lawrence E. Ginsberg, MD and Christine M. Glastonbury, MBBS
PACIFIC C

LWP04 IMAGE GUIDED SURGERY
Michael J. Kaplan, MD and David J. Terris, MD
PACIFIC E

LWP05 IMAGING FOR SURVEILLANCE
Nancy J. Fischbein, MD and Jane L. Weissman, MD, FACR
PACIFIC F

LWP06 PET SCANNING
Homer A. Macapinlac, MD and Mark K. Wax, MD
PACIFIC H

LWP07 THYROID/PARATHYROID
Phil Pellitteri, MD and Khee-Chee Soo, MD
PACIFIC I

LWP08 ULTRASOUND IN HEAD AND NECK CANCER STAGING
Anil T. Ahuja, MD and Beth S. Edeiken-Monroe, MD
PACIFIC J

13:45 - 15:15
SCIENTIFIC SESSIONS – Panels

FUNCTIONAL IMAGING
Panel Moderator: Homer A. Macapinlac, MD
Initial Staging of Head and Neck Cancer
Richard J. Wong, MD
Evaluation of Response to Therapy
Yoshimi Anzai, MD
Radiotherapy Planning Including Novel PET Tracers
Homer A. Macapinlac, MD
Novel Molecular Therapies
Fadlo R. Khuri, MD
Non-PET Based Techniques for Functional Imaging
Nancy J. Fischbein, MD

At the conclusion of the panel, participants will be able to:

- Provide an overview of the clinical utility of FDG PET/CT imaging in the initial staging, and response evaluation in head and neck cancer.
- Review the utility of FDG PET/CT in radiotherapy planning and the use of novel PET tracers to evaluate functional image parameters like proliferation, hypoxia and angiogenesis.
- Provide an overview of the novel molecular therapies applied to head and neck cancer.
- Review the non-PET based techniques of functional imaging in head and neck cancer.
SKULL BASE, IMAGING, IMAGE GUIDED AND ENDOSCOPIC APPROACHES
Panel Moderator: Patrick J. Gullane, MD
Current Concepts in the Diagnosis and Management of Anterior Skull Base Neoplasm Giulio Cantu, MD
Skull Base Surgery: Open vs. Endoscopic - How Do We Decide? Piero Nicolai, MD
Anterior Skull Base Reconstruction After Oncological Resections: A Comprehensive Algorithm Dan M. Fliss, MD
Complications of Skull Base Surgery: How to Avoid Them? Franco DeMonte, MD

This panel will address topics relating to modern day concepts in the diagnosis and management of anterior skull base neoplasms, determine when an open vs. endoscopic approach can be utilized, provide an overview of anterior skull base reconstruction after oncologic resections, and finally discuss complications of skull base surgery with an emphasis on how to avoid them.

At the conclusion of the panel, the participants will be able to:
• Understand the current concepts in the diagnosis and management of skull base neoplasms.
• Determine when an open or an endoscopic approach is employed.
• Appreciate the techniques of skull base reconstruction after endoscopic and/or open oncologic resections.
• Recognize the complications of skull base surgery and understand the techniques employed to minimize and/or avoid them.

HEAD AND NECK AROUND THE WORLD
Panel Moderator: Johannes J. Fagan, MD
Advanced Laryngeal Cancer and the Minimum Infratstructural/ Staffing Requirements to Provide ChemorT June Corry, MD
Near-total Laryngectomy: Indications, Advantages, Limitations, Outcomes and Applicability to Developing World Practice Anil K. D’Cruz, MD
Management of Non-melanoma Cutaneous Malignancy of the Head and Neck Luiz R. Medina Dos Santos, MD
Reconstructive Options Used After Head and Neck Oncologic Resections Alexander D. Rapidis, MD, DDS, PhD

At the conclusion of the panel, the participants will be able to:
• Understand both the strengths and differences in the management of head and neck malignancies around the world.
• Understand the minimum infrastructural staffing requirements to provide chemorT and whether it is a realistic option for developing world practice.
• Understand the place of pedicled flaps in modern day practice.
• Understand indications for bony vs. soft tissue reconstruction of mandibulectomy defects.

HEAD AND NECK CANCER VIROLOGY
Panel Moderator: Maura L. Gillison, MD, PhD
HPV as a Risk Factor for Head and Neck Cancer Ruth Tachezy, PhD
Epidemiology of HPV and Oropharyngeal Cancer Erich M. Sturgis, MD
EBV and NPC: Diagnostic and Therapeutic Opportunities Anthony T.C. Chan, MD
The Impact of Tumor HPV Status on Clinical Trial Design and Interpretation Maura L. Gillison, MD, PhD

At the conclusion of this panel, participants will be able to:
• Understand the role of EBV monitoring in nasopharynx cancers.
• Review data on the epidemiology of HPV in HNSCC from two institutions, one in the U.S. and one in the Czech Republic.

PROFFERED PAPERS
BEST OF OUTCOMES

Moderators: Robert L. Ferris, MD, PhD and Ian J. Witterick, MD
5846: DAHANCA 10 - A RANDOMIZED STUDY OF ARA-24 AS MODIFIER OF RADIOThERAPY IN PATIENTS WITH PRIMARY HNSCC J.Overgaard1, C.M.Hoff2, L.Species3, H.S.Hansen3, M.Overgaard4, C.Grau4, E.Andersen5, J.Johansen5, L.J.Andersen7, J.F.Evensen8, 1Aarhus University Hospital, Aarhus C, Denmark; 2Dept. Exp. Clin. Oncology, Aarhus University Hospital, Aarhus, Denmark; 3Dept. of Oncology, Finsen Centre, Rigshospitalet, Copenhagen, Denmark; 4Dept. of Oncology, Aarhus University Hospital, Aarhus Denmark; 5Dept. of Oncology, Herlev Hospital, Denmark, Herlev, Denmark; 6Dept. of Oncology, Odense University Hospital, Odense Denmark; 7Dept. of Oncology, Aalborg Hospital, Aalborg, Denmark; 8Norwegian Radium Hospital, Oslo, Norway
S047: PHASE II STUDY OF BEVACIZUMAB WITH DOCTETAXEL AND RADIATION IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CANCER
P.Savidas1, J.Greskovicius2, J.Bokari1, C.Kynigos1, W.P.J.M. van Heeckeren1, D.W.S.H. Steepe1, M.I.M. Schuit1, J.W.S. Wasman1, R. Rezaee1, P.Lavertu1, 1Case Comprehensive Cancer Center, Cleveland, OH; 2Medical College of Georgia, Augusta, GA

S048: PHASE I STUDY OF ERLOTINIB WITH DOCTETAXEL AND RADIATION IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CANCER (SCCNH)
P.Savidas1, A.Argiris2, J.Greskovicius3, J.Bokari1, S.Agarralva2, R.Rezaee5, M.Schuit1, J.Wasman3, S.Remick6, P.Lavertu1, 1Case Comprehensive Cancer Center, Cleveland, OH; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Medical College of Georgia, Augusta, GA; 4St Luke’s Hospital and Health Network, Bethlehem, PA; 5Case Comprehensive Cancer Center, Cleveland, OH; 6Mary Babb Randolph Cancer Center, Morgantown, WV

S049: TUMOR VOLUME AS OUTCOME PREDICTOR IN CHEMORADIATION FOR ADVANCED HEAD AND NECK CANCER
J.Knegjens1, F.Pameijer1, A.Balm1, M.Hauptmann1, F.Hoebers1, C.Rao1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands

S050: DOES POST-TREATMENT SURVEILLANCE IMPROVE SURVIVAL IN HEAD & NECK CANCER PATIENTS?
D.O.Francis1, E.A.Weymuller1, T.Vaughan1, B.Yueh2, 1University of Washington, Seattle, WA; 2University of Minnesota, Minneapolis, MN

S051: TUMOR-SPECIFIC ABERRANT METHYLATION IN MATCHED SERUM SAMPLES AS A MARKER FOR TUMOR DIAGNOSIS AND PROGNOSIS IN HNSCC
R.Sawhney1, K.Chen1, M.J.Warsham1, 1Henry Ford Health System, Detroit, MI

S052: QUANTITATIVE METHYLATION ANALYSIS OF RESECTION MARGINS PREDICTS LOCAL RECURRENTITY AND DISEASE SPECIFIC DEATH IN PATIENTS
T.Tan1, L.Lacroix2, S.Temam2, F.Janq1, A.Auperin2, P.Paulin2, F.Fourel2, 1National Cancer Center Singapore; Insecte Gustave Roussy, Bourg-la-Reine, France; 4Institut Gustave Roussy, Villejuif, France

S053: NONINVASIVE DETECTION OF HPV AND ASSOCIATED GENETIC ALTERATIONS IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS
S.Seth1, D.Baza1, M.Wierman1, A.Kapke1, M.Lu1, M.Benninger1, M.J.Warsham1, 1Henry Ford Health Systems, Detroit, MI

S054: HPV-16 INFLUENCE ON OROPHARYNGEAL CANCER AT A LARGE MULTIDISCIPLINARY CENTER: IMPROVED SURVIVAL ONLY FOR NEVER SMOKERS
D.F.Hancock1, G.Li2, C.A.Viamonte3, A.K.El-Naggar2, C.Zhao2, S.Aleem1, G.Wei1, E.M.Sturgis1, 1Louisiana State University Health Sciences Center, New Orleans, LA; 2The University of Texas M.D. Anderson Cancer Center, Houston, TX; 3Baylor College of Medicine Department of Radiology, Houston, TX

CLINICAL: NECK I/SENTINEL NODE
Moderators: Thom R. Loree, MD and Peter Rhys-Evans, MD

S055: RELATIVE Efficacy of Histopathology, IHC and RT-PCR for the Detection of Occult Metastasis in Sentinel Lymph Nodes
N.P.Trivedi1, V.Kekatpure1, A.Suresh1, K.R.Hiran1, S.Sundaram1, T.Jacobi1, S.Iyer1, M.Kuriakose1, 1Amrita Institute of Medical Sciences, Cochin, Kerala, India

S056: THE IMPORTANCE OF IMMUNOCHEMISTRY IN SENTINEL LYMPH NODE ANALYSIS IN HEAD AND NECK CANCER
C.T.Chone1, M.B.Anitel1, R.S.Magalhaes1, A.Alleman1, A.N.Crespo1, 1State University of Campinas, Campinas, Brazil

S057: SENTINEL NODE BIOPSY IN ORAL/OROPHARYNGEAL SQUAMOUS CELL CANCER: FIVE YEAR FOLLOW-UP
J.W.Talks1, G.L.Ross2, T.Shoaib1, J.A.Sorensen3, J.Alvarez4, T.Poli5, A.F.Kovacs6, F.Alberti7, D.S.Soutar1, 1Canniesburn Department of Plastic Surgery, Glasgow United Kingdom; 2Christie Hospital, Manchester, United Kingdom; 3Odense University Hospital, Odense, Denmark; 4Hospital de Cruces, Cruces, Spain; 5University Hospital of Parma, Parma, Italy; 6Johann Wolfgang Goethe University Medical School, Frankfurt, Germany; 7Azienda Ospedaliera OICS, Maria degli Angeli 01D, Pordenone, Italy

S058: SENTINEL NODE BIOPSY FOR STAGING OF ORAL CANCER - AN ANALYSIS OF CLINICOPATHOLOGICAL FACTORS
T.Loree1, M.S.Burke1, S.R.Popat1, M.Merzianu1, W.L.Hicks Jr1, N.R.Rigail1, 1Roswell Park Cancer Institute, Buffalo, NY

S059: HOW MANY NODES ARE NEEDED TO STAGE A NECK? A CRITICAL APPRAISAL
H.F.Kohler1, I.W.Cunha2, F.A.Saore2, L.P.Kowalski1, 1State University of Campinas, Sao Roque, Brazil; 2Hospital A C Camargo, Sao Paulo, Brazil

S060: EXTENT OF NECK DISSECTION REQUIRED AFTER CONCURRENT CHEMORADIATION FOR STAGE IV HEAD AND NECK SQUAMOUS CELL CARCINOMA
S.B.Cannady1, W.Lee1, J.Scharpi1, R.R.Lorenz1, B.G.Wood1, M.Strome1, P.Lavertu1, R.M.Esclamado1, J.F.Paxton1, D.J.Adelstein1, 1Cleveland Clinic, Cleveland, OH; 2University Hospitals, Cleveland, OH; 3Duke University Medical Center, Durham, NC

S061: INCIDENCE OF REGIONAL RECURRENCES AFTER (CHEMO)RADIOTHERAPY FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA
S.Niyogi1, P.Dirix1, M.Lambrecht1, W.Van den Bogaert1, 1University Hospitals Leuven, Leuven, Belgium

S062: SELECTIVE VersUS Comprehensive Neck Dissection after Chemoradiation for Advanced Head and Neck Squamous Cell Carcinoma
A.T.Khalil1, C.Fakhry1, M.F.Williams1, R.G.F.Blanco1, J.R.Saunders2, P.K.Ha2, 1The Johns Hopkins University School of Medicine, Baltimore, MD; 2Greater Baltimore Medical Center, Baltimore, MD

S063: PLANNED NECK DISSECTION AFTER CHEMORADIOThERAPy IN LOCALLY ADVANCED HEAD AND NECK CANCER: ROLE OF NECK US, MRI AND PET
N.P.Trivedi1, V.Kekatpure1, A.Suresh1, K.R.Hiran1, S.Sundaram1, T.Jacobi1, S.Iyer1, M.Kuriakose1, 1Amrita Institute of Medical Sciences, Cochin, Kerala, India

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM ETHICON ENDO-SURGERY, INC.

CLINICAL: SALIVARY GLAND
Moderators: Pierre Laveru, MD and Khee-Chee Soo, MD

S064: RETROSPECTIVE STUDY ON SALIVARY GLAND CARCINOMA: PROGNOSTIC VARIABLES AND ROLE OF ADJUVANT RADIATION THERAPY
G.Bruch Andrews1, E.Barker1, D.H.Brown1, G.Goldstein1, R.W.Gilbert1, T.P.Lavertu2, J.C.Irish1, 1Princess Margaret Hospital, Toronto, ON, Canada

S065: PAROTIDECTOMY: 17 YEAR INSTITUTIONAL EXPERIENCE
P.T.Mahgoub1, J.A.Paydarfar1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH

S066: PROGNOSTIC FACTORS IN MINOR SALIVARY GLAND CANCER OF THE ORAL CAVITY AND OROPHARYNX
P.Carrillo1, J.Gomez-Pizano1, L.F.Onate-Ocana1, 1Instituto Nacional de Cancerologia, Mexico City, Mexico

S067: PROGNOSTIC ROLE OF EPIDERMAL GROWTH FACTOR RECEPTORS 1 & 2, ANDROGEN RECEPTOR AND KIT IN 111 SALIVARY GLAND CANCER
L.D.Locati1, P.Bossi1, S.Io Volto1, M.Losa1, F.Perrone1, L.Mariani1, S.Pilotti1, L.Cicuta1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

S068: EXPRESSION OF EPIDERMAL GROWTH FACTOR FAMILY OF RECEPTORS BY COMPARATIVE METHODS IN SALIVARY DUCT CARCINOMAS
M.D.Williams1, M.S.Kies1, R.S.Webber1, A.K.El-Naggar1, 1M.D. Anderson Cancer Center, Houston, TX
OUTCOMES: PALLIATIVE/SUPPORTIVE CARE/REHABILITATION

YERBA SALON 14

Moderators: Neal D. Futran, MD and Theo R. Gregor, MD

S073: TUBE FEEDING IN HEAD AND NECK CANCER PATIENTS RECEIVING CONCOMITANT CHEMORADIOThERAPY

L.T.Chang1, L.Chen1, E.Y.Chen1, K.Fan2, S.Huang1, C.Liu1, W.J.Chen1, H.Wang1, 1Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; 2Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China

S074: DOES NECK DISSECTION AFTER CHEMORADIOThERAPY AFFECT SWALLOWING FUNCTION?

A.G.Sacco1, D.B.Chepepa1, T.Lyden1, M.Haxer1, F.Feng1, S.Schechtman1, F.P.Worden1, D.Normolle1, A.Eisbruch1, 1Cancer Team 1, 1University of Michigan, Ann Arbor, MI

S075: PROSPECTIVE FUNCTIONAL STUDY IN PATIENTS WITH HEAD AND NECK CANCER AFTER TREATMENT WITH CHEMOTHERAPY AND RADIOThERAPY

G.Broztlman1, L.California1, P.F.Giglio1, M.Perez Rentfiges1, P.Sacco1, R.Adam1, A.Gonzalez1, A.Urrutia1, A.Voogt1, R.Pradler1, 1Instituto Angel H. Roffo, Buenos Aires, Argentina

S076: SWALLOWING FUNCTION FOLLOWING CHEMORADIOThERAPY OR CHEMORADIOThERAPY FOR ADVANCED STAGE HEAD AND NECK CANCER

B.Londergan1, J.D.Spirio1, R.Dowsett1, U.Hegde1, 1University of Connecticut Health Center, Farmington, CT

S077: NUTRITION & DIETIC LED GASTROSTOMY PATHWAY OF CARE FOR INSERTION & REMOVAL CONTRIBUTES TO OUTCOMES

T.Belbin1, N.Schlecht1, M.Brandwein-Gensler2, R.V.Smith2, R.Angeletti1, M.B.Prystowsky1, 1Albert Einstein College of Medicine, Bronx, NY; 2Montefiore Medical Center, Bronx, NY

S078: PARENTERAL VS ENTERAL NUTRITION AFTER MAJOR NECK SURGERIES: IS THERE A DIFFERENCE IN OUTCOMES OR COMPLICATIONS?

M.M.Abu-Samra1, N.El-Bahannawy1, N.M.Rizk1, S.Kalmar1, R.Hewitt2, L.Maher3, A.H.Annemieke1, F.J.Hilgers1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands

S079: THE IMPACT OF PHARYNGOESOPHAGEAL STRICTURES IN THE HEAD AND NECK CANCER PATIENT

B.P.Ronen1, J.P.Malone1, P.Kay2, C.P.Bivens1, L.P.Paruchuri2, Y.Mo1, T.K.Robbins1, S.Ran1, 1SimmonsCooper Cancer Institute, 1University of Texas Southwestern Medical Center, Dallas, TX; 2University of Nebraska Medical Center, Omaha, NE; 3University of Iowa Hospitals & Clinics, Iowa City, IA

S080: LONG-TERM RESULTS OF PROVOK ACTIVALE FOR EARLY LEAKAGE IN LARYNGECTOMY PATIENTS

J.Soolsma1, M.W.van den Brekel1, A.H.Annemieke1, F.J.Hilgers1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands

S081: IS ELECTROGLOTTOGRAPHY-BASED VIDEOSTROBOSCOPIC ASSESSMENT OF POST-LARYNGECTOMY PROSTHETIC SPEECH USEFUL?

R.Kazzi1, A.Singh2, V.Prasad2, C.Johnson2, R.Venkitaraman2, P.Clarke2, C.Nutting2, P.Rhys-Evans2, K.Harrington3, 1Royal Marsden NHS & Institute of Cancer Research, London, UK; 2Head & Neck Cancer Centre, University College Hospital, London, United Kingdom; 3Royal Marsden NHS & Institute of Cancer Research, London, United Kingdom

S082: INTRATUMORAL LYMPHANGIOGENESIS CORRELATES WITH REGIONAL METASTASIS IN THE TONGUE CANCER

B.P.Geen1, B.J.Korey1, L.M.Kline1, 1University of Michigan, Ann Arbor, MI

S083: GENOMIC PROFILE OF METASTASIS IN SQUAMOUS CARCINOMA OF THE ORAL TONGUE

M.M.Abu-Samra1, N.El-Bahannawy1, N.M.Rizk1, S.Kalmar1, R.Hewitt2, L.Maher3, A.H.Annemieke1, F.J.Hilgers1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands

S084: SWALLOWING FUNCTION FOLLOWING CHEMORADIOThERAPY OR CHEMORADIOThERAPY FOR ADVANCED STAGE HEAD AND NECK CANCER

B.Londergan1, J.D.Spirio1, R.Dowsett1, U.Hegde1, 1University of Connecticut Health Center, Farmington, CT

S085: THE IMPACT OF PHARYNGOESOPHAGEAL STRICTURES IN THE HEAD AND NECK CANCER PATIENT

B.P.Ronen1, J.P.Malone1, P.Kay2, C.P.Bivens1, L.P.Paruchuri2, Y.Mo1, T.K.Robbins1, S.Ran1, 1SimmonsCooper Cancer Institute, 1University of Texas Southwestern Medical Center, Dallas, TX; 2University of Nebraska Medical Center, Omaha, NE; 3University of Iowa Hospitals & Clinics, Iowa City, IA

S086: PROSPECTIVE FUNCTIONAL STUDY IN PATIENTS WITH HEAD AND NECK CANCER AFTER TREATMENT WITH CHEMOTHERAPY AND RADIOThERAPY

G.Broztlman1, L.California1, P.F.Giglio1, M.Perez Rentfiges1, P.Sacco1, R.Adam1, A.Gonzalez1, A.Urrutia1, A.Voogt1, R.Pradler1, 1Instituto Angel H. Roffo, Buenos Aires, Argentina

S087: PROSPECTIVE FUNCTIONAL STUDY IN PATIENTS WITH HEAD AND NECK CANCER AFTER TREATMENT WITH CHEMOTHERAPY AND RADIOThERAPY

G.Broztlman1, L.California1, P.F.Giglio1, M.Perez Rentfiges1, P.Sacco1, R.Adam1, A.Gonzalez1, A.Urrutia1, A.Voogt1, R.Pradler1, 1Instituto Angel H. Roffo, Buenos Aires, Argentina

S088: UBC9 EXPRESSION BY HEAD AND NECK SQUAMOUS CELL CARCINOMAS: CORRELATION WITH CLINICAL PARAMETERS AND OUTCOMES

J.A.Califano1, 1Johns Hopkins Medical Institutions, Baltimore, MD

S089: SWALLOWING FUNCTION FOLLOWING CHEMORADIOThERAPY OR CHEMORADIOThERAPY FOR ADVANCED STAGE HEAD AND NECK CANCER

B.Londergan1, J.D.Spirio1, R.Dowsett1, U.Hegde1, 1University of Connecticut Health Center, Farmington, CT

S081: ISO ELECTROGLOTTOGRAPHY-BASED VIDEOSTROBOSCOPIC ASSESSMENT OF POST-LARYNGECTOMY PROSTHETIC SPEECH USEFUL?

R.Kazzi1, A.Singh2, V.Prasad2, C.Johnson2, R.Venkitaraman2, P.Clarke2, C.Nutting2, P.Rhys-Evans2, K.Harrington3, 1Royal Marsden NHS & Institute of Cancer Research, London, UK; 2Head & Neck Cancer Centre, University College Hospital, London, United Kingdom; 3Royal Marsden NHS & Institute of Cancer Research, London, United Kingdom

S082: INTRATUMORAL LYMPHANGIOGENESIS CORRELATES WITH REGIONAL METASTASIS IN THE TONGUE CANCER

B.P.Geen1, B.J.Korey1, L.M.Kline1, 1University of Michigan, Ann Arbor, MI

S083: GENOMIC PROFILE OF METASTASIS IN SQUAMOUS CARCINOMA OF THE ORAL TONGUE

M.M.Abu-Samra1, N.El-Bahannawy1, N.M.Rizk1, S.Kalmar1, R.Hewitt2, L.Maher3, A.H.Annemieke1, F.J.Hilgers1, 1Netherlands Cancer Institute, Amsterdam, The Netherlands

S084: SWALLOWING FUNCTION FOLLOWING CHEMORADIOThERAPY OR CHEMORADIOThERAPY FOR ADVANCED STAGE HEAD AND NECK CANCER

B.Londergan1, J.D.Spirio1, R.Dowsett1, U.Hegde1, 1University of Connecticut Health Center, Farmington, CT

S085: THE IMPACT OF PHARYNGOESOPHAGEAL STRICTURES IN THE HEAD AND NECK CANCER PATIENT

B.P.Ronen1, J.P.Malone1, P.Kay2, C.P.Bivens1, L.P.Paruchuri2, Y.Mo1, T.K.Robbins1, S.Ran1, 1SimmonsCooper Cancer Institute, 1University of Texas Southwestern Medical Center, Dallas, TX; 2University of Nebraska Medical Center, Omaha, NE; 3University of Iowa Hospitals & Clinics, Iowa City, IA

S086: SYSTEMIC ANALYSIS OF HNSCC ARRAYS IN PREDICTING TUMOR BEHAVIOR

A.Adamakos1, T.Bellini1, N.Schlecht1, M.Brandwein-Gensler2, R.V.Smith2, R.Angeletti1, M.B.Prystowsky1, 1Albert Einstein College of Medicine, Bronx, NY; 2Montefiore Medical Center, Bronx, NY

S087: PROFILING OF MIRNA EXPRESSION PATTERNS IN HNSCC REVEALS TUMOR SPECIFIC SIGNATURES

O.Chu1, G.Kung1, B.P.Geen1, J.A.Califano1, 1Johns Hopkins Medical Institutions, Baltimore, MD

S088: UBC9 EXPRESSION BY HEAD AND NECK SQUAMOUS CELL CARCINOMAS: CORRELATION WITH CLINICAL PARAMETERS AND OUTCOMES

J.A.Califano1, 1Johns Hopkins Medical Institutions, Baltimore, MD

S089: PRE-CLINICAL DEVELOPMENT OF A NOVEL CANCER CELL HOMING, PKCEPSILON INHIBITORY PEPTIDE FOR HEAD AND NECK CANCER

M.A.Gorin1, S.D.Merajver1, T.N.Teknos1, Q.Pan1, 1University of Michigan Medical School, Ann Arbor, MI

S090: EIF2C2, A RNA-INDUCED SILENCING COMPLEX (RISC) PROTEIN, IS OVER-EXPRESSED AND AMPLIFIED IN HNSCC

D.S.Chang1, J.A.Califano1, 1Johns Hopkins Medical Institutions, Baltimore, MD

S091: ISO ELECTROGLOTTOGRAPHY-BASED VIDEOSTROBOSCOPIC ASSESSMENT OF POST-LARYNGECTOMY PROSTHETIC SPEECH USEFUL?

R.Kazzi1, A.Singh2, V.Prasad2, C.Johnson2, R.Venkitaraman2, P.Clarke2, C.Nutting2, P.Rhys-Evans2, K.Harrington3, 1Royal Marsden NHS & Institute of Cancer Research, London, UK; 2Head & Neck Cancer Centre, University College Hospital, London, United Kingdom; 3Royal Marsden NHS & Institute of Cancer Research, London, United Kingdom
SCIENTIFIC SESSIONS – Panels

**LOCALLY ADVANCED LARYNX CANCER**

Panel Moderator: Christine M. Glastonbury, MBBS
Role of Radiotherapy in Locally Advanced Larynx Cancer
William M. Mendenhall, MD
IMRT for Larynx Cancer
Steven J. Feigenberg, MD
Chemotherapy for Laryngeal Cancer: Consensus and Controversy
Fadlo R. Khuri, MD
Laser Photoangiolyis of Glottic Cancer: Oncologic and Functional Outcomes
Steven M. Zeitels, MD

At the conclusion of this panel, participants will be able to:

- Understand the role of IMRT for locally advanced laryngeal carcinoma.
- Understand the principles underlying laser photoangiolyis of glottic cancer and the results of implementation.
- Review the selection criteria, treatment, and outcomes after definitive radiotherapy alone or combined with chemotherapy for advanced laryngeal squamous cell carcinoma.
- Understand the data behind the integration of induction chemotherapy into the multi-modality care of patients with laryngeal cancer.

**POST-TREATMENT IMAGING AND COMPLICATIONS**

Panel Moderator: Lawrence E. Ginsberg, MD
Pitfalls in PET/CT of the Post-treatment Head and Neck Cancer Patient
Laurie A. Loevner, MD
Imaging the Post-treatment Head and Neck Patient
Lawrence E. Ginsberg, MD
Imaging of Post-treatment Complications in the Head and Neck
Lawrence E. Ginsberg, MD
Discussion: Difficulties and Challenges in Diagnosing and Managing the Many Post-treatment Complications that Can Afflict the Head and Neck Cancer Patient, with an Emphasis on Imaging and Its Impact on Clinical Management
Fernando L. Dias, MD and Ashok R. Shaha, MD

At the conclusion of the panel, participants will be able to:

- Recognize infections and other post-operative complications pertaining to fistulas in their various forms, and their characteristic imaging appearances.
- Understand post-treatment complications pertaining to radiotherapy, including their detection and differentiation from tumor recurrence by imaging, and their clinical management.
- Appreciate the unique challenges facing the head and neck physician when multiple, serious, and life-threatening complications occur in the post-operative setting.

**FIXING SHORTFALLS IN DATA COLLECTION: A WORLDWIDE, EVIDENCE-BASED APPROACH**

Panel Moderator: Bevan Yueh, MD
Measuring and Assessing Quality of Care
Amy Chen, MD
Evaluation of Quality of Life and Function in Routine Practice
Simon N. Rogers, BDS, MBChB
Common Data Collection in Multi-Institutional Studies
Gerry F. Funk, MD
Creation of the International Classification of Function (ICF) in Head and Neck Cancer
Uta Tschiesner, MD
The Use of ICF in Interpreting Treatment Outcomes
Bevan Yueh, MD

This panel will address limitations in our understanding of head and neck outcomes due to non-systematic data collection strategies. It will discuss the rationale for the adoption of a common dataset and highlight recent work by the World Health Organization (WHO) to develop an International Classification of Function (ICF), analogous to the WHO’s widely accepted International Classification of Disease (ICD) system.
At the conclusion of the panel, the participants will be able to:

- Understand the role of systematic data collection in emerging approaches to assessing the quality of head and neck cancer care.
- Understand considerations for routine collection of functional data in the typical clinical practice.
- Appreciate potential flaws in the data collection approaches used in multi-institutional and intergroup studies.
- Understand the background and rationale for the WHO’s creation of an ICF classification system for head and neck cancer.
- Appreciate how the ICF can be used to interpret the clinical impact of increasingly aggressive treatment regimens.

GENOMICS/PROTEOMICS IN HEAD & NECK CANCERS
Panel Moderator: Wendell G. Yarbrough, MD

Proteomic Profiling of Head and Neck Cancer to Predict Response to Chemotherapy  
Lauren A. Byers, MD

Utilization of Protein Arrays for Head and Neck Cancer Analyses  
Jennifer R. Grandis, MD

Expression Array Analyses to Predict Head and Neck Cancer Behavior  
Wendell G. Yarbrough, MD

Classification of Head and Neck Cancer by Genetic Analyses  
Ruud H. Brakenhoff, MD

This panel will discuss the impact that emerging genomic and proteomic techniques and data will have in determining head and neck cancer behavior and developing optimal therapy.

At the conclusion of the panel, the participants will be able to:

- Understand advantages and disadvantages of global screening strategies using genomics/proteomics to classify head and neck cancers.
- Understand the clinical and research utility and limitations of genomic and proteomic techniques for head and neck cancer.

PROFFERED PAPERS

BASIC SCIENCE: EPIGENETIC, IMMUNE OR EXOGENOUS FACTORS

Moderators: Stephen Y. Lai, MD and Bhuvanesh Singh, MD, PhD

S091: INFLAMMATION-MEDDIATED PROMOTION OF EMT IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: IL-1B DOWN REGULATES E-CADHERIN  
M.St. John 1, M.Dohadwala 1, J.Luo 1, G.Lee 1, S.Dubinett 1, 1University of California, Los Angeles, Los Angeles, CA

S092: INTERLEUKIN 8 IS REGULATED BY TRANSCRIPTION FACTOR ATF2 IN HNSCC  
R.Green 1, S.Dolgilevich 1, D.C.Duffey 2 1Mount Sinai School of Medicine, New York, NY; 2Yale University School of Medicine, New Haven, CT

S093: TH1/TH2 CD4+ T HELPER RESPONSES AGAINST WILD-TYPE SEQUENCE PS3 PEPTIDES IN HLA-DP5 PATIENTS WITH HEAD AND NECK CANCER  
K.Chikamatsu 1, K.Sakakura 2, A.Okamoto 1, T.L.Whiteside 2, A.B.DeLeo 2, K.Masuyama 1, 1University of Yamanashi, Chuo Japan; 2University of Pittsburgh Cancer Institute, Pittsburgh, PA

S094: LIGANDS ON HEAD AND NECK SQUAMOUS CELL CARCINOMA MEDIATE LOW SHEAR-RESISTANT BINDING TO LYMPHOCYTES VIA L-SELECTIN  
T.A.Goldstein 1, V.A.Rees 1, 1University of Texas Medical Branch, Galveston, TX

S095: EPIGENETIC EFFECT OF GOSSYPOL IN THE IN VITRO SUPPRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMA CELLS (HNSCC) C.Xue 1, Y.Wu 1, M.S.Kokoska 1, P.Spring 1, R.Lee 2, Y.C.Un 1, J.Y.Sue 3, C.Fan 1, 1Univ Arkansas for Med Sciences and VA Med Ctr, Little Rock, AR; 2The Ohio State University, Columbus, OH; 3Univ Arkansas for Med Sciences, Little Rock, AR

S096: ANTIGEN SPECIFIC IMMUNE CLEARANCE OF HPV+ HNSCC REQUIRES CD4+ AND CD8+ CELLS  
R.L. Williams 1, M.E.Anderson 2, D.W. Lee 2, J.H.Lee 3, 1University of Iowa, Iowa City, IA; 2University of Iowa, Iowa City, IA

S097: TRIGGERING OF TLR4 OR TLR9 ON HUMAN HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCC) INDUCES DISTINCT BIOLOGICAL EFFECTS  
M.J.Szczepanski 1, M.Szajnik 1, M.Czytowska 1, M.Harasymczuk 2, W.Szyfter 2, T.L.Whiteside 1, 1University of Pittsburgh Cancer Institute, Pittsburgh, PA; 2University of Medical Sciences, Poznan Poland

S098: CONSISTENT ABERRANT DNA METHYLATION EVENTS IN LARYNGEAL PAPILLOMAS IMPLICATE AN EPIGENETIC CONTINUUM TO MALIGNANCY  
J.K.Stephen 1, J.K.Chen 1, L.Vaught 1, Y.Shah 1, V.G.Schweitzer 1, G.Gardner 1, M.S.Benninger 1, M.J.Worsham 1, 1Henry Ford Hospital, Detroit, MI

S099: PROMOTER HYPERMETHYLATION AND HYPMETHYLATION AND ORAL SQUAMOUS CELL CARCINOMA J.Houck 1, P.Garavagliescu 1, D.R.Doody 1, N.Futran 1, E.Mendez 2, B.Yueh 1, M.Upton 2, S.M.Schwartz 1, C.Chen 1, 1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of Washington, Seattle, WA

BEST OF BASIC SCIENCE

Moderators: Xia-Jing Wang, MD, PhD and Barbara Wollenberg, MD

S100: OVEREXPRESSION OF HIF1A AND CA-IX PREDICT LOCAL RECURRENCE IN T1/T2 GLOTTIC CARCINOMA TREATED WITH RADIOTHERAPY  
M.L.Schrijvers 1, B.FAM.van der Laan 1, G.H.de Bock 1, W.J.Patthe 1, M.F.Mastik 1, L.Menkema 1, J.A.Langendijk 1, P.M.Kluin 1, E.Schuuring 1, J.E.van der Wal 1, 1University Medical Center Groningen, Groningen, The Netherlands

S101: CI-1040 INHIBITS GROWTH OF PAPILLARY THYROID CARCINOMA Y.C.Henderson 1, S.Ahn 1, G.I.Clayman 1, 1MD Anderson Cancer Center, Houston

S102: HPV16 E6/E7 TRANSCRIVE A HUMAN ENDOGENOUS RETROVIRUS SUPERANTIGEN THAT IS EXPRESSED IN HPV+ HEAD AND NECK CARCINOMAS S.Rubinchik 1, T.McRackan 1, L.Halstead 1, M.B.Gillespie 1, N.A.Sutkowski 1, 1Medical University of South Carolina, Charleston, SC
S103: ENGINEERING AN ARTIFICIAL SALIVARY GLAND S. Pradhan1, M.C. Farach-Carson2, X. Jiao3, C. Zhang3, R.L. Warrington2, 1University of Delaware, Newark, DE; 2University of Rochester, Rochester, NY; 3University of North Carolina, Chapel Hill, NC

S104: IRX, A MULTI-TARGETED BIOLIGIC, PROTECTS HUMAN T CELLS FROM TUMOR-INDUCED CELL DEATH M. Czyzowska1, M. Szczepanski1, M. Szajek1, T.L. Whiteside1, K. Signorelli2, K. Quadrini2, H. Brandwein2, J.W. Hadden2, 1University of Pittsburgh Cancer Institute, Pittsburgh, PA; 2IRX Therapeutics, Inc., Farmingdale, NY

S105: INVOLVEMENT OF RAS SUPERFAMILY (RHOC) IN HEAD AND NECK METASTASIS M. Islam1, G. Lin1, J.C. Brenner1, Q. Pan1, S.D. Merajver1, T.N. Teknos1, 1University of Michigan, Ann Arbor, MI

S106: GENETIC POLYMORPHISMS OF INVASION AND METASTASIS, INFLAMMATION AND DNA REPAIR IN THE PROGNOSIS OF LARYNGEAL CANCER B. Lopez1, V. Vunshch1, M. Tago1, W. Da Silva1, D. Zanette1, J. Levi1, L. Kowalski2, M. Abrahao3, M. De Carvalho4, J. Eliahu1, 1University of Sao Paulo, Sao Paulo Brazil; 2AC Camargo Hospital, Sao Paulo, Brazil; 3Federal University of Sao Paulo, Sao Paulo, Brazil; 4Heliopolis Hospital, Sao Paulo, Brazil

S107: IMMUNE ACTIVATION AND HEAD AND NECK CANCER CELL LYSIS IS MEDIATED BY CETUXIMAB AND POLYMORPHIC FCR EXPRESSING NK CELLS A. Lopez-Albalaoit1, S. Kim1, W. Gooding1, R.L. Ferris1,2, 1University of Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh

S108: LEVELS OF CD44, A HEAD AND NECK CANCER STEM CELL MARKER CORRELATE WITH TUMOR AGGRESSIVENESS B. Joshua1, M.J. Kaplan1, I. Dowwek2, R. Pai1, M.E. prince4, I.L. Weissman1, L.E. Alles1, 1Stanford University School of Medicine, Stanford, CA; 2Carmel Medical Center, Haifa Israel; 4University of Michigan, Ann Arbor, MI

CLINICAL: PARATHYROID/THYROID II

Moderators: Guy Andry, MD and Jeremy L. Freeman, MD

S109: ACCURACY OF SPECT/CT HYBRID IMAGES IN PREDICTING THE INTRAOPERATIVE LOCATION OF PARATHYROID ADENOMAS L.D. Harris1, J. Yoo1, A. Ariedgger1, K. Fung1, J. Franklin1, D. Gray1, R. Holliday1, 1University of Western Ontario, London, ON, Canada

S110: THE USEFULNESS OF METHYLENE BLUE INFUSION IN PARATHYROIDECTOMY FOR SECONDARY HYPERPARATHYROIDISM J. Hah1, D. Kim1, Y. Jung1, K. Kim1, M. Sung1, 1Department of Otolaryngology, Seoul National University College of Medicine, Seoul, Republic of Korea

S111: MINIMALLY INVASIVE PARATHYROIDECTOMY S112: PAROTHYROTOMAL NECK DISSECTION: INDICATIONS, TECHNIQUE AND RESULTS A. Khahli Helez1, D. M. Fliss2, 1Tel Aviv Sourasky Medical Center, Tel Aviv Israel; 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

S113: BILATERAL SUPERFICIAL CERVICAL PLEXUS ANESTHESIA FOR THYROID SURGERY: PROSPECTIVE RANDOMIZED DOUBLE BLIND STUDY N. Avalos1, L. Marinar1, C. Cabrera1, R. Vega1, S. Schmidt1, J. De La Maza1, G. Fasce1, 1Hospital Fach, Santiago, Chile

S114: OUTPATIENT THYROIDECTOMY: EXPERIENCE IN OVER 200 PATIENTS M. W. Seydel1, E. Chin1, D. J. Terris1, 1Medical College of Georgia, Augusta, GA

S115: COMPARISON OF TRENDS IN INCIDENCE AND MORTALITY FROM THYROID CANCER IN THE UK AND USA H. M. Mehandra1, A. Jain2, V. Madarasinghe1, 1Institute of Head and Neck Studies and Education, University Hospital Coventry, Coventry, United Kingdom; 2Institute of Head and Neck Studies and Education, University Hospital Coventry, Coventry, United Kingdom; 3West Midlands Cancer Intelligence Unit, Birmingham, United Kingdom

S116: EFFICACY OF RECURRENT LARYNGEAL NERVE MONITORING IN AN OTOLARYNGOLOGY ACADEMIC TRAINING PROGRAM T. M. Brickman1, M. J. Ode1, D. A. Harris1, M. A. Varvares1, 1St Louis University, St Louis, MO

S117: THYROIDECTOMY SCAR LENGTH AND POST-OPERATIVE SCAR SATISFACTION: A RANDOMIZED CLINICAL TRIAL J. R. Harris1, J. Dumpe1, D. O. Connell1, H. Seikaly1, 1University of Alberta, Edmonton, AB, Canada

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM ETHICON ENDO-SURGERY, INC.

RISK FACTORS/PREVENTION/SCREENING

Moderators: Sonia A. Duffy, PhD and David Goldstein, MD

S118: EARLY RESULTS OF A LONG-TERM SCREENING PROGRAM FOR NASOPHARYNGEAL CARCINOMA: EVIDENCE FOR SCREENING HIGH RISK COHORT K. S. Loh1, P.P. Hsu2, 1Dept Otolaryngology, National University of Singapore, Singapore Singapore; 2Dept Otolaryngology, Changi General Hospital, Singapore, Singapore

S119: COMPLEMENTARY SERUM TEST OF ANTIBODIES TO EBV EA+EBNA-1: A POSSIBLE ALTERNATIVE FOR PRIMARY SCREENING OF NPC P. Changa1, K. Fang1, S. Hao1, 1Chang Gung Memorial Hospital, Taipei, Taiwan, Republic of China

S120: SEQUENTIAL DETECTION OF PLASMA EBV DNA LEVELS IN A COHORT OF HIGH RISK INDIVIDUALS FOR NASOPHARYNGEAL CARCINOMA C. M. Lim1, K. S. Loh1, L. K. Tan1, 1Dept Otolaryngology Head & Neck Surgery, National University Hospital, Singapore Singapore; 2Dept Otolaryngology, National University of Singapore, Singapore Singapore

S121: AUTOFLUORESCENCE LIGHT SCREENING FOR PRE-MALIGNANT AND MALIGNANT ORAL LESIONS V. Jayaprakash1, M. A. Sullivan1, S. Ramananda1, T. S. Mang1, M. Merzianu1, N. R. Rigel1, T. R. Loree1, 1University of Pittsburgh, Pittsburgh, PA; 2University at Buffalo, SUNY, Buffalo; 3Roswell Park Cancer Institute, Buffalo, NY

S122: BETA-CAROTENE’S OXIDATIVE METABOLISM MAY REPRESENT A CANCER RISK WITH ONGOING TOBACCO USE V. B. Bentz1, M. Wade2, D. M. Burnett1, F. Fitzpatrick2, 1University of Utah School of Medicine, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT

S123: A TALE OF TWO SITES: CORRELATION OF HPV SUBTYPES IN HEAD AND NECK CANCER AND CERVIX IN WEST VIRGINIA C. H. Rasheed1, R. Althoff1, B. D. Cutceman1, S. McEwen1, P. Soisson2, P. Brown1, S. Kennedy1, P. van der Sloot1, W. Petros1, W. Wang1, 1West Virginia University, Morgantown, WV; 2University of Utah, Salt Lake City, UT; 3NIH, Bethesda, MD

S124: CIGARETTE SMOKE REGULATES REACTIVE OXYGEN SPECIES METABOLISM IN THE LARYNX R. R. Bronski1, B. Saltman1, H. Ota2, D. Felsen1, D. Poppas2, L. Sicluf2, D. H. Kraus1, 1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Weill Cornell Medical College, New York, NY

S125: THE PRICE PAID: 20TH CENTURY TOBACCO FUNDED RESEARCH OBSCURED THE EMERGING TRUTH THAT SMOKING CAUSES HEAD & NECK CANCER H. A. Samii1, R. K. Jackler1, 1Department of Otolaryngology - Stanford School of Medicine, Stanford, CA

S126: GENETIC ANALYSIS OF SPORADIC AND FAMILIAL HEAD AND NECK PARAGANGLIOMA TUMORS M. Sevilla1, M. Hermens2, M. Alonso2, E. Allonca2, J. Llorente2, J. Rodrigo1, R. Charloette3, C. Suarez2, 1Hospital Central De Asturias, Oviedo Spain; 2Hospital Central De Asturias, Instituto Universitario de Oncologia del Principado, Oviedo Spain; 3Hospital Patico de Montevideo, Montevideo, Uruguay

www.ahns.info
CLINICAL: SKULL BASE I

Moderators: Giulio Cantu, MD and Jason Newman, MD

5127: ENDOSCOPIC DURAL RESECTION IN THE MANAGEMENT OF SELECTED SINO-NASAL MALIGNANCIES: SURGICAL TECHNIQUE AND MORBIDITY P.Nicolai1, A. Bolzoni Villarell1, D. Lombardi1, D. Tomenzoli1, M. Bigiami2, G. Delu2, P. Battaglia2, P. Castelnovo2, 1Department of Otorhinolaryngology, University of Brescia, Brescia, Italy; 2Department of Otorhinolaryngology, University of Insubria, Varese, Italy

5128: NAVIGATED CONTROL: AUTOPILOT ASSISTANCE FOR SURGICAL DISSECTION IN SKULL BASE MALIGNANCIES G.Strauss1, M. Strauss2, M. Hufn2, A. Dietz2, T. C. Lueh3, 1University Hospital Leipzig, Leipzig, Germany; 2Technical University, Munich, Germany; 3Dept. of ENT, Leipzig, Germany

5129: 3D TOMOSYNTHESIS: NOVEL “REAL-TIME” INTRAOPERATIVE IMAGING TECHNOLOGY FOR GUIDANCE OF SKULL BASE SURGERY G. Bachar1, E. Barker1, N. Sajendra2, M. J. Daly2, J. C. Irish1, J. H. Siewersden2, 1Princess Margaret Hospital - Otolaryngology Head and Neck Surgery, Toronto, ON, Canada; 2Princess Margaret Hospital - Medical Biophysics, Toronto, ON, Canada

5130: LONG TERM FOLLOW-UP OF PROTON BEAM RADIATION THERAPY FOR LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS M. Truong1, U. R. Kamat1, D. T. Lin2, W. T. Curry1, S. Gray2, A. W. Chan1, 1Massachusetts General Hospital, Boston, MA; 2Massachusetts Eye and Ear Infirmary, Boston, MA

5131: CLINICAL OUTCOMES OF SINONASAL CANCERS TREATED WITH ENDOSCOPIC ENDONASAL RESECTION A. M. Zanation1, C. H. Snyderman1, R. Carrau1, A. Kassam1, 1University of Pittsburgh Medical Center, Pittsburgh, PA

5132: TREATMENT OF ESTHESIONEUROBLASTOMA WITH ENDOSCOPIC ENDONASAL CRANIAL BASE RESECTION A. M. Zanation1, R. Carrau1, C. Snyderman1, A. Kassam1, 1University of Pittsburgh Medical Center, Pittsburgh, PA

5133: A PROSPECTIVE EVALUATION OF THE SHORT-TERM IMPACT AND RECOVERY OF QUALITY OF LIFE AFTER ANTERIOR SKULL BASE SURGERY A. Abergel1, Z. A. Gil2, D. M. Fliss1, 1Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv Israel; 2Memorial Sloan-Kettering Cancer Center, New York, NY

5134: SURGICAL TECHNIQUE OF “FACIAL DISMASKING APPROACH” FOR CRANIOFACIAL LESION S. Kishimoto1, A. Tsunoda1, H. Koda1, 1Tokyo Medical and Dental University, Tokyo, Japan

5135: ADVANTAGES AND OUTCOMES OF FREE TISSUE TRANSFER FOR DEFECTS OF THE SCALP AND LATERAL TEMPORAL BONE M. S. Teng1, E. Mendez2, N. D. Futran2, 1Mount Sinai Medical Center, New York, NY; 2University of Washington, Seattle, WA

SUNDAY POSTER SESSION WITH WINE AND CHEESE

POSTER SESSIONS SUPPORTED BY GENEROUS EDUCATIONAL GRANTS FROM OUR BRONZE LEVEL DONORS

EUSA PHARMA/CYTOGEN
IBA PARTICLE THERAPY
OMNIGUIDE
STRYKER
VARIAN MEDICAL SYSTEMS

INTERNATIONAL WELCOME RECEPTION WITH EXHIBITORS

Please join Dr. and Mrs. Ernest Weymuller and Dr. and Mrs. Jeffery Myers in the Exhibit Hall as we welcome you to the 7th International Conference on Head and Neck Cancer. Sponsored by our exhibitors, this event will feature cocktails and light hors d’oeuvres. Event is free to all scientific session attendees and registered accompanying persons. Extra tickets may be purchased for $50 each.
### Monday-at-a-Glance

<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30 - 08:00</td>
<td>BREAKFAST SATELLITE SYMPOSIUM: “NEW APPROACHES TO THE MULTIMODAL TREATMENT OF HEAD AND NECK CANCER”</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td>08:00 - 08:45</td>
<td>AHNS PRESIDENTIAL ADDRESS: “TAILORED TREATMENT, TEAMWORK, TRADEOFFS AND TRADITION: HEAD AND NECK SURGICAL ONCOLOGY IN THE GENOMIC ERA”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>08:45 - 09:15</td>
<td>AHNS RESEARCH AWARDS</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>09:15 - 09:45</td>
<td>KEYNOTE ADDRESS: “TARGETING SIGNALING PATHWAYS IN HEAD AND NECK CANCER”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>09:45 - 10:15</td>
<td>CHRISTOPHER O’BRIEN LECTURE: “MANAGEMENT OF MALIGNANT MELANOMA”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td>JATIN P. SHAH SYMPOSIUM ON CLINICAL CONTROVERSIES IN HEAD AND NECK SURGERY: THE ROLE OF THE SURGEON IN MULTIDISCIPLINARY CARE OF HEAD AND NECK CANCER</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>12:30 - 13:30</td>
<td>LWP09: EARLY LARIKGEAL CANCER</td>
<td>PACIFIC A</td>
</tr>
<tr>
<td>13:45 - 15:15</td>
<td>PANEL: GENETICS/EPIGENETICS IN HEAD AND NECK CANCERS</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>15:45 - 17:15</td>
<td>PANEL: CARCINOMA OF THE ORAL TONGUE</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>17:15 - 18:15</td>
<td>AHNS BUSINESS MEETING</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>18:15 - 19:45</td>
<td>MONDAY POSTER SESSION</td>
<td>GOLDEN GATE HALL</td>
</tr>
<tr>
<td>19:30 - 22:00</td>
<td>DINNER SATELLITE SYMPOSIUM: “TRANSORAL LASER MICROSURGERY: TOWARDS ESTABLISHING A NEW STANDARD OF CARE IN HEAD AND NECK CANCER”</td>
<td>YERBA SALON 1-3</td>
</tr>
</tbody>
</table>
**NEW APPROACHES TO THE MULTIMODAL TREATMENT OF HEAD AND NECK CANCER**

**Chair:** Ann M. Gillenwater, MD, FACS  
Associate Professor, Dept. of Head and Neck Surgery, University of Texas, MD Anderson Cancer Center

**YERBA SALON 4-6**

**FACULTY**

Ezra Cohen, MD, Assistant Professor, The University of Chicago  
Avraham Eisbruch, MD, Professor of Radiation Oncology, University of Michigan Hospital  
Robert Haddad, MD, Clinical Director/Head And Neck Oncology Program, Dana-Farber Cancer Institute  
Paul M. Harari, MD, Jack Fowler Professor, University Of Wisconsin Comprehensive Cancer Center

**AGENDA**

06:00 - 06:30  
Breakfast

06:30 - 06:35  
Welcome and Introduction  
Ann M. Gillenwater, MD

06:35 - 06:40  
Case Study Presentation and Audience Response Activity  
Ann M. Gillenwater, MD

06:40 - 06:50  
Surgical Oncologist Perspective  
Ann M. Gillenwater, MD

06:50 - 07:00  
Medical Oncologist Perspective  
Robert Haddad, MD

07:00 - 07:10  
Radiation Oncologist Perspective  
Avraham Eisbruch, MD

**Session 1: Optimizing Patient Outcomes in the Treatment of Locally Advanced Head and Neck Cancer: Integrating Induction Chemotherapy and Post-Induction IMRT into Clinical Practice**

07:10 - 07:15  
Case Study Presentation and Audience Response Activity  
Ann M. Gillenwater, MD

07:15 - 07:25  
Surgical Oncologist Perspective  
Ann M. Gillenwater, MD

07:25 - 07:25  
Medical Oncologist Perspective  
Ezra Cohen, MD

07:35 - 07:45  
Radiation Oncologist Perspective  
Paul M. Harari, MD

07:45 - 08:00  
Panel Discussion

**Session 2: What Approaches Are Being Used to Optimize EGFR Inhibition in the Treatment of Locally Advanced Head and Neck Cancers?**

08:00 - 08:45  
AHNS PRESIDENTIAL ADDRESS:  
“TAILORED TREATMENT, TEAMWORK, TRADEOFFS AND TRADITION: HEAD AND NECK SURGICAL ONCOLOGY IN THE GENOMIC ERA”  
Gregory T. Wolf, MD, University of Michigan Hospitals, Ann Arbor, Michigan, USA  
Introduction by Wayne M. Koch, MD

AHNS ACKNOWLEDGES UNRESTRICTED EDUCATIONAL GRANTS FROM OUR PLATINUM LEVEL DONORS

BRUSTOL-MEYERS SQUIBB  
IMCLONE SYSTEMS  
MERCK KgaA  
SANOFI-AVENTIS
Scientific Program

08:45 - 09:15

AHNS RESEARCH AWARDS

- AHNS Alando J. Ballantyne Resident Research Pilot Grant
- AHNS Pilot Grants
- AHNS/AAO-HNSF Young Investigator Awards
- 2006 AHNS-ACS Career Development Award Presentation: Stephen Y. Lai, MD, PhD, "Tumor Microenvironment Regulation of HIF-1 in Head and Neck Squamous Cell Carcinoma"

09:15 - 09:45

KEYNOTE ADDRESS:
"TARGETING SIGNALING PATHWAYS IN HEAD AND NECK CANCER"

Jennifer R. Grandis, MD, Eye and Ear Institute, Pittsburgh, Pennsylvania, USA
Introduction by Christine G. Gourin, MD

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM SANOFI-AVENTIS

09:45 - 10:15

CHRISTOPHER O’BRIEN LECTURE:
"MANAGEMENT OF MALIGNANT MELANOMA"

Donald L. Morton, MD, John Wayne Cancer Institute, Santa Monica, California, USA
Introduction by Erich M. Sturgis, MD, MPH

10:00 - 16:00

Exhibit Hall Open

10:45 - 12:15

SCIENTIFIC SESSIONS – Panels

CANCER PREVENTION: CHEMOPREVENTION
Panel Moderator: Scott M. Lippman, MD

The Importance of Risk Modeling in Preventing Head and Neck Cancer
Scott M. Lippman, MD

Targeting EGFR Signaling in High-risk Oral Intraepithelial Neoplasia
Vali A. Papadimitrakopoulou, MD

The Promise of Fenretinide in Patients with Oral Leukoplakia
Fausto Chiesa, MD

Chemoprevention in Patients at Risk of Head and Neck Second Primary Cancers
Jay O. Boyle, MD

This panel will address topics relating to the use of pharmacologic agents to disrupt head and neck carcinogenesis and thus prevent head and neck cancer, with emphases on identifying high-risk populations and on molecular-targeted interventions.

At the conclusion of the panel, the participants will be able to:

- Understand why it is critically important to identify high-risk patients, and be able to assess their risk feasibly in the clinic, in order to design effective head and neck and other chemoprevention trials.
- Describe the strong rationale for targeting EGFR signaling in oral intraepithelial neoplasia patients with a molecularly defined high risk of oral cancer.
- Review the challenges to accrual, ancillary tissue and biomarker studies, and trial design and analysis in the setting of head and neck chemoprevention trials.
- Describe the status and major challenges of chemoprevention in the adjuvant setting of resected early-stage head and neck cancer patients.

TARGETED THERAPIES IN HEAD AND NECK ONCOLOGY
Panel Moderator: Ezra Cohen, MD

Angiogenesis and Vascular Targeting
Jean-Louis Bourhis, MD, PhD

Radiation Interactions with EGFR and IGFR
Paul M. Harari, MD

mTOR Inhibitors: Is There a Role in HNSCC?
Cherie-Ann O. Nathan, MD

PKC in Head and Neck Cancer
Ezra Cohen, MD

The panel will address novel targets in head and neck cancer (HNC) that are currently being investigated as therapeutics.
At the conclusion of the panel, the participants will be able to:

- Understand the difference, rationale, and efficacy of angiogenic and vascular targeting in HNC.
- Understand the mechanism of radiosensitization of receptor tyrosine kinases directed against EGFR and IGFR.
- Understand the prognostic role of the mTOR pathway in HNC and the application of mTOR inhibitors in this disease.
- Define the PKC family of kinases and understand their relevance to HNC.

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM BRISTOL MEYERS SQUIBB AND IMCLONE SYSTEMS

JATIN P. SHAH SYMPOSIUM ON CLINICAL CONTROVERSIES IN HEAD & NECK SURGERY: THE ROLE OF THE SURGEON IN MULTIDISCIPLINARY CARE OF HEAD & NECK CANCER

Panel Moderator: John A. Ridge, MD, PhD

Oral Cavity and Oropharynx Cancer: Treatment Selection
Patrick J. Gullane, MD

Larynx and Hypopharynx Cancer: Treatment Selection
Jonas T. Johnson, MD

Morbidity and Complications of Head & Neck Radiation: When I Need a Surgeon
Parvesh Kumar, MD

At the completion of this panel, participants should be able to identify and to discuss:

- Clinical settings where either surgical or radiotherapeutic management may be employed with comparable results for cancers of the oral cavity and oropharynx.
- Clinical settings where either surgical or radiotherapeutic management may be employed with comparable results for cancers of the larynx and hypopharynx.
- Clinical settings where either surgery or radiation are preferred (due to oncologic or functional considerations) for cancers of the oral cavity or hypopharynx.
- Clinical settings where either surgery or radiation are preferred (due to oncologic or functional considerations) for cancers of the larynx or hypopharynx.
- Limitations of radiation treatment for head and neck cancer.
- Management of stricture, radionecrosis, and post-radiation laryngeal dysfunction.

PROFFERED PAPERS

BASIC SCIENCE: OTHER

Moderators: Marion E. Couch, MD, PhD and Wesley L. Hicks, Jr., MD

S136: DNA DOUBLE STRANDED BREAK REPAIR MECHANISMS IN ORAL CARCINOMAS FROM YOUNG AND OLDER PATIENTS
P.L. Bohrer1, P. Pinter dos Reis1, J. Machado1, R. Bharadwaj1, R. Grénman2, P. Gullane3, J. Irish4, V.D. Silva5, S. Kamei-Reid1, Appied Molecular Oncology, Ontario Cancer Institute and University Health Netwo, Toronto, ON, Canada; 23Otorhinolaryngology/Head and Neck Surgery, and Biochemistry, Turku University C, Turku, Finland; 3Otolaryngology and Surgical Oncology, Princess Margaret Hospital, Toronto, ON, Canada; 4Otolaryngology and Surgical Oncology, Princess Margaret Hospital, Toronto, ON, Canada; 5Pontificia Universidade Catolica do RS, Porto Alegre, Brazil

S137: SALIVARY TRANSCRIPTOMES AS POTENTIAL EARLY DETECTION BIOMARKERS FOR ORAL CANCER
A. Suresh1, M. Vannan1, E. M. Elango1, F. A. Chen1, Z. He1, R. Glickman1, M. Kuriakose1, Amrita Institute of Medical Sciences, Cochin, Kerala, India; 2NYU Dental School, New York, NY; 3Amrita Institute of Medical Sciences, Cochin, Kerala, India

S138: BIOLOGIC EFFECTS OF BONE MORPHOGENETIC PROTEINS ON ORAL CARCINOMA CELL LINES
N. Kakerina1, J. Lewis1, P. H. Krebcha1, C. Stewart1, B. Nussenbaum1, Washington University School of Medicine, Saint Louis, MO; 2University of Michigan, Ann Arbor, MI

S139: GAIN OF FUNCTION OF P53 MUTATIONS DISRUPT THE ATM-MEDIATED DNA DAMAGE RESPONSE IN HNSCC CELL LINES
G. Zhou1, M. Zhao1, T. Xie1, S. A. Jass1, J. N. Myers1, MD Anderson Cancer Center, Houston, TX

S140: RADIATION INDUCES REACTIVE OXYGEN SPECIES METABOLISM AND FIBROTIC GENE EXPRESSION IN LARYNGEAL FIBROBLASTS
B. E. Salaman1, R. C. Branski1, D. Felsen1, D. P. Pappas1, P. H. Hare1, Memorial Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer Center, New York, NY; 3Memorial Sloan-Kettering Cancer Center, New York, NY; 4Weill Medical College of Cornell University, New York, New York

S141: THE EPIGASTRIC ADIPOCUTANEOUS FLAP IN RATS AS A MODEL FOR EVALUATION THE EFFECT OF ISCHEMIC PRECONDITIONING
A. K. Dacho1, S. Lyuten1, P. Madaq-Sterbo2, G. Aus3, A. Dietz1, University Hospital Leipzig, Department of Otolaryngology, Head and Neck Surgery, Leipzig, Germany; 2University Hospital Leipzig, Medical and Experimental Center, Leipzig, Germany; 3University Hospital Leipzig, Department of Surgery II, Leipzig, Germany

S142: FAK-RELATED NON-KINASE (FRNK) BLOCKADE OF FAK INCREASES UVC INDUCED APOPTOSIS IN MURINE SQUAMOUS CELL CARCINOMA CELLS
C. M. Bier-Laning1, C. Bernet1, A. M. Vaughan2, M. Denning1, Loyola University Medical Center, Maywood, IL; 2Hines VA Hospital, Maywood, IL; 3University of California-Davis, Davis, CA

S143: DOWNREGULATION OF LET-7 MICRORNA CORRELATES WITH RAS OVEREXPRESSIN IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
V. F. Wu1, S. Borstein1, P. E. Andersen1, N. D. Grass1, X. J. Wang1, S. L. Lu1, Oregon Health and Science University, Portland, OR

S144: NEW HIGH THROUGHPUT GENOMIC STRATEGIES FOR THE STUDY OF HEAD AND NECK CANCER
D. I. Smith1, L. X. Luo1, A. O’Reilly1, A. Leightner1, E. Moore1, D. Kademani1, Mayo Clinic, Rochester, MN
BEST OF CLINICAL I

Moderators: Roberto Lima, MD and Ellie Maghami, MD

S145: CONCOMITANT CT/VS NEOADJUVANT TPF FOLLOWED BY CT/RT IN LOCALLY ADVANCED H&N CANCER. A PHASE II RANDOMIZED STUDY

M.Ghit1, A.Paccagnella1, A.Buffoli2, H.Kousis3, L.lorenggian4, A.Gava5, A.Boretti6, E.Galligioni7, G.Gardini8, M.Guaraoli9, 1Oncology Department, Venice, Italy; 2Radiology Department, Padova, Italy; 3Oncology Department, Padova, Italy; 4Radiotherapy Department-IOV, Padova, Italy; 5Radiotherapy Department, Treviso, Italy; 6Oncology Department, Legnago, Italy; 7Oncology Department, Trento, Italy; 8Radiotherapy Department, Monza, Italy; 9Oncology Department S. Orsola Malpighi, Bologna, Italy

S146: TREATING ORAL MUCOSITIS WITH RESORBABLE LAMINATED REPAIR MEMBRANE FOR LOCAL DELIVERY OF KERATINOCYTE GROWTH FACTOR

D.M.Cohen1, J.A.Gardello2, L.Sigurdsson1, R.Haas3, F.Bright4, B.Koc5, A.Cartervigh6, M.Sullivan7, W.Hicks8, J.R. Roswell Park Cancer Institute, Department of Head and Neck Surgery, Buffalo, NY; 9State University of New York at Buffalo, Department of Anatomy, Buffalo, NY

S147: COMPLICATIONS OF RADIOThERAPY IN LARYNGOPHARYNGEAL CANCER: EFFECTS OF A PROSPECTIVE SMOKING CESSATION PROGRAM

M.Zevallos. MD1, M.J.Mallen, PhD2, C.Y.Lam, PhD2, M.Karam-Hage, MD2, J.Blacoc, PhD2, D.W.Wetter, PhD2, A.S.Garden, MD3, E.M.Sturgis, MD, MPH4, P.M.Cinciripini, PhD5, 1Department of Head and Neck Surgery, UT MD Anderson Cancer Center, Houston, TX; 2Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX; 3University of Michigan Health System, Ann Arbor, MI; 4Medical College of Georgia, Augusta, GA

S148: THE EFFECT OF TREATMENT ON SURVIVAL IN ADVANCED LARYNGEAL CARCINOMA

C.G.Gourin1, L.M.Burkehead2, C.Sheils2, P.A.Bilodeau2, T.A.Coleman2, E.S.Porubsky2, 1Johns Hopkins University, Baltimore, MD; 2Medical College of Georgia, Augusta, GA

S149: ENDOSCOPIC TREATMENT OF TIS-T3 GLOTTIC CANCER: RETROSPECTIVE ANALYSIS OF 619 PATIENTS TREATED IN A SINGLE INSTITUTION

G.Peretti1, C.Piccola, I.O.Redolfi De Zinis1, D.Cocco1, S.Garrubba1, I.D.Benedett1, F.Del Bon1, R.Nicolai1, 1Department of Otolaryngology- Head and Neck Surgery, University of Verona, Verona, Italy

S150: COMBINED TRANSOSSEOUS AND MICROINTRAVENOUS MICROSDRURY FOR TREATMENT OF HEAD AND NECK CANCER

W.Thosted1, B.Nussenbaum1, D.R.Adkins1, B.H.Haughey1, 1Washington University Medical Center, St. Louis, MO

S151: PREDICTIVE FACTORS FOR OCCULT METASTASES IN SENTINEL LYMPH NODES OF EARLY ORAL SQUAMOUS CELL CARCINOMAS

M.Goerker1, M.Tingely2, J.Braun3, S.J.Schock3, 1University Hospital Zurich, Zurich, Switzerland; 2University Zurich, Zurich, Switzerland; 3University Hospital Zurich, Zurich, Switzerland

S152: SENTINEL LYMPH NODE BIOPSY FOR CLINICALLY NODE-NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

C.Baek1, M.Chung1, Y.Son1, H.Jeong1, Y.So1, K.Park1, J.Jang1, 1Samsung Medical Center, Samsungkyungkwan University School of Medicine, Seoul, Republic of Korea

S153: GUIDELINES FOR NECK DISSECTION AFTER CONCOMITANT CHEMORADIATION IN PATIENTS WITH OROPHARYNGEAL SQUAMOUS CELL CARCINOMA

S.Gandola1, D.B.Chepeha2, A.Donatelli-Lassig2, E.P.Chanowski2, A.G.Sacca2, T.SORE Head & Neck Cancer Team2, 1University of Michigan School of Public Health, Ann Arbor, MI; 2University of Michigan Medical School, Ann Arbor, MI; 3University of Michigan Medical School, Ann Arbor, MI; 4University of Michigan Health System, Ann Arbor, MI

CLINICAL: THYROID III

Moderators: J. Trad Wadsworth, MD and Kenneth A. Woeber, MD, FRCP

S154: PROPHYLACTIC CENTRAL LYMPH NODE DISSECTION IN PAPILLARY THYROID CANCER

S.Costa1, A.Yusuf2, N.Tradati3, B.Giibelli3, 1Hospital do Cancer A.C. Camargo, Sao Paulo, Brazil; 2Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 3Istituto Europeo di Oncologia (IEO), Milan, Italy; 4Hospital do Cancer A.C. Camargo, Sao Paulo, Brazil

S155: CENTRAL COMPARTMENT LYMPH NODE METASTASIS IN WELL-DIFFERENTIATED THYROID CARCINOMA

D.I.Kutler1, A.D.Crummey2, W.I.Kuhel1, 1Weill Cornell Medical College, New York, NY

S156: EXTENT OF PROPHYLACTIC CENTRAL LYMPH NODE DISSECTION IN THE CENTRAL NECK IN PATIENTS WITH PAPILLARY THYROID CARCINOMA

H.Jeong1, Y.Son1, C.Baek1, M.Chung1, Y.So1, J.Jang1, K.Park1, 1Samsung Medical Center, Samsungkyungkwan University School of Medicine, Seoul, Republic of Korea

S157: ARE THERE COLLOID NODULES THAT REQUIRE NO PUNCTURE?

E.Horvat1, S.Majlis1, J.Zilges1, E.Soto1, J.Niedmann1, A.Castro1, A.Madrid1, H.Rojas1, R.Rossi F.1, R.Rossi M.1, J.Ilzauspe1, M.Dominguez1, A.Madrid1, A.Castro1, 1Clinica Alemana, Santiago, Chile

S158: QUALITY OF LIFE IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CARCINOMA

J.P.Almeida1, I.N.Nishimoto1, J.G.Vartanian1, E.N.P.Lima1, J.P.Kowalski1, 1Hospital A. C. Camargo, Sao Paulo, Brazil

S159: THYROID CANCER IN HYPERPARATHYROID PATIENTS UNDERGOING RADIIOGUIDED PARATHYROIDECTOMY

S.Saha1, E.Walsh1, V.K ao1, M.Ghanem2, M.Kaji1, D.Wease1, J.Hammoud1, M.Bakleh1, J.Nelson2, N.Tomycz1, 1McLaren Regional Medical Center, Flint, MI; 2Synergy Medical Education Alliance, Saginaw, MI; 3Genesys Health System, Grand Blanc, MI

S160: THE RELATIONSHIP BETWEEN THYROID NODULE SIZE AND THE RISK OF MALIGNANCY

N.A.Popescu1, J.L.Freeman1, 1Mount Sinai Hospital, Toronto, ON, Canada

S161: A NEW SYSTEM OF ULTRASOUND CATEGORIZATION FOR THYROID NODULES TIRADS CLASSIFICATION (BI-RADS CONCEPT)

E.Horvat1, S.Majlis1, J.Niedmann1, H.Rojas1, R.Rossi F.1, R.Rossi M.1, J.Zilges1, M.Dominguez1, A.Madrid1, A.Castro1, 1Clinica Alemana, Santiago, Chile

S162: INTENSITY MODULATED RADIOTHERAPY FOR DIFFERENTIATED THYROID CANCER

M.Lobo1, A.S.Garden1, W.H.Morrison1, K.K.Ang1, D.I.Rosenthal1, C.Chao1, D.B.Evans1, G.Clayman1, S.Sherman1, D.L.Schwartz1, 1UT MD Anderson Cancer Center, Houston, TX

EPIDEMIOLOGY

Moderators: Dan M. Fliss, MD and Snehal Patel, MD, MS, FRCS

S163: INTESTINAL TYPE ADENOCARCINOMA OF THE ETHMOID SINUS: AN OCCUPATIONAL DISEASE

G.Cantù1, G.Bimbi1, S.Colombo1, S.Riccio1, M.Squadrelli1, 1National Cancer Institute, Milan, Italy

S164: SIXTY YEAR CANCER CENTER EXPERIENCE WITH OROPHARYNGEAL CARCINOMA: YOUNGER PATIENTS, LESS SMOKING, & IMPROVED SURVIVAL

G.G.Calzada1, J.M.Daigle1, R.S.Weber1, A.S.Garden1, D.B.Roberts1, E.M.Sturgis1, 1MD Anderson Cancer Center, Houston, TX
S165: ORAL CANCER TRENDS OVER THREE DECADES FROM 1981-2004 IN THE WEST MIDLANDS, UK
K. Rehman1, A. Monaghan2, S. Parmar2, 1University Hospital Birmingham, Stourbridge, United Kingdom; 2University Hospital Birmingham, Birmingham, United Kingdom

S166: SOCIOECONOMIC STATUS AS A PREDICTOR OF SURVIVAL IN HEAD AND NECK CANCER PATIENTS
S.A. Duffy1, S. McLean2, D.L. Ronis3, K.E. Fowler4, J.E. Terrell1, 1University of Michigan, Ann Arbor, MI; 2Henry Ford Health System, Detroit, MI; 3University of Michigan, Ann Arbor, MI; 4Ann Arbor VA HSRR&D Center of Excellence, Ann Arbor, MI

S167: HOW REPRESENTATIVE IS THE PUBLISHED STUDIES IN PATIENTS WITH HEAD AND NECK CANCER OF THE TOTAL POPULATION OF PATIENTS?
Z. Allibhai1, E. Tsvelkov1, S. El-Sayed1, 1University of Ottawa, Ottawa, ON, Canada

S168: AN EVALUATION OF TRENDS IN THE QUALITY OF RESEARCH IN THE SUBSPECIALTY OF HEAD AND NECK ONCOLOGY
J.R. Harris1, A.T. Morrissey1, D.W. Cote1, H. Seikaly1, 1University of Alberta, Edmonton, AB, Canada

S169: INDIVIDUAL RISK PREDICTION OF NODE METASTASIS FROM UPPER AERO-DIGESTIVE SQUMOUS CARCINOMA ACCORDING TO PRIMARY SITE
E. Stabenow1, R.A. Mayes1, V. Wünsch-Filho2, A.R. Ferraz1, E.H. Tjorar2, I.H. Genome Project / GENCAPO4, P. Michealvert1, 1Head and Neck Surgery Department, São Paulo University Medical School, LM 28, São Paulo - SP, Brazil; 2Epidemiology Department, Public Health School of São Paulo University, São Paulo - SP, Brazil; 3Molecular Biology Department, São José do Rio Preto Medical School, São Paulo - SP, Brazil; 4http://ctc.fmpr.usp.br/clinicalgenomics/cp/group.asp, São Paulo - SP Brazil

S170: SECOND PRIMARY TUMORS IN LARYNGEAL SCCS ARE NOT ASSOCIATED WITH ADVERSE OVERALL SURVIVAL
R.D. Farhadieh1, A. Salardini2, J.L. Yang3, C.O. Rees4, P.J. Russell3, R. Smead4, 1Prince of Wales Hospital, Sydney, Australia; 2UNSW, Yales University, New Haven, CT; 3UNSW, Sydney, Australia; 4Prince of Wales Hospital, UNSW, Sydney, Australia

S171: ARE WE OVERESTIMATING THE RISK OF SECOND MALIGNANCIES IN PATIENTS WITH HEAD AND NECK CANCER? A POPULATION BASED STUDY
S. El-Sayed1, 1University of Ottawa, Ottawa, ON, Canada

LUNCH ON YOUR OWN/POSTER VIEWING/EXHIBIT VIEWING
12:15 - 13:45

LUNCH WITH THE PROFESSORS
12:30 - 13:30
Optional educational lunches are available during the Monday lunch hour.
Space is limited and courses are subject to an additional charge. All courses are available for CME credit.

LWP09 EARLY LARYNGEAL CANCER
Levent Soylu, MD and Giuseppe Spriano, MD

LWP10 INDUCTION CHEMOTHERAPY
Marshall R. Posner, MD, Everett E. Vokes, MD and Frank Worden, MD

LWP11 PALLATIVE CHEMOTHERAPY/PALLATIVE CARE
Renato G. Martins, MD and Randall P. Morton, MD

LWP12 PRACTICE GUIDELINES COST CONTROL
Marion E. Couch, MD, PhD, Jonas T. Johnson, MD and Jacob Kligerman, MD

LWP13 SYMPTOM CONTROL FOR NON-SURGICAL TREATMENTS
Patrick J. Bradley, FRCS, MBA and Fernando Walder, MD

LWP14 SYSTEMIC THERAPY IN SALIVARY AND THYROID CANCERS
Roger B. Cohen, MD and Robert I. Haddad, MD

LWP15 TARGETED THERAPY-ANGIOGENESIS INHIBITION
Ezra Cohen, MD and Vali A. Papadimitrakopoulos, MD

LWP16 TARGETED THERAPY-KINASE INHIBITION
Arlene A. Forastiere, MD, Lisa Licitra, MD and Lillian Siu, MD

LOCAL REGIONAL RECURRENT DISEASE
Panel Moderator: Stuart J. Wong, MD

Role of Reirradiation for Locally Recurrent Previously Irradiated Head and Neck Cancer
Corey J. Langer, MD

Surgical Management of Local Regional Recurrent Head and Neck Cancer
W. Jarrad Goodwin, MD

Preservation of Function, Optimizing Quality of Life: Optimal Management of Local and Regional Recurrent Head and Neck Cancer
Louis B. Harrison, MD
At the conclusion of the panel, participants will be able to:

- Distinguish when reirradiation should be considered, and what toxicities and benefits to expect.
- Understand when surgery would be appropriate to treat recurrent local and regional disease.
- Understand which modalities are appropriate for locally recurrent head and neck cancer while balancing efficacy and toxicity.

**TREATMENT OF LOCALLY ADVANCED CANCERS**

**Panel Moderator: David J. Adelstein, MD**

**Nonoperative, Multi-modality, Organ-preserving Treatment in Locally Advanced Larynx and Hypopharynx Cancer**  
Jean-Louis Lefebvre, MD

**Current Multi-modality Treatments for Oropharynx Cancer**  
Volker G. Budach, MD, PhD

**Nonoperative, Organ-preserving Treatment for Locally Advanced Disease**  
David E. Schuller, MD

**Clinical and Laboratory Markers of Those Most Likely to Benefit from Nonoperative, Multi-modality Organ Preserving Treatment**  
Frank Worden, MD

**Clinical and Laboratory Markers of Those Most Likely to Benefit from Nonoperative, Multi-Modality Organ Preserving Treatment**  
Thomas E. Carey, PhD

At the conclusion of the panel, participants will be able to:

- Summarize the current evidence and indications for nonoperative, multi-modality, organ-preserving treatment in locally advanced larynx and hypopharynx cancer.
- Discuss the limitations and the necessary precautions required in the choice of a nonoperative, organ-preserving treatment for locally advanced disease.
- Summarize the current evidence and indications for nonoperative, multimodality treatment of oropharynx cancer, including the role of and indications for postoperative adjuvant therapy.
- Distinguish the clinical and laboratory markers of potential utility in identifying those most likely to benefit from nonoperative, multimodality organ preserving treatment.

**AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM SANOFI-AVENTIS**

**GENETICS/EPIGENETICS IN HEAD & NECK CANCERS**

**Panel Moderator: Wayne M. Koch, MD**

**Identification of Novel Gene Alterations in HNSCC**  
Bhuvanesh Singh, MD, PhD

**Signal and Transcriptional Regulation of Gene Expression and Malignant Phenotype in HNSCC**  
Carter van Waes, MD, PhD

**Methylation as a Tumor-specific Epigenetic Mechanism for Development of HNSCC**  
Andre L. Carvalho, MD, PhD

**Paraganglioma and Pheochromocytoma: Genetics Relevant for Surgeons**  
Patrick Ha, MD

At the conclusion of the panel, the participants will be able to:

- Understand how alterations affecting several key signal activated transcription factors impact gene expression and the malignant phenotype, and implications for molecular therapy of HNSCC.
- Be familiar with methods being employed to search for and validate the identity of novel genes involved in HNSCC pathogenesis.
- Be familiar with alternate mechanisms for tumor-specific alterations in gene function (epigenetic changes) and how these contribute to the development of malignancy.
- Be aware of mutations in the SDH genes especially as they relate to head and neck paragangliomas, carotid body tumors and the need for surgeons to be aware of the hereditary nature of these as well as the possibility of associated functioning tumors.

**PROFFERED PAPERS**

**CLINICAL: ORAL CAVITY**

**Moderators: Jaimanti Bakshi, MD**

**S172: MARGINAL MANDIBULECTOMY FOR BUCCAL SULCUS CANCERS: 10 YEAR INSTITUTIONAL EXPERIENCE**  
K.A.Pathak, B.C.Shah, M.S.Deshpande, Tata Memorial Hospital, Mumbai India
S196: ORGAN PRESERVATION WITH CONCURRENT CHEMORADIATION FOR ADVANCED LARYNGEAL CANCER: ARE WE SUCCEEDING?
Lambert1, B. Fortin1, D. Soulieres1, L. Guertin1, G. Coulombe1, D. Charpentier1, J. C. Tabel1, M. Belair1, L. Igidbashian1, P. F. Nguyen-Tan1, 1Centre Hospitalier de l’Universite de Montreal (CHUM), Montreal, PQ, Canada

S197: THE USE OF CONCURRENT CHEMORADIATION IN THE TREATMENT OF ADVANCED T4 LARYNGEAL CANCER
A. M. Jarchow1, P. Lavertu1, 1University Hospitals Case Medical Center, Cleveland, OH

S198: CONCURRENT CHEMORADIOThERAPy AND Gefitinib For Locoregionally Advanced Head and Neck Squamous Cell Cancer (HNSCC)
D. J. Adelstein1, J. P. Saxton1, L. A. Rybicki1, C. P. Rodriguez1, R. R. Lorenz1, B. G. Wood1, J. Scharpf1, W. T. Lee1, D. J. Ives1, 1Cleveland Clinic Taussig Cancer Center, Cleveland, OH

ROBOTICS AND INNOVATIVE TECHNOLOGIES

S199: TRANSORAL ROBOTIC SURGICAL EXTRICATION OF OROPHARYNGEAL NEOPLASMS
E. J. Moore1, K. D. Olsen1, J. L. Kasperbauer1, M. L. Hinn1, J. R. Salassa1, 1Mayo Clinic Rochester, Rochester, MN; 2Mayo Clinic Scottsdale, Scottsdale, AZ; 3Mayo Clinic Jacksonville, Jacksonville, FL

S200: TRANS ORAL ROBOTIC SURGERY: INDICATIONS AND LIMITATIONS FOR MANAGEMENT OF LESIONS OF THE UPPER AERODIGESTIVE TRACT
S. Desai1, C. Sung1, E. M. Genden1, 1Mount Sinai School of Medicine, New York, NY; 2Mount Sinai School of Medicine, New York, NY

S201: TRANSORAL ANATOMY IN THE CONTEXT OF TRANSORAL ROBOTIC SURGERY (TORS): A CADAVER STUDY
N. Kokot1, G. S. Weinstein1, B. O’Malley1, 1The University of Pennsylvania, Philadelphia, PA

S202: RECONSTRUCTION OF THE SKULL BASE WITH A TRANSANTRAL ROBOTIC SURGICAL APPROACH
E. Y. H. A. Y. M. E. K u p f e r 1, F. DeMonte1, E. Y. H. A. Y. M. E. K u p f e r 1, 1MD Anderson Cancer Center, Houston, TX

S203: ENDOSCOPIC ROBOTIC TOTAL LARYNGECTOMY
R. V. Smith1, B. A. Schiff1, 1Albert Einstein College of Medicine, Bronx, NY

S204: ROBOTIC NASOPHARYNGECTOMY - A FEASIBILITY STUDY ON A CADAVERIC MODEL
H. Tay1, D. S. Sethi1, K. Sato1, 1Singapore General Hospital, Singapore, Singapore; 2National Cancer Centre, Singapore, Singapore

S205: A PILOT STUDY ASSESSING SURGICAL EXPOSURE DURING TRANSORAL ROBOTIC SURGERY (TORS) USING THE DA VINCI ROBOTIC SYSTEM
G. S. Weinstein1, B. W. O’Malley1, 1The University of Pennsylvania, Philadelphia, PA

S206: FEASIBILITY AND SAFETY OF ROBOTIC SURGERY FOR UPPER AERODIGESTIVE TRACT NEOPLASMS
B. A. Boudreaux1, E. L. Rosenthal1, J. S. Magnuson1, L. K. Clemans1, J. R. Newman1, W. R. Carroll1, 1University of Alabama, Birmingham, AL

S207: FUNCTIONAL OUTCOMES FOLLOWING TRANSORAL ROBOTIC PHARYNGOPLASTY FOR MANAGEMENT OF POST-ABLATIVE AND PRE-EXISTING PHARYN
S. Desai1, C. Sung1, T. Kato1, E. M. Genden2, 1Mount Sinai School of Medicine, New York, NY; 2Mount Sinai School of Medicine, New York, NY

15:45 - 17:15 SCIENTIFIC SESSIONS – Panels

SEQUENTIAL CHEMORADIOThERAPY

Panel Moderator: Merrill S. Kies, MD
Update on Induction Chemotherapy: Recent Trials and Current Initiatives
Marshall R. Posner, MD
Sequential Chemotherapy and Radiotherapy, Rationale and Potential Hazards
Everett E. Vokes, MD
Integration of IMRT with Chemotherapy in the Treatment of Locally Advanced Squamous Cancer of the Head and Neck
David M. Brizel, MD

At the conclusion of the panel, the participants will be able to:
• Review current induction chemotherapy strategies.
• Consider the rationale and potential hazard of sequencing induction chemotherapy with chemoradiation.
• Understand the indications for intensity modulated radiotherapy (IMRT) and the integration of this treatment modality with chemotherapy.

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM SANOFI-AVENTIS

SYSTEMIC THERAPY FOR DISTANT METASTASES

Panel Moderator: Yungpo Bernard Su, MD
Current standards in the Treatment of Metastatic Squamous Head and Neck Cancer
Jennifer E. Tseng, MD
EGFR-Targeted Therapies: Emerging Data and Future Directions
Jan B. Vermorken, MD
VEGF and Emerging Targets for Treatment of Metastatic Squamous Head and Neck Cancer
Anthanassios E. Argiris, MD

This panel will address topics relating to the systemic treatment of distant metastatic disease from squamous cell carcinoma of the head and neck (SCCHN), with an emphasis on recent randomized data, as well as current clinical trial therapies and related issues.
Scientific Program

At the conclusion of the panel, the participants will be able to:

- Identify and understand the current data guiding standard-of-care systemic treatment for recurrent and/or metastatic SCCHN in the first line setting.
- Identify and understand the current data guiding standard-of-care systemic treatment for recurrent and/or metastatic SCCHN in the salvage setting.
- Understand selected current strategies and ongoing clinical trial efforts in the development of new systemic therapies for recurrent and/or metastatic SCCHN.

CARCINOMA OF THE ORAL TONGUE

Panel Moderator: Anil K. D’Cruz, MD

Introduction

Prognostic Factors, Molecular Genetics and Management of Tumors Anthony Po-Wing Yuen, MBBS, FRCS, FHKAM

Surgical Management, Reconstruction and Quality of Life Issues After Resection Snehal Patel, MD

Radiotherapy and Postoperative Adjuvant Treatments in Early Tongue Cancers Vincent Grégoire, MD, PhD

Role of Chemo in Multidisciplinary Care Bonnie S. Glisson, MD

Reconstruction of the Oral Tongue- Surgical Techniques Uttam K. Sinha, MD

At the conclusion of this panel, participants will be able to:

- Understand the global incidence of tongue cancers.
- Understand the role of the work up, MRI and intraoral ultrasound measurement of tumor thickness in tongue cancers.
- Identify brachytherapy/external beam and postoperative adjuvant treatments.
- Understand the role of organ preservation, as induction, in palliation and chemoprevention in carcinomas of the tongue.
- Understand when to reconstruct the oral tongue, surgical techniques and QOL issues

15:45 - 17:15

PROFFERED PAPERS

BASIC SCIENCE: EXPERIMENTAL THERAPEUTICS/TISSUE ENGINEERING

Moderators: Lisa Licitra, MD and Antti Makitie, MD

S208: PREVENTING HPV+ HNSCC USING AN ADENOVIRAL VACCINE THAT TARGETS HPV16 VIRAL ONCOGENES D.Wook Lee¹, S.Woo¹, M.E.Anderson¹, J.H.Lee¹, ¹University of Iowa, Iowa City

S209: FG2-RETARGETED ADENOVIRAL GENE THERAPY FOR MRN DISRUPTION INDUCES CISPLATIN CHEMOSENSITIZATION FOR HEAD AND NECK CANCER K.Aoki¹, S.M.Ahmed¹, W.Abuzeid¹, D.Wang¹, E.Katme¹, B.W.O’Malley¹, D.Li¹ ¹University of Pennsylvania School of Medicine, Philadelphia, PA

S210: ETHANOL TRIGGERS APOPTOSIS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA R.Rahmati¹, G.Sun¹, G.Kouike¹, Y.Tokumaru¹ ¹National Tokyo Medical Center, Tokyo, Japan

S211: IDENTIFICATION OF STEM-LIKE CELLS IN HEAD AND NECK CANCER CELL LINES M.Fuji¹, G.Sun¹, H.Kouike¹, Y.Tokumaru¹ ¹National Tokyo Medical Center, Tokyo, Japan

S212: NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PEPTIDE-SPECIFIC T CELLS FOR COMBINATORIAL THERAPY WITH EGFR-SPECIFIC ANTI PA.Andrade Filho¹, A.Lopez-Albalerot, R.L. Ferris¹, ¹University of Pittsburgh, Pittsburgh, PA

S213: THE TOLL-LIKE RECEPTOR 9 AGONIST ODN1826 INHIBITS CACHEXIA AND TUMOR GROWTH IN C26 TUMOR-BEARING MICE M.R.Goer³, S.A.Asher¹, D.Bellnier¹, D.J.Heaton¹, R.L. Ferris¹, ¹University of North Carolina School of Medicine, Chapel Hill, NC; ²Duke University School of Medicine, Durham, NC; ³Lineberger Clinical Cancer Center, UNC-Chapel Hill, Chapel Hill, NC

S214: VOCAL FOLD TISSUE ENGINEERING USING ADIPOSE DERIVED STEM CELLS: EFFECT OF SCAFFOLD MATERIALS ON GENE EXPRESSION H.Park¹, S.Karajanagi2, J.B.Kobler¹, G.Lopez-Guerra¹, J.T.Heaton¹, R.S.Langer², S.M.Zeitels¹, ¹Massachusetts General Hospital, Boston, MA; ²Massachusetts Institute of Technology, Cambridge, MA

S215: ACUTE VASCULAR DISRUPTION INDUCED BY ASA404 IN AN ORTHOTOPIC MODEL OF HUMAN HEAD AND NECK CANCER M.Seshadri¹, S.D.Oven¹, B.G.Trautman¹, L.G.Heberer¹, N.R.Rigual¹, ¹Roswell Park Cancer Institute, Buffalo, NY

CLINICAL: SKIN/MELANOMA/SARCOMA

Moderators: Remco De Bree, MD, PhD and Gary L. Ross, MD

S217: INFLUENCE OF NECK DISSECTION +/- RADIOTHERAPY ON REGIONAL CONTROL IN PATIENTS WITH MELANOMA NECK NODE METASIASIS O.Hamming-Vrieze¹, A.J.M.Bals¹, T.Hoof van Huysduynen¹, W.D.Heesmens¹, C.R.N.Rasch¹, ¹Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

S218: THE BENEFIT OF ADJUVANT POST-OPERATIVE RADIOTHERAPY TO CERVICAL LYMPH NODES IN CUTANEOUS MELANOMA M.D.Macrie¹, K.F.Shih¹, J.Clark², W.H.McCarty¹, K.Goo³, J.O’Brien³, J.F.Thompson³, ¹Sydney Melanoma Unit, Sydney, Australia; ²Sydney Head & Neck Cancer Institute, Sydney, Australia; ³Sydney Head & Neck Cancer Institute, Sydney, Australia

www.ahns.info
5219: THE MANAGEMENT AND PROGNOSIS OF CERVICAL NODE METASTASES IN CUTANEOUS MELANOMA R.Martin1, K.F.Shannon2, C.J.O’Brien2, K.Gao2, M.Coleman1, J.F.Thompson1, 1Sydney Melanoma Unit, Sydney, Australia; 2Sydney Head & Neck Cancer Institute, Sydney, Australia

5220: SINOSAL MUCOSAL MELANOMA: A RETROSPECTIVE REVIEW OF 18 CASES AND OUTCOMES K.Nagashima1, O.Kucuk2, L.Heilbrun2, R.Mathog1, M.Carron1, 1Wayne State University School of Medicine, Detroit, MI; 2Karmanos Cancer Center, Detroit, MI

5221: SINOSAL MUCOSAL MELANOMA: THE MD ANDERSON CANCER CENTER EXPERIENCE M.A.Mareno1, D.B.Roberts1, M.E.Kuperman1, F.DeMonte1, A.K.El-Naggar1, M.D.Williams1, D.Rosenthal1, R.S.Weber1, E.Y.Hanna1, 1MD Anderson Cancer Center, Houston, TX

5222: COMPLETE SURGICAL RESECTION FOLLOWED BY POST-OPERATIVE RADIOThERAPY IN THE TREATMENT OF HEAD AND NECK MUCOSAL MELANOMA J.I.Gomez1, 1Memorial Sloan Kettering Cancer Center, NYC, NY

5223: SENTINEL LYMPH NODE BIOPSY FOR HEAD AND NECK CUTANEOUS MELANOMA A.B.Frano1, T.M.Johnson1, C.R.Bradford1, 1University of Michigan, Ann Arbor, MI

5224: EXTRACAPSULAR SPREAD IN REGIONAL METASTASIS FROM SQUAMOUS CELL CARCINOMA OF THE SKIN R.J.Walker1, D.Oliver1, M.A.Varvares1, 1Saint Louis University, Saint Louis, MO

5225: CARCINOSARCOMAS OF HEAD AND NECK: CLINICAL OUTCOME OF 56 PATIENTS TREATED IN A SINGLE INSTITUTION K.L.Fernandes1, F.L.Dias1, R.A.Lima1, U.B.Tascano2, R.A.Sepeulver1, A.L.Costa1, P.C.Maio Filho1, P.B.R.Milei1, T.P.Farias1, F.G.Botelho1, 1Brazilian National Cancer Institute-BNCI, Rio de Janeiro, Brazil; 2Brazilian National Cancer Institute-BNCI, Rio de Janeiro, Brazil

IMAGING

Moderators: Patricia A. Hudgins, MD and Rainald Knecht, MD, PhD

5226: DETECTION OF LUNG TUMOURS IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AT THE TIME OF PRESENTATION A.K.Ghosh1, A.K.Kumar2, S.Tandon3, N.J.Roland3, J.Lancaster3, S.R.Jackson3, H.Lewis Jones3, R.Hanlon3, T.M.Jones4, Aintree University Hospital Foundation NHS Trust, Liverpool, United Kingdom; 2Aintree University Hospital Liverpool, United Kingdom; 3University Hospital Aintree, Liverpool, United Kingdom; 4University Hospital Aintree, Liverpool, United Kingdom

5227: THE ROLE OF IMAGING STUDIES FOR THE DETECTION OF RETROPHARYNGEAL LYMPH NODE METASTASIS IN HEAD AND NECK CANCER H.Chu1, I.Park1, J.Kim1, Y.Roh1, D.Yoon1, 1Hallym University Medical Center, Seoul Republic of Korea

5228: DYNAMIC CONTRAST-ENHANCED MR IMAGING: A RELIABLE DIAGNOSTIC TOOL FOR RECURRENT HEAD AND NECK TUMORS E.M.Kamel1, B.Duvisoir2, P.Hauser2, I.Borchardt2, P.Schnyder2, P.Phaske2, 1Lausanne University Hospital, Lausanne, Switzerland; 2Lausanne University Hospital, Lausanne, Switzerland

5229: PET-CT IN THE MANAGEMENT OF HEAD AND NECK MALIGNANCIES: CLINICAL CORRELATION IMPROVES ACCURACY OF INTERPRETATION M.A.Varvares1, D.J.Weinhart1, M.Amine1, D.S.Oliver1, M.J.Odell1, N.C.Nguyen1, M.M.Osman1, St Louis University, St Louis, MO

5230: UTILIZATION OF FDG PET SCANS ON NODAL STAGING IN PATIENTS WITH SQUAMOUS CELL CARCINOMA IN ORAL CAVITY AND OROPHARYNX M.Kim1, J.Yoo1, K.Choo1, Y.Park1, I.Yoo1, The Catholic University of Korea, College of Medicine, Seoul Republic of Korea

5231: IS THERE AN ADDITIONAL VALUE OF SPECT/CT OVER LYMPHOSCINTIGRAPHY FOR SENTINEL NODE MAPPING IN ORAL/OROPHARYNGEAL SCC S240: QUANTITATIVE EXPRESSION AND IMMUNOGENICITY OF MAGE-3 IN UPPER AERODIGESTIVE TRACT CANCER AND AFTER SURGERY M.E.Kupferman1, F.DeMonte1, A.K.El-Naggar1, M.D.Williams1, D.Rosenthal1, R.S.Weber1, E.Y.Hanna1, 1MD Anderson Cancer Center, Houston, TX

5232: SCREENING OF HYPOPHARYNGEAL CANCER WITH HOODED VIDEOENDOSCOPY AND NARROW BAND IMAGING FOR ESOPHAGEAL CANCER PATIENTS K.Okami1, A.Sakai1, T.Hamano1, K.Sugimoto1, H.Shimada2, S.Yamamoto2, H.Makuchichi2, M.Iida1, Dept. of Otolaryngology, Tokai University, Isehara, Japan; 2Dept. of Surgery, Tokai University, Isehara, Japan

5233: RECOGNIZING THE NECK: INTEROBSERVER VARIABILITY IN THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS FOR HEAD/NECK CANCERS D.Grozicz1, Y.Anzai1, D.Shibata1, 1University of Washington, Seattle, WA

5234: AUTOFLUORESCENCE IMAGING AND MOLECULAR MARKERS COMBINED, PROVIDE A ROBUST PREDICTIVE STRATEGY IN ORAL CAVITY MALIGNANCY E.Barry1, P.Reis1, G.Bachas2, A.Douplik2, D.Goldstein2, B.Wilson2, J.Irish2, S.Kamel-Reid2, 1Princess Margaret Hospital, Toronto, Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Canada

TRANSLATIONAL: OTHER

5235: DEREGRULATED MICRORNA EXPRESSION IN PROGRESSION OF ESOPHAGEAL AND ORAL CARCINOMA N.K.Cervign1, P.Printor dos Reis1, N.Narangai Galliani1, G.Brady1, I.Iurisica1, F.Pugliane2, J.Irish4, S.R.Ragga1, S.Kamel-Reid1, 1Ontario Cancer Institute and University Health Network, Toronto, ON, Canada; 2Faculty of Dentistry, University of Toronto, Toronto, ON, Canada; 3MaRS Centre, Toronto Medical Discovery, University Health Network, Toronto, ON, Canada; 4Princess Margaret Hospital, University Health Network, Toronto, ON, Canada; 5GeneCine Laboratory, Faculty of medicine, UNESP, Botucatu, SP, Brazil

5236: MICROVASCULAR CHANGES IN ORAL MUCOSITIS S.J.Hamilton1, J.Yoo2, A.Badhiwar3, A.Hammond2, V.Venkatesan2, N.Read2, 1London Health Sciences Centre, London, ON, Canada; 2London Regional Cancer Program, London, ON, Canada; 3Lawson Health Research Institute, London, ON, Canada

5237: BIOENGINEERED HUMAN SALIVARY GLAND TISSUE FOR THE TREATMENT OF RADIATION INDUCED XEROSTOMIA C.A.Cleland1, J.Yoo1, S.Sakari1, A.Ato1, 1Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC

5238: PHASE III RANDOMIZED STUDY COMPARING PILOCARPINE VS. SUBMANDIBULAR GLAND TRANSFER PROTOCOL FOR MANAGEMENT OF XEROSTOMIA N.Ioka1, J.Harris2, H.Seikaly2, D.Williams2, K.Sultanum3, M.Hier3, J.Butter4, P.Kern4, M.Black4, S.Ghosh5, 1Cross Cancer Institute, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada; 3McGill University, Montreal, PQ, Canada; 4University of Manitoba, Winnipeg, MB, Canada; 5Cross cancer institute, University of Alberta, Edmonton, AB, Canada

5239: TELOMERASE ACTIVITY IN PERIPHERAL WHOLE BLOOD OF HEAD AND NECK SQUAMOUS CELL CARCINOMA PATIENT BEFORE AND AFTER SURGERY Y.lee1, K.Tae1, K.Shin1, J.Chung1, K.Kim1, S.Lee1, 1Hanyang University Hospital, Seoul, Republic of Korea

5240: QUANTITATIVE EXPRESSION AND IMMUNOGENICITY OF MAGE-3 IN UPPER AERODIGESTIVE TRACT CANCER P.A.Andrade1, A.Lopes-Albair2, M.K.Kit1, J.W.Rocco3, W.Gooding4, T.Godfrey5, R.L.Ferris1, 1University of Pittsburgh, Pittsburgh, PA; 2Mount Sinai School of Medicine, New York, NY; 3Massachusetts Eye and Ear Infirmary, Boston, MA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA; 5Mount Sinai School of Medicine, New York, NY, New York, NY

www.ahns.info
S241: A NON-INVASIVE DIAGNOSTIC TECHNIQUE USING TIME-RESOLVED LASER-INDUCED FLUORESCENCE SPECTROSCOPY IN THE HAMSTER MODEL
J.Meire1, H.Coffman1, J.Park2, L.Marcu2, Y.Sun2, Y.Sun2, S.Tinling2, B.Poirier1, D.J.Enepekides3, D.Greg.Farwell1, 1University of California, Davis Medical Center, Sacramento, CA; 2University of California, Davis, Davis, CA; 3University of Toronto, Toronto, ON, Canada

S242: A THREE-DIMENSIONAL INTERACTIVE PATHOLOGY VISUALIZATION SYSTEM
K.A.Peperzak1, D.E.Eibling1, B.E.Chapman1, 1University of Pittsburgh, Pittsburgh, PA

S243: A THREE-DIMENSIONAL INTERACTIVE PATHOLOGY VISUALIZATION SYSTEM
K.A.Peperzak1, D.E.Eibling1, B.E.Chapman1, 1University of Pittsburgh, Pittsburgh, PA

17:15 - 18:15
AHNS BUSINESS MEETING
YERBA SALON 8

18:15 - 19:45
MONDAY POSTER SESSION WITH WINE AND CHEESE
GOLDEN GATE HALL 8

POSTER TOUR MODERATORS: Multidisciplinary Care: Paul M. Spring, MD; Thyroid/Parathyroid: David J. Terris, MD; General: Christine G. Gourin, MD

Basic Science: Biomarkers
Basic Science: Experimental Therapeutics
Chemotherapy
Epidemiology
Imaging/Early Detection
Melanoma
Nonmelanoma Skin
OralCavity II
Parathyroid II
Radiation
Reconstruction II
Sarcoma
Skull Base II
Speech/Swallowing/QOL II
Surgery
Targeted Therapy
Thyroid II

POSTER SESSIONS SUPPORTED BY GENEROUS EDUCATIONAL GRANTS FROM OUR BRONZE LEVEL DONORS
EUSA PHARMA/CYTOGEN
IBA PARTICLE THERAPY
OMNIGUIDE
STRYKER
VARIAN MEDICAL SYSTEMS

19:30 - 22:00
DINNER SATELLITE SYMPOSIUM: “TRANSORAL LASER MICRO SURGERY: TOWARDS ESTABLISHING A NEW STANDARD OF CARE IN HEAD AND NECK CANCER”
YERBA SALON 1-3

A panel discussion on the latest innovations in endoscopic Head & Neck surgery, current clinical data and the health economics considerations of TLM vs. open surgery or radiation and chemotherapy.

Presenting:
Bruce Haughey, MD, MBChB, FACS, FRACS, Washington University School of Medicine
Eric Genden, MD, FACS, Mount Sinai School of Medicine
Guy Petruzzelli, MD, PhD, MBA, FACS Rush University Medical Center
Petra Ambrosch, MD, Klinikum Christian-Albrechts Universitat, Kiel
Yoel Fink, PhD, CEO, OmniGuide, Inc.

Moderating:
Chris Holsinger, MD, FACS, University of Texas MD Anderson Cancer Center

This is a non-CME activity presented and supported by OmniGuide.
<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:30 - 08:00</td>
<td>BREAKFAST SATELLITE SYMPOSIUM: “A CALL TO ACTION: ASSESSING NEW STANDARDS OF CARE IN ADVANCED HEAD AND NECK CANCER”</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td>06:30 - 08:00</td>
<td>BREAKFAST SATELLITE SYMPOSIUM: “NEW PARADIGM FOR THE TREATMENT FOR HEAD AND NECK CANCER”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>08:00 - 08:45</td>
<td>NEW YORK HEAD AND NECK SOCIETY LECTURE: “NASOPHARYNGEAL CANCER”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>08:45 - 09:15</td>
<td>KEYNOTE LECTURE: “RADIATION THERAPY”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>09:15 - 10:00</td>
<td>HAYES MARTIN LECTURE: “HEAD AND NECK CANCER IN THE 21ST CENTURY: MOLECULAR TARGETS FOR TREATMENT AND PREVENTION”</td>
<td>YERBA SALON 7-8</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PANEL: IMRT AND OTHER CONFORMAL TECHNIQUES</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PANEL: MELANOMA/NON-MELANOMA SKIN CANCER</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PANEL: XRT AND TARGETED THERAPY</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PROFFERED PAPERS: BASIC SCIENCE: GENE PROFILING</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PROFFERED PAPERS: BEST OF CLINICAL II</td>
<td>YERBA SALON 1-3</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>PROFFERED PAPERS: CLINICAL: RECONSTRUCTION II</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP17: ADJUVANT RADIOTHERAPY/ CHEMORADIOTHERAPY</td>
<td>PACIFIC A</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP18: HYPOXIA RESEARCH AND CLINICAL PRACTICE</td>
<td>PACIFIC B</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP19: IMAGING FOR RADIOTHERAPY PLANNING</td>
<td>PACIFIC C</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP20: NEUTRON/PROTON THERAPY</td>
<td>PACIFIC E</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP21: RADIATION FOR SALIVARY/THYROID CANCERS</td>
<td>PACIFIC F</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP23: SKULL BASE</td>
<td>PACIFIC I</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LWP24: VASCULAR TUMORS</td>
<td>PACIFIC J</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PANEL: FRONTIERS IN BASIC/TRANSLATIONAL RESEARCH OF HEAD AND NECK CANCERS</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PANEL: NASOPHARYNX</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PANEL: OROPHARYNX</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PROFFERED PAPERS: CLINICAL: NECK II/IMAGING</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PROFFERED PAPERS: CLINICAL: RECONSTRUCTION III</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PROFFERED PAPERS: CLINICAL: THYROID IV</td>
<td>YERBA SALON 1-3</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>PROFFERED PAPERS: OUTCOMES: RADIATION ONCOLOGY-OTHER</td>
<td>YERBA SALON 14-15</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PANEL: ADJUVANT THERAPY AFTER SURGICAL TREATMENT</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PANEL: EARLY LARYNGEAL CANCER</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PANEL: RECONSTRUCTION</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PROFFERED PAPERS: BASIC SCIENCE: IN VIVO/IN VITRO MODELING</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PROFFERED PAPERS: OUTCOMES: GENERAL</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PROFFERED PAPERS: OUTCOMES: REHABILITATION/Therapeutic Support</td>
<td>YERBA SALON 14-15</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>PROFFERED PAPERS: THYROID-PATHOLOGY/CYTOLOGY/GENETICS/ MOLECULAR BIOLOGY</td>
<td>YERBA SALON 1-3</td>
</tr>
<tr>
<td>17:30 - 19:00</td>
<td>TUESDAY POSTER SESSION</td>
<td>GOLDEN GATE HALL</td>
</tr>
<tr>
<td>19:00 - 21:00</td>
<td>AHNS PRESIDENT’S RECEPTION</td>
<td>YERBA SALON 9</td>
</tr>
</tbody>
</table>
TUESDAY, JULY 22, 2008

06:30 - 08:00  BREAKFAST SATELLITE SYMPOSIUM: “NEW PARADIGM FOR THE TREATMENT FOR HEAD AND NECK CANCER”  
YERBA SALON 7-8

Chairman: Dr. Gregory T. Wolf, Professor and Chair – Department of Otolaryngology, University of Michigan

I. Overview of Current Therapies for Head and Neck Cancer Arlene A. Forastiere, MD
II. Overcoming the Immunosuppressive Effects of Head and Neck Cancer Theresa L. Whiteside, MD
III. IRX-2: Promising New Immunotherapy for Head and Neck Cancer Gregory T. Wolf, MD
IV. Panel Discussion: The Role of Immunotherapy in Head and Neck Cancer Treatment

Moderator: Gregory T. Wolf, MD

THIS IS A NON-CME EVENT PRESENTED AND SUPPORTED BY IRX THERAPEUTICS.

06:30 - 08:00  BREAKFAST SATELLITE SYMPOSIUM: “A CALL TO ACTION: ASSESSING NEW STANDARDS OF CARE IN ADVANCED HEAD AND NECK CANCER”  
YERBA SALON 4-6

Symposium Chair: Marshall R. Posner, MD

06:30  Welcome and Introductory Remarks  
Marshall R. Posner, MD

06:40  New Directions and Ongoing Research: The Evolving Role of Targeted Biologic Agents in the Era of Chemoradiotherapy  
James A Bonner, MD

07:00  Integrating Management Modalities and Selecting Patients to Individualize Therapy  
Marshall Posner, MD

07:20  Therapeutic Options for Relapsed/Metastatic Disease: Opportunities for Improved Outcomes  
Jan B. Vermorken MD

07:40  Take Home Perspectives and Audience Questions  
Panel Discussion

08:00  Close

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Strategic Consultants International. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant provided by Bristol-Myers Squibb Company and ImClone Systems Incorporated.

NEW YORK HEAD AND NECK SOCIETY LECTURE: “NASOPHARYNGEAL CANCER”  
YERBA SALON 7-8

William I. Wei, MD, Queen Mary Hospital, Hong Kong, China

Introduction by Mark E. Izzard, MD

08:45 - 09:15  KEYNOTE LECTURE: “RADIATION THERAPY”  
YERBA SALON 7-8

Jens Overgaard, MD, Aarhus University Hospital, Aarhus, Denmark

Introduction by Paul M. Harari, MD
**Scientific Program**

**09:15 - 10:00**

**HAYES MARTIN LECTURE:**

"HEAD AND NECK CANCER IN THE 21ST CENTURY: MOLECULAR TARGETS FOR TREATMENT AND PREVENTION"

Waun Ki Hong, MD, MD Anderson Cancer Center, Houston, Texas, USA

Introduction by Gregory T. Wolf, MD

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM
BRISTOL MEYERS SQUIBB AND IMCLONE SYSTEMS

---

**10:00 - 13:30**

**EXHIBIT HALL OPEN**

**10:30 - 12:00**

**SCIENTIFIC SESSIONS – Panels**

**XRT AND TARGETED THERAPY**

Panel Moderator: James A. Bonner, MD

- **Introduction to Radiotherapy with Targeted Agents**
  - James A. Bonner, MD

- **Optimizing Combinations of Radiation with Cetuximab and Other Agents**
  - Kie-Kian Ang, MD, PhD

- **The Future Implications of Hypoxia in the Treatment of Head and Neck Cancer**
  - Jean Bourhis, MD, PhD

- **Targeted Therapies and Radiation: What Lies Beyond EGFR Inhibition?**
  - David Raben, MD

- **The Role of Surgery in Patients Treated with Organ-Preservation Strategies**
  - Eben L. Rosenthal, MD

At the conclusion of this panel, participants will be able to:

- Understand the multidisciplinary approach to locoregionally advanced head and neck cancer.
- Identify promising new targeted therapies in head and neck cancer.
- Appreciate how targeted therapies may enhance the effects of radiation or chemotherapy.
- Understand the complex role of surgery when organ preservation is the initial intent.

AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM
BRISTOL MEYERS SQUIBB AND IMCLONE SYSTEMS

**IMRT AND OTHER CONFORMAL TECHNIQUES**

Panel Moderator: Jonathan J. Beitler, MD, FACP

- **Chemo/IMRT is Either Too Toxic or Too Dangerous – Pro**
  - Avraham Eisbruch, MD

- **Chemo/IMRT is Either Too Toxic or Too Dangerous – Con**
  - Vincent Grégoire, MD, PhD

- **Neck Dissections are Irrelevant – Pro**
  - Avraham Eisbruch, MD

- **Neck Dissections are Irrelevant – Con**
  - Clifford K.S. Chao, MD

- **The Radiation Oncologists Cannot Reproducibly Choose What to Treat – Pro**
  - Clifford K.S. Chao, MD

- **The Radiation Oncologists Cannot Reproducibly Choose What to Treat – Con**
  - Vincent Grégoire, MD, PhD

At the conclusion of the panel, participants will be able to:

- Understand the potential benefits and liabilities of definitive chemotherapy and IMRT for treatment of head and neck malignancies.
- Understand and appreciate the uncertainties in target volume definitions when planning IMRT treatment.

**MELANOMA/NON-MELANOMA SKIN CANCER**

Panel Moderator: Claudio R. Cernea, MD

- **Introduction**
  - Claudio R. Cernea, MD

- **Imagining Diagnosis of Perineural Invasion by Nonmelanoma Skin Cancer: Is it feasible?**
  - Lawrence E. Ginsberg, MD

- **Clinical Staging of Metastatic Cutaneous Squamous Carcinoma of the Head and Neck: Relevance of Parotid Metastases**
  - Kerwin F. Shannon, MD

- **Sentinel Lymph Node Biopsy of Head and Neck Melanomas: State of the Art**
  - Jesus E. Medina, MD

At the conclusion of the panel, participants will be able to:

- Understand preoperative evaluation of perineural invasion by skin carcinomas.
• Understand prognostic relevance of perineural invasion by skin carcinomas.
• Understand state of the art of sentinel lymph node biopsy in head and neck melanomas.
• Understand management of skin carcinomas with skull base invasion.

PROFFERED PAPERS

BASIC SCIENCE: GENE PROFILING

Moderators: Thomas E. Carey, PhD and Luiz P. Kowalski, MD, PhD

S244: THE ROLE OF PGRPR AS A TUMOR SUPPRESSOR GENE IN HEAD AND NECK CANCER Y.Tokumaru1, M.Fujii1, K.Yamashita2, M.S.Kim3, H.L.Park3, M.Osada3, J.A.Califano3, D.Sidransky3, 1Tokyo Medical Center, Tokyo, Japan; 2Kitasato University, Tokyo, Japan; 3Johns Hopkins University, Baltimore, MD

S245: THE PROGNOSTIC SIGNIFICANCE OF TUMOR HIF-1381 EXPRESSION FOR OUTCOME FOLLOWING RADIOTHERAPY IN OROPHARYNGEAL CANCER P.Silva1, K.Slevin2, P.Sloan3, P.Price4, C.West4, J.Homer1, 1Department of Clinical Oncology, Christie Hospital, Manchester, United Kingdom; 2Department of Clinical Oncology, Christie Hospital, Manchester, United Kingdom; 3Dental Hospital, Manchester, United Kingdom; 4Academic Radiation Oncology, Christie Hospital, Manchester, United Kingdom

S246: EXPRESSION OF CD24, EGFR, AND MDM2 PREDICT DISEASE-FREE SURVIVAL IN PATIENTS WITH ADVANCED LARYNGEAL CANCER B.Kumar1, K.O.Cordell1, M.E.Prince1, J.S.Lee1, N.J.D’Silva1, G.T.Wolf1, A.El-Naggar2, S.G.Usba1, T.E.Carey1, C.R.Bradford1, 1University of Michigan, Ann Arbor, MI; 2MD Anderson Cancer Center, Houston, TX

S247: RESPONSE TO CHEMORADIATION IS PREDICTED BY LOW EXPRESSION OF BAK AND NFKAPPA2 IN ADVANCED LARYNGEAL CANCER P.Scarl1, K.O.Cordell1, M.E.Prince1, J.S.Lee1, N.J.D’Silva1, G.T.Wolf1, S.G.Usba1, T.E.Carey1, C.R.Bradford1, 1University of Michigan, Ann Arbor, MI

S248: BIOMARKERS IN DYSPLASIA OF THE ORAL CAVITY: A SYSTEMATIC REVIEW J.A.Smith1, T.Rattay1, H.M.Mehanna1, 1The Institute of Head and Neck Studies and Education, Coventry, United Kingdom

S249: CLINICAL SIGNIFICANCE OF LOSS OF HETEROZYGOSITY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA M.Kim1, Y.Park1, D.Sun1, S.Cho1, 1The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

S250: MOLECULAR STAGING OF SURGICALLY TREATED HEAD AND NECK CANCER PATIENTS A.Graveland1, M.de Maaker1, B.J.M.Braakhuis1, R.de Bree1, S.E.J.Eerenstein1, E.Bloemena1, C.Leemans1, R.H.Brakenhoff1, 1VU University Medical Center, Amsterdam, The Netherlands

S251: FC3B3RIIIA POLYMORPHISMS AND CETUXIMAB INDUCED CYTOTOXICITY IN SQUAMOUS CARCINOMA OF THE HEAD AND NECK R.Taylor1, S.Chan1, A.Wood2, C.Voskens1, J.Wolf1, L.Weil1, A.Chapoval1, D.Schulze1, S.Strome1, 1University of Maryland School of Medicine, Baltimore, MD; 2University of Maryland, Baltimore

S252: HEDGEHOG SIGNALLING PATHWAY IN MERKEL CELL CARCINOMA M.Brunner1, D.Thurnher1, J.Pomer1, S.Geoff1, G.Heiduschka1, C.Reinisch1, M.Grais1, B.M.Erovic1, 1Medical University, Vienna, Austria

BEST OF CLINICAL II

Moderators: Jose G. Vartanian, MD and John H. Yoo, MD

S253: INDUCTION CHEMOTHERAPY SELECTS FOR THE SUCCESSFUL TREATMENT OF ADVANCED LARYNGEAL CANCER WITH CARCILAGE INVASION J.S.Moyer1, F.Worden1, A.Eisbruch1, C.Bradford1, D.Chepeha1, T.Teknos1, M.Prince1, A.Lassig1, K.Emerick1, G.Wolf1, 1University of Michigan, Ann Arbor, MI

S254: COLOUR FLOW DOPPLER ASSESSMENT OF THE ANTEROLATERAL THIGH: INTRA-OPERATIVE CORRELATION AND UTILITY ASSESSMENT K.M.Higgins1, D.Enepikides2, 1Sunnybrook Health Sciences Centre/Odette Cancer Centre, Toronto, ON, Canada; 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada

S255: SHOULDER DISABILITY FOLLOWING PECTORALIS MAJOR FLAP RECONSTRUCTION R.V.Maukarbe1, J.Franklin1, J.Yoo1, R.Rastogi1, C.Anderson1, K.Fung1, 1University of Western Ontario, London, ON, Canada

S256: GELDANAMYCIN TREATMENT RADIOSENSITIZE HEAD AND NECK CARCINOMA CELLS BY PROMOTING EGFR DEGRADATION A.Ahson1, M.A.Davis1, T.S.Lawrence1, M.K.Nyquist1, 1Univ of Michigan, Ann Arbor, MI

S257: FDG-PET/CT IMAGING DOES NOT IMPACT POST-RADIATION RESPONSE ASSESSMENT FOR ADVANCED HEAD AND NECK CANCER B.Goh1, B.A.Cannon1, K.Kang1, G.M.Chronowski1, S.J.Frank1, A.S.Garden1, W.H.Morrison1, D.I.Rosenthal1, D.L.Schwartz1, 1MD Anderson Cancer Center, Houston, TX

S258: MOLECULAR IMAGING OF SENTINEL LYMPH NODE METASTASES USING ONCOCYTIC HERPES SIMPLEX VIRUS-MEDIATED TRANSGENE EXPRESSION G.Cantù1, P.Brasier1, K.Kelly1, J.P.Shah1, R.J.Wong1, Y.Fong1, 1Memorial Sloan Kettering Cancer Center, New York, NY

S259: EARLY EXPERIENCE USING TIME- AND SWEPT SOURCE FREQUENCY DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN HEAD AND NECK ONCOLOGY C.S.Betz1, H.Stepp1, W.Jerjes2, B.Conn3, A.Leunig1, C.Hopper2, 1Ludwig Maximilian University, Munich, Germany; 2University College London, London, United Kingdom; 3Royal Free and University College Medical School, London, United Kingdom

S260: MARGINAL MANDIBULAR NERVE INJURY IN NECK DISSECTION AND ITS IMPACT ON PATIENTS PERCEPTION OF APPEARANCE M.D.Batsone1, B.Sacle2, S.N. Rogers2, 1University Hospital Aintree, Liverpool, Australia; 2University Hospital Aintree, Liverpool, United Kingdom

S261: THE INFLUENCE OF PASSIVE VS SUCTION DRAINAGE ON COMPLICATIONS FOLLOWING NECK DISSECTION M.D.Batsone1, R.J.Shaw2, J.S.Brown2, E.D.Vaughan2, D.Lowe2, S.N.Rogers2, 1University Hospital Aintree, Brisbane, Australia; 2University Hospital Aintree, Liverpool, United Kingdom

CLINICAL: RECONSTRUCTION II

Moderators: Frederic W.B. Deleyiannis, MD and Hadi Seikal, MD, FRCS

S262: MANDIBULAR RECONSTRUCTION WITH AUTOLOGOUS FREEZE-TREATED BONE AFTER MALIGNANT TUMOR RESECTION. AN EXPERIENCE OF 72 CASES G.Cantù1, G.Bimbi1, S.Riccio1, M.Squadrelli1, 1National Cancer Institute, Milano, Italy
Scientific Program

5263: BONE IMPACTED FIBULA (BIF), A NEW TECHNIQUE OF INCREASING BONE DENSITY FOR PLACING DENTAL IMPLANTS
H.Seikaly1, A.M.Mlynares1, J.Rieger1, R.Swan1, A.Hrdlicka2, D.Raboud2, K.Ansari1, K.Al-Qahtani1, J.Wolfraad1, J.R.Harris1, 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada

5264: MICROVASCULAR RECONSTRUCTION OF THE MANDIBLE: CAN FIXATION BE TOO RIGID? R.A.Zoumalan1, D.Hirsch1, J.Levine1, P.Saadah1, 1New York University, New York, NY

5265: RECONSTRUCTION AFTER ORAL CANCER ABLATION: COMPARISON OF MICROSURGICAL FLAPS OR THE PECTORALIS MAJOR MYOCUTANEOUS FLAP M.L.Rodrigues1, H.F.Koehler2, J.G.Vartanian1, A.Bressan1, J.CM.de Faria1, L.P.Kowski1, 1Hospital A C Camargo, São Paulo, Brazil; 2State University of Campinas, São Roque, Brazil

5266: A PROSPECTIVE ANALYSIS OF FACTORS PREDICTING MORBIDITY IN MICROVASCULAR FREE FLAP RECONSTRUCTION: INDICATIONS, CHALLENGES, AND PROSPECTIVE FUNCTIONAL OUTCOMES K.Harris1, J.P.Guillemaud1, D.Cole1, J.M.Rieger2, J.Wolfraad2, M.Nesbit1, H.Seikaly1, 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada

5267: THE INCREASING USE OF DOUBLE FREE FLAP RECONSTRUCTION: INDICATIONS, CHALLENGES, AND PROSPECTIVE FUNCTIONAL OUTCOMES K.Harris1, J.P.Guillemaud1, D.Cole1, J.M.Rieger2, J.Wolfraad2, M.Nesbit1, H.Seikaly1, 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada

5268: COMBINATORIAL THERAPY FOR HEALING CRANIAL DEFECTS COMPROMISED BY PREOPERATIVE RADIATION B.Nussenbaum1, Z.Wang2, P.Krecbsadski1, 1Washington University School of Medicine, Saint Louis, MO; 2University of Michigan, Ann Arbor, MI

5269: THE ROLE OF SALVAGE SURGERY IN RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA M.E.Zafeiroo1, M.M.Hanasono1, D.I.Rosenthal1, E.M.Sturgis1, J.S.Levin1, D.B.Roberts1, R.S.Weber1, 1MD Anderson Cancer Center, Houston, TX

5270: MICROVASCULAR RECONSTRUCTION IN THE SETTING OF PRIOR RADIATION WITH CONCOMITANT INTRAARTERIAL CHEMOTHERAPY (RADPLAT) B.Helton1, T.J.Cal1, J.Valentino1, R.Ushikrishnan1, M.Kudrimoti1, S.M.Arnold1, 1University of Kentucky, Lexington, KY

LASER AND OTHER PHYSICAL THERAPIES

Moderators: Petra Ambrosch, MD, PhD and Gregory S. Weinstein, MD

5271: IMPACT OF RESECTION MARGINS IN EARLY GLOTTIC CANCER TREATED BY CO2 LASER ON LOCAL CONTROL, AND ORGAN PRESERVATION M.Ansarin1, L.CalaBrese1, G.GiugiGano1, M.A.Massaro1, L.Santoro1, F.Maffini1, F.Chiesa1, 1European Institute of Oncology, Milan, Italy

5272: PHONOSURGICAL TREATMENT OF EARLY GLOTTIC CANCER: INNOVATIONS THROUGH THE PAST 15 YEARS S.M.Zeitels1, G.Lopez-Guerra1, J.A.Burns1, 1Harvard Medical School, Boston, MA

5273: FUNCTION PRESERVING TRANSORAL LASER MICROSURGERY (TLM) FOR CANCER OF THE ORAL CAVITY A.Martin1, M.C.Jaeckel2, H.Christiansen1, M.Meyer1, M.Kron3, W.Steiner1, 1University of Essen, Essen, Germany; 2University of Ulm, Ulm, Germany

5274: LASER VESTIBULECTOMY FOR SUPRAGLOTTIC CARCINOMAS: FEASIBILITY AND LONG TERM RESULTS P.Demez1, P.Moreau1, 1CHU Liége, Liége, Belgium

5275: ENDOSCOPIC CO2 LASER SUPRAGLOTTIC LARYNGECTOMY(ELSI): MULTICENTER ANALYSIS OF 144 CASES G.Lawan1, P.Moreau2, B.Guerrier3, D.Chevallier3, G.Poissne3, A.Cosmil4, M.Remacle1, J.Jamart1, B.Toussaint7, 1Cliniques universitaires UCL de Mont-Godinne, Yuvar, Belgium; 2CHU de Liége, Liége, Belgium; 3CHU Montpellier, Montpellier, France; 4CHU Lille, Lille, France; 5Centre Antoine Lacassagne Nice, Nice, France; 6CHU Lyon, Lyon, France; 7CHU Nancy, Nancy, France

5276: CLINICAL IMPACT OF INTRODUCING SUPRACRICOID LARYNGECTOMY WITH CHEP TO TREAT GLOTTIC CANCERS: EXPERIENCE ON 41 PATIENTS M.Nakayama1, Y.Seino1, S.Hayashi1, S.Miyamoto1, M.Takeda1, M.Okamoto1, 1Kitasato University School of Medicine, Sagamihara Kanagawa, Japan

5277: TRANSORAL LASER MICROSFURGERY FOR HYPOPHARYNGEAL CANCER D.G.Grant1, J.R.Salassa1, M.L.Hinni2, R.E.Hayden2, B.W.Pearson1, W.E.Perry2, 1Mayo Clinic, Jacksonville, FL; 2Mayo Clinic, Arizona, AZ

5278: TREATMENT OF PHARYNGEAL CARCINOMAS BY LASER ENDOSCOPIC MICROSFURGERY P.Moreau1, O.Bouchain2, P.Demez2, 1University of Liége, Liége, Belgium; 2University of Liége, Liége, Belgium

5279: PALLIATION OF RECURRENT HEAD AND NECK CARCINOMA WITH INTERSTITIAL PHOTODYNAMIC THERAPY M.H.Wijes1, S.de Visscher1, J.LN.Roodenburg1, B.Tan2, 1University Medical Center, Groningen, The Netherlands; 2Netherlands Cancer Institute, Amsterdam, The Netherlands

= extra fees for session.
13:30 - 15:00

SCIENTIFIC SESSIONS – Panels

**NASOPHARYNX**
Panel Moderator: Nancy Lee, MD

- Neuroradiology of Nasopharyngeal Cancer, Diagnosis and Patterns of Spread
  - Yoshimi Anzai, MD

- Combined Modality Therapy for Nasopharyngeal Cancer
  - Lillian Siu, MD

- Treatment of Recurrent Nasopharyngeal Cancer
  - Stuart Wong, MD

- Intensity-modulated Radiation Therapy for Nasopharyngeal Cancer Focusing on Target Delineation
  - Yungpo Bernard Su, MD

This panel will address topics relating to the diagnosis, imaging, and treatment of nasopharyngeal cancer. At the conclusion of the panel, the participants will be able to:

- Understand the imaging characteristics and patterns of spread for nasopharyngeal cancer.
- Understand the multidisciplinary treatment approach for nasopharyngeal cancer.
- Understand the role of reirradiation and chemotherapy for recurrent nasopharyngeal cancer.
- Understand the importance of accurate target delineation for nasopharyngeal cancer when using intensity-modulated radiation therapy.

**OROPHARYNX**
Panel Moderator: David I. Rosenthal, MD

- Surgery: Indications and New Technology
  - Young-Ik Son, MD, PhD

- Understand the Rationale and Current Role of Induction Chemotherapy
  - David G. Pfister, MD

- HPV: Prognosis, Prevention, Treatment Selection
  - Frank Worden, MD

- Functional MR: Assessing Treatment Response
  - Laurie A. Loevner, MD

- Concurrent Chemoradiation for Stage III/IV: Initial or after induction
  - David I. Rosenthal, MD

This panel will address topics relating to oropharynx cancer, with an emphasis on treatment selection options and how they are affected by evolving developments in causation and the therapeutic and diagnostic modalities. The speakers are listed along with panel objectives related to the presentations. At the conclusion of the panel, the participants will be able to:

- Understand the still current indications for surgery in oropharynx cancer that has evolved in the last decade to a predominantly non-surgical disease.
- Understand the indications, contraindications, rationale, and options for induction chemotherapy.
- Understand the evolving role of HPV in causation, prevention, and affect on selection of treatment and treatment intensity for HPV+ tumors.
- Understand new and emerging MR imaging techniques to assess response to therapy.

**FRONTIERS IN BASIC/TRANSLATIONAL RESEARCH OF HEAD AND NECK CANCERS**
Panel Moderator: Joseph A. Califano, MD

- Emerging Utility of Kinase Inhibitors for the Treatment of Advanced Thyroid Cancers
  - Roger B. Cohen, MD

- Screening for Oral Precursor Lesions by a Non-Invasive Genetic Test
  - Ruud H. Brakenhoff, MD

- Hypothesis-driven Clinical Investigation Can Identify and Confirm Markers of Therapeutic Response in Head and Neck Squamous Cell Carcinoma
  - James Rocco, MD, PhD
Modulation of HNSCC Disease Progression by the Tumor Microenvironment

Stephen Y. Lai, MD, PhD

This panel will address topics relating to novel strategies and tools for the detection and treatment of head and neck squamous cell carcinoma.

At the conclusion of the panel, the participants will be able to:

- Understand the molecular pathogenesis of papillary and medullary thyroid cancer and how this information might inform the selection of and response to kinase inhibitor therapy for advanced disease.
- Understand the possibilities and limitations for non-invasive screening and early detection of preneoplastic lesions in the oral cavity by a variety of non-invasive genetic methods.
- Understand how biomarkers of therapeutic response can be readily identified from in vitro models, confirmed in pretreatment tumor specimens when correlated with clinical outcome, and used to direct existing therapies or select novel targets for future clinical trials.
- Understand the effect of tumor microenvironment factors (e.g., hypoxia, erythropoietin) on HNSCC disease progression.

13:30 - 15:00

**PROFFERED PAPERS**

**CLINICAL: NECK II/IMAGING**

Moderators: C. Rene Leemans, MD, PhD and Homer A. Macapinlac, MD

**YERBA SALON 10-11**

**S280: PALLIATION OF RECURRENT HEAD AND NECK CARCINOMA WITH INTERSTITIAL PHOTODYNAMIC THERAPY**

M.J.H. Wijte1, S.de Visscher1, J.N. Roedenburg1, B.Tarn2, 1University Medical Center, Groningen, The Netherlands; 2University of Liverpool, Liverpool, United Kingdom

**S281: QUALITY OF LIFE AFTER NECK DISSECTION - JAPANESE MULTICENTER LONGITUDINAL STUDY**

K.Nishib1, K.Kawabata2, T.Oshitansu3, I.Taji4, M.Sakaiwa5, 1Kobe University, Kobe Japan; 2Cancer Institute Hospital, Tokyo, Japan; 3Shizuoka Cancer Center, Shizuoka, Japan; 4Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan; 5National Cancer Center Hospital East, Chiba, Japan

**S282: SHOULDER MORBIDITY AFTER SURGICAL AND NON-SURGICAL TREATMENT OF THE NECK**

M.van Wouwe1, E.de Bree1, J.E.Lee1, I.Verdonck2, D.Kuit3, C.de Goede1, P.Doornaert1, C.Leemans1, 1VU University Medical Center, Amsterdam, The Netherlands

**S283: DECREASED DISTANT METASTASIS AND IMPROVED SURVIVAL WITH NECK DISSECTION FOLLOWING CHEMORADIATION FOR N3 DISEASE**

I.Lapidbash1, B.Fortin1, D.Soulieres2, L.Guerin2, G.Coulombe3, M.Belair4, D.Charpentier2, J.C LABEL2, P.F.Nguyen1, 1Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, PQ, Canada; 2Department of Medical Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, PQ, Canada; 3Department of Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, PQ, Canada; 4Department of Radiology, Centre Hospitalier de l'Universite de Montreal, Montreal, PQ, Canada

**S284: ULTRASOUND GUIDED ASPIRATION CYTOLGY FOR THE ASSESSMENT OF THE CLINICALLY NO NECK; FACTORS INFLUENCING ITS ACCURACY**

M.W.van den Brekel1, M.C.Borgemeester1, F.A.Pameijer1, M.F.van Velthuijse1, A.J.Balm1, E.L.Smelee1, 1University Medical Center, Amsterdam, The Netherlands

**S285: INITIAL STAGING OF THE NECK IN HNSCC: IS PET/CT THE BEST?**

S.J.Snęk1, T.Hany1, B.Schuknec1, 1University Hospital Zurich, Zurich, Switzerland

**S286: DW-MRI FOR NODAL STAGING OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: IMPACT ON RADIOTHERAPY PLANNING**


**S287: DCE-MRI PEFUSION IMAGING OF HNSCC NODAL METASTASIS: IDENTIFYING RADIORESISTANCE AND THE DISTANT METASTATIC PHENOTYPE**

H.Tsang1, S.Kim2, M.Pintilie2, M.Rosen1, E.Sherman1, A.Kilger1, H.Poapnati2, 1University of Pennsylvania, Philadelphia, PA; 2University of Pennsylvania, Philadelphia, PA

**S288: POSTER EMISION TOMOGRAPHY IN THE MANAGEMENT OF HEAD AND NECK CANCER OF UNKNOWN PRIMARY**

T.C.Kelly1, K.Opfermann1, G.Tolunay2, H.Lin3, G.Yoo1, J.J.Jacobs1, 1Wayne State University, Detroit, MI

**CLINICAL: RECONSTRUCTION III**

Moderators: Kevin M. Higgins, MD and Douglas B. Villaret, MD

**YERBA SALON 12-13**

**S289: FREE JEJUNUM VS. TUBED-FREE FLAPS FOR TOTAL LARYNGOPHARYNGECTOMY DEFECTS: PATTERNS OF USE AND OUTCOMES**

P.A.Ghannoun1, S.McClurg2, J.Kostrzewa3, E.L.Rosenthal4, N.D. Gross1, P.E.Andersen1, M.K.Wax1, 1Oregon Health and Science University, Portland, OR; 2University of Kansas, Kansas City, MO; 3University of Alabama, Birmingham, AL

**S290: RADIAL FOREARM VERSUS ANTEROLATERAL THIGH FREE FLAPS FOR LARYNGOPHARYNGECTOMY DEFECTS: A RANDOMIZED TRIAL**

J.R.Harris1, A.T.Morrissey1, D.A.O.Connell 1, H.Seikaly1, 1University of Alberta, Edmonton, AB, Canada

**S291: PECTORALIS MYOFASCIAL FLAP REINFORCEMENT IN SALVAGE LARYNGECTOMY PREVENTS PHARYNGOCUTANEOUS FISTULA**

U.A.Patel1, S.P.Kem1, 1Northwestern University, Chicago, IL

**S292: RADIAL FOREARM FREE FLAP FOR TOTAL LOWER LIP RECONSTRUCTION: THE ANALYSIS OF 10 CASES AND QUALITY OF LIFE EVALUATION**

C.A.Szymczyk1, A.Maciejewski1, J.Wierzganz1, S.Poltorak2, P.Zeman2, 1Dept. Surgical Oncology, Cancer Center, Gliwice, Poland; 2Dept. Surgical Oncology, Gliwice, Poland

**S293: EFFICACY OF LOW MOLECULAR WEIGHT HEPARIN IN PREVENTING FREE FLAP FAILURE: A RAT MODEL**

J.R.Harris1, J.Zhu1, L.Zhu1, W.Tates1, N.Kneteman1, H.Seikaly1, 1University of Alberta, Edmonton, AB, Canada

**S294: LOW MOLECULAR WEIGHT HEPARIN THROMBOPROPHYLAXIS AND BLEEDING RISK IN HEAD AND NECK CANCER MICROVASCULAR RECONSTRUCTION**

T.K.Blackburn1, K.Joza1, D.Lowe1, S.N.Rogers1, J.S.Brown1, E.D.Vaughan1, 1Mersey Regional Head and Neck Cancer Centre, Liverpool, United Kingdom

**S295: THE ANGULAR ARTERY TIP OF SCAPULA FREE FLAP: A NEW OPTION IN MAXILLARY RECONSTRUCTION**

N.A.Pagedar1, R.Patel1, D.Goldstein1, J.Irish1, D.Brown1, P.J.Gullane1, R.W.Gilbert1, 1University of Toronto, Toronto, ON, Canada

**S296: MAXILLECTOMY DEFECT RECONSTRUCTION OPTIONS AND OUTCOME**

K.Thankappan1, M.Sharma1, S.S.Chatt1, M.Kuriakose1, S.Ver1, 1Amrita Institute of Medical Sciences, Cochin, Kerala, India
S297: A PRACTICAL APPROACH TO MAXIMUM RECONSTRUCTION BASED UPON THE PATIENT’S DESIRE FOR DENTAL REHABILITATION  
B. Bell 1, J.K. Potter 1, B.E. Potter 1, E.J. Dierks 1, Legacy Emanuel Hospital and Health Center, Portland, OR

CLINICAL: THYROID IV  
Moderators: M. Boyd Gillespie, MD, MS and Johan Wennerberg, MD, PhD

S298: POST-OPERATIVE COMPLICATIONS AFTER CENTRAL COMPARTMENT ELECTIVE LYMPH NODE EXCISION FOR PAPILLARY THYROID CANCER  
A. Stern 1, M. Shindo 1, Y. Cheng Low 1, 1 Stony Brook University Medical Center, Stony Brook, NY

S299: COMPLICATIONS OF TOTAL THYROIDECTOMY IN BENIGN VS. MALIGNANT DISEASE  
S. Saha 1, E. Walsh 1, M. Rajai 1, M. Ghanem 2, V. Rao 1, D. Wease 1, J. Hammoud 1, M. Bakleh 1, J. Nelson 3, N. Tomycz 1, 1 McLaren Regional Medical Center, Flint, MI; 2 Synergy Medical Education Alliance, Saginaw, MI; 3 Genesys Regional Medical Center, Grand Blanc, MI

S300: UNILATERAL THYROID LOBECTOMY FOR DIFFERENTIATED THYROID CARCINOMA  
G. Andrea 1, M. Paesmans 1, M. Delmelle 1, E. Willemsen 1, C. Dekeser 1, V. Vandevelde 1, S. De Cooman 1, I. Abbatoy 1, D. Larmsmont 1, M. Lemort 1, 1 Institut Jules Bordet – ULB, Brussels, Belgium

S301: COMPARING PROGNOSTIC OUTCOMES OF TALL CELL VARIANT TO NORMAL VARIANT PAPILLARY THYROID CARCINOMA: A META-ANALYSIS  
S. Jami 1, T. Ainsworth 1, M. LaValley 2, 1 Boston University Medical Center, Boston, MA; 2 Boston University, Boston, MA

S302: THE OUTCOME OF UNTREATED THYROID CANCER CONFINED TO THE THYROID GLAND  
L. Davies 1, H. G. Welch 1, 1 White River Junction VA Outcomes Group, White River Junction, VT

S303: PAPILLARY THYROID CANCER IN CHILDREN: MANAGEMENT AND PATTERNS OF FAILURE  
U. B. Toscano 1, F. Dias 1, R. A. Lima 1, C. C. Pessoa 1, K. L. Fernandes 1, A. L. C. Costa 1, R. M. Costa 1, P. B. Milet 1, J. R. N. Soares 1, F. G. Bolehno 1, 1 Brazilian National Cancer Institute–BNCI, Rio de Janeiro, Brazil

S304: PHASE II STUDY OF COMBRETASTATIN A4 PHOSPHATE (CA4P) IN PATIENTS WITH ADVANCED ANAPLASTIC THYROID CARCINOMA (ATC)  
P. S. Vrba 1, C. J. Mooney 1, M. M. Cooney 1, S. S. Agarwal 1, 1 Bavaria Klinik, Kreischa, Germany; 2 Bavaria Klinik, Dresden, Germany; 3 Jena University, Jena, Germany; 4 Halle University, Halle, Germany; 5 Krankenhaus Dresden-Friedrichstadt, Dresden, Germany; 6 Halle University, Halle, Germany; 7 Helios Klinikum, Erfurt, Germany

S305: SUBSTERNAL GOITER AND STERNOTOMY  
J. P. Cohen 1, 1 H&N Institute, Vassar Brothers Medical Center, Poughkeepsie, NY

S306: SURGICAL MANAGEMENT OF THYROID CANCER: A PRACTICE OF PATIENTS OF OTOLARYNGOLOGISTS AND GENERAL SURGEONS  
N. A. Herrera 1, D. B. Villanen 1, E. Mazzarella 1, 1 University of Florida, Department of Otolaryngology, Gainesville, FL; 2 University of Florida, Department of Endocrinology, Gainesville, FL

OUTCOMES: RADIATION ONCOLOGY-OTHER  
Moderators: Paul M. Harari, MD and David Raben, MD

S307: FUNCTIONAL OUTCOMES AND QUALITY OF LIFE ASSOCIATED WITH TWO TREATMENTS FOR PREVENTION OF RADIATION INDUCED XEROSTOMIA  
J. M. Rieger 1, H. Selikay 2, N. Jhun 2, J. Harris 1, D. Williams 1, 1 University of Alberta, Edmonton, AB, Canada; 2 Cross Cancer Institute, Edmonton, AB, Canada

S308: TWO YEAR LONGITUDINAL STUDY OF SWALLOWING AFTER CHEMO-IMRT OF HEAD AND NECK CANCER  
M. J. Haxer, MA, CCC-SLP 1, T. H. Lyden, MA, CCC-SLP 1, A. Sacco, BS 1, F. Feng, MD 1, D. Normolle, PhD 1, F. P. Worden, MD 1, D. B. Chepeha, MD 1, E. Isbruch, MD 1, 1 University of Michigan Health System, Ann Arbor, MI

S309: CLINICAL PREDICTORS OF SURVIVAL WITH A FUNCTIONAL LARYNX AFTER MULTIAGENT CONCURRENT CHEMOTHERAPY AND RADIATION  
C. Rodriguez 1, D. J. Adelstein 1, L. A. Rybicki 1, J. P. Saxton 1, R. R. Lorenz 1, B. G. Wood 1, M. Stromme 1, R. M. Esclamado 2, P. Lavertu 3, D. I. Ives 1, 1 Tausig Cancer Center, Cleveland Clinic, Cleveland, OH; 2 Duke University Medical Center, Durham, NC; 3 University Hospitals of Cleveland, Cleveland, OH

S310: VALIDATION OF THE EORTC QUALITY OF LIFE INSTRUMENTS IN LARYNGEAL CANCER PATIENTS AFTER SURGERY  
S. Singer 1, A. Dietz 1, J. Ocken 2, E. Klemm 2, S. Koscielny 2, A. Thiele 2, A. Kluge 2, G. Kathrin 1, K. Breitenstein 2, R. Schwarz 2, 1 Leipzig University, Leipzig, Germany; 2 Klinikum Chemnitz, Chemnitz, Germany; 3 Krankenhaus Dresden-Friedrichstadt, Dresden, Germany; 4 Jena University, Jena, Germany; 5 Halle University, Halle, Germany; 6 Bavaria Klinik, Kreischa, Germany; 7 Helios Klinikum, Erfurt, Germany

S311: DO TEAM MEMBERS MANAGING HEAD AND NECK CANCER HAVE THE SAME OR DIFFERENT VIEWS WHEN PREDICTING QUALITY OF LIFE?  
K. J. Reid 1, S. Parmar 1, J. P. Tracy 1, C. M. Hicks 2, 1 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; 2 University of Birmingham, Birmingham, United Kingdom

S312: PREDICTORS OF OUTCOME FOR ADVANCED STAGE SUPRAGLOTTIC LARYNGEAL CANCER  
J. Gardy 1, S. G. Patel 1, J. M. Matsuo 1, B. Singh 1, D. Kraus 1, J. Boyle 1, R. Wong 1, N. Lee 1, A. Shaia 1, J. P. Shah 1, 1 Memorial Sloan Kettering Cancer Center, New York, NY

S313: IF COMBINATION-BOOST RT IS USED FOR PATIENTS WITH HEAD AND NECK CANCER THE WEEKEND BREAKS HAVE NOT WORSENED THE OUTCOME  
K. Sklodowski 1, M. Hutnik 1, T. Rutkowski 1, A. Wygoda 1, M. Golen 1, B. Pilecki 1, W. Przeorek 1, B. Maciejewski 1, 1 Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

S314: COMPLICATIONS AND FINDINGS IN PARENDOCTOMY OF CHEMORADIATED PATIENTS  
A. Langgerman 1, R. Comstock 1, K. Kasza 1, E. E. Vokes 1, L. Portugal 1, K. M. Stenson 1, 1 University of Chicago, Chicago, IL

S315: RANDOM POSITIONAL VARIATION AMONGST THE SKULL, MANDIBLE AND CERVICAL SPINE IN DAILY SETUP FOR HEAD AND NECK RADIOTherapy  
P. H. Ahn 1, A. I. Ahn 2, C. Lee 1, J. Shin 1, E. Miller 1, A. Lukai 1, E. Milan 1, R. Yaparpalav 1, S. Kalnicki 1, M. K. Garg 1, 1 Montefiore Medical Center, Bronx, NY; 2 Albert Einstein College of Medicine, Bronx, NY
This panel will address the management of early stage squamous cell carcinoma (SCC) of the glottic and supraglottic larynx. It will address the following issues in relation to the diagnosis, evaluation and treatment of T1-2N0 SCC in these anatomic sites.

At the conclusion of this panel, participants will have an enhanced knowledge about the management of early larynx cancer and be able to:

- Identify and clinically evaluate a patient with early stage laryngeal cancer.
- Determine the appropriate use of imaging investigations.
- Present a balanced view of the options for management.
- Discuss target volumes, planning techniques and dose fractionation approaches for radiotherapy.
- Describe the role of laser treatment in early laryngeal cancer.
- Understand conservation partial laryngectomy techniques and the clinical situations guiding their choice.
- Appreciate the indications for and the techniques employed for management of the ‘at risk’ neck.
- Know the indications for adjuvant radiotherapy following surgical management.
- Have awareness of a potential emerging role for chemotherapy in early laryngeal cancer.
- Be aware of results of voice rehabilitation and speech therapy.

**ADJUVANT THERAPY AFTER SURGICAL TREATMENT**

Panel Moderator: Jacques Bernier, MD

- Biomolecular Outcome Predictors for Adjuvant Treatment
  - Pierre Lavertu, MD
- Risk Level vs. Treatment Type and Intensity: A Critical Appraisal
  - Jay S. Cooper, MD
- Potential Role of Targeted Therapies in the Adjuvant Treatment of Locally Advanced Disease
  - Jacques Bernier, MD

At the conclusion of the panel, participants will be able to:

- Understand the impact of adjuvant multidisciplinary approaches, ranging from radiotherapy to systemic treatments, on the treatment outcome in patients presenting with locally advanced disease and treated with curative surgery.
- Understand recent breakthroughs in the field of biomarkers and potential use of non-cytotoxic, targeted therapies in the postoperative setting.
- Understand postoperative treatment intensity on function.

**RECONSTRUCTION**

Panel Moderator: Gerry F. Funk, MD

- The Evolving Role of Reconstruction in Contemporary Head and Neck Cancer Management
  - Gerry F. Funk, MD
- The Role of Reconstructive Surgery in Managing the Complications of Prior Treatment of Head and Neck Cancer
  - Neal D. Futran, MD, DMD
- Contemporary Management of Midfacial Defects
  - Ralph W. Gilbert, MD
- Comprehensive Functional Evaluation Following Oropharyngeal Reconstruction
  - Jeffrey R. Harris, MD
- Reconstruction of the Patient with a “Frozen Neck”
  - Peirong Yu, MD

At the conclusion of the panel, the participants will be able to:

- Understand the evolving role that reconstruction (including free tissue transfer) plays in contemporary head and neck cancer management.
- Understand the major challenges and solutions associated with reconstruction of the midface, reconstructive candidates with a “frozen neck” and reconstruction of patients with complications following prior treatment of head and neck cancer.
- Understand the state of the art in comprehensive, functional evaluation following oropharyngeal reconstruction.

**PROFFERED PAPER SESSIONS**

**BASIC SCIENCE: IN VIVO/IN VITRO MODELING**

Moderators: Carter van Waes, MD, PhD

- **S316**: RADIOSENSITIZATION BY HISTONE DEACETYLASE INHIBITORS +/- DEMETHYLATING AGENTS IN HEAD AND NECK CANCER CELL LINES
  - H.De Schutter 1, M.Kimpe 1, W.Van Criekinge 1, S.Nuyts 1, 1University Hospitals Leuven, Leuven Belgium
- **S317**: THE EFFECTS OF RADIATION ON ANTI-APOPTOTIC PATHWAYS IN HEAD AND NECK CANCER
  - K.Malhotra 1, O.Ekshyyan 1, Y.Rong 1, 1Louisiana State University, Shreveport, LA
- **S318**: CURCUMIN: A POTENTIAL RADIO-SENSITIZER IN HEAD AND NECK CANCER
  - A.Khaliq-Heftetz 1, S.Lev Avi 1, D.M.Fliss 1, A.Star 2, A.Vexler 1, V.Karasch 1, S.Hai 3, D.Aderka 1, R.Ben Yosef 1, 1Tel Aviv Sourasky Medical Center, Tel Aviv Israel; 2Tel Aviv Sourasky Medical Center, Tel Aviv, 1ID Israel; 3Tel Aviv Sourasky Medical Center, Tel Aviv, Ireland
5319: CURCUMIN INHIBITS HNSCC IN AN IN VIVO MODEL K.Bloodbochik1, C.Clark1, M.Racchuen1, D.Wallace1, G.Caldito1, C.O.Mahan1, 
1LSU Health Science Center, Shreveport, LA; 4LSU Health Science Center, Shreveport, LA,
S342: COMPARATIVE EVALUATION OF PRIMARY AND SECONDARY TRACHEOESOPHAGEAL PUNCTURE FOR ALARYNGEAL SPEECH RESTORATION
Moderators: D. Gregory Farwell, MD and Baroardo Perez-Ordonez, MD

THYROID-PATHOLOGY/CYTOTOLOGY/GENETICS/MOLECULAR BIOLOGY

S343: CORRELATION OF ARACHIDONIC ACID 5-LIPOXYGENASE EXPRESSION WITH TUMOR INVASION IN PAPILLARY THYROID CARCINOMA
N.Kummer1, J.Azzi1, C.Iacob2, N.Suslina2, Z.Komorowski2, S.Schafer2, R.K.Tiwari1, J.Gleieteria1, S.Schantz2, 1New York Medical College, Valhalla, NY, 2New York Eye and Ear Infirmary, New York, NY

S344: ZD6474 CAUSES SIGNIFICANT INHIBITION OF ANAPLASTIC THYROID CANCER IN AN ORTHOTOPIC MURINE MODEL
M.K.Gule1, D.Sano1, Z.L.Milas1, M.Zhao2, S.A.Jasser1, J.N.Myers1, 1MD Anderson Cancer Centre, Houston; 2MD Anderson Cancer Center, Houston

S345: A NOVEL MECHANISM OF THYROID TUMORIGENESIS BASED ON INACTIVATION OF P53 BY THE PTG-BINDING FACTOR PBF
D.Kim1, M.Reid1, A.Turnell1, J.Watkinson1, J.Franklyn1, C.McCabe1, 1University of Birmingham, Birmingham, United Kingdom

S346: WITHDRAWN

S347: PRESENCE OF GENETIC AND EPIGENETIC ALTERATIONS IN PAPILLARY THYROID CARCINOMA AND HASHIMOTO THYROIDITIS
M.S.Kokoska1, L Li2, S.Schichman1, B.R.Smoller2, J.Y.Suen1, C.Fan1, 1Central Arkansas Veterans Healthcare System and UAMS, Little Rock, AR; 2University of Arkansas for Medical Sciences, Little Rock, AR

S348: RECURSIVE PARTITIONING ANALYSIS REVEALS MOLECULAR SIGNATURE FOR DISTINGUISHING THYROID CARCINOMA FROM BENIGN DISEASE
P.M.Weinberger1, R.J.Bollag1, J.R.Lee2, D.J.Terri1, 1Medical College of Georgia, Augusta, GA; 2Veterans Affairs Medical Center, Augusta, GA

S349: THE INFLUENCE OF PREVIOUS RADIATION ON PATHOLOGICAL FEATURES AND CLINICAL OUTCOME IN PATIENTS WITH THYROID CANCER
J.M.Seaberg1, S.Eski2, J.L.Freeman2, 1University of Toronto, Toronto, ON, Canada; 2Mount Sinai Hospital, Toronto, ON, Canada

S350: INCIDENTAL PAPILLARY THYROID MICROCARCINOMA - A HARMLESS CONDITION?
S.Majlis1, E.Horvath1, A.Madrid1, J.Ilzauspe1, A.Castro1, J.Niedmann1, M.Dominguez1, R.Rossi F.1, H.Amaral1, L.Castro1, 1Clinica Alemana, Santiago, Chile

S351: COARSE CALCIFICATIONS IN THYROID NODULES - DO THEY RULE OUT MALIGNANCY?
E.Horvath1, S.Majlis1, A.Madrid1, J.Ilzauspe2, E.Soto1, H.Rojas1, F.Capdeville1, H.Tala1, M.Dominguez1, R.Rossi F.1, Clínica Alemana, Santiago, Chile; 2Clinica Alemana, Santiago, Cocos (Keeling) Islands

17:30 - 19:00
TUESDAY POSTER SESSION WITH WINE AND CHEESE

POSTER TOUR MODERATORS: Basic Science: Richard J. Wong, MD; Epidemiology/Prevention: Andre L. Carvalho, MD, PhD; Larynx/Pharynx: Chris Holsinger, MD

Basic Science: Carcinogenesis
P506 – P529

Basic Science: Models
P530 – P539

Epidemiology II
P540 – P552

Hyopopharynx
P553 – P567

Imaging II
P568 – P587

Larynx II
P588 – P605

Nasopharynx
P606 – P622

OralCavity III
P623 – P641

Prevention
P642 – P657

Radiation II
P658 – P676

Rare Tumors
P677 – P725

Reconstruction III
P726 – P741

Thyroid III
P742 – P754

POSTER SESSIONS SUPPORTED BY GENEROUS EDUCATIONAL GRANTS FROM OUR BRONZE LEVEL DONORS

EUSA PHARMA/CYTOSCA
IBA PARTICLE THERAPY
OMNIGUIDE
STYKER
VARIAN MEDICAL SYSTEMS

19:00 - 21:00
AHNS PRESIDENT’S RECEPTION

Please join Dr. and Mrs. Gregory Wolf for an evening reception with the AHNS President. Don’t miss your opportunity to interact with top head and neck professionals from around the world. Entertainment and great food will be on hand. Event is free to all scientific session attendees and registered accompanying persons. Extra tickets may be purchased for $100 each.
<table>
<thead>
<tr>
<th>TIME</th>
<th>EVENT</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 08:00</td>
<td>CLOSING COMMENTS</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>08:00 - 08:30</td>
<td>KEYNOTE LECTURE: “EPIGENETICS AND ORAL CANCER”</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>MILTON J. DANCE, JR. LECTURE: “EVALUATION AND MANAGEMENT OF THE N0 NECK”</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td>09:30 - 11:00</td>
<td>PANEL: IMMUNOLOGY/STEM CELLS</td>
<td>YERBA SALON 1-3</td>
</tr>
<tr>
<td></td>
<td>PANEL: NECK DISEASE – MULTIDISCIPLINARY</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td></td>
<td>PANEL: PARATHYROID SURGERY</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td></td>
<td>PANEL: SWALLOWING</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: NPC/SINUS/SKULL BASE II</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: ORAL CANCER SCREENING/PREVENTION</td>
<td>YERBA SALON 12-13</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: TRANSLATIONAL: MEDICAL ONCOLOGY/GENE THERAPIES</td>
<td>YERBA SALON 14-15</td>
</tr>
<tr>
<td>11:00 - 12:30</td>
<td>PANEL: EVOLUTION OF MOUSE MODELS IN HEAD AND NECK CANCER</td>
<td>YERBA SALON 4-6</td>
</tr>
<tr>
<td></td>
<td>PANEL: SALIVARY CANCERS</td>
<td>YERBA SALON 7</td>
</tr>
<tr>
<td></td>
<td>PANEL: WELL-DIFFERENTIATED THYROID CANCER</td>
<td>YERBA SALON 8</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: BASIC SCIENCE: INVASION AND METASTASES</td>
<td>YERBA SALON 1-3</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: CLINICAL: PHARYNX-LARYNX</td>
<td>YERBA SALON 10-11</td>
</tr>
<tr>
<td></td>
<td>PROFFERED PAPERS: RADIATION ONCOLOGY</td>
<td>YERBA SALON 12-13</td>
</tr>
</tbody>
</table>
Scientific Program

WEDNESDAY, JULY 23, 2008

07:30 - 08:00  CLOSING COMMENTS  YERBA SALON 8

08:00 - 08:30  KEYNOTE LECTURE:  
“EPIGENETICS AND ORAL CANCER”  YERBA SALON 8

Richard Shaw, MD, FRCS, FDS, University of Liverpool, Liverpool, England, United Kingdom
Introduction by Eduardo Mendez, MD

08:30 - 09:00  MILTON J. DANCE, JR. LECTURE:  
“EVALUATION AND MANAGEMENT OF THE N0 NECK”  YERBA SALON 8

C. René Leemans, MD, PhD, VU Medical Center, Amsterdam, The Netherlands
Introduction by Andre L. Carvalho, MD, PhD

09:30 - 11:00  SCIENTIFIC SESSIONS – Panels  YERBA SALON 1-3

IMMUNOLOGY/STEM CELLS
Panel Moderator: Robert L. Ferris, MD, PhD
Identification and Marker Characteristics of Head and Neck Cancer Stem Cells and Their Biology  Mark E. Prince, MD
Novel Immunotherapeutic Approaches and Development from Mouse Models to Humans  Duane A. Sewell, MD
Human Head and Neck Cancer Vaccine Trials and Novel Approaches to Immunostimulation  Barbara Wollenberg, MD
Inflammatory and Pattern Recognition Receptors Expressed by Cancer Cells and the Role of Inflammation in Carcinogenesis  Vicente Resto, MD, PhD
Migratory and Invasive Functions Related to Lymphocyte Homing Receptor/Ligand Interactions Promoting Immune Tolerance

At the conclusion of the panel, participants will be able to:
• Understand the role of immune/inflammatory cells and stem cells in the biology of head and neck cancer development, recurrence, and treatment resistance.
• Understand the dual role of inflammation in stimulating anti-tumor immunity as well as promoting cancer development.

NECK DISEASE - MULTIDISCIPLINARY  YERBA SALON 7
Panel Moderator: Randall P. Morton, MD
Identifying the “At-Risk” N0 Neck: When and How to Treat  Luiz P. Kowalski, MD, PhD
Management of the Contralateral Neck: Observation, Radiotherapy or Surgery?  Greg Kreml, MD
PET-CT Scans: Role in RT Planning and Surveillance  June Corry, MD
Surgical Salvage of the Irradiated Neck  Paul M. Spring, MD, MS

At the conclusion of the panel, participants will be able to:
• Appreciate factors that determine the need for treatment of a N0 neck.
• Understand the role of PET-CT scanning in patients with advanced metastatic neck disease.
• Be familiar with the issues relating to surgery in the irradiated neck.
PARATHYROID SURGERY
Panel Moderator: Ashok R. Shaha, MD
Role of Ultrasound and Intraoperative PTH in Parathyroid Surgery
Endoscopic and Video Assisted Parathyroidectomy
Reoperative Parathyroid Surgery

This panel will discuss mainly the current advances and controversial issues in the management of hyperparathyroidism. Three expert surgeons will discuss the current issues and there will be lively panel discussion and active interaction with the audience.

At the conclusion of the panel, the participants will be able to:

- Understand the current controversy related to endoscopic parathyroidectomy.
- Determine if there is a definite role of video assisted parathyroidectomy and its advantages.
- Understand the current role of preoperative localization studies in parathyroid surgery.
- Understand the role of ultrasound.
- Understand a focused parathyroid exploration.
- Identify the role of intraoperative PTH in parathyroid surgery.
- Determine if intraoperative PTH is a must.
- Understand the issues related to the failed parathyroid surgery and re-exploration.
- Overall, the participants will understand the current advances in the management of hyperparathyroidism.

SWALLOWING
Panel Moderator: Jan S. Lewin, PhD

Introduction

XRT for Cure and Organ Preservation, New Methods and Future Initiatives to Prevent Long-term Dysphagia
Avraham Eshbruch, MD

Surgery for Preservation of Swallowing Function
Alfonsus J. Balm, MD

Quality of Life as a Measure of Swallowing Function and its Impact on the Patient
J. Scott Magnuson, MD

Measuring and Quantifying Dysphagia and Can We Predict It?
Bonnie Martin-Harris, MD

At the conclusion of the panel, participants will be able to:

- Identify key factors that predispose individuals to dysphagia after organ preservation and techniques for prevention of swallowing dysfunction.
- Identify those individuals for whom surgery may provide superior swallowing outcomes.
- Describe the role quality of life instruments play in the evaluation and management of patients with head and neck cancer.
- Discuss methods for objectively quantifying swallowing physiology in patients with dysphagia and the importance of scientific measurement for the prediction of long-term swallowing outcomes.

PROFFERED PAPERS

09:30 - 11:00

CLINICAL: NPC/SINUS/SKULL BASE II
Moderators: Kwok Seng Loh, MD and William I. Wei, MD

S352: SALVAGE SURGERY FOR RECURRENT NASOPHARYNGEAL CARCINOMA USING A PARTIAL MAXILLECTOMY APPROACH
L.S.Ng1, K.S.Loh2, 1Dept Otolaryngology, National University Hospital, Singapore, Singapore; 2Dept Otolaryngology, National University of Singapore, Singapore, Singapore

S353: NASOPHARYNGECTOMY FOR RECURRENT NASOPHARYNGEAL CARCINOMA : A REVIEW OF 57 PATIENTS AND PROGNOSTIC FACTORS
S.Hao1, N.Tsang2, 1Chang Gung Memorial Hospital, Taipei, Taiwan, Republic of China; 2Chung Gung Memorial Hospital, Taipei, Taiwan, Republic of China

S354: ENDOSCOPIC TRANSPTERYGOID NASOPHARYNGECTOMY FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA
A.M.Zareda1, S.Alsheibani1, R.Carrau1, C.Snyderman1, A.Kassam1, 1University of Pittsburgh Medical Center, Pittsburgh, PA

S355: THE ROLE OF INDUCTION CHEMOTHERAPY IN THE MANAGEMENT OF SINONASAL UNDIFFERENTIATED CARCINOMA
U.Duvvuri1, J.Goddard1, D.Roberts1, S.Ibrahim1, N.Ark1, M.Kupferman1, M.Kies1, A.S.Garden1, F.DeMonte1, E.Y.Hanna1, 1MD Anderson Cancer Center, Houston, TX

S356: STEREOTACTIC RADIOSURGERY FOR HEAD & NECK AND SKULL BASE CANCER
A.Pinheiro1, N.Kim1, H.Kim1, 1St. John’s Clinic, Springfield, MO

S357: MR-EVIDENT RETROPHARYNGEAL LYMPH NODE METASTASIS IN NPC PATIENTS: CLINICAL IMPACT
S.Chin1, C.Lin2, J.Chang2, 1Chang Gung Memorial Hospital at Linko, Tao-Yuan, Taiwan, Republic of China; 2Departments of Radiation Oncology, Tao-Yuan, Taiwan, Republic of China
S358: FALSE POSITIVES AND SPECIFICITY WITH PET/CT IN THE ASSESSMENT OF RECURRENT MALIGNANT DISEASE OF THE SKULL
BASE
G.Pitez1, R.J.Harvey1, D.B.Nissman1, Z.Rumboldt1, R.J.Schlosser1, 1Medical University of South Carolina, Charleston, SC

S359: GENE EXPRESSION AND PROMOTER POLYMORPHISMS OF DNMT3B IN NPCS IN TAIWAN: A CASE-CONTROL STUDY
K.Chang1, K.Fang1, S.Hao1, 1Chang Gung Memorial Hospital, Taipei, Taiwan, Republic of China

S360: FASCIA-ONLY FREE RADIAL FOREARM FLAP FOR RESURFACING THE NASOPHARYNX FOLLOWING NASOPHARYNGECTO-
MY
C.H.Teo1, M.L.C.Khoo1, 1Tan Tock Seng Hospital, Singapore, Singapore

ORAL CANCER SCREENING/PREVENTION
YERBA SALON 12-13
Moderators: TBD

S361: A POPULATION-BASED ANALYSIS OF THE ASSOCIATION OF ORAL/PHARYNGEAL CARCINOMAS WITH HPV-RELATED
ANOGENDICAL CANCERS IN MEN A.G.Sikora1, L.G.T.Morris2, E.M.Sturgis1, 1UT MD Anderson Cancer Center, Houston, TX; 2New York University School of Medicine, New York, NY

S362: LACK OF ASSOCIATION BETWEEN HPV INFECTION AND ORAL TONGUE CANCER IN YOUNG AND OLDER ADULTS
C.H.Shibata1, M.M.Da Costa1, J.M.Palesky1, R.C.K.Jordan1, 1University of California San Francisco, San Francisco, CA

S363: SQUAMOUS CELL CARCINOMA OF ORAL TONGUE IN YOUNG ADULTS: A CLINICAL AND PATHOLOGICAL ANALYSIS OF RISING
ETIOLOGIC ENTITY R.Yahalom1, L.Bedrin1, M.Verdi1, Y.P.Taibl1, R.Pfeffer1, S.Teicher1, A.Dobriyan1, 1Sheba Medical Center, Tel Aviv, Israel

S364: GENOMIC DIFFERENCES BETWEEN SMOKING AND DRINKING PATIENTS AND NON-SMOKING AND NON-DRINKING
PATIENTS WITH ORAL TONGUE CANCER X.Liang1, A.O.Keil2, A.Leighton2, J.Lewis3, R.Foote4, D.Smith5, D.Kademani1, 1Oral and Maxillofacial Surgery, Mayo Clinic, Rochester, MN; 2Division of Experimental Pathology, Mayo Clinic, Rochester, MN; 3Anatomic Pathology, Mayo Clinic, Rochester, Rochester, MN; 4Radiation Oncology, Mayo Clinic, Rochester, MN

S365: ASSESSMENT OF ORAL SELF-EXAMINATION FOR EARLY DETECTION OF ORAL CANCERS AND PRECANCERS IN A HIGH-RISK
RURAL POPULATION J.K.Elanga1, S.Iyer2, M.Karikoski1, 1Amrita Institute of Medical Sciences, Cochin, Kerala, India; 2Amrita Institute of Medical Sciences, Cochin, Kerala, India

S366: ENCOURAGING EARLY PRESENTATION OF ORAL CANCER IN A HIGH RISK GROUP S.E.Scott1, E.A.Grunfeld1, J.Weinman1, M.McGurk1, 1King’s College London, London, United Kingdom

S367: UTILIZING 5-AMINOLOVULIC ACID AND PULSED DYE LASER FOR PHOTODYNAMIC THERAPY OF ORAL LEUKOPLAKIA
G.Shahrestani1, P.Spring1, E.Vural1, T.Stack1, C.Fan1, W.Baumler2, J.V.Suen1, 1University of Arkansas for Medical Sciences, Little Rock, AR; 2Regensburg University, Regensburg, Germany

S368: TREATMENT AND FOLLOW-UP OF ORAL DYSPLASTIC LESIONS - SYSTEMATIC REVIEW AND META-ANALYSIS T.Rattay1, J.Smith1, H.Mehanna1, 1Institute of Head and Neck Studies and Education, Coventry, United Kingdom

S369: A FOOD-BASED APPROACH TO ORAL CANCER CHEMOPREVENTION C.M.Woehl1, B.Costa1, J.K.Nobloch1, B.M.Warner1, Z.Yu1, G.D.Stoner1, S.K.Clinton1, E.Ozer1, D.E.Schuller1, A.Agrawal1, 1The Ohio State University, Columbus, OH

TRANSLATIONAL: MEDICAL ONCOLOGY/GENE THERAPIES
YERBA SALON 14-15
Moderators: David J. Adelstein, MD and Chu Chen, MD

S370: METRONOMIC ADMINISTRATION OF SMALL MOLECULE INHIBITOR OF BCL-2 COMBINED WITH CISPLATIN IN XPORNGRAFTED
HEAD & NECK CANCER N.Ashimon1, B.D.Zeilin1, A.Spalding1, J.E.Nor1, 1University of Michigan, Ann Arbor, MI

S371: CISPLATIN AND THE JAK/STAT INHIBITOR JSI-124 INDUCE SYNERGISTIC CELL DEATH IN A CISPLATIN RESISTANT CELL LINE
C.Benner1, L.M.Saunders1, B.Kumar1, C.R.Bradford1, T.E.Carey1, 1University of Michigan, Ann Arbor, MI

S372: SENSITIZATION OF SQUAMOUS CELL CANCER TO CISPLATIN IS POTENTIATED BY SOY ISOFAVONE L.M.Periera1, O.E.Tulunay2, L.Varghese2, S.Ali2, O.Kucuk2, F.H.Sarkar2, T.Carey3, G.Wolf3, 1Karmanos Cancer Center, Detroit, MI; 2Karmanos Cancer Center, Detroit, MI; 3Department of Otolaryngology - University of Michigan, Ann Arbor, MI

S373: HYALURONAN AND CD44 INTERACT WITH ROK AND PI-3 KINASE TO PROMOTE GROWTH, MIGRATION, AND CISPLATIN
RESISTANCE IN HN5C J.Wang1, C.Torre1, L.Y.Bourguignon1, 1University of California, San Francisco, San Francisco, CA

S374: DUAL DISRUPTION THERAPY FOR HEAD AND NECK CANCER: TARGETING DNA REPAIR PATHWAYS TO INDUCE CANCER
CELL DEATH W.M.Abrazeid1, K.Khan1, D.P.Paulson1, X.Jiang1, K.Araki1, N.Reddy1, D.B.Jungreis1, B.W.O’Malley, Jr.1, D.Li1, 1University of Pennsylvania School of Medicine, Philadelphia, PA

S375: ASSESSMENT OF EGFR INHIBITION BY ERTONIB IN TUMORS AS COMPARED TO NORMAL MUCOSA IN ORAL CAVITY SQUA-
MOUS CELL CA C.Tien1, M.Nyati1, B.Teknos1, D.Chepeha1, C.Bradford1, M.Prince1, G.Wolf1, A.Eisbruch1, 1University of Michigan, Ann Arbor, MI

S376: PERITUMORAL INJECTIONS OF PURIFIED TUMSTATIN DELAY TUMOR GROWTH AND LYMPHATIC METASTASIS IN AN ORAL
CANCER MODEL H.M.C.Khoo1, J.Fang1, K.Khan1, D.P.Paulson1, X.Jiang1, K.Araki1, N.Reddy1, D.B.Jungreis1, B.W.O’Malley, Jr.1, D.Li1, 1University of Pennsylvania School of Medicine, Philadelphia, PA

S377: SINGLE-WALLED CARBON NANOTUBES ASSOCIATED WITH PACITAXEL INHIBIT THE GROWTH OF HEAD AND NECK SQUA-
MOUS CELL TUMORS Z.L.Mills1, R.Luciente-Schultz2, D.Sano1, C.Galer1, M.Gule1, A.Leonard2, K.Price2, D.Roskopkin2, J.Tour2, J.N.Myers2, 1MD Anderson Cancer Center, Houston, TX; 2 Rice University, Houston, TX; 3MD Anderson Cancer Center, Houston

S378: PRECLINICAL EVALUATION OF SUNITINIB IN HEAD AND NECK SQUAMOUS CELL CARCINOMA J.H.Shin1, D.Le1, J.Bao1, R.Uppaluri1, J.B.Sunwoo1, 1Washington University School of Medicine, Saint Louis, MO

11:00 - 12:30

SCIENTIFIC SESSIONS - Panels

EVOLUTION OF MOUSE MODELS IN HEAD AND NECK CANCER
Panel Moderator: Michiel W.M. van den Brekel, MD
Orthotropic Xenografts Models of Head and Neck Cancer Including Thyroid CA, Oral SCCA, and Salivary Cancer
Seungwon (Steve) Kim, MD
The Role of p53 Mutations in Mouse Models for Oral Cancer
Carlos Cainin, PhD

Dissecting Genetic Alterations and Microenvironment Contributing to HNSCC Using Mouse Tumors as Model System
Xiao-Jing Wang, MD, PhD

At the conclusion of the panel, participants will be able to:
• Understand the possibilities and limitations of the currently available model systems targeting different cell populations.
• Emphasize the complexity of the head and neck area and the genetic complexity of squamous cell carcinomas.
• Show examples of the current research in this field.
• Stimulate the audience to put more effort in establishing good model systems.

SALIVARY CANCERS
Panel Moderator: Kerry D. Olsen, MD
Changing Patterns of Surgical Care for Salivary Cancer
Eugene N. Myers, MD
Pathology and Molecular Biomarkers in the Assessment of Salivary Gland Cancer
Adel Elnaggar, MD, PhD
Treatment of Radiated Salivary Glands, Bottled Water to Tissue Engineering
Robert L. Witt, MD
Radiation for Salivary Cancers
Adam S. Garden, MD
Medical Treatment for Salivary Gland Cancer
Lisa Licitra, MD

At the conclusion of the panel, participants will be able to:
• Determine how the surgical management of salivary gland cancers changing.
• Determine when radiation therapy should be used to treat salivary gland malignancies.
• Determine what is the value of adding chemotherapy, hormonal or targeted therapy to the management of salivary gland cancer.

WELL-DIFFERENTIATED THYROID CANCER
Panel Moderator: Keith S. Heller, MD
Ultrasonographic Preoperative Evaluation: The Rational Approach to Lymphadenectomy
Gregory L. Randolph, MD
Central Compartment Lymph Node Dissection
David W. Eisele, MD
RAI Therapy
Kenneth A. Woebber, MD
Thyroid Cancer in the Pediatric Age Group
Ralph P. Tufano, MD

This panel will address topics relating to controversies in the evaluation and treatment of patients with well-differentiated thyroid cancer as well as special considerations for the treatment of children.

At the conclusion of the panel, the participants will be able to:
• Understand the role of ultrasonography in the evaluation of patients with well-differentiated thyroid cancer with particular emphasis on surgical treatment of lymph nodes.
• Understand the techniques, prognostic significance, and indications for central compartment lymph node dissection.
• Understand the use of RAI therapy both to ablate residual thyroid tissue and to treat possible microscopic disease.
• Understand the special factors to be considered in planning the treatment of thyroid cancer in children.

PROFFERED PAPERS
BASIC SCIENCE: INVASION AND METASTASES
Moderators: Jean-Pierre Jeannon, MBChB, FRCS and Eduardo Mendez, MD

S379: PREDICTION OF LOCAL RECURRENT AFTER RADIOTHERAPY FOR LARYNX CARCINOMA USING TISSUE ARRAY IMMUNOHISTOCHEMISTRY
M.A. Wildman1, J.H. Gibcus1, G.B. van den Brekel1, E. Schuring2, M. Hauptmann3, M.F. van Velthuijsen1, J.H. Hoebers1, J.E. van der Wal2, M.W. van den Brekel4
1Netherlands Cancer Institute, Amsterdam, The Netherlands; 2University Medical Center Groningen, Groningen, The Netherlands

S380: EGFRVIII INDUCES HNSCC TUMOR CELL MIGRATION AND INVASION VIA ACTIVATION OF STAT3
S.Suzuki1, S.M. Thomas1, J.R. Grandis1
1University of Pittsburgh, Pittsburgh, PA

S381: PREVALENCE OF K-RAS CODON 12 MUTATIONS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA AND IMPACT ON CLINICAL OUTCOMES
E.Bissada1, Z.Abou Chacra1, L.Guerin1, X.Wang1, P.Nguyen-Tan1, J.Tabet1, L.Robin1, V.St-Onge1, B.Fortin1, D.Soulières1
1Centre Hospitalier de l’Université de Montréal, Montreal, PQ, Canada

S382: HEPARANASE INDUCES VEGF C LEVELS AND FACILITATES TUMOR LYMPH ANGIOGENESIS
I.Doweck1, V.Cohen-Kaplan2, I.Naroditsky3, A.Zeter4, N.Ilan2, I.Vlodavsky2, 1Carmel Medical Center, Haifa, Israel; 2Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Haifa, Israel; 3Department of Pathology, Rambam Health Care Campus, Haifa, Israel

S383: TETRATHIOMOLYBDATE INHIBITS HEAD AND NECK CANCER METASTASIS BY DECREASING TUMOR CELL INVASION AND...
### Scientific Program

#### INDUCING ANOKIA

<table>
<thead>
<tr>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kumar 1, S.N. Patel 1, Y. Ning 1, M. Islam 1, T. Nagel 1, Q. Pan 1, P. J. Polverini 1, S. Merajver 1, T. N. Teknas 1</td>
<td>University of Michigan, Ann Arbor, MI</td>
</tr>
</tbody>
</table>

**S384: RT-PCR FOR CYTOKERATIN 20 FOR MOLECULAR DIAGNOSIS OF LYMPHATIC METASTASES IN PATIENTS WITH HEAD AND NECK CANCER**

P. Chone 1, F. A. Silva 1, H. F. Kohler 1, S. C. Costa 1, A. Altemani 1, A. N. Crespo 1, 1State University of Campinas, Campinas Brazil

**S385: PGE2 PRODUCTION IS ENHANCED IN UV EXPOSED KERATINOCYTES. EVIDENCE FOR THE ROLE OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE**

E. Ludus 1, S. V. Ragnini 2, J. O. Boyle 1, K. Subbarandaike 2, A. J. Dannenberg 2, 1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Weill Medical College of Cornell University, New York, NY

**S386: IDENTIFICATION OF UNIQUE AND COMMON LOW ABUNDANCE TUMOR-SPECIFIC TRANSCRIPTS BY SUPPRESSION SUBTRACTION HYBRIDIZATION**

C. Goh 1, B. Liu 2, L. Ooi 3, K. Hu 2, 1Singapore General Hospital, Singapore, Singapore; 2National Cancer Centre, Singapore, Singapore; 3Singapore General Hospital, Singapore, Singapore

**S387: PRODRUG ACTIVATION BY ONCOLYTIC HSV-1 EXPRESSING CD/UPRT ENHANCES CYTOTOXICITY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA**

D. L. Price 1, S. Lin 1, Z. Han 2, R. S. Cottin 2, Y. Fong 1, R. J. Wong 1, 1Memorial Sloan Kettering Cancer Center, New York, NY; 2BioVex Incorporated, Woburn, MA

#### CLINICAL: PHARYNX-LARYNX

**YERBA SALON 10-11**

**Moderators:** Ricardo Simo, MD

**S388: ENDOSONTOGRAPHIC TREATMENT OF T1-T3 SUPRALATROGIC CANCER: A MULTINATIONAL SERIES OF 127 PATIENTS**

G. Piazza 1, G. Paludetti 2, M. Ansarin 3, R. Ruxted 4, D. Cocco 1, L. De Benedito 1, P. Nicipoli 1, 1Department of Otolaryngology - Head and Neck Surgery, University of Brescia, Brescia, Italy; 2Department of Otolaryngology - University Cattolica Del Sacro Cuore of Rome, Rome, Italy; 3Department of Head and Neck Surgery, European Institute of Oncology of Milan, Milan, Italy; 4ENT Department, Queen Alexandra Hospital of Portsmouth, Portsmouth, United Kingdom

**S389: CHANGING TREATMENT PARADIGMS IN THE MANAGEMENT OF SQUAMOUS CELL CARCINOMA OF THE SUPRALATROGIC LARYNX**

J. S. Kerst 1, J. Lavin 1, K. Muzaffar 1, C. Zender 1, 1Iyola University Medical Center, Maywood, IL


J. D. Squail 1, D. Love 1, D. Errington 1, J. S. Brown 1, E. D. Vaughan 1, N. J. Rawlans 1, S. N. Rogers 1, 1University Hospital Aintree, Liverpool, United Kingdom

**S391: SALVAGE LARYNGECTOMY FOLLOWING ORGAN PRESERVATION APPROACHES**

V. Lee 1, A. Derz 1, D. Chaukar 1, M. Despande 1, P. Pal 1, P. Chatwade 1, R. Halvard 1, 1Tata Memorial Hospital, Mumbai, India

**S392: WIDE VERTICAL HEMILARYNGECTOMY(VHML) FOR LOCALLY ADVANCED PHARYNGOLARYNGEAL CANCER AND ITS CLASSIFICATION**

K. Kim 1, J. Yoon 1, D. Sun 1, K. Cho 1, S. Cho 1, 1The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

**S393: SUPRACRICOID PARTIAL LARINGECTOMIES AS SALVAGE SURGERY AFTER RADIATION FAILURE**

P. Bellini 1, P. Rusci 2, G. Spirito 1, National Cancer Institute “Regina Elena” Rome, Rome, Italy; 2National Cancer Institute Regina Elena Rome, Rome, Italy

**S394: ASSESSMENT OF SPEECH AND SWALLOWING FOLLOWING MICROSURGICAL RECONSTRUCTION OF OROPHARYNGEAL AND PALATAL DEFECTS**

P. Paveen 1, Kate Reid 1, S. Parmar 1, T. Martin 1, S. Kotecha 1, 1University Hospitals Birmingham, Birmingham, United Kingdom

**S395: EARLY ORAL FEEDING AFTER SALVAGE LARYNGECTOMY**

M. E. Eustaquio 1, N. W. Hoels 1, G. A. Kempi 1, J. E. Medina 1, 1The University of Oklahoma Health Science Center, Oklahoma City, OK

**S396: CONSERVATIVE MANAGEMENT OF IATROGENIC ESOPHAGEAL PERFORATION IN HEAD AND NECK CANCER PATIENTS WITH ESOPHAGEAL STRICTURE**

C. T. Chan 1, V. A. Silva 1, L. C. Costa 1, A. Altemani 1, A. N. Crespo 1, 1State University of Campinas, Campinas Brazil

**S397: PRODRUG ACTIVATION BY ONCOLYTIC HSV-1 EXPRESSING CD/UPRT ENHANCES CYTOTOXICITY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA**

D. L. Price 1, S. Lin 1, Z. Han 2, R. S. Cottin 2, Y. Fong 1, R. J. Wong 1, 1Memorial Sloan Kettering Cancer Center, New York, NY; 2BioVex Incorporated, Woburn, MA

#### RADIATION ONCOLOGY

**YERBA SALON 12-13**

**Moderators:** Parvesh Kumar, MD

**S397: SQUAMOUS CELL CARCINOMA REGIONAL METASTASES TREATED WITH RADIATION THERAPY: CORRELATION BETWEEN CT AND HISTOLOGY**

M. V. Sampathino 1, A. Sharma 1, M. Richardson 1, T. Rumbold 1, T. A. Day 1, Z. Rumbold 1, 1Medical University of South Carolina, Charleston, SC

**S398: DOSIMETRIC UNCERTAINTIES IN MATCHED IRMT AND CONVENTIONAL FIELDS FOR HEAD AND NECK CANCER RADIOTHERAPY**

J. Rembert 1, A. Z. Hu 1, C. Akazawa 1, M. K. Bucci 1, S. S. Yam 1, J. M. Quivey 1, P. Lee 1, University of California San Francisco, San Francisco, CA

**S399: PATTERNS AND SITES OF FAILURE AFTER RADIATION TREATMENT OF HEAD AND NECK SQUAMOUS CELL CANCER (HNSCC). WHAT SHOULD WE IRRADIATE?**

A. Papavizas 1, C. R. Bradford 1, T. N. Teknas 1, D. B. Shepha 1, M. E. Prince 1, J. S. Moyer 1, N. D. Higuiken 1, F. F. Ward 1, G. T. Woll 1, A. Esbruch 1, 1University of Michigan, Ann Arbor, MI; 2University of Michigan, Ann Arbor, MI; 3University of Michigan, Ann Arbor, MI

**S400: RADICAL RADIATION FOR UNKNOWN PRIMARY SQUAMOUS CANCER YIELDS HIGH CONTROL BUT HAS MAJOR TOXICITY**

H. J. Wanek 1, B. Bhandari 2, R. Brotman 2, R. Rathore 2, 1Landmark Medical Center, Woonsocket, RI; 2Roger Williams Medical Center, Providence, RI

**S401: RADIOTHERAPY AS SINGLE-MODALITY THERAPY FOR HEAD AND NECK PARAGANGLIOMAS: TWENTY-TWO YEAR RESULTS FROM A SINGLE CENTER**

K. J. Otto 1, J. Franklin 2, D. Goldstein 1, F. J. Gullane 1, B. Cummings 1, 1University of Toronto, Toronto, ON, Canada; 2University of Western Ontario, London, ON, Canada

**S402: FUNCTIONAL ORGAN PRESERVATION IN T4 LARYNGEAL/MYOPHARYNGEAL SQUAMOUS CELL CARCINOMA (SCLC)**

L. Pereira 1, M. Shkoukani 1, J. Ma 1, N. Gorki 1, O. Tulunay 1, J. Jacob 1, 1Wayne State University, Detroit, MI

**S403: SWALLOWING FUNCTION AFTER CONCOMITANT BOOST RADIOTHERAPY FOR OROPHARYNGEAL CARCINOMA**

A. W. Chen 1, H. R. Kamat 1, M. Truong 1, A. S. Holman 1, T. A. Goldsmith 1, 1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Memorial Sloan-Kettering Cancer Center, New York, NY; 3The Catholic University of Korea, College of Medicine, Seoul, Republic of Korea

**S404: XEROSTOMIA IN PATIENTS WITH HEAD AND NECK TUMORS TREATED BY IMRT: IMPORTANCE OF ABSOLUTE SPARED PAROTID VOLUME**

H. Villeneuve 1, J. Carrier 1, F. Dhuy 1, G. Coulombe 1, L. Guertin 1, J. Label 1, D. Soulaires 1, D. Charpentier 1, M. Belair 1, 1CHUM Notre-Dame Hospital, Montreal, PQ, Canada

**S405: PREDICTION OF TREATMENT COMPLICATIONS IN PATIENTS WITH OROPHARYNGEAL CANCER**

E. D. McCauley 1, G. Har-El 1, K. Sundaram 1, 1SUNY Downstate, Brooklyn, NY
Faculty Listing

AUSTRALIA
William B. Coman, MD, University of Queensland, Woolloongabba, QLD, Australia
June Corry, MD, Peter MacCallum Cancer Institute, East Melbourne, VIC, Australia
Sandra V. Porceddu, MD, Princess Alexander Hospital, Brisbane, QLD, Australia
Kerwin F. Shannon, MD, Sydney Head and Neck Cancer Institute, Newton, NSW, Australia

BELGIUM
Guy Andry, MD, Jules Bordet Institute, Brussels, Belgium
Vincent Grégoire, MD, PhD, St. Luc University Hospital, Brussels, Belgium
Jan B. Vermorken, MD, PhD, University Hospital of Antwerp, Edegem, Belgium

BRAZIL
Andre Lopes Carvalho, MD, PhD, Cancer Hospital of Barretos, Barretos, São Paulo, Brazil
Claudio R. Cernea, MD, University of São Paulo Medical School, São Paulo, Brazil
Fernando L. Dias, MD, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
Jacob Kligerman, MD, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
Luis P. Kowalski, MD, PhD, A.C. Camargo Hospital, São Paulo, Brazil
Roberto Lima, MD, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
Luiz R. Medina Dos Santos, MD, CEPON-Center for Oncological Research, Florianópolis, Brazil

CANADA
Patrick J. Gullane, MD, University Health Network, Toronto, ON, Canada
Naresh Jha, MD, University of Alberta - Cross Cancer Institute, Edmonton, AB, Canada
Jeffrey R. Harris, MD, University of Alberta, Edmonton, AB, Canada
Jonathan Irish, MD, FRCS, FACS, University Health Network and Mt. Sinai Hospital, Toronto, ON, Canada
Brian O’Sullivan, MD, University of Toronto, Toronto, ON, Canada
Bayardo Perez-Ordonez, MD, University Health Network, Toronto, ON, Canada
Hadi Seikaly, MD, FRCS, University of Alberta, Edmonton, AB, Canada
Lillian Siu, MD, Princess Margaret Hospital, Toronto, ON, Canada
Ian J. Witterick, MD, Mt. Sinai Hospital, Toronto, ON, Canada
Robert Wood, MD, Princess Margaret Hospital, Toronto, ON, Canada
John H. Yao, MD, London Health Sciences Center/Victoria Hospital, London, ON, Canada

CHINA
Anil T. Ahuja, MD, The Chinese University of Hong Kong, Hong Kong, China
Anthony T.C. Chan, MD, The Chinese University of Hong Kong, Shatin, Hong Kong, China
Yolanda YP Lee, MD, The Chinese University of Hong Kong, China
William I. Wei, MD, Queen Mary Hospital, Hong Kong, SAR, China

CROATIA
Milenko Bura, MD, PhD, KBC Zagreb Hospital, Zagreb, Croatia

CZECH REPUBLIC
Jan Klozar, MD, Motol Faculty Hospital, Prague, Czech Republic
Ruth Tachezy, PhD, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

DENMARK
Jens Overgaard, MD, Aarhus University Hospital, Aarhus, Denmark

FINLAND
Anti Mäkinen, MD, Helsinki University Central Hospital, Helsinki, Finland

FRANCE
Jean Bouhis, MD, PhD, Cancer Institute Gustave Roussy, Villejuif, France
Jean Louis Lefebvre, MD, Centre Oscar Lambret, Lille, France
Stéphane Temam, MD, PhD, Cancer Institute Gustave Roussy, Villejuif, France

GERMANY
Petra Ambrosch, MD, PhD, University Hospital, Kiel, Germany
Volker G. Budach, MD, PhD, Charité University Medicine Berlin, Berlin, Germany
Rainald Knecht, MD, PhD, University of Frankfurt/Main, Frankfurt am Main, Germany
Uta Tschesneler, MD, Clinic and Hospital for Neck, Nose and Ohroneklinik, Munich, Germany
Jochen A. Werner, MD, University of Marburg, Marburg, Germany
Barbara Wollenberg, MD, University of Lubeck, Lübeck, Germany

GREECE
Alexander D. Rapidis, MD, DDS, PhD, Greek Anticancer Institute, Athens, Greece

INDIA
Jaimanti Bakshi, MD, Postgraduate Institute of Medical Education and Research, Chandigarh, U.T., India
Anil K. D'Cruz, MD, DDS, PhD, Greek Anticancer Institute, Athens, Greece

IRELAND
Conrad I. Timon, MD, FRCS, St. James's Hospital, Dublin, Ireland

ISRAEL
Lev Bedrin, MD, PhD, The Sheba Medical Center, Tel Hashomer, Israel
Dan M. Fliss, MD, Tel-Aviv Sourasky Medical Centre, Tel-Aviv, Israel
Yoav P. Talmi, MD, The Sheba Medical Center, Tel Hashomer, Israel

ITALY
Giulio Cantu, MD, National Cancer Institute of Milan, Italy, Milan, Italy
Fausto Chiesa, MD, European Institute of Oncology, Milan, Italy
Lisa Licitara, MD, National Institute of Tumors, Milan, Italy
Piero Nicolai, MD, University of Brescia, Brescia, Italy
Giuseppe Spriano, MD, National Cancer Institute “Regina Elena” Rome Italy, Rome, Italy

JAPAN
Hiroshi E. Takami, MD, Teikyo University School of Medicine, Tokyo, Japan

NEW ZEALAND
Theo R. Gregory, MD, Waikato Hospital, Hamilton, New Zealand
Mark E. Izzard, MD, Greenlane Hospital, Auckland, New Zealand
Randall P. Morton, MD, Manukau SuperClinic, Auckland, New Zealand

NORWAY
Jan Olofsson, MD, Helse Bergen HF, Bergen, Norway

RUSSIAN FEDERATION
Igor Reshetov, MD, P.A. Hertzen Moscow Cancer Research Institute, Moscow, Russian Federation

SINGAPORE
Kwok Seng Loh, MD, National University Hospital, Singapore, Singapore
Khee-Chee Soo, MD, Singapore General Hospital, Singapore

SOUTH AFRICA
Johannes F. Fagan, MD, University of Cape Town School of Medicine, Cape Town, South Africa

SOUTH KOREA
Chung-Hwan Baek, MD, PhD, Samsung Medical Center, Seoul, South Korea
Kwang Hyun Kim, MD, PhD, HNS Seoul National University College of Medicine, Seoul, South Korea
Young-Ik Son, MD, PhD, Sung Kyun Kwan University School of Medicine, Seoul, South Korea
Myung-Whun Sung, MD, Seoul National University Hospital, Seoul, South Korea

SPAIN
Javier Gavilán, MD, La Paz University Hospital, Madrid, Spain

SWEDEN
Johan Wennberg, MD, PhD, University Hospital, Lund, Sweden

SWITZERLAND
Jacques Bernier, MD, PhD, Genoiler Swiss Medical Network, Bellinzona, Switzerland
Michel Nuyens, MD, University of Bern, Berne, Switzerland
Sandro J. Steockli, MD, Kantonsspital St. Gallen, St. Gallen, Switzerland

THE NETHERLANDS
Alfonsus J. Balm, MD, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Faculty Listing

Ruud H. Brakenhoff, MD, VU University Medical Center, Amsterdam, The Netherlands
Remco De Bree, MD, PhD, VU University Med Ctr, Amsterdam, The Netherlands
C. Rene Leemans, MD, PhD, VU Medical Center, Amsterdam, The Netherlands
Michiel W.M. van den Brekel, MD, Netherlands Cancer Institute AVL, HNS, Amsterdam, The Netherlands

Turkey

Sefik A. Hosal, MD, Hacettepe University School of Medicine, Ankara, Turkey
Metin T. Önerci, MD, Hacettepe University School of Medicine, Ankara, Turkey
Levent Soylu, MD, Çukurova University, Adana, Turkey

United Kingdom

Patrick J. Bradley, FRCS, MBA, Nottingham, England, United Kingdom
Jean-Pierre Jeannon, MBChB, FRCS, Guy’s Hospital, London, England, United Kingdom
Peter Rhys-Evans, MD, FRCS, The Royal Marsden Hospital, London, England, United Kingdom
Simon N. Rogers, BDS, MBChB, Mersey Regional Head and Neck Cancer Centre, Liverpool, England, United Kingdom
Gary L. Ross, MD, Christie Hospital, Manchester, United Kingdom
Richard Shaw, MD, FRCS, FDS, University of Liverpool, Liverpool, United Kingdom
Ricard Simo, MD, Guy’s and St. Thomas Hospital NHS Foundation Trust, London, United Kingdom

United States

David J. Adelstein, MD, Taussig Cancer Center, Cleveland, OH, USA
Jennifer Alpard, PA-c, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Peter E. Andersen, MD, Oregon Health Science Center, Portland, OR, USA
Kie-Kian Ang, MD, PhD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Yoshimi Anzai, MD, University of Washington, Seattle, WA, USA
Anathanasios E. Argiris, MD, University of Pittsburgh, Pittsburgh, PA, USA
Jonathan J. Beiter, MD MBA, FACR, Emory University School of Medicine, Atlanta, GA, USA
Elizabeth A. Blair, MD, University of Chicago Hospital, Chicago, IL, USA
James A. Bonner, MD, University of Alabama at Birmingham, Birmingham, AL, USA
Jay O. Boyle, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Carol R. Bradford, MD, University of Michigan, Ann Arbor, MI, USA
David M. Brizel, MD, Duke Comprehensive Cancer Center, Durham, NC, USA
Paul M. Busse, MD, PhD, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Lauren A. Byers, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Joseph A. Califano, MD, Johns Hopkins Medicine, Baltimore, MD, USA
David L. Callender, MD, The University of Texas Medical Branch, Galveston, TX, USA
Thomas E. Carey, PhD, University of Michigan, Ann Arbor, MI, USA
Ricardo L. Carrau, MD, Eye & Ear Institute, Pittsburgh, PA, USA
Carlos Caulin, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Ara A. Chalian, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Mark S. Chambers, DMD, MS, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Clifford K.S. Chao, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Amy Chen, MD, MPH, Emory University, Atlanta, GA, USA
Chu Chen, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Douglas B. Chepeha, MD, University of Michigan, Ann Arbor, MI, USA
Francisco J. Civantos, MD, University of Miami School of Medicine, Miami, FL, USA
Gary L. Clayman, MD, DDS, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Ezra Cohen, MD, University of Chicago, Chicago, IL, USA
Roger B. Cohen, MD, Fox Chase Cancer Center, Philadelphia, PA, USA
Marc D. Caltrera, MD, University of Washington, Seattle, WA, USA
Barbara A. Conley, MD, Michigan State University, East Lansing, MI, USA
Marion E. Couch, MD, PhD, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Terry A. Day, MD, FACS, Medical University of South Carolina, Charleston, SC, USA
Frederic W.B. Deleyiannis, MD, University of Pittsburgh, Pittsburgh, PA, USA
Franco DeMonte, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Carolyn Dresler, MD, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Sonia A. Duffy, PhD, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA
Beth S. Edeiken-Monroe, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Ahram Eischbruch, MD, University of Michigan Health System, Ann Arbor, MI, USA
David W. Eisele, MD, University of California, San Francisco, San Francisco, CA, USA
Adel El-Naggar, MD, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Joel B. Epstein, DMD, MSD, FRCD(C), Chicago Cancer Center, Chicago, IL, USA
D. Gregory Farwell, MD, UC Davis Medical Center, Sacramento, CA, USA
Steven J. Feigenberg, MD, Fox Chase Cancer Center, Philadelphia, PA, USA
Robert L. Ferris, MD, PhD, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Michelle Corcoran Fingeret, PhD, MD The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Nancy J. Fischbein, MD, Stanford School of Medicine, Stanford, CA, USA
Ariene A. Forastiere, MD, Johns Hopkins Oncology Center, Baltimore, MD, USA
Gerry F. Funk, MD, University of Iowa, Iowa City, IA, USA
Neal D. Futran, MD, DMD, University of Washington Medical Center, Seattle, WA, USA
Brian R. Gastman, MD, University of Maryland Medical Center, Baltimore, MD, USA
Ann M. Gillenwater, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
M. Boyd Gillespie, MD, MS, Medical University of South Carolina, Charleston, SC, USA
Maura L. Gillison, MD, PhD, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Lawrence E. Ginsberg, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Christine M. Glastonbury, MBBS, University of California, San Francisco, San Francisco, CA, USA
Bonnie S. Glisson, MD, The University of Texas M.D. Anderson Cancer Center cology, Houston, TX, USA
W. Jarad Goodwin, MD, University of Miami Hospital, Miami, FL, USA
Christine G. Gourin, MD, Johns Hopkins University, Baltimore, MD, USA
Jennifer R. Grandis, MD, Eye & Ear Institute, Pittsburgh, PA, USA
Ellen R. Gritz, PhD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Patrick Ha, MD, Johns Hopkins Department of Otolaryngology, Sparks Glencoe, MD, USA
Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston, MA, USA
Ehab Y. Hanna, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Paul M. Harari, MD, University of Wisconsin, Madison, WI, USA
Gady Har-El, MD, Long Island College Hospital, Hollis, NY, USA
Louis B. Harrison, MD, Continuum Cancer Centers Of New York, New York, NY, USA
Bruce H. Haughey, MD, Washington University School of Medicine, St Louis, MO, USA
Keith S. Heller, MD, New York University School of Medicine, New York, NY, USA
Wesley L. Hicks, Jr., MD, Roswell Park Cancer Inst, Buffalo, NY, USA
Henry T. Hoffman, MD, University of Iowa, Iowa City, IA, USA
Chris Holsinger, MD, FACS, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Waun Ki Hong, MD, MD The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Faculty Listing

Patricia A. Hudgins, MD, Emory University, Atlanta, GA, USA
Jonas T. Johnson, MD, Eye & Ear Institute, Pittsburgh, PA, USA
Michael J. Kaplan, MD, Stanford Cancer Center, Stanford, CA, USA
Fadlo R. Khuri, MD, Winship Cancer Institute at Emory University, Atlanta, GA, USA
Merrill S. Kies, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Seungwon (Steve) Kim, MD, University of Pittsburgh, Pittsburgh, PA, USA
Wayne M. Koch, MD, Johns Hopkins University, Baltimore, MD, USA
Dennis H. Kraus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Greg Krempa, MD, University of Oklahoma, Oklahoma City, OK, USA
Parvesh Kumar, MD, University of Southern California: Keck School of Medicine, Los Angeles, CA, USA
Stephen Y. Lai, MD, PhD, University of Pittsburgh, Pittsburgh, PA, USA
Corey J. Langer, MD, Fox Chase Cancer Center, Philadelphia, PA, USA
George E. Laramore, MD, University of Washington, Seattle, WA, USA
Pierre Lavertu, MD, University Hospitals Case Medical Center, Cleveland, OH, USA
Quynh-Thu Le, MD, Stanford University School of Medicine, Stanford, CA, USA
Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Eric J. Lentsch, MD, Medical University of South Carolina, Charleston, SC, USA
Roger J. Levin, MD, Associated Otolaryngologists of Pennsylvania, Camp Hill, PA, USA
Jan S. Lewin, PhD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Scott M. Lippman, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Laurie A. Loevner, MD, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Jeri A. Logemann, MD, PhD, Northwestern University, Evanston, IL, USA
Thom R. Loree, MD, Roswell Park Cancer Inst, Buffalo, NY, USA
Daniel D. Lydiatt, DDS, MD, University of Nebraska Medical Center, Omaha, NE, USA
William M. Lydiatt, MD, University of Nebraska Medical Center, Omaha, NE, USA
Homer A. Macapinlac, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Mitchell Machtay, MD, Kimmel Cancer Center and Jefferson Medical College, Philadelphia, PA, USA
Ellie Maghmi, MD, City of Hope National Medical Center, Duarte, CA, USA
J. Scott Magnuson, MD, FACS, University of Alabama at Birmingham, Birmingham, AL, USA
Bonnie Martin-Harris, PhD, Medical University of South Carolina, Charleston, SC, USA
Renato G. Martins, MD, Seattle Cancer Care Alliance, Seattle, WA, USA
Bryan McIver, MBChB, PhD, Mayo Clinic, Rochester, MN, USA
Carol E. Medina, MD, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
William M. Mendenhall, MD, University of Florida Shands Cancer Center, Gainesville, FL, USA
Eduardo Mendez, MD, University of Washington, Seattle, WA, USA
Albert L. Merati, MD, Medical College of Wisconsin, Milwaukee, WI, USA
William Morrison, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Donald L. Morton, MD, John Wayne Cancer Institute, Santa Monica, CA, USA
Suresh Mukherji, MD, University of Michigan, Ann Arbor, MI, USA
Barbara A. Murphy, MD, Vanderbilt Medical Center, Nashville, TN, USA
Eugene N. Myers, MD, FACS, FRCS (Hon), University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Jeffrey N. Myers, MD, PhD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Cherie-Ann O. Nathan, MD, FACS, Louisiana State University Health Sciences Center - Shreveport, Shreveport, LA, USA
Peter C. Nelligan, MD, University of Washington, Seattle, WA, USA
James L. Netterville, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Jason Newman, MD, University of Pennsylvania, Philadelphia, PA, USA
Kerry D. Olsen, MD, Mayo Clinic, Rochester, MN, USA
Bert W. O'Malley, Jr., MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Vali A. Papadimitropoulos, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Upendra Parvatheneni, MD, University of Washington Medical Center, Seattle, WA, USA
Snehal Patel, MD, MS, FRCs, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Guy J. Petruzzelli, MD, PhD, Rush Head & Neck Associates, Chicago, IL, USA
David G. Pfister, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
David G. Posner, MD, Dana-Farber Cancer Institute, Boston, MA, USA
Mark E. Prince, MD, University of Michigan, Ann Arbor, MI, USA
Kristen Pytynia, MD, University of Illinois Chicago, Chicago, IL, USA
David Raben, MD, University of Colorado Health Sciences Center, Aurora, CO, USA
Gregory L. Randolph, MD, Harvard Medical School, Boston, MA, USA
Christopher H. Rassekh, MD, West Virginia University, Morgantown, WV, USA
Vincente Resto, MD, PhD, University of Texas Medical Branch, Galveston, TX, USA
John A. Ridge, MD, PhD, Fox Chase Cancer Center, Philadelphia, PA, USA
K. Thomas Robbins, MD, SimmonsCooper Cancer Institute, Springfield, IL, USA
James L. Rosenthal, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Eben L. Rosenthal, MD, University of Arizona at the University of Arizona, Tucson, AZ, USA
Robert I. Schnell, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA
Ashok R. Shah, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Karen D. Schupak, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Karen D. Schupak, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
David L. Schwartz, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Duane A. Sewell, MD, University of Maryland, Baltimore, MD, USA
Jatin P. Shah, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Maise Shindo, MD, SUNY Stony Brook Health Sciences Center, Stony Brook, NY, USA
Alfred Simental, MD, Loma Linda University, Loma Linda, CA, USA
Bhuvarnesh Singh, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Uttam K. Sinha, MD, University of Southern California – Keck School of Medicine, Los Angeles, CA, USA
Carl H. Snyderman, MD, Eye & Ear Institute, Pittsburgh, PA, USA
Robert A. Soifferman, MD, University of Vermont - Fletcher Allen Health Care, Burlington, VT, USA
Paul M. Spring, MD, MS, University of Arkansas for Medical Science, Little Rock, AR, USA
Brendan C. Stack, Jr., MD, University of Arkansas for Medical Services, Little Rock, AR, USA
Carol Stimson, ARNP, University of Washington, Seattle, WA, USA
Erich M. Sturgis, MD, MPH, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Yungpo Bernard Su, MD, Methodist Estabrook Cancer Center, Omaha, NE, USA
James Y. Suem, MD, University of Arkansas Medical School, Little Rock, AK, USA
David J. Terris, MD, Medical College of Georgia, Augusta, GA, USA
Allan F. Thornton, Jr., MD, DABR, Midwest Proton Radiotherapy Institute, Bloomington, IN, USA
Andy Troatti, MD, H. Lee Moffitt Cancer Center, Tampa, FL, USA
Jennifer Tseng, MD, MD Anderson Cancer Center Orlando, Orlando, FL, USA
Ralph P. Tutano, MD, John Hopkins School of Medicine, Baltimore, MD, USA
Faculty Listing

Mark L. Urken, MD, Beth Israel Hospital, New York, NY, USA
Carter van Waes, MD, PhD, National Institute on Deafness and Other Communication Disorders, Bethesda, MD, USA
Douglas B. Villaret, MD, University of Florida, Gainesville, FL, USA
Everett E. Vokes, MD, University of Chicago Medical Center, Chicago, IL, USA
J. Trad Waddsworth, MD, Eastern Virginia Medical School, Norfolk, VA, USA
Xiao-Jing Wang, MD, PhD, Portland VA Cancer Center, Portland, OR, USA
Mark K. Wax, MD, Oregon Health & Science Univ, Portland, OR, USA
Randal S. Weber, MD, University of Texas, Houston, TX, USA
Gregory S. Weinstein, MD, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Jane L. Weissman, MD, FACR, Oregon Health Sciences University, Portland, OR, USA
Ernest A. Weymuller, MD, University of Washington, Seattle, WA, USA
Mark E. Whipple, MD, University of Washington Medical Center, Seattle, WA, USA
Michelle Williams, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Robert L. Witt, MD, Jefferson Medical College, Newark, DE, USA
Kenneth A. Woebner, MD, FRCP, University of California, San Francisco Medical Center, San Francisco, CA, USA
Gregory T. Wolf, MD, University of Michigan Hospitals, Ann Arbor, MI, USA
David T. Wong, DMD, DMS, University of California, Los Angeles, Los Angeles, CA, USA
Richard J. Wong, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Stuart J. Wong, MD, Medical College of Wisconsin, Milwaukee, WI, USA
Frank Worden, MD, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
Wendell G. Yarbrough, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Peirong Yu, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Bevan Yueh, MD, University of Minnesota, Minneapolis, MN, USA
Steven M. Zeitels, MD, FACS, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

Faculty & Presenter Disclosures

The following faculty & presenters do not have any relevant financial relationships or significant commercial interests associated with their participation at the 7th International Conference on Head and Neck Cancer. If name is not listed below, please refer to the following pages.


The following faculty & presenters provided information indicating they have a financial relationship with a proprietary entity producing health care goods or services, with the exemption of non-profit or government organizations and non-health care related companies. (Financial relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speaker’s bureau, etc.)

<table>
<thead>
<tr>
<th>NAME</th>
<th>COMMERCIAL INTEREST</th>
<th>WHAT WAS RECEIVED</th>
<th>FOR WHAT ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>David J. Adelstein</td>
<td>AstraZeneca Pharmaceuticals</td>
<td>Research Support</td>
<td>Research Support</td>
</tr>
<tr>
<td>Pedro Andrade</td>
<td>Spore in Head and Neck Cancer</td>
<td>Research Support</td>
<td>Research Support</td>
</tr>
<tr>
<td>Kie-Kian Ang</td>
<td>Eli Lilly</td>
<td>Honorarium</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td>Honorarium</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Honorarium</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>BristolMyersSquibb</td>
<td>Honorarium</td>
<td>Consultant</td>
</tr>
<tr>
<td>Aghanassios E. Argiris</td>
<td>Amgen</td>
<td>Consultant Fees</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td>Genentech</td>
<td>Research Support</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td>BristolMyersSquibb</td>
<td>Research Support</td>
<td>Investigator</td>
</tr>
<tr>
<td>Jonathan J. Beitler</td>
<td>Oakstone Medical Publishing</td>
<td>Money</td>
<td>Editor-Practical Reviews in Cancer Management</td>
</tr>
<tr>
<td>Jacques Bernier</td>
<td>Merck</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Sanofi Aventis</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>James A. Bonner</td>
<td>BristolMyersSquibb</td>
<td>Honorarium</td>
<td>Consulting/Advisory</td>
</tr>
<tr>
<td></td>
<td>ImClone Systems</td>
<td>Honorarium</td>
<td>Consulting/Advisory</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siciliano M. Brizel</td>
<td>Sanofi</td>
<td>Honorarium</td>
<td>Consensus Panel</td>
</tr>
<tr>
<td>Andre Lopes Carvalho</td>
<td>Ethicon Endosurgery</td>
<td>Instruments</td>
<td>Research</td>
</tr>
<tr>
<td>Ricardo L. Barra</td>
<td>Storz Endoscopy Inc.</td>
<td>Honoraria</td>
<td>Instruction Courses/Speaker</td>
</tr>
<tr>
<td>Mark S. Chambers</td>
<td>Endo Pharmaceuticals Nuvelo, Inc.</td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td>Shamar Chandarana</td>
<td>Biomet Biologics</td>
<td>Consulting Fee</td>
<td>Product Development Consultant</td>
</tr>
<tr>
<td>Clifford KS Chao</td>
<td>Astra Zeneca</td>
<td>Honoraria</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>IKOE</td>
<td>Ownership Interest</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td>Amy Chen</td>
<td>Mednet</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td>Ezra Cohen</td>
<td>Genentech</td>
<td>Honoraria</td>
<td>Speaker</td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson</td>
<td>Ownership Interest</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td>Ownership Interest</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td>Roger B. Cohen</td>
<td>AstraZeneca</td>
<td>Research Grant</td>
<td>Research grant paid to Fox Chase</td>
</tr>
<tr>
<td></td>
<td>Bayer</td>
<td>Research Grant</td>
<td>Research grant paid to Fox Chase</td>
</tr>
<tr>
<td></td>
<td>BristolMyersSquibb</td>
<td>Research Grant</td>
<td>Research grant paid to Fox Chase</td>
</tr>
<tr>
<td>Małgorzata Czystowska</td>
<td>IRX Therapeutics Inc</td>
<td>Fees</td>
<td>Employees</td>
</tr>
<tr>
<td>Terry A. Day</td>
<td>Gyrus</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Honoraria</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td>Honoraria</td>
<td>Speakers Bureau</td>
</tr>
<tr>
<td>Joel B. Epstein</td>
<td>Endo Inc.</td>
<td>Consulting Fee</td>
<td>Consulting/Advisory Board</td>
</tr>
<tr>
<td></td>
<td>EKR RX</td>
<td>Consulting Fee</td>
<td>Speaking/Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Zila Inc</td>
<td>Consulting Fee</td>
<td>Consulting/Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Amgen Inc.</td>
<td>Consulting Fee</td>
<td>Speaking</td>
</tr>
<tr>
<td>Robert L. Farris</td>
<td>Bristol-Myers Squibb/ImClone</td>
<td>Honorarium</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Gyrus</td>
<td>Honorarium</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>Ethicon</td>
<td>Honorarium</td>
<td>Consulting</td>
</tr>
<tr>
<td>Arlene A. Forastiere</td>
<td>Astra-Zeneca</td>
<td>Research Support</td>
<td>Research Contract</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td>Research Support</td>
<td>Research Contract</td>
</tr>
<tr>
<td></td>
<td>Oxigene</td>
<td>Research Support</td>
<td>Research Contract</td>
</tr>
<tr>
<td>Gerry F. Funk</td>
<td>KLS Martin L.P.</td>
<td>Research Funds</td>
<td>Research</td>
</tr>
<tr>
<td>Maura L. Gillison</td>
<td>Amgen Inc</td>
<td>Honoraria</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>Merck Inc</td>
<td>Research Funding</td>
<td>Research</td>
</tr>
<tr>
<td>Christine M. Glastonbury</td>
<td>Amirisis</td>
<td>Royalty and Consulting Fee</td>
<td>Consulting, Book author</td>
</tr>
<tr>
<td>Paul M. Harari</td>
<td>BristolMyers</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>Genetech</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
</tbody>
</table>

Faculty & Presenter Disclosures
<table>
<thead>
<tr>
<th>NAME</th>
<th>COMMERCIAL INTEREST</th>
<th>WHAT WAS RECEIVED</th>
<th>FOR WHAT ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Holsinger</td>
<td>Sanofi Aventis</td>
<td>Honoraria</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Waun Ki Hong</td>
<td>Zila Inc.</td>
<td>Stock Options</td>
<td>Scientific Advisory Board</td>
</tr>
<tr>
<td>Patricia A. Hudgins</td>
<td>Amirsy Inc.</td>
<td>Royalty</td>
<td>Consulting</td>
</tr>
<tr>
<td>Fadlo R. Khuri</td>
<td>Novartis</td>
<td>Research Funding</td>
<td>PI</td>
</tr>
<tr>
<td>Merrill S. Kies</td>
<td>Imclone Systems</td>
<td>Honorarum</td>
<td>Consultant</td>
</tr>
<tr>
<td>Wayne M. Koch</td>
<td>Zila, Inc.</td>
<td>Honoraria</td>
<td>Medical Advisory Board</td>
</tr>
<tr>
<td>Dennis H. Kraus</td>
<td>Merck/Imclone</td>
<td>Consultant Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td>Corey J. Langer</td>
<td>Intrabiotics</td>
<td>Fee</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Novartis</td>
<td>Fee</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Bayer</td>
<td>Fee</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Vertex</td>
<td>Grant/Research Support</td>
<td>Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>OrthoBiontech (OBT)</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Pharmacy</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Genentech</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Celgene</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td></td>
<td>Cell Therapeutics Inc.</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Aventis</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Schering Plough Research Institute</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Bristol Myers Squibb</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Lilly</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Millennium</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>MedImmune</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Active Biothech</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Sanofi Aventis</td>
<td>Grant/Research Support</td>
<td>Scientific Advisor/ Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>GSK</td>
<td>Grant Support</td>
<td>Contracted Research</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td>Grant Support: Research Study</td>
<td>Contracted Research</td>
</tr>
<tr>
<td></td>
<td>American Cancer Center LTD</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Yolanda YP Lee</td>
<td>Amirsy</td>
<td>Royalty</td>
<td>Author</td>
</tr>
<tr>
<td>Jean Louis Lefebvre</td>
<td>Merck Serono</td>
<td>Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Sanofi Aventis</td>
<td>Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Lisa Licitra</td>
<td>GlaxoSmithKline</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>ERBE</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>Sanofi Aventis</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td>Laurie A. Laevner</td>
<td>Iron Medical Imaging</td>
<td>Consulting Fees</td>
<td>Consulting</td>
</tr>
<tr>
<td>Jeri A. Logemann</td>
<td>Northern Speech Service Pro Ed</td>
<td>Salary</td>
<td>Independent Contract</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Royalty for Books</td>
<td>Independent Contract</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Honorarum</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Honorarum</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td>Mitchell Machtay</td>
<td>MedImmune</td>
<td>Honoraria</td>
<td>Consulting/ Speaking</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Honoraria</td>
<td>Consulting/ Speaking</td>
</tr>
<tr>
<td></td>
<td>Bristol Myers Squibb</td>
<td>Honoraria</td>
<td>Consulting/ Speaking</td>
</tr>
<tr>
<td></td>
<td>Sanofi Aventis</td>
<td>Honoraria</td>
<td>Consulting/ Speaking</td>
</tr>
<tr>
<td>J. Scott Magnuson</td>
<td>Ethicon EndoSurgery</td>
<td>Nothing</td>
<td>Consultant</td>
</tr>
<tr>
<td>Renato G. Martins</td>
<td>Amgen</td>
<td>Grant/Research Support</td>
<td>Research</td>
</tr>
<tr>
<td></td>
<td>Eli Lilly</td>
<td>Honoraria, Grant/Research Support</td>
<td>Speaking</td>
</tr>
<tr>
<td></td>
<td>Genentech</td>
<td>Honoraria, Grant/Research Support</td>
<td>Speaking, Advisory Committee and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Review Panel</td>
</tr>
<tr>
<td></td>
<td>Infinity</td>
<td>Grant/Research Support</td>
<td>Research</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td>Grant/Research Support</td>
<td>Research</td>
</tr>
<tr>
<td>William Morrison</td>
<td>Varian</td>
<td>Own Stock</td>
<td>Stockholder</td>
</tr>
<tr>
<td>Suresh Mukherji</td>
<td>Xoran</td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>Philips</td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td></td>
<td>Bayer</td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td>Barbara A. Murphy</td>
<td>Amgen</td>
<td>Research Support</td>
<td>Private Investigator</td>
</tr>
<tr>
<td></td>
<td>MedImmune</td>
<td>Research Support</td>
<td>Private Investigator</td>
</tr>
<tr>
<td></td>
<td>Bristol Myers</td>
<td>Research Support</td>
<td>Private Investigator</td>
</tr>
<tr>
<td>NAME</td>
<td>COMMERCIAL INTEREST</td>
<td>WHAT WAS RECEIVED</td>
<td>FOR WHAT ROLE</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Vali A. Papadimitrakopoulou</td>
<td>Genentech</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Novartis</td>
<td>Consulting Fee</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Upendra Parvathaneni</td>
<td>ImClone</td>
<td>Honoraria</td>
<td>Speaking and Teaching LOHRAN Advisory Boar Consultant July 2007</td>
</tr>
<tr>
<td></td>
<td>ImClone</td>
<td>Consulting Fee</td>
<td></td>
</tr>
<tr>
<td>Snehal Patel</td>
<td>Elsevier Science</td>
<td>Royalty</td>
<td>Co-Author of a textbook</td>
</tr>
<tr>
<td>David G. Pfister</td>
<td>AstraZeneca</td>
<td>Clinical Trial Support</td>
<td>Principal Investigator Member, Independent Data Safety Monitoring Board</td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Lilly</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td>Salary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BristolMyersSquibb</td>
<td>Honorarium</td>
<td></td>
</tr>
<tr>
<td>John A. Ridge</td>
<td>Sanofi-Aventis</td>
<td>Honoraria</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>K. Thomas Robbins</td>
<td>Genetech</td>
<td>Clinical Trial Funding</td>
<td>Private Investigator</td>
</tr>
<tr>
<td>Cristina Rodriguez</td>
<td>Astra-Zeneca Pharmaceuticals</td>
<td>Research Support</td>
<td>Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fee</td>
<td></td>
</tr>
<tr>
<td>David I. Rosenthal</td>
<td>Bristol-Myers Squibb</td>
<td>Honoraria</td>
<td>Advisory Committee, Research Support</td>
</tr>
<tr>
<td></td>
<td>Imclone</td>
<td>Honoraria</td>
<td>Advisory Committee, Research Support</td>
</tr>
<tr>
<td></td>
<td>MedImmune</td>
<td>Honoraria</td>
<td>Advisory Committee, Research Support</td>
</tr>
<tr>
<td>Panos Savvides</td>
<td>Genentech</td>
<td>Research Support</td>
<td>Research</td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td>Fee</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Alfred Simental</td>
<td>Ethicon Endosurgery</td>
<td>Honoraria</td>
<td>Teaching, Surgical Partnership</td>
</tr>
<tr>
<td>Uttam K. Sinha</td>
<td>Stryker CMF</td>
<td>Educational Grant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol Myers Squibb</td>
<td>Honoraria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ethicon EndoSurgery</td>
<td>Research Grant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lillian Siu</td>
<td>Pfizer</td>
<td>Research Funding</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td>BristolMyersSquibb</td>
<td>Research Funding</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td>Bayer Inc.</td>
<td>Research Funding</td>
<td>Investigator</td>
</tr>
<tr>
<td></td>
<td>Amgen Inc.</td>
<td>Research Funding</td>
<td>Investigator</td>
</tr>
<tr>
<td>Carl H. Snyderman</td>
<td>Stryker</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td></td>
<td>Carl Storz</td>
<td>Consulting Fee</td>
<td>Consulting</td>
</tr>
<tr>
<td>Khee-Chee Soo</td>
<td>Merck</td>
<td>Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td>Ruth Tachezy</td>
<td>GSK</td>
<td>Consulting Fee</td>
<td>Members of adns.com</td>
</tr>
<tr>
<td></td>
<td>GSK</td>
<td>Consulting Fee</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td></td>
<td>MSD</td>
<td>Consulting Fee</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td></td>
<td>Dynex</td>
<td>Consulting Fee</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td>David J. Terris</td>
<td>Medtronic ENT</td>
<td>Honoraria</td>
<td>Director, Thyroid Courses</td>
</tr>
<tr>
<td></td>
<td>Apeon</td>
<td>Stock Options</td>
<td>Scientific Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Ethicon Endosurgery</td>
<td>Honoraria</td>
<td>Teaching, Surgical Partnership</td>
</tr>
<tr>
<td></td>
<td>Aspire</td>
<td>Stock Options</td>
<td>Scientific Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Johnson and Johnson</td>
<td>Honoraria</td>
<td>Director, Thyroid Courses</td>
</tr>
<tr>
<td>Allan F. Thornton, Jr.</td>
<td>ProCure</td>
<td>Ownership Interest</td>
<td>Consulting</td>
</tr>
<tr>
<td>Andy Trotti</td>
<td>Viventia</td>
<td>Consulting</td>
<td>Safety Advisor</td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td>Consulting</td>
<td>Monitoring Committee</td>
</tr>
<tr>
<td></td>
<td>National Comprehensive Cancer Network (NCCN)</td>
<td>Consulting</td>
<td>Speaker</td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute</td>
<td>Consulting</td>
<td></td>
</tr>
<tr>
<td>Minh Tam Truong</td>
<td>National Institute of Health</td>
<td>Research Support</td>
<td>Research</td>
</tr>
<tr>
<td>Uta Tschiesner</td>
<td>Heimomed</td>
<td>Honorarium</td>
<td>Contract Research</td>
</tr>
<tr>
<td>Jennifer E. Tseng</td>
<td>OSI</td>
<td>Honoraria</td>
<td>Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Genetech</td>
<td>Honoraria</td>
<td>Speakers Bureau</td>
</tr>
<tr>
<td>Christina Tsien</td>
<td>Genetech</td>
<td>Research Support</td>
<td>Research</td>
</tr>
<tr>
<td>Ralph P. Tufano</td>
<td>Ethicon Endosurgery</td>
<td>Honoraria</td>
<td>Speaking and Teaching</td>
</tr>
<tr>
<td>Michiel W.M. van den Brekel</td>
<td>ATOS</td>
<td>Research Grant</td>
<td>Independent Contractor</td>
</tr>
</tbody>
</table>
## Faculty & Presenter Disclosures

<table>
<thead>
<tr>
<th>NAME</th>
<th>COMMERCIAL INTEREST</th>
<th>WHAT WAS RECEIVED</th>
<th>FOR WHAT ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan B. Vermorken</td>
<td>Amgen, Merck</td>
<td>Consulting Fee,</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consulting Fee/Honoraria</td>
<td></td>
</tr>
<tr>
<td>Everett E. Vokes</td>
<td>ImClone, Bristol-Myers Squibb,</td>
<td>Honoraria, Honoraria,</td>
<td>Consultant, Consultant,</td>
</tr>
<tr>
<td></td>
<td>AstroZeneca, Sanofi</td>
<td>Honoraria</td>
<td>Consultant</td>
</tr>
<tr>
<td>Randal S. Weber</td>
<td>Bristol-Myers Squibb/Imclone</td>
<td>Honoraria</td>
<td>Educational Materials</td>
</tr>
<tr>
<td>Gregory T. Wolf</td>
<td>IRX Therapeutics</td>
<td>Consulting Fee</td>
<td>Consultant</td>
</tr>
<tr>
<td>Stuart J. Wong</td>
<td>ImClone</td>
<td>Consulting Fee</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td>Frank Worden</td>
<td>Imclone, Sanofi-Aventis</td>
<td>Honoraria, Honoraria</td>
<td>Speaking/Advisory Board</td>
</tr>
<tr>
<td>Steven M. Zeitels</td>
<td>Cynosure, Laserscope Inc., EndoCraft</td>
<td>Instruments/No Funds,</td>
<td>Research, Research,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Equity Interest</td>
<td>Stockholder</td>
</tr>
</tbody>
</table>
Exhibit Hall

EXHIBIT HALL HOURS

Sunday, July 20, 2008
Exhibit Hall Open 10:00 - 16:00
International Welcome Reception 19:00 - 21:00

Monday, July 21, 2008
Exhibit Hall Open 10:00 - 16:00

Tuesday, July 22, 2008
Exhibit Hall Open 10:00 - 13:30
Free Attendee Lunch 12:00 - 13:30
2008 Exhibitors

3DMD #300
100 Galleria Parkway   Suite 1070
Atlanta, GA 30339
Tel: 770-612-8002   Fax: 770-612-0833
Website: www.3dmd.com
3dMD provides high-precision, ultra-fast (1.5 milliseconds) 3D surface imaging systems and sophisticated 3D volumetric imaging software for measurement, evaluation, and surgical outcome simulation. This interactive 3D environment supports next-generation surgical planning by enabling the surgeon to simulate hard and soft tissue outcomes with the combined CT/CBCT and 3dMD data set.

ALLEN STEWART, PC #203
Republic Center
325 North St. Paul St.   Suite 2750
Dallas, Texas 75201
Tel: 214-965-8700   Fax: 214-965-8701
Website: www.allenstewart.com
Allen Stewart, PC is a law firm in Dallas, Texas dedicated to representing individuals who have suffered injuries from toxic exposures, including sinonasal cancer victims with a history of exposure to wood dust, leather dust, or metals. We provide a means for sinonasal cancer victims to seek a financial recovery that, in many cases, may be critical to help those patients pay for reconstructive cranio-facial surgeries following tumor removal, which often may not be fully covered by insurance.

AMERICAN ACADEMY OF OTOLARYNGOLOGY HEAD AND NECK SURGERY #T-1
One Prince St
Alexandria, VA 22314
Tel: 1-703-703-535-3738
Website: www.entnet.org
Visit our exhibit booth for member information, AcademyU, 2008 Annual Meeting & OTO EXPO in Chicago, 2009 Call for Papers, journal subscriptions, and great services.

APTIUM ONCOLOGY #115
8201 Beverly Blvd
Los Angeles, CA 90048
Tel: 323-966-3400   Fax: 323-966-3688
Website: www.aptiumorcerology.com
For 25 years, Aiptum Oncology has designed, built and managed cancer centers at leading hospitals, with the vision of bringing core clinical services to one central place that helps patients achieve greater, better lives. Aiptum brings patient-focused, leading-edge cancer care to new regions of the country through significant investments in clinical research and new technologies.

ATOS MEDICAL INC. #101
11390 W. Theodore Trecker Way
West Allis, WI 53214-1135
Tel: 1-800-217-0025   Fax: 414-227-9033
Atos Medical manufactures innovative products to serve the head/neck patient, from superior Provox® Voice Systems for laryngectomees to Therabite® Jaw Motion Rehabilitation for TMJ and Trismus.

BIOFORM MEDICAL, INC. #311
1875 South Grant Street, Suite 110
San Mateo, CA 94402
Tel: 866-862-1211   Fax: 866-862-1212
Website: www.radiesse.com
BioForm Medical manufactures Radiesse® Voice, an injectable implant containing synthetic Calcium Hydroxylapatite microspheres suspended in an aqueous gel carrier. Radiesse Voice provides long lasting vocal fold augmentation, while Radiesse Voice Gel, containing synthetically derived polymers, is ideal for short-term treatment.

BIOTENE/LACLEDE, INC. #202
2103 E. University Drive
Rancho Dominguez, CA 90220
800-922-5856
Website: www.laclede.com
Biotene Dry Mouth products contain a unique enzyme formulation, which utilizes saliva’s protective elements to protect against Dry mouth, a common side effect of hundreds of prescription drugs and medical conditions and treatments.

BOSTON MEDICAL PRODUCTS, INC. #100
117 Flanders Road, Westborough, MA 01581 USA
TollFree: 1-800-433-2674
Tel: 508-898-9300   Fax: 508-898-2373
Websites: www.bosmed.com / www.trachs.com
Boston Medical Products manufactures high quality otology, rhinology, laryngology, and tracheostomy products. Products include ear dressings, nasal packs, splints, stents, buttons, and epistaxis catheters; tracheostomy tubes, Montgomery T-Tubes, buttons, and speaking valves; tracheal and bronchial stents, bronchoscopes, forceps, and accessories; laryngeal stents and keels; esophageal tubes; thyroplasty medialization implants; accessories for tracheostomy and laryngectomy patients.

BRISTOL-MYERS SQUIBB #102
P. O. Box 4500
Princeton, NJ 08543
Tel: 609-897-2000   Fax: 609-897-6722
Website: www.bms.com
Bristol-Myers Squibb welcomes you to San Francisco! We invite you to visit our exhibit and learn of the products and services Bristol-Myers Squibb has to offer to your specialty.
BSD MEDICAL CORP. #111
2188 W 2200 S
Salt Lake City, UT 84119
Tel: 801-972-5555 Fax: 801-972-5930
Website: wwwbsdmedicalcom, wwwheatcancercom
BSD Medical Corp. is the leading developer of systems used
to deliver hyperthermia therapy for the treatment of cancer.
Hyperthermia therapy is used to kill cancer directly and increase
the effectiveness of companion radiation treatments.

CEREDAS #310
191 Rue Adolphe Pajeaud
92160 ANTONY - FRANCE
Tel: 00 33 (1) 42 37 11 12 Fax: 00 33 (1) 42 37 90 91
Website: www.ceredas.com
For more than ten years, Ceredas has offered all its innovation
skills to the laryngectomized in order to improve the quality of
their life. The artificial nose or HME Cyranose®, a permanent
solution for pulmonary rehabilitation, and Tracheoclean™, a dis-
posable tracheal protection, are the result of the same know-how.

DNA GENOTEK #400
29 Camelot Drive
Ottawa, Ontario, K2G 5W6
Canada
Tel: 613 723 5757 Fax: 613 723 5057
Website: wwwdnagenotekcom
DNA Genotek is focused on improving nucleic acid sample col-
collection. The company’s Oragene® product line offers researchers
a non-invasive, all-in-one system for the collection, stabilization,
transportation and purification of high quality DNA or RNA from
saliva. Oragene’s reliability and ease-of-use have resulted in
rapid worldwide adoption by top-tier health institutions.

ELLMAN INTERNATIONAL #116
3333 Royal Ave.
Oceanside, NY 11572
Tel: 800 835 5355 Fax: 516 569 0054
Website: wwwellmancom
Ellman International, a worldwide leader and manufacturer of
high frequency radiosurgical equipment, presents the Surgitron
IEC Dual Frequency. This device utilizes 4.0 MHz for cut, blend,
and coag. Bipolar utilizes 1.7 MHz. It provides pressureless inci-
sions with minimal tissue alteration, superior biopsy specimens
and excellent cosmetic results. Please visit our booth for a demon-
stration on how radiosurgery can benefit your practice.

ENDOCRAFT LLC #200
3 Catalpa Road
Providence, RI 02906
Tel: 401 454 7267 Fax: 401 331 2742
Website: wwwendocraftcom
Manufacture and sales of the Zeitels Universal Modular
Glottoscope, True Gallows Suspension Device, Vocal Fold Infusion
Needles, and cable for Glottoscope.
GENZYME CORPORATION  #309
500 Kendall Street
Cambridge, MA 02142
Tel: 617-252-7500  Fax: 617-252-7600
Website: www.genzyme.com
One of the world’s leading biotechnology companies, Genzyme Corporation, makers of Thyrogen® (thyrotropin alfa for injection), is dedicated to making a major positive impact on the lives of people with serious diseases. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing.

GLAXOSMITHKLINE ONCOLOGY  #212
1250 S. Collegeville Road
Collegeville, PA 19426
Tel: 610-917-4425
Website: www.gsk.com
GSK Oncology is dedicated to pursuing innovations in cancer that will make profound differences in the lives of patients. Focused on therapies for prevention, supportive care, and treatment, GSK is developing multiple lines of defense to help patients in their individual strive against the causes and consequences of cancer.

GRIFFIN LABORATORIES  #108
27636 Yenez Road, L7199
Temecula, CA 92591
Tel: 800-330-5969  Fax: 951-587-0359
Website: www.griffinlab.com
Manufacturer of voice & speech tools, our TruTone™ & SolaTone™ artificial larynx devices offer unmatched durability, and the only electrolarynx allowing full prosody. Our SoniVox™ waistband amplifier sets new standards in voice quality, and the BoomVox™ amplifier offers wireless convenience.

GYRUS ACMI  #105
“Power through integration — Olympus”
ENT Division
2925 Appling Road
Bartlett, TN 38133
Tel: 1-800-262-3540  Fax: 901-373-0276
www.gyrusacmi.com
Olympus and Gyrus ACMi, two of the world’s leading suppliers of medical visualization and energy systems, have joined forces to create a more versatile organization destined to push beyond the boundaries of minimally invasive surgery.

HEMOSTATIX MEDICAL TECHNOLOGIES, LLC  #312
Tel: 1-800-SCALPEL  Fax: 1-901-261-0012
Website: www.hemostatix.com
The Hemostatix Thermal Scalpel System utilizes state-of-art electronic circuitry incorporated onto a surgically sharp scalpel blade. The result is a product which allows the surgeon to achieve precise hemostasis at a surgeon defined blade temperature without giving up tactile feedback.

IBA PARTICLE THERAPY, INC.  #107
225 Water Street - Suite 2200
Jacksonville, FL 32202
Toll Free: 1-877-IBA-4 PBT  
Tel: 1-904-491-6080
Website: www.iba-worldwide.com/healthcare/radiotherapy/particle-therapy
Founded in 1986, Ion Beam Applications (IBA) is a world leader in the research, development, installation and operation of particle accelerators for medical and industrial use. Over the last 15 years, IBA has designed and equipped more than half of the clinical-based proton therapy facilities in the world. With its world headquarters in Brussels, Belgium, IBA has operations in more than 50 sites, spanning 12 countries and three continents. Contact: Stephen Sledge

IFHNOS 2010 SEOUL Secretariat  #T-3
c/o MECI International Convention Services, Inc.
Tel: +82-2-2082-2310  Fax: +82-2-2082-2314
Website: www.ifhnos2010.org
4th World Congress of International Federation of Head and Neck Oncologic Societies: June 15 - 19, 2010, Seoul, Korea
Shifting Paradigms in Head and Neck Oncology
The congress aims to provide superb opportunities to the high-level experts and decision makers in acquiring valuable information about the management of the head and neck tumors. It is further expected to lay the foundation for continuing its cooperative efforts and for bringing a significant enhancement among surgeons, radiation oncologists and medical oncologists as well as plastic surgeons.

IMCLONE SYSTEMS INCORPORATED  #114
180 Varick Street
New York, NY 10014
Tel: 212.645.1012  Fax: 212.645.2054
Website: www.imclone.com
ImClone is dedicated to developing and commercializing novel therapeutic products in the field of oncology. Our efforts have resulted in a commercially available novel therapy, ERBITUX® (cetuximab), as well as a broad spectrum of innovative product candidates.
INHEALTH TECHNOLOGIES

1110 Mark Avenue
Carpinteria, CA 93013
Tel: 805-576-6536 Fax: 805-684-8594
Website: www.inhealth

InHealth Technologies, market leader in surgical voice restoration products for over 30 years. Products include Blom-Singer® voice prostheses and accessories, hands-free speech valves, heat and moisture exchange systems, HydroPore® and Bac-T® Bacteriostatic packs, and Katz Extractor® Oto-Rhino Foreign Body Remover.

IRX THERAPEUTICS, INC.

140 West 57th Street, Suite 9C
New York, NY 10019
Tel: 212-582-1199 Fax: 212-582-3659
Website: www.irxtherapeutics.com

IRX Therapeutics seeks to restore an effective cellular immune response for treatment of cancers and viral diseases. The lead product, IRX-2, completed Phase 1/2a and 2b trials in late-stage H&NSCC patients and will soon begin a global Phase 3 trial.

KARGER PUBLISHERS

26 West Avon Road
P.O. Box 529
Unionville, CT 06085
Tel: (800) 828-5479 Fax: (860) 675-7302
Website: www.karger.com

Karger Publishers will display books and journals, including the unique new book, Pearls And Pitfalls In Head And Neck Surgery: Practical Tips To Minimize Complications.

KARL STORZ ENDOSCOPY-AMERICA, INC.

600 Corporate Pointe
Culver City, CA 90230
Tel: 310-338-8100 Fax: 310-410-5537
Website: www.ksea.com

KARL STORZ Endoscopy-America, Inc., is an international leader in endoscopic equipment and instruments that emphasize the visionary design, precision craftsmanship and clinical effectiveness required for aesthetic nasal plastic surgery. KARL STORZ produces a broad range of precision instruments and telescopes offering superior optics to facilitate the most demanding rhinoplasty procedures.

KAYPENTAX

A Division of Pentax Medical Company
2 Bridgewater Lane
Lincoln Park, NJ 07006
Tel: 800-289-5297 Fax: 973-628-6363
Website: www.kaypentax.com

KayPentax is the world leader in instrumentation used in the assessment and treatment of speech, voice and swallowing disorders. On display will be the Digital Stroboscopy System, Digital Endoscopy Systems, Digital Swallowing Workstation, Flexible endoscopes (Video and Fiber scopes) and other products.

KLS MARTIN L.P.

P.O. Box 50249
Jacksonville, FL 32250-0249
Tel: 904-641-7746 or 1-800-625-1557 Fax 904-641-7378
Website: www.klsmartin.com

KLS Martin is a company dedicated to producing innovative medical devices for craniomaxillofacial surgery including surgical instruments, distraction osteogenesis devices, and power systems.

LIPPINCOTT, WILLIAMS AND WILKINS

Tel: 925-944-9517 Fax: 925-932-1631
Website: www.lww.com

Lippincott, Williams and Wilkins is a leading publisher of textbooks, journals, and electronic products for medical professionals. Also represented at our booth will be medical publishers Thieme and Springer.

LISA LASER USA

7083 Commerce Circle, Ste. E
Pleasanton CA 94588
Tel: 925-468-0433 Fax: 925-399-5984
Website: www.lisalaserusa.com

LISA laser products presents the RevoLix Jr, a continuous wave 2 micron laser, the chromophore is water, the same as the CO2 laser, with a penetration depth of approx 0.4mm. The laser energy is fiber delivered, using Autoclavable and reusable fibers.

MEDICAL MODELING INC.

17301 W. Colfax Avenue, Suite 300
Golden, CO 80401 USA
Tel: 303-273-5344 Toll-free: 888-273-5344 Fax: 303-273-6463
Website: www.medicalmodeling.com

Medical Modeling specializes in providing custom anatomical models produced from your patient’s CT scan. Their ClearView® and OsteoView® products are the industry standard. Stop by our booth to learn more about model-based surgical planning and orthognathic planning software products.

MEDTRONIC ENT

6743 Southpoint Drive North
Jacksonville, FL 32216
Tel: 904-296-9600 Toll Free: 800-874-5797 Fax: 904-281-0966
Website: www.medtronic.com

Medtronic ENT is a leading developer, manufacturer and marketer of surgical products for use by ENT specialists. Medtronic ENT markets over 5,000 surgical products worldwide addressing the major ENT subspecialties – Sinus, Rhinology, Laryngology, Otology, Pediatric ENT, and Image Guided Surgery.
2008 Exhibitors

MERCK KGaA  #112
Frankfurter Str. 250
Darmstadt, 64293
Germany
Tel.: +49 6151 72-0 Fax: +49 6151 72 2000
Website: www.merck.de
With a tradition of over three hundred years Merck KGaA is the oldest pharmaceutical and chemical company in the world. Merck Serono, the division for innovative small molecules and biopharmaceuticals of Merck KGaA, is internationally recognized as a biotechnology leader and for its commitment to bringing new therapies through its own research and development.

MICHELSON DIAGNOSTICS  #303
11A Grays Farm Production Village
Orpington, Kent BR5 3BD, UK
Tel: +44 (0) 20 8308 1695 Fax: +44 (0)121 275 6237
Website: www.michelsondiagnostics.com
Michelson Diagnostics is the UK’s leading independent manufacturer and developer of Optical Coherence Tomography imaging equipment. Their EX1301 Microscope offers near-cellular (<10 micron) sub-surface images for research; 2/3D tissue architecture is captured non-invasively, in real-time & without ionising radiation.

MICROSURGERY INSTRUMENTS, INC.  #302
PO Box 1378
Bellaire, TX 77402-1378
Tel: 713-664-4707 Fax: 713-664-8873
Website: www.microsurgeryusa.com
Microsurgery Instruments is one of the leading suppliers of microsurgical equipment in the US, and well known in many surgical fields. Apart from our Wide-Field loupes, we supply Super-Cut scissors; titanium needleholders, scissors and forceps; Vas-clamps; light sources; sutures; microscopes and other instruments.

OLYMPUS AMERICA INC.  #104
One Corporate Drive
Orangeburg, NY 10962
Tel: 800-548-5515
Website: www.olympusamerica.com
Olympus America Inc. is a precision technology leader that provides knowledge and solutions, which enable healthcare professionals to achieve excellent clinical and financial outcomes across the continuum of care in the field of Otolaryngology.

OMNIGUIDE, INC.  #313
One Kendall Square
Building 100
Cambridge, MA 02139
Tel: 617-551-8444 Fax: 617-551-8445
Website: www.omniguide.com
OmniGuide manufactures and sells the BeamPath™ CO2 laser fiber system, a clinically targeted optical scalpel optimized for specific surgical procedures. OmniGuide is committed to developing products that improve and expand surgical treatment options while reducing treatment complexity and cost.

PLURAL PUBLISHING, INC.  #201
5521 Ruffin Road
San Diego, CA 92123
Tel: 858-492-1555 Fax: 858-492-1020
Website: www.pluralpublishing.com
Plural is a leading publisher of books, journals, and multimedia in the areas of otolaryngology and head and neck surgery. Enjoy exclusive conference savings and browse our latest titles at the Plural booth.

PROSTRAKAN INC  #403
1430 Route 206
Bedminster, NJ 07921
Website: www.prostrakan-us.com
Headquartered in Scotland, ProStrakan is one of Europe’s fastest growing pharmaceutical companies. Our primary inspiration is to develop medicines for the treatment of unmet needs. Where others aren’t able to address these needs, we try to make a difference by putting patients first. Our U.S. launch will continue this tradition.

SANOFI-AVENTIS  #316
55 Corporate Drive
Bridgewater, NJ 08807-5925
Tel: 908-981-6656 Fax: 908-575-4468
Website: www.sanofi-aventis.com
Sanofi-Aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, Sanofi-Aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines.

SAUNDERS/MOSBY/CHURCHILL  #214
1593 Krpan Drive
Roseville, CA 95747
Tel: 916-787-1041 Fax: 916-787-1042
Please visit the Saunders/Mosby (Elsevier) booth to view the latest titles in Head & Neck Cancer. We recently published the new edition of Myers, “Head & Neck Surgery,” a two-volume set with online access, as well as Wenig, “Atlas of Head & Neck Pathology.” There are also several new journals and clinics on Head & Neck Surgery and Head & Neck Cancer.

STRYKER  #217
750 Trade Centre Way, Suite 200
Portage, MI 49002
Tel: 269.324.5346 Fax: 269.324.5446
www.stryker.com
Stryker is one of the world’s leading medical technology companies with the most broadly based range of products, including: implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic and interventional pain equipment; endoscopic, surgical navigation and communications systems; as well as patient handling equipment.
SYNTHES CMF #213
1301 Goshen Parkway
West Chester, PA 19380
Website: www.Synthes.com
Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

UNITED MEDICAL INSTRUMENTS #305
2370-D Qume Drive
San Jose, CA 95131
Tel: 408-383-9700 Fax: 408-383-9010
Toll Free: 877-490-7036
Website: www.umiltrasound.com
United Medical Instruments (UMI) is a dedicated worldwide Ultrasound company based in San Jose, California. UMI has been providing practitioners high quality new Siemens ultrasound systems and certified, pre-owned ultrasound equipment by all major manufacturers at competitive prices.

VARIAN MEDICAL SYSTEMS #216
3100 Hansen Way, M/S MGM
Palo Alto, California 94304
Tel. (650)493-4000 Fax: (650)493-5637
Website: www.varian.com
Varian Medical Systems is the world’s leading manufacturer of integrated cancer therapy equipment and software products. Varian’s offerings include the ARIA(tm) Oncology Information System - an oncology-specific electronic medical record (EMR) that manages clinical, financial, and administrative processes in medical, radiation and surgical oncology departments.

VIOPTIX, INC. #215
44061-B Old Warm Springs Blvd.
Fremont, CA 94538
Tel: 510-226-5860 Fax: 510-226-5864
Website: www.vioptix.com
The ViOptix™ Tissue Oximeter provides continuous, non-invasive, direct, real-time measurements of local tissue oxygen saturation. It is used for post-operative monitoring of flaps and digit replants to assess and monitor tissue, thereby improving medical outcomes and decreasing cost. The system consists of a monitor and sterile single-use optical sensors.

XLEAR INC. #306
PO Box 970911
Orem, UT 84097
Tel: 877-599-5327 Fax: 801-224-4283
Website: www.xlear.com
Xlear manufactures natural, health-enhancing products using Xylitol, which has been proven to provide substantial health and dental benefits. There are five product lines: Xlear Nasal Wash, Spry Dental Defense System, Rain Dry Mouth Spray, Xylosweet Sweetener, Fine and Dandy Candy.

THE YUL BRYNNER HEAD AND NECK CANCER FOUNDATION, INC. #T-2
135 Rutledge Avenue, MSC 550
Charleston, SC 29425-5500
Tel: 843-792-6624
Fax: 843-792-0546
Website: www.headandneck.org/
As part of our Mission to both educate and increase awareness about Oral, Head and Neck Cancer, the Yul Brynner Foundation sponsors the Oral, Head & Neck Cancer Awareness Week (OHANCAW) every year. Please visit our booth to learn more and to sign up to participate in 2009.

ZILA PHARMACEUTICALS #210
5227 North 7th Street
Phoenix, AZ 85014
Tel: 602-266-6700
Toll Free: 800-228-5595 Fax: 870-793-5554
Website: www.vizilite.com
Zila, Inc., is dedicated to the prevention, detection and treatment of oral cancer. ViziLite® Plus, the company’s flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.